KR20220078552A - A composition for diagnosing severe patient of COVID-19 - Google Patents

A composition for diagnosing severe patient of COVID-19 Download PDF

Info

Publication number
KR20220078552A
KR20220078552A KR1020220066643A KR20220066643A KR20220078552A KR 20220078552 A KR20220078552 A KR 20220078552A KR 1020220066643 A KR1020220066643 A KR 1020220066643A KR 20220066643 A KR20220066643 A KR 20220066643A KR 20220078552 A KR20220078552 A KR 20220078552A
Authority
KR
South Korea
Prior art keywords
leu
ser
val
thr
ala
Prior art date
Application number
KR1020220066643A
Other languages
Korean (ko)
Other versions
KR102578616B1 (en
Inventor
이흥규
김채원
Original Assignee
한국과학기술원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국과학기술원 filed Critical 한국과학기술원
Priority to KR1020220066643A priority Critical patent/KR102578616B1/en
Publication of KR20220078552A publication Critical patent/KR20220078552A/en
Application granted granted Critical
Publication of KR102578616B1 publication Critical patent/KR102578616B1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

본 발명은 코로나바이러스감염증-19 중증 환자 진단용 조성물에 관한 것이다. 이와 같은 본 발명은 목적하는 개체의 대식세포, B 세포 및 플라즈마 세포로부터 유래된 다양한 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준을 비교함으로써 항체 의존적 감염 촉진 현상이 유도되며, B 세포가 활성화될 뿐만 아니라 과도한 염증반응이 일어나는 코로나바이러스감염증-19 중증 환자를 특이적으로 진단해낼 수 있다.The present invention relates to a composition for diagnosing severe patients with COVID-19. As described above, the present invention provides a variety of genes derived from macrophages, B cells and plasma cells of a subject; Alternatively, by comparing the expression level of the protein encoded by this, an antibody-dependent infection promotion phenomenon is induced, and it is possible to specifically diagnose a severe patient with coronavirus infection-19, in which B cells are activated as well as an excessive inflammatory response.

Description

코로나바이러스감염증-19 중증 환자의 진단용 조성물{A composition for diagnosing severe patient of COVID-19}A composition for diagnosing severe patient of coronavirus infection-19 {A composition for diagnosing severe patient of COVID-19}

본 발명은 코로나바이러스감염증-19 중증 환자의 진단용 조성물에 관한 것이다.The present invention relates to a composition for diagnosis of severe coronavirus infection-19 patients.

코로나바이러스감염증-19(Coronavirus disease 2019; COVID-19)는 2019년 중국 우한에서 시작된 감염증으로서, 세계보건기구에서 팬데믹(Pandemic)으로 지정된 SARS-CoV-2 바이러스 감염에 의한 호흡기 질병이다. 또한, 인플루엔자바이러스의 경우 사망률이 1%에 불과하나, COVID-19의 경우에는 그 사망률이 약 5%에 해당하므로, 기존의 감염성 바이러스에 비하여 COVID-19는 인류에게 매우 위협적인 바이러스 감염병에 해당한다. COVID-19로 인한 사망의 원인 중 가장 큰 요소는 사이토카인 폭풍(Cytokine storm), 즉 염증 반응이 과도하게 활성화되는 현상인 과염증 반응 증후군(Hyper-inflammatory response syndrome)으로, 이와 같은 증후군이 발생되면 개체가 결국 사망에 이르게 하는 것으로 보고되어 있다.Coronavirus disease 2019 (COVID-19) is an infectious disease that originated in Wuhan, China in 2019 and is a respiratory disease caused by infection with the SARS-CoV-2 virus, which has been designated as a pandemic by the World Health Organization. In addition, in the case of influenza virus, the mortality rate is only 1%, but in the case of COVID-19, the mortality rate is about 5%, so compared to the existing infectious virus, COVID-19 is a very threatening viral infectious disease to mankind. . The largest cause of death from COVID-19 is a cytokine storm, or hyper-inflammatory response syndrome, a phenomenon in which the inflammatory response is over-activated. Subjects have been reported to eventually lead to death.

기존 호흡기 바이러스 감염증으로 인해 나타나는 과염증 반응 증후군의 원인 중 하나로 항체 의존적 감염 촉진 현상(Antibody-dependent enhancement)이 알려져 있다. 항체의 원래 역할은 바이러스와 특이적으로 결합하여 바이러스의 활성을 중화하고, 면역세포의 대사 작용을 촉진하는 것으로 알려져 있다. 그러나, 과염증 반응 증후군에서의 항체는 오히려 대식 작용 촉진으로 인해 면역세포로 바이러스가 감염되도록 유도하는 역할을 할 수 있다. 구체적으로, 항체가 바이러스와 결합한 뒤에 상기 항체의 불변 부위 수용체(Fc receptor)를 통해 항체와 결합된 바이러스가 면역세포 안으로 들어가고, 이를 통해 면역세포에 들어간 바이러스에 의해 톨 유사 수용체가 활성화되어 과도한 면역반응이 일어나게 되는 것이다. 이와 같은 현상은 기존의 코로나 바이러스 감염에서 유도되는 것으로 알려져 있으나, COVID-19에서는 이와 같은 현상에 대해서는 알려진 바 없다. 그러나, 항체를 이용한 치료법을 사용하는 경우 이와 같은 현상에 의해 바이러스에 의한 감염을 더욱 악화시키고 환자의 병증을 중증으로 악화시킬 수 있으므로 이와 관련된 추가적인 연구가 절실한 실정이다.Antibody-dependent enhancement is known as one of the causes of hyperinflammatory reaction syndrome caused by existing respiratory viral infections. It is known that the original role of the antibody is to neutralize the activity of the virus by specifically binding to the virus, and to promote the metabolism of immune cells. However, antibodies in hyperinflammatory response syndrome may rather play a role in inducing virus infection into immune cells by promoting phagocytosis. Specifically, after the antibody binds to the virus, the antibody-bound virus enters the immune cells through the constant region receptor (Fc receptor) of the antibody. this is going to happen This phenomenon is known to be induced by the existing corona virus infection, but there is no known about such a phenomenon in COVID-19. However, in the case of using a treatment using an antibody, this phenomenon further aggravates the infection caused by the virus and worsens the patient's condition, so additional research related thereto is urgently needed.

본 발명의 일 목적은 코로나바이러스감염증-19(COVID-19) 중증 환자의 진단용 조성물; 및 이를 포함하는 키트를 제공하는 것이다.One object of the present invention is a composition for diagnosis of severe patients with coronavirus infection-19 (COVID-19); And to provide a kit comprising the same.

본 발명의 다른 목적은 코로나바이러스감염증-19 중증 환자의 진단을 위한 정보 제공 방법을 제공하는 것이다.Another object of the present invention is to provide an information providing method for diagnosing a patient with severe COVID-19.

그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업계에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problems, and other problems not mentioned will be clearly understood by those of ordinary skill in the art from the following description.

본 발명의 일 구현 예에서는 코로나바이러스감염증-19(coronavirus disease 2019; COVID-19) 중증 환자의 진단용 조성물을 제공한다.One embodiment of the present invention provides a composition for diagnosis of severe patients with coronavirus disease 2019 (COVID-19).

본 발명의 상기 진단용 조성물은 하기 제1군 내지 제5군에서 선택되는 적어도 하나 이상의 유전자 또는 이에 의해 암호화되는 단백질의 발현 수준을 측정하는 제제를 포함한다:The diagnostic composition of the present invention includes an agent for measuring the expression level of at least one gene selected from the following first to fifth groups or a protein encoded by the gene:

제1군: FCGR1A, FCGR2A 및 FCARGroup 1: FCGR1A, FCGR2A and FCAR

제2군: TNFSF13B 및 TNFSF13Group 2: TNFSF13B and TNFSF13

제3군: IGHG1, IGHG2, IGHG3, IGHG4 및 IGHA1Group 3: IGHG1, IGHG2, IGHG3, IGHG4 and IGHA1

제4군: CD69 및 FOSGroup 4: CD69 and FOS

제5군: CCR7, CXCR3, CCR2, CCR10 및 CCR4Group 5: CCR7, CXCR3, CCR2, CCR10 and CCR4

본 발명의 상기 "코로나바이러스감염증-19"는 코로나비리데(Coronaviridae)에 속하는 RNA 바이러스에 해당하는 SARS-CoV-2 바이러스에 의해 발생하는 동물 기원의 바이러스성 호흡기 질환을 의미한다. 이러한 코로나바이러스감염증-19는 1~14일의 잠복기를 가진다. 나아가, 발열, 권태감, 기침, 호흡곤란 및 폐렴 등과 같은 경증에서 중증까지 매우 다양한 호흡기감염증이 나타나며, 가래, 인후통, 두통, 객혈과 오심, 설사 등과 같은 증상을 나타내기도 한다. 상기 코로나바이러스감염증-19는 이와 같은 증상의 정도에 따라 코로나바이러스감염증-19 경증 환자 및 코로나바이러스감염증-19 중증 환자로 구분될 수 있다.The "coronavirus infection-19" of the present invention means a viral respiratory disease of animal origin caused by SARS-CoV-2 virus, which is an RNA virus belonging to Coronaviridae. This coronavirus infection-19 has an incubation period of 1 to 14 days. Furthermore, a wide variety of respiratory infections, ranging from mild to severe, such as fever, malaise, cough, shortness of breath, and pneumonia, appear, and symptoms such as sputum, sore throat, headache, hemoptysis, nausea, and diarrhea. According to the severity of these symptoms, the coronavirus infection-19 may be divided into mild coronavirus infection-19 patients and severe coronavirus infection-19 patients.

본 발명의 상기 "코로나바이러스감염증-19 중증 환자"는 발열, 호흡기 증상 및 폐의 CT 촬영 이미지에 따라 분류되는 것으로서, 1) 호흡률에 따른 호흡 곤란이 30분 이상 나타나거나, 2) 휴식 상태에서 손끝의 산소 포화도가 93% 이하이거나, 3) 흡기에서 산소 분포율에 대한 동맥산소의 부분압 비율이 300 mmHg 이하이거나, 또는 4) 폐 CT 영상에서 24시간 내지 48시간 안에 명확하게 병변이 진행된 부분이 50% 이상인 경우에 해당하는 개체를 의미한다.The "coronavirus infection-19 severe patient" of the present invention is classified according to fever, respiratory symptoms, and CT scan images of the lungs. is less than 93% of oxygen saturation, 3) the ratio of partial pressure of arterial oxygen to oxygen distribution in inspiration is less than 300 mmHg, or 4) 50% of the area in which the lesion has clearly progressed within 24 to 48 hours on a lung CT image It means an object corresponding to the above cases.

본 발명의 상기 "코로나바이러스감염증-19 경증 환자"는 코로나바이러스감염증-19 중증 환자의 분류 기준에 속하지 않으면서, 일반적인 호흡기 질환의 치료제 또는 치료 방법에 의해 그 증상이 완화되어 수일 내에 완치될 수 있는 개체를 의미한다.The "coronavirus infection-19 mild patient" of the present invention does not belong to the classification criteria for severe coronavirus infection-19 patients, and the symptoms are alleviated by a treatment or treatment method for a general respiratory disease and can be cured within a few days. means an object.

본 발명의 상기 제1군 및 제2군에 포함되는 유전자; 또는 이에 의해 암호화되는 단백질은 대식세포로부터 유래된 것일 수 있다.genes included in the first and second groups of the present invention; Alternatively, the protein encoded thereby may be derived from macrophages.

본 발명의 상기 제1군에 포함되는 "FCGR1A, FCGR2A 및 FCAR" 유전자는 항체 불변 수용체를 암호화하는 유전자로서, 이와 같은 항체 불변 부위 수용체를 통해 바이러스가 면역세포 내로 유입되어 감염이 촉진되는 현상인 항체 의존적 감염 촉진을 일으킬 수 있다. 본 발명의 목적상 상기 FCGR1A, FCGR2A 및 FCAR 유전자; 또는 이에 의해 암호화되는 단백질은 코로나바이러스감염증-19 경증 환자에 비하여 코로나바이러스감염증-19 중증 환자에서 발현 수준이 증가된 것일 수 있으나, 이에 제한되는 것은 아니다.The "FCGR1A, FCGR2A, and FCAR" genes included in the first group of the present invention are genes encoding antibody constant receptors, and the virus is introduced into immune cells through such antibody constant region receptors to promote infection. May cause dependent infection promotion. For the purposes of the present invention, the FCGR1A, FCGR2A and FCAR genes; Alternatively, the protein encoded by this may have an increased expression level in patients with severe COVID-19 compared to patients with mild COVID-19, but is not limited thereto.

본 발명의 상기 FCGR1A 유전자는 서열번호 1로 표시되는 염기서열로 이루어진 것일 수 있고, FCGR1A 유전자에 의해 암호화되는 단백질은 서열번호 2로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The FCGR1A gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 1, and the protein encoded by the FCGR1A gene may consist of the amino acid sequence shown in SEQ ID NO: 2, but is not limited thereto.

본 발명의 상기 FCGR2A 유전자는 서열번호 3으로 표시되는 염기서열로 이루어진 것일 수 있고, FCGR2A 유전자에 의해 암호화되는 단백질은 서열번호 4로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The FCGR2A gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 3, and the protein encoded by the FCGR2A gene may consist of the amino acid sequence shown in SEQ ID NO: 4, but is not limited thereto.

본 발명의 상기 FCAR 유전자는 서열번호 5로 표시되는 염기서열로 이루어진 것일 수 있고, FCAR 유전자에 의해 암호화되는 단백질은 서열번호 6으로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The FCAR gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 5, and the protein encoded by the FCAR gene may consist of the amino acid sequence shown in SEQ ID NO: 6, but is not limited thereto.

본 발명의 상기 제2군에 포함되는 "TNFSF13B 및 TNFSF13" 유전자는 각각 B세포활성인자(B cell-activating factor; BAFF) 및 증식유도리간드(A proliferation-inducing ligand; APRIL)를 암호화하는 유전자로서, 대식세포에서 이와 같은 유전자가 발현됨으로써 B 세포를 활성화시킬 수 있다. 본 발명의 목적상 코로나바이러스감염증-19 경증 환자에 비하여 코로나바이러스감염증-19 중증 환자에서 상기 TNFSF13B 유전자; 또는 이에 의해 암호화되는 단백질은 발현 수준이 증가되고, TNFSF13 유전자; 또는 이에 의해 암호화되는 단백질은 발현 수준이 감소된 것일 수 있으나, 이에 제한되는 것은 아니다.The "TNFSF13B and TNFSF13" genes included in the second group of the present invention are genes encoding a B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), respectively, Expression of these genes in macrophages can activate B cells. For the purpose of the present invention, the TNFSF13B gene in patients with severe coronavirus infection-19 compared to patients with mild COVID-19; or the protein encoded thereby has an increased expression level, TNFSF13 gene; Or the protein encoded thereby may have a reduced expression level, but is not limited thereto.

본 발명의 상기 TNFSF13B 유전자는 서열번호 7로 표시되는 염기서열로 이루어진 것일 수 있고, TNFSF13B 유전자에 의해 암호화되는 단백질은 서열번호 8로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The TNFSF13B gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 7, and the protein encoded by the TNFSF13B gene may consist of the amino acid sequence shown in SEQ ID NO: 8, but is not limited thereto.

본 발명의 상기 TNFSF13 유전자는 서열번호 9로 표시되는 염기서열로 이루어진 것일 수 있고, TNFSF13 유전자에 의해 암호화되는 단백질은 서열번호 10으로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The TNFSF13 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 9, and the protein encoded by the TNFSF13 gene may consist of the amino acid sequence shown in SEQ ID NO: 10, but is not limited thereto.

본 발명의 상기 제3군 및 제4군에 포함되는 유전자; 또는 이에 의해 암호화되는 단백질은 B세포로부터 유래된 것일 수 있다.genes included in the third and fourth groups of the present invention; Alternatively, the protein encoded thereby may be derived from B cells.

본 발명의 상기 제3군에 포함되는 "IGHG1, IGHG2, IGHG3, IGHG4 및 IGHA1" 유전자는 활성화된 B 세포에서 발현되는 면역글로불린 유전자로서, 항원이 존재하는 경우 B 세포가 활성화되어 이와 같은 항원을 인지함으로써 발현된다. 본 발명의 목적상 코로나바이러스감염증-19 경증 환자에 비하여 코로나바이러스감염증-19 중증 환자에서 상기 IGHG1, IGHG2, IGHG3, IGHG4 및 IGHA1에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준이 증가된 것일 수 있으나, 이에 제한되는 것은 아니다.The "IGHG1, IGHG2, IGHG3, IGHG4 and IGHA1" genes included in the third group of the present invention are immunoglobulin genes expressed in activated B cells. is expressed by For the purpose of the present invention, at least one gene selected from IGHG1, IGHG2, IGHG3, IGHG4 and IGHA1 in patients with severe coronavirus infection-19 compared to patients with mild COVID-19; Or the expression level of the protein encoded thereby may be increased, but is not limited thereto.

본 발명의 IGHG1 유전자는 서열번호 11로 표시되는 염기서열로 이루어진 것일 수 있고, IGHG1 유전자에 의해 암호화되는 단백질은 서열번호 12로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The IGHG1 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 11, and the protein encoded by the IGHG1 gene may consist of the amino acid sequence shown in SEQ ID NO: 12, but is not limited thereto.

본 발명의 IGHG2 유전자는 서열번호 13으로 표시되는 염기서열로 이루어진 것일 수 있고, IGHG2 유전자에 의해 암호화되는 단백질은 서열번호 14로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The IGHG2 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 13, and the protein encoded by the IGHG2 gene may consist of the amino acid sequence shown in SEQ ID NO: 14, but is not limited thereto.

본 발명의 IGHG3 유전자는 서열번호 15로 표시되는 염기서열로 이루어진 것일 수 있고, IGHG3 유전자에 의해 암호화되는 단백질은 서열번호 16으로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The IGHG3 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 15, and the protein encoded by the IGHG3 gene may consist of the amino acid sequence shown in SEQ ID NO: 16, but is not limited thereto.

본 발명의 IGHG4 유전자는 서열번호 17로 표시되는 염기서열로 이루어진 것일 수 있고, IGHG4 유전자에 의해 암호화되는 단백질은 서열번호 18로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The IGHG4 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 17, and the protein encoded by the IGHG4 gene may consist of the amino acid sequence shown in SEQ ID NO: 18, but is not limited thereto.

본 발명의 IGHA1 유전자는 서열번호 19로 표시되는 염기서열로 이루어진 것일 수 있고, IGHA1 유전자에 의해 암호화되는 단백질은 서열번호 20으로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The IGHA1 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 19, and the protein encoded by the IGHA1 gene may consist of the amino acid sequence shown in SEQ ID NO: 20, but is not limited thereto.

본 발명의 상기 제4군에 포함되는 "CD69 및 FOS " 유전자는 대식세포에서 발현되는 B세포활성인자 및 증식유도리간드를 통해 활성화된 B 세포에서 발현되는 유전자로서, 본 발명의 목적상 코로나바이러스감염증-19 경증 환자에 비하여 코로나바이러스감염증-19 중증 환자에서, CD69 및 FOS에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준이 증가된 것일 수 있으나, 이에 제한되는 것은 아니다.The "CD69 and FOS" genes included in the fourth group of the present invention are genes expressed in B cells activated through B cell activator and proliferation inducing ligand expressed in macrophages, and for the purpose of the present invention, coronavirus infection - at least one or more genes selected from CD69 and FOS in patients with severe COVID-19 compared to patients with mild -19; Or the expression level of the protein encoded thereby may be increased, but is not limited thereto.

본 발명의 상기 CD69 유전자는 서열번호 21로 표시되는 염기서열로 이루어진 것일 수 있고, CD69 유전자에 의해 암호화되는 단백질은 서열번호 22로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The CD69 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 21, and the protein encoded by the CD69 gene may consist of the amino acid sequence shown in SEQ ID NO: 22, but is not limited thereto.

본 발명의 상기 FOS 유전자는 서열번호 23으로 표시되는 염기서열로 이루어진 것일 수 있고, FOS 유전자에 의해 암호화되는 단백질은 서열번호 24로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The FOS gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 23, and the protein encoded by the FOS gene may consist of the amino acid sequence shown in SEQ ID NO: 24, but is not limited thereto.

본 발명의 상기 제5군에 포함되는 유전자; 또는 이에 의해 암호화되는 단백질은 플라즈마 세포로부터 유래된 것일 수 있다.genes included in the fifth group of the present invention; Alternatively, the protein encoded thereby may be derived from a plasma cell.

본 발명의 상기 제5군에 포함되는 "CCR7, CXCR3, CCR2, CCR10 및 CCR4" 유전자는 활성화된 B 세포가 분화된 형태에 해당하는 플라즈마 세포에서 발현되는 케모카인 수용체를 암호화하는 유전자로서, 본 발명의 목적상 코로나바이러스감염증-19 경증 환자에 비하여 코로나바이러스감염증-19 중증 환자에서, CCR7, CCR4 및 CXCR3에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준이 감소된 것일 수 있고, CCR2 및 CCR10 에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준이 증가된 것일 수 있으나, 이에 제한되는 것은 아니다. 본 발명의 목적상 상기 제5군에 포함되는 케모카인 및 이를 암호화하는 유전자의 발현 수준의 비교는 코로나바이러스감염증-19 경증 및 중증 환자에 존재하는 플라즈마 세포의 수를 기준으로 일반화하여 측정된 값을 통해 비교되는 것일 수 있으나, 이에 제한되는 것은 아니다.The "CCR7, CXCR3, CCR2, CCR10 and CCR4" genes included in the fifth group of the present invention are genes encoding chemokine receptors expressed in plasma cells corresponding to the differentiated form of activated B cells. At least one or more genes selected from CCR7, CCR4 and CXCR3 in patients with severe COVID-19 compared to patients with mild COVID-19 for purpose; Or the expression level of the protein encoded thereby may be reduced, and at least one gene selected from CCR2 and CCR10; Or the expression level of the protein encoded thereby may be increased, but is not limited thereto. For the purpose of the present invention, the comparison of the expression level of the chemokines included in the fifth group and the genes encoding them is based on the number of plasma cells present in mild and severe patients with coronavirus infection-19. It may be compared, but is not limited thereto.

본 발명의 상기 CCR7 유전자는 서열번호 25로 표시되는 염기서열로 이루어진 것일 수 있고, CCR7 유전자에 의해 암호화되는 단백질은 서열번호 26으로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The CCR7 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 25, and the protein encoded by the CCR7 gene may consist of the amino acid sequence shown in SEQ ID NO: 26, but is not limited thereto.

본 발명의 상기 CXCR3 유전자는 서열번호 27로 표시되는 염기서열로 이루어진 것일 수 있고, CXCR3 유전자에 의해 암호화되는 단백질은 서열번호 28로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The CXCR3 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 27, and the protein encoded by the CXCR3 gene may consist of the amino acid sequence shown in SEQ ID NO: 28, but is not limited thereto.

본 발명의 상기 CCR2 유전자는 서열번호 29로 표시되는 염기서열로 이루어진 것일 수 있고, CCR2 유전자에 의해 암호화되는 단백질은 서열번호 30으로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The CCR2 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 29, and the protein encoded by the CCR2 gene may consist of the amino acid sequence shown in SEQ ID NO: 30, but is not limited thereto.

본 발명의 상기 CCR10 유전자는 서열번호 31로 표시되는 염기서열로 이루어진 것일 수 있고, CCR10 유전자에 의해 암호화되는 단백질은 서열번호 32로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The CCR10 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 31, and the protein encoded by the CCR10 gene may consist of the amino acid sequence shown in SEQ ID NO: 32, but is not limited thereto.

본 발명의 상기 CCR4 유전자는 서열번호 33으로 표시되는 염기서열로 이루어진 것일 수 있고, CCR4 유전자에 의해 암호화되는 단백질은 서열번호 34로 표시되는 아미노산 서열로 이루어진 것일 수 있으나, 이에 제한되는 것은 아니다.The CCR4 gene of the present invention may consist of the nucleotide sequence shown in SEQ ID NO: 33, and the protein encoded by the CCR4 gene may consist of the amino acid sequence shown in SEQ ID NO: 34, but is not limited thereto.

본 발명의 상기 조성물은 상기 유전자; 및 이에 의해 암호화되는 단백질의 발현 수준을 통해 코로나바이러스감염증-19 경증 환자에 비하여 코로나바이러스감염증-19 중증 환자에서 B 세포가 활성화되어 있으며, 플라즈마 세포의 형태가 중증 및 경증 환자에서 서로 다른 것을 알 수 있다. 따라서, 이를 통해 코로나바이러스감염증-19 중증 환자를 매우 효과적으로 진단해 낸 뒤에, 이에 따라 적절한 처치를 최적의 시기에 시도하여 코로나바이러스감염증-19에 의한 치사율을 매우 효과적으로 낮출 수 있다.The composition of the present invention comprises the gene; And through the expression level of the protein encoded by it, B cells are activated in patients with severe coronavirus infection-19 compared to patients with mild COVID-19, and it can be seen that the form of plasma cells is different in patients with severe and mild cases. have. Therefore, after very effectively diagnosing a patient with severe COVID-19, it is possible to very effectively lower the fatality rate due to COVID-19 by attempting appropriate treatment at the optimal time.

본 발명의 상기 "진단"은 병리 상태의 존재 또는 특징을 확인하는 것을 의미한다. 본 발명의 목적상, 상기 진단은 코로나바이러스감염증-19 중증 환자인지 여부 또는, 그 가능성을 예상하는 것으로서, 본 발명의 유전자 또는 이에 의해 암호화되는 단백질의 발현 수준 측정을 통해 상기 질환의 중증 여부 또는 가능성을 매우 효과적으로 예상할 수 있다.The "diagnosis" of the present invention means identifying the presence or characteristics of a pathological condition. For the purpose of the present invention, the diagnosis is to predict whether or not a patient with severe coronavirus infection-19, or the possibility thereof, and whether the disease is severe or likely by measuring the expression level of the gene of the present invention or a protein encoded by it can be predicted very effectively.

본 발명의 상기 유전자의 발현 수준을 측정할 수 있는 제제는 본 발명의 상기 유전자와 상보적으로 결합하여 그 발현 수준을 측정할 수 있는 것이라면 제한되지 않고 모두 포함될 수 있다. 예를 들면, 상기 유전자의 발현 수준을 측정할 수 있는 제제는 상기 유전자에 상보적으로 결합하는 프라이머, 프로브 및 안티센스 뉴클레오티드로 이루어진 군으로부터 선택되는 적어도 하나인 것일 수 있다.The agent capable of measuring the expression level of the gene of the present invention is not limited as long as it can measure the expression level by complementary binding to the gene of the present invention. For example, the agent capable of measuring the expression level of the gene may be at least one selected from the group consisting of a primer, a probe, and an antisense nucleotide complementary to the gene.

본 발명의 상기 "프라이머"는 표적 유전자 서열을 인지하는 단편으로서, 정방향 및 역방향의 프라이머 쌍을 포함하나, 바람직하게는, 특이성 및 민감성을 가지는 분석 결과를 제공하는 프라이머 쌍이다. 프라이머의 핵산 서열이 시료 내 존재하는 비-표적 서열과 불일치하는 서열이어서, 상보적인 프라이머 결합 부위를 함유하는 표적 유전자 서열만 증폭하고 비특이적 증폭을 유발하지 않는 프라이머일 때, 높은 특이성이 부여될 수 있다.The "primer" of the present invention is a fragment recognizing a target gene sequence, and includes a pair of forward and reverse primers, but preferably, a primer pair that provides analysis results having specificity and sensitivity. High specificity can be conferred when the primer's nucleic acid sequence is a sequence that is inconsistent with a non-target sequence present in the sample, thus amplifying only the target gene sequence containing the complementary primer binding site and not causing non-specific amplification. .

본 발명의 상기 "프로브"란 시료 내의 검출하고자 하는 표적 물질과 상보적으로 결합할 수 있는 물질을 의미하며, 상기 결합을 통하여 특이적으로 시료 내의 표적 물질의 존재를 확인할 수 있는 물질을 의미한다. 프로브의 종류는 당업계에서 통상적으로 사용되는 물질로서 제한은 없으나, 바람직하게는 PNA(peptide nucleic acid), LNA(locked nucleic acid), 펩타이드, 폴리펩타이드, 단백질, RNA 또는 DNA일 수 있으며, 가장 바람직하게는 PNA이다. 보다 구체적으로, 상기 프로브는 바이오 물질로서 생물에서 유래되거나 이와 유사한 것 또는 생체 외에서 제조된 것을 포함하는 것으로, 예를 들어, 효소, 단백질, 항체, 미생물, 동식물 세포 및 기관, 신경세포, DNA, 및 RNA일 수 있으며, DNA는 cDNA, 게놈 DNA, 올리고뉴클레오타이드를 포함하며, RNA는 게놈 RNA, mRNA, 올리고뉴클레오타이드를 포함한다.The "probe" of the present invention means a substance capable of complementary binding to a target substance to be detected in a sample, and means a substance capable of specifically confirming the presence of a target substance in the sample through the binding. The type of probe is not limited as a material commonly used in the art, but preferably PNA (peptide nucleic acid), LNA (locked nucleic acid), peptide, polypeptide, protein, RNA or DNA, and most preferably It is PNA. More specifically, the probe is a biomaterial derived from or similar thereto, or manufactured in vitro, and includes, for example, enzymes, proteins, antibodies, microorganisms, animal and plant cells and organs, neurons, DNA, and It may be RNA, and DNA includes cDNA, genomic DNA, and oligonucleotides, and RNA includes genomic RNA, mRNA, and oligonucleotides.

본 발명의 상기 "LNA(Locked nucleic acids)"란, 2'-O, 4'-C 메틸렌 브릿지를 포함하는 핵산 아날로그를 의미한다 [J Weiler, J Hunziker and J Hall Gene Therapy (2006) 13, 496.502]. LNA 뉴클레오사이드는 DNA와 RNA의 일반적 핵산 염기를 포함하며, Watson-Crick 염기 쌍 규칙에 따라 염기 쌍을 형성할 수 있다. 하지만, 메틸렌 브릿지로 인한 분자의 'locking'으로 인해, LNA는 왓슨-크릭 결합에서 이상적 형상을 형성하지 못하게 된다. LNA가 DNA 또는 RNA 올리고뉴클레오티드에 포함되면, LNA는 보다 빠르게 상보적 뉴클레오티드 사슬과 쌍을 이루어 이중 나선의 안정성을 높일 수 있다.The "LNA (Locked nucleic acids)" of the present invention means a nucleic acid analog comprising a 2'-O, 4'-C methylene bridge [J Weiler, J Hunziker and J Hall Gene Therapy (2006) 13, 496.502) ]. LNA nucleosides include common nucleic acid bases in DNA and RNA, and can form base pairs according to Watson-Crick base pairing rules. However, due to the 'locking' of the molecule due to the methylene bridge, the LNA does not form an ideal shape at the Watson-Crick bond. When LNA is incorporated into DNA or RNA oligonucleotides, LNA can pair with complementary nucleotide chains more rapidly, increasing the stability of the double helix.

본 발명의 상기 "안티센스 뉴클레오티드"는 안티센스 올리고머가 왓슨-크릭 염기쌍 형성에 의해 RNA 내의 표적 서열과 혼성화되어, 표적서열 내에서 전형적으로 mRNA와 RNA:올리고머 헤테로 이중체의 형성을 허용하는, 뉴클레오티드 염기서열 및 서브유닛간 백본을 갖는 올리고머를 의미한다. 올리고머는 표적 서열에 대한 정확한 서열 상보성 또는 근사 상보성을 가질 수 있다.The "antisense nucleotide" of the present invention is a nucleotide sequence in which an antisense oligomer is hybridized with a target sequence in RNA by Watson-Crick base pairing, typically mRNA and RNA: oligomeric heteroduplex formation in the target sequence. and oligomers having an inter-subunit backbone. An oligomer may have exact sequence complementarity or approximate complementarity to a target sequence.

본 발명의 상기 유전자의 발현 수준을 측정할 수 있는 제제는 본 발명의 상기 유전자들의 염기서열을 토대로, 통상의 기술자에 의해 상기 유전자에 상보적으로 결합하는 프라이머, 프로브 등에 해당하는 상기 제제가 쉽게 제작될 수 있다.The agent capable of measuring the expression level of the gene of the present invention is based on the nucleotide sequence of the gene of the present invention, and the agent corresponding to the primer, probe, etc. that complementarily binds to the gene can be easily prepared by a person skilled in the art. can be

본 발명의 상기 단백질의 발현 수준을 측정할 수 있는 제제는 상기 단백질에 특이적으로 결합하여 그 단백질의 발현 수준을 측정할 수 있는 제제라면 제한되지 않는다. 예를 들면, 상기 단백질의 발현 수준을 측정할 수 있는 제제는 상기 단백질에 특이적으로 결합하는 항체, 올리고펩타이드, 리간드, PNA(Peptide nucleic acid) 및 앱타머(Aptamer)로 이루어진 군으로부터 선택되는 적어도 하나인 것일 수 있다.The agent capable of measuring the expression level of the protein of the present invention is not limited as long as it is an agent capable of measuring the expression level of the protein by specifically binding to the protein. For example, the agent capable of measuring the expression level of the protein is at least selected from the group consisting of an antibody, oligopeptide, ligand, PNA (Peptide nucleic acid) and aptamer that specifically binds to the protein. may be one.

본 발명의 상기 "항체"는 항원과 특이적으로 결합하여 항원-항체 반응을 일으키는 물질을 가리킨다. 본 발명의 목적상, 항체는 상기 단백질에 대해 특이적으로 결합하는 항체를 의미한다. 본 발명의 항체는 다클론 항체, 단일클론 항체 및 재조합 항체를 모두 포함한다. 상기 항체는 당업계에 널리 공지된 기술을 이용하여 용이하게 제조될 수 있다. 예를 들어, 다클론 항체는 상기 단백질의 항원을 동물에 주사하고 동물로부터 채혈하여 항체를 포함하는 혈청을 수득하는 과정을 포함하는 당업계에 널리 공지된 방법에 의해 생산될 수 있다. 이러한 다클론 항체는 염소, 토끼, 양, 원숭이, 말, 돼지, 소, 개 등의 임의의 동물로부터 제조될 수 있다. 또한, 단일클론 항체는 당업계에 널리 공지된 하이브리도마 방법(hybridoma method; Kohler 및 Milstein (1976) European Journal of Immunology 6:511-519 참조), 또는 파지 항체 라이브러리 기술(Clackson et al, Nature, 352:624-628, 1991; Marks et al, J. Mol. Biol., 222:58, 1-597, 1991 참조)을 이용하여 제조될 수 있다. 상기 방법으로 제조된 항체는 겔 전기영동, 투석, 염 침전, 이온교환 크로마토그래피, 친화성 크로마토그래피 등의 방법을 이용하여 분리, 정제될 수 있다. 또한, 본 발명의 항체는 2개의 전장의 경쇄 및 2개의 전장의 중쇄를 갖는 완전한 형태뿐만 아니라, 항체의 기능적인 단편을 포함한다.The "antibody" of the present invention refers to a substance that specifically binds to an antigen and causes an antigen-antibody reaction. For the purposes of the present invention, an antibody refers to an antibody that specifically binds to said protein. Antibodies of the present invention include polyclonal antibodies, monoclonal antibodies and recombinant antibodies. The antibody can be readily prepared using techniques well known in the art. For example, the polyclonal antibody can be produced by a method well known in the art, including the process of injecting an antigen of the protein into an animal and collecting blood from the animal to obtain a serum containing the antibody. Such polyclonal antibodies can be prepared from any animal such as goat, rabbit, sheep, monkey, horse, pig, cow, dog, and the like. In addition, monoclonal antibodies can be prepared using the hybridoma method well known in the art (see Kohler and Milstein (1976) European Journal of Immunology 6:511-519), or the phage antibody library technology (Clackson et al, Nature, 352:624-628, 1991; Marks et al, J. Mol. Biol., 222:58, 1-597, 1991). The antibody prepared by the above method may be separated and purified using methods such as gel electrophoresis, dialysis, salt precipitation, ion exchange chromatography, and affinity chromatography. In addition, the antibody of the present invention includes a complete form having two full-length light chains and two full-length heavy chains, as well as functional fragments of the antibody.

본 발명의 상기 항체의 기능적인 단편이란, 적어도 항원 결합 기능을 보유하고 있는 단편을 의미하며, Fab, F(ab'), F(ab')2 및 Fv 등이 있다.The functional fragment of the antibody of the present invention means a fragment having at least an antigen-binding function, and includes Fab, F(ab'), F(ab')2 and Fv.

본 발명에 상기 "PNA(Peptide Nucleic Acid)"는 인공적으로 합성된, DNA 또는 RNA와 비슷한 중합체를 가리키며, 1991년 덴마크 코펜하겐 대학교의 Nielsen, Egholm, Berg와 Buchardt 교수에 의해 처음으로 소개되었다. DNA는 인산-리보스당 골격을 갖는데 반해, PNA는 펩타이드 결합에 의해 연결된 반복된 N-(2-아미노에틸)-글리신 골격을 가지며, 이로 인해 DNA 또는 RNA에 대한 결합력과 안정성이 크게 증가되어 분자 생물학, 진단 분석 및 안티센스 치료법에 사용되고 있다. PNA는 문헌[Nielsen PE, Egholm M, Berg RH, Buchardt O (December 1991). "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide". Science 254 (5037): 1497-1500]에 상세하게 개시되어 있다.In the present invention, the "PNA (Peptide Nucleic Acid)" refers to an artificially synthesized polymer similar to DNA or RNA, and was first introduced by Professors Nielsen, Egholm, Berg and Buchardt of the University of Copenhagen, Denmark in 1991. Whereas DNA has a phosphate-ribose sugar backbone, PNA has a repeated N-(2-aminoethyl)-glycine backbone linked by peptide bonds, which greatly increases binding strength and stability to DNA or RNA, resulting in molecular biology , diagnostic assays and antisense therapy. PNA is described in Nielsen PE, Egholm M, Berg RH, Buchardt O (December 1991). "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide". Science 254 (5037): 1497-1500.

본 발명의 상기 "앱타머"는 올리고핵산 또는 펩타이드 분자이며, 앱타머의 일반적인 내용은 문헌[Bock LC et al., Nature 355(6360):5646(1992); Hoppe-Seyler F, Butz K "Peptide aptamers: powerful new tools for molecular medicine". J Mol Med. 78(8):42630(2000); Cohen BA, Colas P, Brent R. "An artificial cell-cycle inhibitor isolated from a combinatorial library". Proc Natl Acad Sci USA. 95(24): 142727(1998)]에 상세하게 개시되어 있다.The "aptamer" of the present invention is an oligonucleic acid or peptide molecule, and the general description of the aptamer is described in Bock LC et al., Nature 355(6360):5646(1992); Hoppe-Seyler F, Butz K "Peptide aptamers: powerful new tools for molecular medicine". J Mol Med. 78(8):42630(2000); Cohen BA, Colas P, Brent R. "An artificial cell-cycle inhibitor isolated from a combinatorial library". Proc Natl Acad Sci USA. 95(24): 142727 (1998).

본 발명의 상기 단백질의 발현 수준을 측정할 수 있는 제제는 본 발명의 상기 단백질들을 이루는 아미노산 서열을 토대로, 통상의 기술자에 의해 상기 단백질에 특이적으로 결합하는 항체, PNA 및 앱타머 등에 해당하는 상기 제제가 쉽게 제작될 수 있다.The agent capable of measuring the expression level of the protein of the present invention is based on the amino acid sequence constituting the proteins of the present invention, which corresponds to an antibody, PNA, and aptamer that specifically binds to the protein by those skilled in the art. The formulation can be easily manufactured.

본 발명의 다른 구현 예에서는 코로나바이러스감염증-19 중증 환자의 진단용 키트를 제공한다.Another embodiment of the present invention provides a kit for diagnosing a patient with severe COVID-19.

본 발명의 상기 키트는 코로나바이러스감염증-19 중증 환자의 진단용 조성물을 포함한다.The kit of the present invention includes a composition for diagnosis of a patient with severe COVID-19.

본 발명의 상기 키트에서, 제1군 내지 제5군에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질, 코로나바이러스감염증-19, 코로나바이러스감염증-19 중증 환자, 코로나바이러스감염증-19 경증 환자, 유전자의 발현 수준을 측정할 수 있는 제제, 단백질의 발현 수준을 측정할 수 있는 제제 등과 관련된 내용은 앞서 기재된 바와 동일하여, 명세서의 과도한 복잡성을 피하기 위해 생략한다.In the kit of the present invention, at least one or more genes selected from the first to fifth groups; Or a protein encoded by it, coronavirus infection-19, coronavirus infection-19 severe patient, coronavirus infection-19 mild patient, agent capable of measuring the expression level of the gene, agent capable of measuring the expression level of the protein Contents related to and the like are the same as described above, and are omitted to avoid excessive complexity of the specification.

본 발명의 상기 키트는 RT-PCR 키트, DNA 칩 키트, ELISA 키트, 단백질 칩 키트, 래피드(rapid) 키트 또는 MRM(Multiple reaction monitoring) 키트일 수 있으나, 이에 제한되는 것은 아니다.The kit of the present invention may be an RT-PCR kit, a DNA chip kit, an ELISA kit, a protein chip kit, a rapid kit, or a multiple reaction monitoring (MRM) kit, but is not limited thereto.

본 발명의 상기 키트는 분석 방법에 적합한 한 종류 또는 그 이상의 다른 구성 성분 조성물, 용액 또는 장치를 더 포함할 수 있다. 예를 들면, 본 발명의 진단용 키트는 역전사 중합효소반응을 수행하기 위해 필요한 필수 요소를 더 포함할 수 있다. 역전사 중합효소반응 키트는 단백질을 코딩하는 유전자에 대해 특이적인 프라이머 쌍을 포함한다. 프라이머는 상기 유전자의 핵산서열에 특이적인 서열을 가지는 뉴클레오티드로서, 약 7 bp 내 지 50 bp의 길이, 보다 바람직하게는 약 10 bp 내지 30 bp의 길이를 가질 수 있다. 또한 대조군 유전자의 핵산 서열에 상보적인 프라이머를 포함할 수 있다. 그 외 역전사 중합효소반응 키트는 테스트 튜브 또는 다른 적절한 용기, 반응 완충액(pH 및 마그네슘 농도는 다양), 데옥시뉴클레오타이드(dNTPs), Taq-폴리머라아제 및 역전사효소와 같은 효소, DNase, RNase 억제제 DEPC-수(DEPC-water), 멸균수 등을 포함할 수 있다.The kit of the present invention may further include one or more other component compositions, solutions or devices suitable for the assay method. For example, the diagnostic kit of the present invention may further include essential elements necessary for performing the reverse transcription polymerase reaction. The reverse transcription polymerase reaction kit includes a pair of primers specific for the gene encoding the protein. The primer is a nucleotide having a sequence specific to the nucleic acid sequence of the gene, and may have a length of about 7 bp to 50 bp, more preferably, about 10 bp to 30 bp. It may also include a primer complementary to the nucleic acid sequence of the control gene. Other reverse transcription polymerase reaction kits include test tubes or other suitable containers, reaction buffers (with varying pH and magnesium concentrations), deoxynucleotides (dNTPs), enzymes such as Taq-polymerase and reverse transcriptase, DNase, RNase inhibitor DEPC -Water (DEPC-water), sterile water, etc. may be included.

본 발명의 진단용 키트는 DNA 칩을 수행하기 위해 필요한 필수 요소를 포함할 수 있다. DNA 칩 키트는 유전자 또는 그의 단편에 해당하는 cDNA 또는 올리고뉴클레오티드(oligonucleotide)가 부착되어 있는 기판, 및 형광표지 프로브를 제작하기 위한 시약, 제제, 효소 등을 포함할 수 있다. 또한 기판은 대조군 유전자 또는 그의 단편에 해당하는 cDNA 또는 올리고뉴클레오티드를 포함할 수 있다.The diagnostic kit of the present invention may include essential elements necessary for performing a DNA chip. The DNA chip kit may include a substrate to which cDNA or oligonucleotide corresponding to a gene or fragment thereof is attached, and reagents, agents, enzymes, etc. for preparing a fluorescently-labeled probe. The substrate may also contain cDNA or oligonucleotides corresponding to control genes or fragments thereof.

본 발명의 진단용 키트는 ELISA를 수행하기 위해 필요한 필수 요소를 포함할 수 있다. ELISA 키트는 상기 단백질에 대해 특이적인 항체를 포함한다. 항체는 마커 단백질에 대한 특이성 및 친화성이 높고 다른 단백질에 대한 교차 반응성이 거의 없는 항체로, 단클론 항체, 다클론 항체 또는 재조합 항체이다. 또한 ELISA 키트는 대조군 단백질에 특이적인 항체를 포함할 수 있다. 그 외 ELISA 키트는 결합된 항체를 검출할 수 있는 시약, 예를 들면, 표지된 2차 항체, 발색단(chromophores), 효소(예: 항체와 컨주게이트됨) 및 그의 기질 또는 항체와 결합할 수 있는 다른 물질 등을 포함할 수 있다.The diagnostic kit of the present invention may include essential elements necessary for performing ELISA. The ELISA kit contains an antibody specific for this protein. Antibodies are antibodies with high specificity and affinity for a marker protein and little cross-reactivity with other proteins, and are monoclonal antibodies, polyclonal antibodies, or recombinant antibodies. The ELISA kit may also include an antibody specific for a control protein. Other ELISA kits include reagents capable of detecting bound antibody, for example, labeled secondary antibodies, chromophores, enzymes (eg, conjugated with an antibody) and their substrates or capable of binding the antibody. other materials and the like.

본 발명의 또 다른 구현 예에서는 코로나바이러스감염증-19 중증 환자를 진단하기 위한 정보 제공 방법을 제공한다.Another embodiment of the present invention provides a method for providing information for diagnosing a patient with severe COVID-19.

본 발명의 상기 정보 제공 방법은 목적하는 개체로부터 분리된 생물학적 시료에서, 하기 제1군 내지 제5군에서 선택되는 적어도 하나 이상의 유전자; 또는 이를 암호화하는 단백질의 발현 수준을 측정하는 단계를 포함한다:The information providing method of the present invention, in a biological sample isolated from a target individual, at least one or more genes selected from the following first to fifth groups; or measuring the expression level of a protein encoding it:

제1군: FCGR1A, FCGR2A 및 FCARGroup 1: FCGR1A, FCGR2A and FCAR

제2군: TNFSF13B 및 TNFSF13Group 2: TNFSF13B and TNFSF13

제3군: IGHG1, IGHG2, IGHG3, IGHG4 및 IGHA1Group 3: IGHG1, IGHG2, IGHG3, IGHG4 and IGHA1

제4군: CD69 및 FOSGroup 4: CD69 and FOS

제5군: CCR7, CXCR3, CCR2, CCR10 및 CCR4Group 5: CCR7, CXCR3, CCR2, CCR10 and CCR4

본 발명의 상기 정보 제공 방법에서, 제1군 내지 제5군에서 선택되는 적어도 하나 이상의 유전자 또는 이에 의해 암호화되는 단백질, 코로나바이러스감염증-19, 코로나바이러스감염증-19 중증 환자, 코로나바이러스감염증-19 경증 환자, 프라이머, 프로브, 안티센스 뉴클레오티드, 항체 등과 관련된 내용은 앞서 기재된 바와 동일하여, 명세서의 과도한 복잡성을 피하기 위해 생략한다.In the information providing method of the present invention, at least one or more genes selected from group 1 to group 5 or a protein encoded by it, coronavirus infection-19, severe coronavirus infection-19 patient, mild coronavirus infection-19 Contents related to patients, primers, probes, antisense nucleotides, antibodies, etc. are the same as those described above, and thus are omitted to avoid excessive complexity of the specification.

본 발명의 상기 정보 제공 방법에서, 대조군과 비교하여 상기 TNFSF13, CCR7, CCR4 및 CXCR3에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준이 감소되고, 상기 FCGR1A, FCGR2A, FCAR, TNFSF13B, IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, FOS, CCR2 및 CCR10에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준이 증가된 경우, 코로나바이러스감염증-19 중증 환자로 진단할 수 있다. 본 발명의 목적상 상기 제5군에 포함되는 케모카인 및 이를 암호화하는 유전자의 발현 수준의 비교는 코로나바이러스감염증-19 경증 및 중증 환자에 존재하는 플라즈마 세포의 수를 기준으로 일반화하여 측정된 값을 통해 비교되는 것일 수 있으나, 이에 제한되는 것은 아니다.In the information providing method of the present invention, at least one or more genes selected from TNFSF13, CCR7, CCR4 and CXCR3 compared to the control; or at least one gene selected from the group consisting of FCGR1A, FCGR2A, FCAR, TNFSF13B, IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, FOS, CCR2 and CCR10; Or, when the expression level of the protein encoded thereby is increased, it can be diagnosed as a severe patient with coronavirus infection-19. For the purpose of the present invention, the comparison of the expression level of the chemokines included in the fifth group and the genes encoding them is based on the number of plasma cells present in mild and severe patients with coronavirus infection-19. It may be compared, but is not limited thereto.

본 발명의 상기 대조군은 정상 대조군 또는 코로나바이러스감염증-19 경증 환자일 수 있고, 예를 들면, 코로나바이러스감염증-19 경증 환자일 수 있으나, 이에 제한되는 것은 아니다.The control group of the present invention may be a normal control group or a patient with mild COVID-19, for example, a patient with mild COVID-19, but is not limited thereto.

본 발명의 상기 "정상 대조군"은 진단을 위한 검사기준에 따라 감염병원체에 의한 감염이 없는 것으로 확인된 개체일 수 있고, 나아가 기타 다른 호흡기 질환이나 다른 만성 질환의 이력이 없는 개체를 의미한다.The "normal control" of the present invention may be an individual confirmed to be free of infection by an infectious pathogen according to the diagnostic test criteria, and further refers to an individual without a history of other respiratory diseases or other chronic diseases.

본 발명에서 상기 "목적하는 개체"란 코로나바이러스감염증-19의 발병 여부가 불확실한 개체로, 질환이 발병되었거나, 또는 발병 가능성이 높은 개체를 의미한다.In the present invention, the "target individual" means an individual who is uncertain whether or not the onset of coronavirus infection-19, has developed a disease, or has a high probability of onset.

본 발명의 상기 "생물학적 시료"는 개체로부터 얻어지거나 개체로부터 유래된 임의의 물질, 생물학적 체액, 조직 또는 세포를 의미하는 것으로, 예를 들면, 전혈(whole blood), 백혈구(leukocytes), 말초혈액 단핵 세포(peripheral blood mononuclear cells), 백혈구 연층(buffy coat), 혈장(plasma) 및 혈청(serum)을 포함하는) 혈액, 객담(sputum), 눈물(tears), 점액(mucus), 세비액(nasal washes), 비강 흡인물(nasal aspirate), 호흡(breath), 소변(urine), 정액(semen), 침(saliva), 복강 세척액(peritoneal washings), 골반 내 유체액(pelvic fluids), 낭종액(cystic fluid), 뇌척수막 액(meningeal fluid), 양수(amniotic fluid), 선액(glandular fluid), 췌장액(pancreatic fluid), 림프액(lymph fluid), 흉수(pleural fluid), 유두 흡인물(nipple aspirate), 기관지 흡인물(bronchial aspirate), 활액(synovial fluid), 관절 흡인물(joint aspirate), 기관 분비물(organ secretions), 세포(cell), 세포 추출물(cell extract) 또는 뇌척수액(cerebrospinal fluid)을 포함할 수 있으나, 이에 제한되는 것은 아니다.The "biological sample" of the present invention refers to any material, biological fluid, tissue or cell obtained from or derived from an individual, for example, whole blood, leukocytes, peripheral blood mononuclear blood, sputum, tears, mucus, nasal washes, including peripheral blood mononuclear cells, buffy coat, plasma and serum ), nasal aspirate, breath, urine, semen, saliva, peritoneal washings, pelvic fluids, cystic fluid, meningeal fluid, amniotic fluid, glandular fluid, pancreatic fluid, lymph fluid, pleural fluid, nipple aspirate, bronchial aspiration It may include bronchial aspirate, synovial fluid, joint aspirate, organ secretions, cell, cell extract or cerebrospinal fluid, However, the present invention is not limited thereto.

본 발명의 상기 단백질의 발현 수준을 측정하는 방법은 단백질 칩 분석, 면역측정법, 리간드 바인딩 어세이, MALDI-TOF(Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, SELDI-TOF(Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, 방사선 면역 분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 로케트 면역전기영동, 조직면역 염색, 보체 고정 분석법, 2차원 전기영동 분석, 액상 크로마토그래피-질량분석(liquid chromatography-Mass Spectrometry, LC-MS), LC-MS/MS(liquid chromatography-Mass Spectrometry/ Mass Spectrometry), 웨스턴 블랏팅 및 ELISA(enzyme linked immunosorbentassay)로 이루어진 군으로부터 선택되는 적어도 하나인 것일 수 있다.The method of measuring the expression level of the protein of the present invention is a protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Sulface Enhanced Laser) Desorption/Ionization Time of Flight Mass Spectrometry) analysis, radioimmunoassay, radioimmunodiffusion method, Oukteroni immunodiffusion method, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, 2D electrophoresis analysis, liquid chromatography-mass Analysis (liquid chromatography-Mass Spectrometry, LC-MS), LC-MS/MS (liquid chromatography-Mass Spectrometry/ Mass Spectrometry), Western blotting and ELISA (enzyme linked immunosorbent assay) may be at least one selected from the group consisting of have.

본 발명의 상기 단백질의 발현 수준은 단백질의 발현 수준을 측정할 수 있는 제제를 이용하여 측정될 수 있다. 상기 단백질의 발현 수준을 측정할 수 있는 제제는 상기 단백질에 특이적으로 결합하는 항체, 올리고펩타이드, 리간드, PNA(Peptide nucleic acid) 및 앱타머(aptamer)로 이루어진 군으로부터 선택되는 적어도 하나인 것일 수 있다.The expression level of the protein of the present invention can be measured using an agent capable of measuring the expression level of the protein. The agent capable of measuring the expression level of the protein may be at least one selected from the group consisting of an antibody, oligopeptide, ligand, PNA (peptide nucleic acid) and aptamer that specifically binds to the protein. have.

본 발명의 상기 유전자의 발현 수준을 측정하는 방법은 역전사 중합효소반응(RT-PCR), 경쟁적 역전사 중합효소반응(Competitive RT-PCR), 실시간 역전사 중합효소반응(Real-time RT-PCR), RNase 보호 분석법(RPA; RNase protection assay), 노던 블랏팅(Northern blotting) 및 DNA 칩으로 이루어진 군으로부터 선택되는 적어도 하나인 것일 수 있다.The method of measuring the expression level of the gene of the present invention is reverse transcription polymerase reaction (RT-PCR), competitive reverse transcription polymerase reaction (Competitive RT-PCR), real-time reverse transcription polymerase reaction (Real-time RT-PCR), RNase It may be at least one selected from the group consisting of a protection assay (RPA; RNase protection assay), Northern blotting, and a DNA chip.

본 발명의 상기 유전자의 발현 수준은 유전자의 발현 수준을 측정할 수 있는 제제를 이용하여 측정될 수 있다. 상기 유전자의 발현 수준을 측정할 수 있는 제제는 상기 유전자에 상보적으로 결합하는 프라이머, 프로브 및 안티센스 뉴클레오티드로 이루어진 군으로부터 선택되는 적어도 하나인 것일 수 있다.The expression level of the gene of the present invention can be measured using an agent capable of measuring the expression level of the gene. The agent capable of measuring the expression level of the gene may be at least one selected from the group consisting of primers, probes and antisense nucleotides that complementarily bind to the gene.

본 발명의 상기 정보 제공 방법에서, 코로나바이러스감염증-19 중증 환자로 진단되거나 또는 진단될 가능성이 높을 것으로 예측되는 경우, 상기 목적하는 개체에 대하여 해당 질환에 대한 약제, 예를 들면, 항체 의약품, 구체적으로 바이러스 중화 항체를 제외한 코로나바이러스감염증-19 관련 치료제 등을 투여하는 등의 적절한 치료를 수행하는 단계를 추가로 포함할 수 있다.In the method for providing information of the present invention, when a patient diagnosed with or predicted to be highly likely to be diagnosed with severe coronavirus infection-19, a drug for the target disease, for example, an antibody drug, specifically It may further include the step of performing appropriate treatment, such as administering a therapeutic agent related to coronavirus infection-19 except for the virus-neutralizing antibody.

[서열목록][Sequence List]

서열번호 1: FCGR1A mRNA 염기서열SEQ ID NO: 1: FCGR1A mRNA base sequence

AATATCTTGCATGTTACAGATTTCACTGCTCCCACCAGCTTGGAGACAACATGTGGTTCTTGACAACTCTAATATCTTGCATGTTACAGATTTCACTGCTCCCACCAGCTTGGAGACAACATGTGGTTCTTGACAACTCT

GCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGG

GTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTAGTCACGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTA

CACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGT

CAATGACAGTGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATCCAATGACATGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC

CACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTGGCCTTGAGGTCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTGGCCTTGAGGT

GTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTT

CCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGCCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGC

ATGGGAAAGCATCGCTACACATCAGCAGGAATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCATGGGAAAGCATCGCTACACATCAGCAGGAATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGC

TGAATGCATCTGTGACATCCCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTTGAATGCATCTGTGACATCCCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCT

CTTGCAGAGGCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAACCTTGCAGAGGCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC

ACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGCGAGGCTGCCAACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGCGAGGCTGCCA

CAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTGCTTGGCCTCCAGTTACCAACCAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTGCTTGGCCTCCAGTTACCAAC

TCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGAATAATGTTTTTAGTGAACACTGTTCTCTGGTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGAATAATGTTTTTAGTGAACACTGTTCTCTGG

GTGACAATACGTAAAGAACTGAAAAGAAAGAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGGTGACAATACGTAAAGAACTGAAAAGAAAGAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATG

AGAAGAAGGTAATTTCCAGCCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAAGGTAATTTCCAGCCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAA

AGAAGAACAGCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAGCAGCGGCTCAGTGGGAGAAGAACAGCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAGCAGCGGCTCAGTGGG

TGGCCATCGATCTGGACCGTCCCCTGCCCACTTGCTCCCCGTGAGCACTGCGTACAAACATCCAAAAGTTTGGCCATCGATCTGGACCGTCCCCTGCCCACTTGCTCCCCGTGAGCACTGCGTACAAACATCCAAAAGTT

CAACAACACCAGAACTGTGTGTCTCATGGTATGTAACTCTTAAAGCAAATAAATGAACTGACTTCAACTGCAACAACACCAGAACTGTGTGTCTCATGGTATGTAACTCTTAAAGCAAATAAATGAACTGACTTCAACTG

GGAGGA

서열번호 2: FCGR1A 아미노산 서열SEQ ID NO: 2: FCGR1A amino acid sequence

MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGATMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAGISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRNTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVGIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQLQEGVHRKEPQGAT

*서열번호 3: FCGR2A mRNA 염기서열*SEQ ID NO: 3: FCGR2A mRNA base sequence

ACAGTGCTGGGATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACAGTGCTGGGATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCA

ACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTG

AAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCA

GCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTA

CAGGTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCAGGTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGAC

CCTGTGCATCTGACTGTGCTTTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGCCTGTGCATCTGACTGTGCTTTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAG

AAACCATCATGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGAAACCATCATGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGG

AAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTAAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGT

GATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCTGTGACCATCACTGTCCAAGGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCTGTGACCATCACTGTCCAAG

TGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTGGCTGTGGTCATTGCGACTGCTGTAGCAGCTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTGGCTGTGGTCATTGCGACTGCTGTAGCAGC

CATTGTTGCTGCTGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTCATTGTTGCTGCTGTAGTGGCCTTGATCTACTGCAGGAAAAAAGCGGATTTCAGCCAATTCCACTGATCCT

GTGAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAAGTGAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAA

CCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGA

TAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAAAGAGTAACGTTATGCTAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAAAGAGTAACGTTATGC

CATGTGGTCATACTCTCAGCTTGCTGAGTGGATGACAAAAAGAGGGGAATTGTTAAAGGAAAATTTAAATCATGTGGTCATACTCTCAGCTTGCTGAGTGGATGACAAAAAGAGGGGAATTGTTAAAGGAAAATTTAAAT

GGAGACTGGAAAAATCCTGAGCAAACAAAACCACCTGGCCCTTAGAAATAGCTTTAACTTTGCTTAAACTGGAGACTGGAAAAATCCTGAGCAAACAAAACCACCTGGCCCTTAGAAATAGCTTTAACTTTGCTTAAACT

ACAAACACAAGCAAAACTTCACGGGGTCATACTACATACAAGCATAAGCAAAACTTAACTTGGATCATTTACAAACACAAGCAAAACTTCACGGGGTCATACTACATACAAGCATAAGCAAAACTTAACTTGGATCATTT

CTGGTAAATGCTTATGTTAGAAATAAGACAACCCCAGCCAATCACAAGCAGCCTACTAACATATAATTAGCTGGTAAATGCTTATGTTAGAAATAAGACAACCCCAGCCAATCACAAGCAGCCTACTAACATATAATTAG

GTGACTAGGGACTTTCTAAGAAGATACCTACCCCCAAAAAACAATTATGTAATTGAAAACCAACCGATTGGTGACTAGGGACTTTCTAAGAAGATACCTACCCCCAAAAAACAATTATGTAATTGAAAACCAACCGATTG

CCTTTATTTTGCTTCCACATTTTCCCAATAAATACTTGCCTGTGACATTTTGCCACTGGAACACTAAACTCCTTTATTTTGCTTCCACATTTTCCCAATAAATACTTGCCTGTGACATTTTGCCACTGGAACACTAAACT

TCATGAATTGCGCCTCAGATTTTTCCTTTAACATCTTTTTTTTTTTTGACAGAGTCTCAATCTGTTACCCTCATGAATTGCGCCTCAGATTTTTCCTTTAACATCTTTTTTTTTTTTGACAGAGTCTCAATCTGTTACCC

AGGCTGGAGTGCAGTGGTGCTATCTTGGCTCACTGCAAACCCGCCTCCCAGGTTTAAGCGATTCTCATGCAGGCTGGAGTGCAGTGGTGCTATCTTGGCTCACTGCAAACCCGCCTCCCAGGTTTAAGCGATTCTCATGC

CTCAGCCTCCCAGTAGCTGGGATTAGAGGCATGTGCCATCATACCCAGCTAATTTTTGTATTTTTTATTTCTCAGCCTCCCAGTAGCTGGGATTAGAGGCATGTGCCATCATACCCAGCTAATTTTTGTATTTTTTATTT

TTTTTTTTTAGTAGAGACAGGGTTTCGCAATGTTGGCCAGGCCGATCTCGAACTTCTGGCCTCTAGCGATTTTTTTTTTAGTAGAGACAGGGTTTCGCAATGTTGGCCAGGCCGATCTCGAACTTCTGGCCTCTAGCGAT

CTGCCCGCCTCGGCCTCCCAAAGTGCTGGGATGACCAGCATCAGCCCCAATGTCCAGCCTCTTTAACATCCTGCCCGCCTCGGCCTCCCAAAGTGCTGGGATGACCAGCATCAGCCCCAATGTCCAGCCTCTTTAACATC

TTCTTTCCTATGCCCTCTCTGTGGATCCCTACTGCTGGTTTCTGCCTTCTCCATGCTGAGAACAAAATCATTCTTTCCTATGCCCTCTCTGTGGATCCCTACTGCTGGTTTCTGCCTTCTCCATGCTGAGAACAAAATCA

CCTATTCACTGCTTATGCAGTCGGAAGCTCCAGAAGAACAAAGAGCCCAATTACCAGAACCACATTAAGTCCTATTCACTGCTTATGCAGTCGGAAGCTCCAGAAGAACAAAGAGCCCAATTACCAGAACCACATTAAGT

CTCCATTGTTTTGCCTTGGGATTTGAGAAGAGAATTAGAGAGGTGAGGATCTGGTATTTCCTGGACTAAACTCCATTGTTTTGCCTTGGGATTTGAGAAGAGAATTAGAGAGGTGAGGATCTGGTATTTCCTGGACTAAA

TTCCCCTTGGGGAAGACGAAGGGATGCTGCAGTTCCAAAAGAGAAGGACTCTTCCAGAGTCATCTACCTGTTCCCCTTGGGGAAGACGAAGGGATGCTGCAGTTCCAAAAGAGAAGGACTCTTCCAGAGTCATCTACCTG

AGTCCCAAAGCTCCCTGTCCTGAAAGCCACAGACAATATGGTCCCAAATGACTGACTGCACCTTCTGTGCAGTCCCAAAGCTCCCTGTCCTGAAAGCCACAGACAATATGGTCCCAAATGACTGACTGCACCTTCTGTGC

CTCAGCCGTTCTTGACATCAAGAATCTTCTGTTCCACATCCACACAGCCAATACAATTAGTCAAACCACTCTCAGCCGTTCTTGACATCAAGAATCTTCTGTTCCACATCCACACAGCCAATACAATTAGTCAAACCACT

GTTATTAACAGATGTAGCAACATGAGAAACGCTTATGTTACAGGTTACATGAGAGCAATCATGTAAGTCTGTTATTAACAGATGTAGCAACATGAGAAACGCTTATGTTACAGGTTACATGAGAGCAATCATGTAAGTCT

ATATGACTTCAGAAATGTTAAAATAGACTAACCTCTAACAACAAATTAAAAGTGATTGTTTCAAGGTGATATATGACTTCAGAAATGTTAAAATAGACTAACCTCTAACAACAAATTAAAAGTGATTGTTTCAAGGTGAT

GCAATTATTGATGACCTATTTTATTTTTCTATAATGATCATATATTACCTTTGTAATAAAACATTATAACGCAATTATTGATGACCTATTTTATTTTTCTATAATGATCATATATTACCTTTGTAATAAAACATTATAAC

CAAAACATTCTGTTTACCTTTTCAGGGCTGTATTGATTGGGGTGTAGACTGAACTATCCGGGGTCTGTTTCAAAACATTCTGTTTACCTTTTCAGGGCTGTATTGATTGGGGTGTAGACTGAACTATCCGGGGTCTGTTTT

CTTTTCGGTGATGAAAGTCTTGAGAAGGTAGTAATGGATAAGATGTGAGGGAGAGGAGAGAGGGAGATTTCTTTTCGGTGATGAAAGTCTTGAGAAGGTAGTAATGGATAAGATGTGAGGGAGAGGAGAGAGGGAGATTT

GGAGTGTAGGGTGAGTGCCCCTCTTCTTAGAACTGAATACTCTTCTTCTAATGAACTTGTATTCTTGTTTGGAGTGTAGGGTGAGTGCCCCTCTTCTTAGAACTGAATACTCTTCTTCTAATGAACTTGTATTCTTGTTT

CCATGTCTTCTTCCCTTTCCTTCTATAGCAAATAAAGCATTCACTTTGTTTTGGAACCATGTCTTCTTCCCTTTCCTTCTATAGCAAATAAAGCATTCACTTTGTTTTGGAA

서열번호 4: FCGR2A 아미노산 서열SEQ ID NO: 4: FCGR2A amino acid sequence

MTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNIYLTLPPNDHVNSNNMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTLTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVLSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHSHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDDKNIYLTLPPNDHVNSNN

서열번호 5: FCAR mRNA 염기서열SEQ ID NO: 5: FCAR mRNA base sequence

ATCCTGCTAATGTGCATTGAAAGGAGAGCAACGGGGCTGAGGCCGTGTCAGCACGATGGACCCCAAACAGATCCTGCTAATGTGCATTGAAAGGAGAGCAACGGGGCTGAGGCCGTGTCAGCACGATGGACCCCAAACAG

ACCACCCTCCTGTGTCTTGTGCTCTGTCTGGGCCAGAGGATTCAGGCACAGGAAGGGGACTTTCCCATGCACCACCCTCCTGTGTCTTGTGCTCTGTCTGGGCCAGAGGATTCAGGCACAGGAAGGGGACTTTCCCATGC

CTTTCATATCTGCCAAATCGAGTCCTGTGATTCCCTTGGATGGATCTGTGAAAATCCAGTGCCAGGCCATCTTTCATATCTGCCAAATCGAGTCCTGTGATTCCCTTGGATGGATCTGTGAAAATCCAGTGCCAGGCCAT

TCGTGAAGCTTACCTGACCCAGCTGATGATCATAAAAAACTCCACGTACCGAGAGATAGGCAGAAGACTGTCGTGAAGCTTACCTGACCCAGCTGATGATCATAAAAAACTCCACGTACCGAGAGATAGGCAGAAGACTG

AAGTTTTGGAATGAGACTGATCCTGAGTTCGTCATTGACCACATGGACGCAAACAAGGCAGGGCGCTATCAAGTTTTGGAATGAGACTGATCCTGAGTTCGTCATTGACCACATGGACGCAAACAAGGCAGGGCGCTATC

AGTGCCAATATAGGATAGGGCACTACAGGTTCCGGTACAGTGACACCCTGGAGCTGGTAGTGACAGGCTTAGTGCCAATATAGGATAGGGCACTACAGGTTCCGGTACAGTGACACCCTGGAGCTGGTAGTGACAGGCTT

GTATGGCAAACCCTTCCTCTCTGCAGATCGGGGTCTGGTGTTGATGCCAGGAGAGAATATTTCCCTCACGGTATGGCAAACCCTTCCTCTCTGCAGATCGGGGTCTGGTGTTGATGCCAGGAGAGAATATTTCCCTCACG

TGCAGCTCAGCACACATCCCATTTGATAGATTTTCACTGGCCAAGGAGGGAGAACTTTCTCTGCCACAGCTGCAGCTCAGCACACATCCCATTTGATAGATTTTCACTGGCCAAGGAGGGAGAACTTTCTCTGCCACAGC

ACCAAAGTGGGGAACACCCGGCCAACTTCTCTTTGGGTCCTGTGGACCTCAATGTCTCAGGGATCTACAGACCAAAGTGGGGAACACCCGGCCAACTTCTCTTTGGGTCCTGTGGACCTCAATGTCTCAGGGATCTACAG

GTGCTACGGTTGGTACAACAGGAGCCCCTACCTGTGGTCCTTCCCCAGTAATGCCTTGGAGCTTGTGGTCGTGCTACGGTTGGTACAACAGGAGCCCCTACCTGTGGTCCTTCCCCAGTAATGCCTTGGAGCTTGTGGTC

ACAGACTCCATCCACCAAGATTACACGACGCAGAACTTGATCCGCATGGCCGTGGCAGGACTGGTCCTCGACAGACTCCATCCACCAAGATTACACGACGCAGAACTTGATCCGCATGGCCGTGGCAGGACTGGTCCTCG

TGGCTCTCTTGGCCATACTGGTTGAAAATTGGCACAGCCATACGGCACTGAACAAGGAAGCCTCGGCAGATGGCTCTCTTGGCCATACTGGTTGAAAATTGGCACAGCCATACGGCACTGAACAAGGAAGCCTCGGCAGA

TGTGGCTGAACCGAGCTGGAGCCAACAGATGTGTCAGCCAGGATTGACCTTTGCACGAACACCAAGTGTCTGTGGCTGAACCGAGCTGGAGCCAACAGATGTGTCAGCCAGGATTGACCTTTGCACGAACACCAAGTGTC

TGCAAGTAAACACCTGGAGGTGAAGGCAGAGAGGAGCCAGGACTGTGGAGTCCGACAAAGCTACTTGAAGTGCAAGTAAACACCTGGAGGTGAAGGCAGAGAGGAGCCAGGACTGTGGAGTCCGACAAAGCTACTTGAAG

GACACAAGAGAGAAAAGCTCACTAAGAAGCTTGAATCTACTTTTTTTTTTTTTTGAGACAGAGTCTGGCTGACACAAGAGAGAAAAGCTCACTAAGAAGCTTGAATCTACTTTTTTTTTTTTTTGAGACAGAGTCTGGCT

CTGTCACCCAGGCTGGAGTGCAGTGGAGCAATCTCGGCTCATTGAACCTCTTGGGTTCAAGTGATTCTTGCTGTCACCCAGGCTGGAGTGCAGTGGAGCAATCTCGGCTCATTGAACCTCTTGGGTTCAAGTGATTCTTG

TGCCTCAGCCTCCCAAGTAGCTGGAATTACAGGCACATACCACTGCACCCAGCTAATTTTTGTATTTTTATGCCTCAGCCTCCCAAGTAGCTGGAATTACAGGCACATACCACTGCACCCAGCTAATTTTTGTATTTTTA

GTAGAGATGGGGTTTCACTGTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGGTGATCCACCCACCTGTAGAGATGGGGTTTCACTGTGTTGGCCAGGCTGGTCTCGAACTCCTGACCTCAGGTGATCCACCCACCT

TGGCCTCCCAAAGTGCTGAGATTATAGGCATGAGCCACCACGCCTGGCCAGATGCATGTTCAAACCAATCTGGCCTCCCAAAGTGCTGAGATTATAGGCATGAGCCACCACGCCTGGCCAGATGCATGTTCAAACCAATC

AAATGGTGTTTTCTTATGCAGGACTGATCGATTTGCACCCACCTTTCTGCACATAAGTTATGGTTTTCCAAAATGGTGTTTTCTTATGCAGGACTGATCGATTTGCACCCACCTTTCTGCACATAAGTTATGGTTTTCCA

TCTTATCTGTCTTCTGATTTTTTATATCCTGTTTAATTTCTTCCTTCATTGTTCTTCTCTTTTTTTATTTTCTTATCTGTCTTCTGATTTTTTATATCCTGTTTAATTTCTTCCTTCATTGTTCTTCTCTTTTTTTTTTTT

ATTTTATTTATTTTTATTTTTATTTTTATTTGAGACAGAGTCTCACTCTGTTGCCCAGGCTGGAGTGCAGATTTTATTTATTTTTATTTTTATTTTTATTTGAGACAGAGTCTCACTCTGTTGCCCAGGCTGGAGTGCAG

TGGCACGATCTCGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGATTCTCCTGCCTCGGCCTCCCAATGGCACGATCTCGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGTGATTCTCCTGCCTCGGCCTCCCAA

GTAGCTGGGATTGCAGGCTCCCACCATCACGCCCAGCTACTTTTACAGTATTTTTAGTAGAGACGGGGTTGTAGCTGGGATTGCAGGCTCCCACCATCACGCCCAGCTACTTTTACAGTATTTTTAGTAGAGACGGGGTT

TCATCACATTGGCCAAGCTGGTCTCAAACTTCTGACCTCGTGATCTGCCCGCCTCGGCCTCCCAAAGTGCTCATCACATTGGCCAAGCTGGTCTCAAACTTCTGACCTCGTGATCTGCCCGCCTCGGCCTCCCAAAGTGC

TGGGATTACAGATGTGAGCCACTGCGCCCAGCCTTCTTTTTATATTTTTAAATGTGTCTTCCCCAAATATTGGGATTACAGATGTGAGCCACTGCGCCCAGCCTTCTTTTTATATTTTTAAATGTGTCTTCCCCAAATAT

AAATGGTTGGTAAGCATGCCAAATATATTCAATAACCCCCCTCCTTTATTTTTTTTTGTTGAAGTGAGGCAAATGGTTGGTAAGCATGCCAAATATATTCAATAACCCCCCTCCTTTATTTTTTTTTTGTTGAAGTGAGGC

TCTCCCTATGTTGCCTAAGCTGGTCTTGAACTCCTGGTCTCAAGCAATCCTCCTACCTCAGCCTCCTGCTTCTCCCTATGTTGCCTAAGCTGGTCTTGAACTCCTGGTCTCAAGCAATCCTCCTACCTCAGCCTCCTGCT

GTGTTCATCTACAAATTGATAAGAGTGAAAGTCATAATCCTACAGGAGGATTACCCTATTTATTTCACAAGTGTTCATCTACAAATTGATAAGAGTGAAAGTCATAATCCTACAGGAGGATTACCCTATTTATTTCACAA

ACCCTATTTCTACCGGATTTTCATACAAGGAATACAGGCATGTGTTTCACCTCATTAATTTATTTTTTCAACCCTATTTCTACCGGATTTTCATACAAGGAATACAGGCATGTGTTTCACCTCATTAATTTATTTTTTCA

CTTAGTTTTGATGATATTCACATATATTATCAAGTGTGCAAACATTAAATTCTTGTGTACAAAACTCAAACTTAGTTTTGATGATATTCACATATATTATCAAGTGTGCAAACATTAAATTCTTGTGTACAAAACTCAAA

TGGTCTTCCAAATAATTCCCCATTCTTTTTTCTTATAAACTTTCACAGCTTTACCCTTGACAGACTTTACTGGTCTTCCAAATAATTCCCCATTCTTTTTTCTTATAAACTTTCACAGCTTTACCCTTGACAGACTTTAC

TCAAGGAAATCTAAGTTGGTCATATGTGGCTCTTTCACTGATTGCTATTTACTTCATTGTCCAGTAGCTTTCAAGGAAATCTAAGTTGGTCATATGTGGCTCTTTCACTGATTGCTATTTACTTCATTGTCCAGTAGCTT

ATGTATGAAAATATAATTATAAAATGTAAGGGTCCTACTTCCAGTGAAACTGAAGGGACTTAGGCCCACTATGTATGAAAATATAATTATAAAATGTAAGGGTCCTACTTCCAGTGAAACTGAAGGGACTTAGGCCCACT

TTTATCCTTTACTGAGAGCTTATCTCTACTTGATAAAATTTCTACTGTATTCTTGGCTTAACTCAGGTCCTTTATCCTTTACTGAGAGCTTATCTCTACTTGATAAAATTTCTACTGTATTCTTGGCTTAACTCAGGTCC

TGTGATTAAAAAAAAAATGCAAAGTATGTGATTAAAAAAAAAATGCAAAGTA

서열번호 6: FCAR 아미노산 서열SEQ ID NO: 6: FCAR amino acid sequence

MDPKQTTLLCLVLCLGQRIQAQEGDFPMPFISAKSSPVIPLDGSVKIQCQAIREAYLTQLMIIKNSTYREIGRRLKFWNETDPEFVIDHMDANKAGRYQCQYRIGHYRFRYSDTLELVVTGLYGKPFLSADRGLVLMPGENISLTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSLGPVDLNVSGIYRCYGWYNRSPYLWSFPSNALELVVTDSIHQDYTTQNLIRMAVAGLVLVALLAILVENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCKMDPKQTTLLCLVLCLGQRIQAQEGDFPMPFISAKSSPVIPLDGSVKIQCQAIREAYLTQLMIIKNSTYREIGRRLKFWNETDPEFVIDHMDANKAGRYQCQYRIGHYRFRYSDTLELVVTGLYGKPFLSADRGLVLMPGENISLTCSSAHIPFDRFSLAKEGELSLPQHQSGEHPANFSLGPVDLNVSGIYRCYGWYNRSPYLWSFPSNALELVVTDSIHQDYTTQNLIRMAVAGLVLVALLAILVENWHSHTALNKEASADVAEPSWSQQMCQPGLTFARTPSVCK

서열번호 7: TNFSF13B mRNA 염기서열SEQ ID NO: 7: TNFSF13B mRNA base sequence

GAAATTCTTACAAAAACTGAAAGTGAAATGAGGAAGACAGATTGAGCAATCCAATCGGAGGGTAAATGCCGAAATTCTTACAAAAACTGAAAGTGAAATGAGGAAGACAGATTGAGCAATCCAATCGGAGGGTAAATGCC

AGCAAACCTACTGTACAGTAGGGGTAGAGATGCAGAAAGGCAGAAAGGAGAAAATTCAGGATAACTCTCCAGCAAACCTACTGTACAGTAGGGGTAGAGATGCAGAAAGGCAGAAAGGAGAAAATTCAGGATAACTCTCC

TGAGGGGTGAGCCAAGCCCTGCCATGTAGTGCACGCAGGACATCAACAAACACAGATAACAGGAAATGATTGAGGGGTGAGCCAAGCCCTGCCATGTAGTGCACGCAGGACATCAACAAACACAGATAACAGGAAATGAT

CCATTCCCTGTGGTCACTTATTCTAAAGGCCCCAACCTTCAAAGTTCAAGTAGTGATATGGATGACTCCACCATTCCCTGTGGGTCACTTATTCTAAAGGCCCCAACCTTCAAAGTTCAAGTAGTGATATGGATGACTCCA

CAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAAGAAATGAAACTGAAGGAGTGTGTCAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAAGAAATGAAACTGAAGGAGTGTGT

*TTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGATCCTCCAAAGACGGAAAGCTGCTGGCTGCAACC*TTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGATCCTCCAAAGACGGAAAGCTGCTGGCTGCAACC

TTGCTGCTGGCACTGCTGTCTTGCTGCCTCACGGTGGTGTCTTTCTACCAGGTGGCCGCCCTGCAAGGGGTTGCTGCTGGCACTGCTGTCTTGCTGCCTCACGGTGGTGTCTTTCTACCAGGTGGCCGCCCTGCAAGGGG

ACCTGGCCAGCCTCCGGGCAGAGCTGCAGGGCCACCACGCGGAGAAGCTGCCAGCAGGAGCAGGAGCCCCACCTGGCCAGCCTCCGGGCAGAGCTGCAGGGCCACCACGCGGAGAAGCTGCCAGCAGGAGCAGGAGCCCC

CAAGGCCGGCCTGGAGGAAGCTCCAGCTGTCACCGCGGGACTGAAAATCTTTGAACCACCAGCTCCAGGACAAGGCCGGCCTGGAGGAAGCTCCAGCTGTCACCGCGGGACTGAAAATCTTTGAACCACCAGCTCCAGGA

GAAGGCAACTCCAGTCAGAACAGCAGAAATAAGCGTGCCGTTCAGGGTCCAGAAGAAACAGGATCTTACAGAAGGCAACTCCAGTCAGAACAGCAGAAATAAGCGTGCCGTTCAGGGTCCAGAAGAAACAGGATCTTACA

CATTTGTTCCATGGCTTCTCAGCTTTAAAAGGGGAAGTGCCCTAGAAGAAAAAGAGAATAAAATATTGGTCATTTGTTCCATGGCTTCTCAGCTTTAAAAGGGGAAGTGCCCTAGAAGAAAAAGAGAATAAAATATTGGT

CAAAGAAACTGGTTACTTTTTTATATATGGTCAGGTTTTATATACTGATAAGACCTACGCCATGGGACATCAAAGAAACTGGTTACTTTTTTATATATGGTCAGGTTTTATATACTGATAAGACCTACGCCATGGGACAT

CTAATTCAGAGGAAGAAGGTCCATGTCTTTGGGGATGAATTGAGTCTGGTGACTTTGTTTCGATGTATTCCTAATTCAGAGGAAGAAGGTCCATGTCTTTGGGGATGAATTGAGTCTGGTGACTTTGTTTCGATGTATTC

AAAATATGCCTGAAACACTACCCAATAATTCCTGCTATTCAGCTGGCATTGCAAAACTGGAAGAAGGAGAAAAATATGCCTGAAACACTACCCAATAATTCCTGCTATTCAGCTGGCATTGCAAAACTGGAAGAAGGAGA

TGAACTCCAACTTGCAATACCAAGAGAAAATGCACAAATATCACTGGATGGAGATGTCACATTTTTTGGTTGAACTCCAACTTGCAATACCAAGAGAAAATGCACAAATATCACTGGATGGAGATGTCACATTTTTTGGT

GCATTGAAACTGCTGTGACCTACTTACACCATGTCTGTAGCTATTTTCCTCCCTTTCTCTGTACCTCTAAGCATTGAAACTGCTGTGACCTACTTACACCATGTCTGTAGCTATTTTCCTCCCTTTCTCTGTACCTCTAA

GAAGAAAGAATCTAACTGAAAATACCAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGTAGTTACCATTGGAAGAAAGAATCTAACTGAAAATACAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGTAGTTACCATTG

CCTTTTCTGTGAGCTATTTGTTTTGGTTTGCTGAAACTAGTCCAAAACAGGAAATTTAACAGACAGCCACCCTTTTCTGTGAGCTATTTGTTTTGGTTTGCTGAAACTAGTCCAAAACAGGAAATTTAACAGACAGCCAC

AGCCAAAGAGTGTCATGTGAATTACAAGAAATAGAGCCCATTTAGGGAAAGATAGAACTAGAAAGGCTTTAGCCAAAGAGTGTCATGTGAATTACAAGAAATAGAGCCCATTTAGGGAAAGATAGAACTAGAAAGGCTTT

TCATTATAATTCCATGTTGAACAATTGAGTCATAGCTTCTTATCTTGGAGGAAGGACACAATTCAAAGGGTCATTATAATTCCATGTTGAACAATTGAGTCATAGCTTCTTATCTTGGAGGAAGGACACAATTCAAAGGG

GCAGTAAGGATTTTGTAAAACGTGGCATCCATAATTTACTATGGAGCAAGTGCCCACATCTCTAGGACATGCAGTAAGGATTTTGTAAAACGTGGCATCCATAATTTACTATGGAGCAAGTGCCCACATCTCTAGGACAT

TAAGACATTTATGAGAAATCTCAGGATTCATCTTCTGTTTTTATGTTAAATGCACTCCCTCCTTTTCAGTTAAGACATTTATGAGAAATCTCAGGATTCATCTTCTGTTTTTATGTTAAATGCACTCCCTCCTTTTCAGT

TAACATTATAAAAAGTAAAAAATGAAAATTTTAGAAATCTTGCATTAGACACATGAAAAAATAACTAAAATAACATTATAAAAAGTAAAAAATGAAAATTTTAGAAATCTTGCATTAGACACATGAAAAAATAACTAAAA

GTTTAAATTTAAATATGAAACAATTTTGCTGAAAATAGTATCCATATACTATTTAAGTCTTTTATGGTTAGTTTAAATTTAAATATGAAACAATTTTGCTGAAAATAGTATCCATATACTATTTAAGTCTTTTATGGTTA

TTTCAAGTATACAATTTCTATCTGTAATGTAATATATTACCCACACATTTTTTTCACAGGAGAGAGAGAATTTCAAGTATACAATTTCTATCTGTAATGTAATATATTACCCACACATTTTTTTCACAGGAGAGAGAGAA

TATCCTCATTTGTTTATGCTCATGTGTATTTTCTATAGTGAATTTCAGAAACTTTTAATATCAGGTAATTTATCCTCATTTGTTTATGCTCATGTGTATTTTCTATAGTGAATTTCAGAAACTTTTAATATCAGGTAATT

TCAATTTATGCCTATAAAGCATTGATTGAAAAATAACTAGAATTGTGCATATATAACACATAATCTCCAATCAATTTATGCCTATAAAGCATTGATTGAAAAATAACTAGAATTGTGCATATATAACACATAATCTCCAA

CAGAAGTTACTGAATACATTCATACTAATGTAATGTAATTTCCCTTTATTTCTTGCTCTTCTGTTTCAAACAGAAGTTACTGAATACATTCATACTAATGTAATGTAATTTCCCTTTATTTCTTGCTCTTCTGTTTCAAA

CTGCTGCTATTGTAGTTTACATATCCCAACCTTTAAAAATATTCCTCTTATTAGCTTTATATTCACTTTACTGCTGCTATTGTAGTTTACATATCCCAACCTTTAAAAATATTCCTCTTATTAGCTTTATATTCACTTTA

TAGAAGTTGAGTTTTAATTAAAATTCTTGGCATCCTGAAGTATGTCACATAGCATGTGCTCCTTATAAATTAGAAGTTGAGTTTTAATTAAAATTCTTGGCATCCTGAAGTATGTCACATAGCATGTGCTCCTTATAAAT

ATGTTGATATCTCAGAAGACAGCATCCCGGTTTTCATTTTATAAAGTACCATACTTAAGAATGCTGTAATATGTTGATATCTCAGAAGACAGCATCCCGGTTTTCATTTTATAAAGTACCATACTTAAGAATGCTGTAAT

ACTTATCTTTTATAACATGTTTCCTTCGCTTTGCTTGTCTTTTATGTCATCAGTTTTAACTGTTTACTTCACTTATCTTTTATAACATGTTTCCTTCGCTTTGCTTGTCTTTTATGTCATCAGTTTTAACTGTTTACTTC

ATTTAACAGTTTACATCATTCAACAGTTTACTTCATTAAACAGTAGGTGGAAAAATAGATGCCAGTCTATATTTAACAGTTTACATCATTCAACAGTTTACTTCATTAAACAGTAGGTGGAAAAATAGATGCCAGTCTAT

GAAAATCTTCCCATCTATATCAAAATACTTTTCAAGGATATACTTTTCAAAACAAACGATTTAAATTTTAGAAAATCTTCCCATCTATATCAAAATACTTTTCAAGGATATACTTTTCAAAACAAACGATTTAAATTTTA

TGTTTAAAATATAAACTTTAGATTTAAACTTTATTTAAATATCTGGTTCCTATGATTTTGACTTCAGTAATGTTTAAAATATAAACTTTAGATTTAAACTTTATTTAAATATCTGGTTCCTATGATTTTGACTTCAGTAA

GTTCAAATAAAATATATTTTGCAATTCATTTTTACATTATAATTTAAAAAGAAGAAGCGATAAGTGGAGTGTTCAAATAAAATATATTTTGCAATTCATTTTTACATTATAATTTAAAAAGAAGAAGCGATAAGTGGAGT

CAGTTTCAATGCTAGGTGGGGTGGTTAATGATTTTTCTGGTGTTGCTGCTAATGTGGATTAACAAATAAACAGTTTCAATGCTAGGTGGGGTGGTTAATGATTTTTCTGGTGTTGCTGCTAATGTGGATTAACAAATAAA

AACATTCATTGCCTTTTGCCTCATAAAAAACATTCATTGCCTTTTGCCTCATAAAA

서열번호 8: TNFSF13B 아미노산 서열SEQ ID NO: 8: TNFSF13B amino acid sequence

MDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCCLTVVSFYQVAALQGDLASLRAELQGHHAEKLPAGAGAPKAGLEEAPAVTAGLKIFEPPAPGEGNSSQNSRNKRAVQGPEETGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLLMDDSTEREQSRLTSCLKKREEMKLKECVSILPRKESPSVRSSKDGKLLAATLLLALLSCCLTVVSFYQVAALQGDLASLRAELQGHHAEKLPAGAGAPKAGLEEAPAVTAGLKIFEPPAPGEGNSSQNSRNKRAVQGPEETGSYTFVPWLLSFKRGSALEEKENKILVKETGYFFIYGQVLYTDKTYAMGHLIQRKKVHVFGDELSLVTLFRCIQNMPETLPNNSCYSAGIAKLEEGDELQLAIPRENAQISLDGDVTFFGALKLL

서열번호 9: TNFSF13 mRNA 염기서열SEQ ID NO: 9: TNFSF13 mRNA base sequence

CCGGAACCCTGTGTGCTGGGGAGGAATCCCGCAGTGGCCGGGGGGCTTGAGGCCGCTGCTTTGTCTCTTCCCGGAACCCTGTGTGCTGGGGAGGAATCCCGCAGTGGCCGGGGGGCTTGAGGCCGCTGCTTTGTCTCTTC

GTCCAGAGCCTTATGTAAGAGCTTTTCTCGGGAAACAGGAAGTCCTGCTTGCCAATTTCAGCACAGGGAGGTCCAGAGCCTTATGTAAGAGCTTTTCTCGGGAAACAGGAAGTCCTGCTTGCCAATTTCAGCACAGGGAG

TAGTGCAGGCCTTATTCCAACACACCCGGCCCAGCCTTAACCCCAGAACTCAGCCAGTTTCTTGCTTCCGTAGTGCAGGCCTTATTCCAACACACCCGGCCCAGCCTTAACCCCAGAACTCAGCCAGTTTCTTGCTTCCG

TGCCCCTGGTTCTCCTCCCCATCGAGCCCACCCCTCCTTTCCCACCTTCAGTCACCCCTAGTGAACTGCCTGCCCCTGGTTCTCCTCCCCATCGAGCCCACCCCTCCTTTCCCACCTTCAGTCACCCCTAGTGAACTGCC

CCAGCGATCTCTGCTGTGCTTGACCCCGAGGGTCTTCCACCCTCGCCCTGACCCTGGACACTGCCCAGCTCCAGCGATCTCTGCTGTGCTTGACCCCGAGGGTCTTCCACCCTCGCCCTGACCCTGGACACTGCCCAGCT

TGGCCCCCCATCCTGCTCCTGGCACAATGCCCTCTAGCCAGCCAACCTTCCCTCCCCCAACCCTGGGGCCTGGCCCCCCATCCTGCTCCTGGCACAATGCCCTCTAGCCAGCCAACCTTCCCTCCCCCAACCCTGGGGCC

GCCCCAGGGTTCCTGCGCACTGCCTGTTCCTCCTGGGTGTCACTGGCAGCCCTGTCCTTCCTAGAGGGACGCCCCAGGGTTCCTGCGCACTGCCTGTTCCTCCTGGGTGTCACTGGCAGCCCTGTCCTTCCTAGAGGGAC

TGGAACCTAATTCTCCTGAGGCTGAGGGAGGGTGGAGGGTCTCAAGGCAACGCTGGCCCCACGACGGAGTTGGAACCTAATTCTCCTGAGGCTGAGGGAGGGTGGAGGGTCTCAAGGCAACGCTGGCCCCACGACGGAGT

GCCAGGAGCACTAACAGTACCCTTAGCTTGCTTTCCTCCTCCCTCCTTTTTATTTTCAAGTTCCTTTTTAGCCAGGAGCACTAACAGTACCCTTAGCTTGCTTTCCTCCTCCCTCCTTTTTATTTTCAAGTTCCTTTTTA

TTTCTCCTTGCGTAACAACCTTCTTCCCTTCTGCACCACTGCCCGTACCCTTACCCGCCCCGCCACCTCCTTTCTCCTTGCGTAACAACCTTCTTCCCTTCTGCACCACTGCCCGTACCCTTACCCGCCCCGCCACCTCC

TTGCTACCCCACTCTTGAAACCACAGCTGTTGGCAGGGTCCCCAGCTCATGCCAGCCTCATCTCCTTTCTTTGCTACCCCACTCTTGAAACCACAGCTTGTTGGCAGGGTCCCCAGCTCATGCCAGCCTCATCTCCTTTCT

TGCTAGCCCCCAAAGGGCCTCCAGGCAACATGGGGGGCCCAGTCAGAGAGCCGGCACTCTCAGTTGCCCTTGCTAGCCCCCAAAGGGCCTCCAGGCAACATGGGGGGCCCAGTCAGAGAGCCGGCACTCTCAGTTGCCCT

CTGGTTGAGTTGGGGGGCAGCTCTGGGGGCCGTGGCTTGTGCCATGGCTCTGCTGACCCAACAAACAGAGCTGGTTGAGTTGGGGGGCAGCTCTGGGGGCCGTGGCTTGTGCCATGGCTCTGCTGACCCAACAAACAGAG

CTGCAGAGCCTCAGGAGAGAGGTGAGCCGGCTGCAGGGGACAGGAGGCCCCTCCCAGAATGGGGAAGGGTCTGCAGAGCCTCAGGAGAGAGGTGAGCCGGCTGCAGGGGACAGGAGGCCCCTCCCAGAATGGGGAAGGGT

ATCCCTGGCAGAGTCTCCCGGAGCAGCAGCACTCTGTCCTGCACCTGGTTCCCATTAACGCCACCTCCAAATCCCTGGCAGAGTCTCCCGGAGCAGCAGCACTCTGTCCTGCACCTGGTTCCCATTAACGCCACCTCCAA

GGATGACTCCGATGTGACAGAGGTGATGTGGCAACCAGCTCTTAGGCGTGGGAGAGGCCTACAGGCCCAAGGATGACTCCGATGTGACAGAGGTGATGTGGCAACCAGCTCTTAGGCGTGGGAGAGGCCTACAGGCCCAA

GGATATGGTGTCCGAATCCAGGATGCTGGAGTTTATCTGCTGTATAGCCAGGTCCTGTTTCAAGACGTGAGGATATGGTGTCCGAATCCAGGATGCTGGAGTTTATCTGCTGTATAGCCAGGTCCTGTTTCAAGACGTGA

CTTTCACCATGGGTCAGGTGGTGTCTCGAGAAGGCCAAGGAAGGCAGGAGACTCTATTCCGATGTATAAGCTTTCACCATGGGTCAGGTGGTGTCTCGAGAAGGCCAAGGAAGGCAGGAGACTCTATTCCGATGTATAAG

AAGTATGCCCTCCCACCCGGACCGGGCCTACAACAGCTGCTATAGCGCAGGTGTCTTCCATTTACACCAAAAGTATGCCCTCCCACCCGGACCGGGCCTACAACAGCTGCTATAGCGCAGGTGTCTTCCATTTACACCAA

GGGGATATTCTGAGTGTCATAATTCCCCGGGCAAGGGCGAAACTTAACCTCTCTCCACATGGAACCTTCCGGGGATATTCTGAGTGTCATAATTCCCCGGGCAAGGGCGAAACTTAACCTCTCTCTCCACATGGAACCTTCC

TGGGGTTTGTGAAACTGTGATTGTGTTATAAAAAGTGGCTCCCAGCTTGGAAGACCAGGGTGGGTACATATGGGGTTTGTGAAACTGTGATTGTTGTTATAAAAAAGTGGCTCCCAGCTTGGAAGACCAGGGTGGGTACATA

CTGGAGACAGCCAAGAGCTGAGTATATAAAGGAGAGGGAATGTGCAGGAACAGAGGCGTCTTCCTGGGTTCTGGAGACAGCCAAGAGCTGAGTATATAAAGGAGAGGGAATGTGCAGGAACAGAGGCGTCTTCCTGGGTT

TGGCTCCCCGTTCCTCACTTTTCCCTTTTCATTCCCACCCCCTAGACTTTGATTTTACGGATATCTTGCTTGGCTCCCCGTTCCTCACTTTTCCCTTTTCATTCCCACCCCCTAGACTTTGATTTTACGGATATCTTGCT

TCTGTTCCCCATGGAGCTCCGAATTCTTGCGTGTGTGTAGATGAGGGGCGGGGGACGGGCGCCAGGCATTTCTGTTCCCCATGGAGCTCCGAATTCTTGCGTGTGTGTAGATGAGGGGCGGGGGACGGGCGCCAGGCATT

GTCCAGACCTGGTCGGGGCCCACTGGAAGCATCCAGAACAGCACCACCATCTAGCGGCCGCTCGAGGGAAGTCCAGACCTGGTCGGGGCCCACTGGAAGCATCCAGAACAGCACCACCATCTAGCGGCCGCTCGAGGGAA

GCACCCGCCGGTTGGCCGAAGTCCACGAAGCCGCCCTCTGCTAGGGAAAACCCCTGGTTCTCCATGCCACGCACCCGCCGGTTGGCCGAAGTCCACGAAGCCGCCCTCTGCTAGGGAAAACCCCTGGTTCTCCATGCCAC

ACCTCTCTCCAGGTGCCCTCTGCCTCTTCACCCCACAAGAAGCCTTATCCTACGTCCTTCTCTCCATCTAACCTCTCTCCAGGTGCCCTCTGCCTCTTCACCCCACAAGAAGCCTTATCCTACGTCCTTCTCTCCATCTA

TCGGACCCCAGTTTCCATCACTATCTCCAGAGATGTAGCTATTATGCGCCCGTCTACAGGGGGTGCCCGATCGGACCCCAGTTTCCATCACTATCTCCAGAGATGTAGCTATTATGCGCCCGTCTACAGGGGGTGCCCGA

CGATGACGGTGCCTTCGCAGTCAAATTACTCTTCGGGTCCCAAGGTTTGGCTTTCACGCGCTCCATTGCCCGATGACGGTGCCTTCGCAGTCAAATTACTCTTCGGGTCCCAAGGTTTGGCTTTCACGCGCTCCATTGCC

CCGGCGTGGCAGGCCATTCCAAGCCCTTCCGGGCTGGAACTGGTGTCGGAGGAGCCTCGGGTGTATCGTACCGGCGTGGCAGGCCATTCCAAGCCCTTCCGGGCTGGAACTGGTGTCGGAGGAGCCTCGGGTGTATCGTA

CGCCCTGGTGTTGGTGTTGCCTCACTCCTCTGAGCTCTTCTTTCTGATCAAGCCCTGCTTAAAGTTAAATCGCCCTGGTGTTGGTGTTGCCTCACTCCTCTGAGCTCTTCTTTCTGATCAAGCCCTGCTTAAAGTTAAAT

AAAATAGAATGAATGATACCCCGGCAAAAAAAAAAAAAAAAAAAAATAGAATGAATGATACCCCGGCAAAAAAAAAAAAAAAAA

서열번호 10: TNFSF13 아미노산 서열SEQ ID NO: 10: TNFSF13 amino acid sequence

MPASSPFLLAPKGPPGNMGGPVREPALSVALWLSWGAALGAVACAMALLTQQTELQSLRREVSRLQGTGGPSQNGEGYPWQSLPEQQHSVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQVVSREGQGRQETLFRCIRSMPSHPDRAYNSCYSAGVFHLHQGDILSVIIPRARAKLNLSPHGTFLGFVKLMPASSPFLLAPKGPPGNMGGPVREPALSVALWLSWGAALGAVACAMALLTQQQTELQSLRREVSRLQGTGGPSQNGEGYPWQSLPEQQHSVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTFTMGQVPRVSREGHLGFLSQLLYSQVLFQDVTFTMGDIQVPRVSREGGLFN

서열번호 11: IGHG1 mRNA 염기서열SEQ ID NO: 11: IGHG1 mRNA base sequence

GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCAGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGCCCATCGAGAAAACCATCTCCAAAGCCAAAGAGCTGCAACTGGAGGAGAGCTGTGCGGAGGCGCAGGACGGGGAGCTGGACGGGCTGTGGACGACCATCACCATCTTCATCACACTCTTCCTGTTAAGCGTGTGCTACAGTGCCACCGTCACCTTCTTCAAGGTGAAGTGGATCTTCTCCTCGGTGGTGGACCTGAAGCAGACCATCATCCCCGACTACAGGAACATGATCGGACAGGGGGCCTAGGGCCACCCTCTGCGGGGTGTCCAGGGCCGCCCAGACCCCACACACCAGCCATGGGCCATGCTCAGCCACCACCCAGGCCACACCTGCCCCCGACCTCACCGCCCTCAACCCCATGACTCTCTGGCCTCGCAGTTGCCCTCTGACCCTGACACACCTGACACGCCCCCCTTCCAGACCCTGTGCATAGCAGGTCTACCCCAGACCTCCGCTGCTTGGTGCATGCAGGGCACTGGGGGCCAGGTGTCCCCTCAGCAGGACGTCCTTGCCCTCCGGACCACAAGGTGCTCACACAAAAGGAGGCAGTGACCGGTATCCCAGGCCCCCACCCAGGCAGGACCTCGCCCTGGAGCCAACCCCGTCCACGCCAGCCTCCTGAACACAGGCGTGGTTTCCAGATGGTGAGTGGGAGCGTCAGCCGCCAAGGTAGGGAAGCCACAGCACCATCAGGCCCTGTTGGGGAGGCTTCCGAGAGCTGCGAAGGCTCACTCAGACGGCCTTCCTCCCAGCCCGCAGCCAGCCAGCCTCCATTCCGGGCACTCCCGTGAACTCCTGACATGAGGAATGAGGTTGTTCTGATTTCAAGCAAAGAACGCTGCTCTCTGGCTCCTGGGAACAGTCTCAGTGCCAGCACCACCCCTTGGCTGCCTGCCCACACTGCTGGATTCTCGGGTGGAACTGGACCCGCAGGGACAGCCAGCCCCAGAGTCCGCACTGGGGAGAGAAGGGGCCAGGCCCAGGACACTGCCACCTCCCACCCACTCCAGTCCACCGAGATCACTCAGAGAAGAGCCTGGGCCATGTGGCCGCTGCAGGAGCCCCACAGTGCAAGGGTGAGGATAGCCCAAGGAAGGGCTGGGCATCTGCCCAGACAGGCCTCCCAGAGAAGGCTGGTGACCAGGTCCCAGGCGGGCAAGACTCAGCCTTGGTGGGGCCTGAGGACAGAGGAGGCCCAGGAGCATCGGGGAGAGAGGTGGAGGGACACCGGGAGAGCCAGGAGCGTGGACACAGCCAGAACTCATCACAGAGGCTGGCGTCCAGCCCCGGGTCACGTGCAGCAGGAACAAGCAGCCACTCTGGGGGCACCAGGTGGAGAGGCAAGACGACAAAGAGGGTGCCCGTGTTCTTGCGAAAGCAGGGCTGCTGGCCACGAGTGCTGGACAGAGGCCCCCACGCTCTGCTGCCCCCATCACGCCGTTCCGTGACTGTCACGCAGAATCTGCAGACAGGAAGGGAGACTCGAGCGGGAGTGCGGCCAGCGCCTGCCTCGGCCGTCAGGGAGGACTCCTGGGCTCACTCGAAGGAGGTGCCACCATTTCAGCTTTGGTAGCTTTTCTTCTTCTTTTAAATTTTCTAAAGCTCATTAATTGTCTTTGATGTTTCTTTTGTGATGACAATAAAATATCCTTTTTAAGTCTTGTAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCAGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCCGGCCCATCGAGAAAACCATCTCCAAAGCCAAAGAGCTGCAACTGGAGG AGAGCTGTGCGGAGGCGCAGGACGGGGAGCTGGACGGGCTGTGGACGACCATCACCATCTTCATCACACTCTTCCTGTTAAGCGTGTGCTACAGTGCCACCGTCACCTTCTTCAAGGTGAAGTGGATCTTCTCCTCGGTGGTGGACCTGAAGCAGACCATCATCCCCGACTACAGGAACATGATCGGACAGGGGGCCTAGGGCCACCCTCTGCGGGGTGTCCAGGGCCGCCCAGACCCCACACACCAGCCATGGGCCATGCTCAGCCACCACCCAGGCCACACCTGCCCCCGACCTCACCGCCCTCAACCCCATGACTCTCTGGCCTCGCAGTTGCCCTCTGACCCTGACACACCTGACACGCCCCCCTTCCAGACCCTGTGCATAGCAGGTCTACCCCAGACCTCCGCTGCTTGGTGCATGCAGGGCACTGGGGGCCAGGTGTCCCCTCAGCAGGACGTCCTTGCCCTCCGGACCACAAGGTGCTCACACAAAAGGAGGCAGTGACCGGTATCCCAGGCCCCCACCCAGGCAGGACCTCGCCCTGGAGCCAACCCCGTCCACGCCAGCCTCCTGAACACAGGCGTGGTTTCCAGATGGTGAGTGGGAGCGTCAGCCGCCAAGGTAGGGAAGCCACAGCACCATCAGGCCCTGTTGGGGAGGCTTCCGAGAGCTGCGAAGGCTCACTCAGACGGCCTTCCTCCCAGCCCGCAGCCAGCCAGCCTCCATTCCGGGCACTCCCGTGAACTCCTGACATGAGGAATGAGGTTGTTCTGATTTCAAGCAAAGAACGCTGCTCTCTGGCTCCTGGGAACAGTCTCAGTGCCAGCACCACCCCTTGGCTGCCTGCCCACACTGCTGGATTCTCGGGTGGAACTGGACCCGCAGGGACAGCCAGCCCCAGAGTCCGCACTGGGGAGAGAAGGGGCCAGGCCCAGGACACTGCCACCTCCCACCCACTCCAGTCCACCGAGATCACTCAGAGAAGAGCCTGGGCCATG TGGCCGCTGCAGGAGCCCCACAGTGCAAGGGTGAGGATAGCCCAAGGAAGGGCTGGGCATCTGCCCAGACAGGCCTCCCAGAGAAGGCTGGTGACCAGGTCCCAGGCGGGCAAGACTCAGCCTTGGTGGGGCCTGAGGACAGAGGAGGCCCAGGAGCATCGGGGAGAGAGGTGGAGGGACACCGGGAGAGCCAGGAGCGTGGACACAGCCAGAACTCATCACAGAGGCTGGCGTCCAGCCCCGGGTCACGTGCAGCAGGAACAAGCAGCCACTCTGGGGGCACCAGGTGGAGAGGCAAGACGACAAAGAGGGTGCCCGTGTTCTTGCGAAAGCAGGGCTGCTGGCCACGAGTGCTGGACAGAGGCCCCCACGCTCTGCTGCCCCCATCACGCCGTTCCGTGACTGTCACGCAGAATCTGCAGACAGGAAGGGAGACTCGAGCGGGAGTGCGGCCAGCGCCTGCCTCGGCCGTCAGGGAGGACTCCTGGGCTCACTCGAAGGAGGTGCCACCATTTCAGCTTTGGTAGCTTTTCTTCTTCTTTTAAATTTTCTAAAGCTCATTAATTGTCTTTGATGTTTCTTTTGTGATGACAATAAAATATCCTTTTTAAGTCTTGTA

서열번호 12: IGHG1 아미노산 서열SEQ ID NO: 12: IGHG1 amino acid sequence

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQGAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQGA

서열번호 13: IGHG2 mRNA 염기서열SEQ ID NO: 13: IGHG2 mRNA base sequence

GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCGTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGAGCTGCAACTGGAGGAGAGCTGTGCGGAGGCGCAGGACGGGGAGCTGGACGGGCTGTGGACCACCATCACCATCTTCATCACACTCTTCCTGCTAAGCGTGTGCTACAGTGCCACCATCACCTTCTTCAAGGTGAAGTGGATCTTCTCCTCAGTGGTGGACCTGAAGCAGACCATCGTCCCCGACTACAGGAACATGATCAGGCAGGGGGCCTAGGGCCACCCTCTGTGGGGTGTCCAGGGCCGCCCAGACCCCACACAGGAGCCGTGGGCCATGCTCAGCCATCACCCAGGCCACACCTGCCCCCGACCTCACCGCCCTCAACCCCATGGCTCTCTGGCCTCGCAGTCGCCCTCTGACCCTGACACGCCCCCCTTCCAGACCCTGTGCATAGCAGGTCTACCCCAGACCTCCGCTGCTTGGTGCATGCAGGGCGCTGGGGGCCAAGTGTCCCCTCAGCAGGACGTCCCTGCCCTCCGGCCCGCCAGGTGCTCACACAAAAGGAGGTAGTGACCAGCATCCCAGGCCCCCACTCAGGCAGGACCTCGCCCTGGAGCCAACCCTGTCCACGCCAGCCTCCTGAACACAGGCGTGGTTTCCAGATGGTGAGTGGGAGCATCAGTCGCCAAGGTAGGGAAGTCACAGCACCATCAGGCCCTGTTGGGGAGGCTTCCGAGAGCTGCGAAGGCTCACTCAGACGGCCTTCCTCCCAGCCCGCAGCCAGCCAGCCTCCATTCCAGGCACTCCCGTGAACTCCTGACATGAGGAATGAGGTTGTTCTGATTTCAAGCAAAGAACGCTGCTCTCTGGCTCCTGGGAACAGTCTCAGTGCCAGCACCACCCCTTGGCTGCCTGCCCACACTGCTGGATTCTCGGGTGGAACTCGACCCGCAGGGACAGCCAGCCCCAGAGTCCGCACTGGGGAGAGAAGGGGCCAGGCCCAGGACACTGCCACCTACCACCCACTCCAGTCCACCGAGATCACTCGGAGAAGAGCCTGGGCCATGTGGCCGCTGCAGGAGCCCCACGGTGCAAGGGTGAGGATAGCCCAAGGAAGGGCTGGGCATCTGCCCAGACAGGCCTCCCAGAGAAGGCTGGTGACCAGGTCCCAGGCGGGCAAGACTCAGCCTTGGTGGGGCCTGAGGACAGAGGAGGCCCAGGAGCATCGGGGAGAGAGGTGGAGGGACACCGGGAGAGCCAGGAGCGTGGACACAGCCAGAACTCATCACAGAGGCTGGCGTCCAGCCCCGGGTCACGTGCAGCAGGAACAAGCAGCCACTCTGGGGGCACCAGGTGGAGAGGCAAGACGACAAAGAGGGTGCCCGTGTTCTTGTGAAAGCGGGGCTGCTGGCCACGAGTGCTGGACAGAGGCCCCCACGCTCTGCTGCCCCCATCACGCCGTTCCGTGACTGTCACGCAGAATCCGCAGACAGGGAGACTCGAGCGGGAGTGCGGCCAGCGCCTGCCTCAGCTGTCAGGGAGGACTCCCGGGCTCACTCGAAGGAGGTGCCACCATTTCAGCTTTGGTAGCTTTTCTTCTTCTTTTAAATTTTCTAAAGCTCATTAATTGTCTTTGATGTTTCTTTTGTGATGACAATAAAATATCCTTTTTAAGTCTTGTAGCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCTCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAACTTCGGCACCCAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGACAGTTGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCACGGGAGGAGCAGTTCAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCGTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGAGCTGCAACTGGAGGAGAGCTGTGCGGAGGCGCAGGACGGGGAGCTGGACGGGCTGTGGACCACCATCACCATCTTCATCACACTCTTCCTGCTAAGCGTGTGCTACAGTGCCACCATCACCTTCTTCAAGGTGAAGTGGATCTTCTCCTCAGTGGTGGACCTGAAGCAGACCATCGTCCCCGACTACAGGAACATGATCAGGCAGGGGGCCTAGGGCCACCCTCTGTGGGGTGTCCAGGGCCGCCCAGACCCCACACAGGAGCCGTGGGCCATGCTCAGCCATCACCCAGGCCACACCTGCCCCCGACCTCACCGCCCTCAACCCCATGGCTCTCTGGCCT CGCAGTCGCCCTCTGACCCTGACACGCCCCCCTTCCAGACCCTGTGCATAGCAGGTCTACCCCAGACCTCCGCTGCTTGGTGCATGCAGGGCGCTGGGGGCCAAGTGTCCCCTCAGCAGGACGTCCCTGCCCTCCGGCCCGCCAGGTGCTCACACAAAAGGAGGTAGTGACCAGCATCCCAGGCCCCCACTCAGGCAGGACCTCGCCCTGGAGCCAACCCTGTCCACGCCAGCCTCCTGAACACAGGCGTGGTTTCCAGATGGTGAGTGGGAGCATCAGTCGCCAAGGTAGGGAAGTCACAGCACCATCAGGCCCTGTTGGGGAGGCTTCCGAGAGCTGCGAAGGCTCACTCAGACGGCCTTCCTCCCAGCCCGCAGCCAGCCAGCCTCCATTCCAGGCACTCCCGTGAACTCCTGACATGAGGAATGAGGTTGTTCTGATTTCAAGCAAAGAACGCTGCTCTCTGGCTCCTGGGAACAGTCTCAGTGCCAGCACCACCCCTTGGCTGCCTGCCCACACTGCTGGATTCTCGGGTGGAACTCGACCCGCAGGGACAGCCAGCCCCAGAGTCCGCACTGGGGAGAGAAGGGGCCAGGCCCAGGACACTGCCACCTACCACCCACTCCAGTCCACCGAGATCACTCGGAGAAGAGCCTGGGCCATGTGGCCGCTGCAGGAGCCCCACGGTGCAAGGGTGAGGATAGCCCAAGGAAGGGCTGGGCATCTGCCCAGACAGGCCTCCCAGAGAAGGCTGGTGACCAGGTCCCAGGCGGGCAAGACTCAGCCTTGGTGGGGCCTGAGGACAGAGGAGGCCCAGGAGCATCGGGGAGAGAGGTGGAGGGACACCGGGAGAGCCAGGAGCGTGGACACAGCCAGAACTCATCACAGAGGCTGGCGTCCAGCCCCGGGTCACGTGCAGCAGGAACAAGCAGCCACTCTGGGGGCACCAGGTGGAGAGGCAAGACGACAAAGAGGGTGCCCGTGTTCTTGTGAAAGCGGG GCTGCTGGCCACGAGTGCTGGACAGAGGCCCCCCCACGCTCTGCTGCCCCCATCACGCCGTTCCGTGACTGTCACGCAGAATCCGCAGACAGGGAGACTCGAGCGGGAGTGCGGCCAGCGCCTGCCTCAGCTGTCAGGGAGGACTCCCGGGCTCACTCGAAGGAGGTGCCACCATTGTTCAGCTTCTTGGTAGCTTTTCATTAGATTGATTGATTGA

서열번호 14: IGHG2 아미노산 서열SEQ ID NO: 14: IGHG2 amino acid sequence

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

서열번호 15: IGHG3 mRNA 염기서열SEQ ID NO: 15: IGHG3 mRNA base sequence

*CTTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCAGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACACCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCTCAAAACCCCACTTGGTGACACAACTCACACATGCCCACGGTGCCCAGAGCCCAAATCTTGTGACACACCTCCCCCGTGCCCACGGTGCCCAGAGCCCAAATCTTGTGACACACCTCCCCCATGCCCACGGTGCCCAGAGCCCAAATCTTGTGACACACCTCCCCCGTGCCCAAGGTGCCCAGCACCTGAACTCCTGGGAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGATACCCTTATGATTTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAAGTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGGACAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAGCGGGCAGCCGGAGAACAACTACAACACCACGCCTCCCATGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACATCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCGCTTCACGCAGAAGAGCCTCTCCCTGTCTCCGGAGCTGCAACTGGAGGAGAGCTGTGCGGAGGCGCAGGACGGGGAGCTGGACGGGCTGTGGACGACCATCACCATCTTCATCACACTCTTCCTGTTAAGCGTGTGCTACAGTGCCACCGTCACCTTCTTCAAG*CTTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCAGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACACCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGCTCAAAACCCCACTTGGTGACACAACTCACACATGCCCACGGTGCCCAGAGCCCAAATCTTGTGACACACCTCCCCCGTGCCCACGGTGCCCAGAGCCCAAATCTTGTGACACACCTCCCCCATGCCCACGGTGCCCAGAGCCCAAATCTTGTGACACACCTCCCCCGTGCCCAAGGTGCCCAGCACCTGAACTCCTGGGAGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGATACCCTTATGATTTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCACGAAGACCCCGAGGTCCAGTTCAAGTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTTCCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAACCAAAGGACAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAGCGGGCAGCCGGAGAACAACTACAACACCACGCCTCCCATGCTGGACTCCGACGGCTCCT TCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACATCTTCTCATGCTCCGTGATGCATGAGGCTTCTGCACAACCGCTTCACGCAGAAGAGCCTCTCCCTGTCTCCGGAGCTGCAACTGGAGGAGAGCTGTGTGCGGAGGACTCTCTGGACGGGGAGCTGGACGGACTGACTGGACGACTGACCATCATTC

서열번호 16: IGHG3 아미노산 서열SEQ ID NO: 16: IGHG3 amino acid sequence

XSTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQGAXSTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPELQLEESCAEAQDGELDGLWTTITIFITLFLLSVCYSATVTFFKVKWIFSSVVDLKQTIIPDYRNMIGQGA

서열번호 17: IGHG4 mRNA 염기서열SEQ ID NO: 17: IGHG4 mRNA base sequence

GCTTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCATCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAATGAGTGCCAGGGCCGGCAAGCCCCCGCTCCCCGGGCTCTCGGGGTCGCGCGAGGATGCTTGGCACGTACCCCGTGTACATACTTCCCGGGCGCCCAGCATGGAAATAAAGCACCCAGCGCTGCCCTGGGCCCCTGCGAGCTTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCGCCCTGCTCCAGGAGCACCTCCGAGAGCACAGCCGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACGAAGACCTACACCTGCAACGTAGATCACAAGCCCAGCAACACCAAGGTGGACAAGAGAGTTGAGTCCAAATATGGTCCCCCATGCCCATCATGCCCAGCACCTGAGTTCCTGGGGGGACCATCAGTCTTCCTGTTCCCCCCAAAACCCAAGGACACTCTCATGATCTCCCGGACCCCTGAGGTCACGTGCGTGGTGGTGGACGTGAGCCAGGAAGACCCCGAGGTCCAGTTCAACTGGTACGTGGATGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTTCAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAACGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGGCCTCCCGTCCTCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAGCCACAGGTGTACACCCTGCCCCCATCCCAGGAGGAGATGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTACCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAGGCTCACCGTGGACAAGAGCAGGTGGCAGGAGGGGAATGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACACAGAAGAGCCTCTCCCTGTCTCTGGGTAAATGAGTGCCAGGGCCGGCAA GCCCCCGCTCCCCGGGCTCTCGGGGTCGCGCGAGGATGCTTGGCACGTACCCCGTGTACATACTTCCCGGGCGCCCAGCATGGAAATAAAGCACCCAGCGCTGCCCTGGGCCCCTGCGA

서열번호 18: IGHG4 아미노산 서열SEQ ID NO: 18: IGHG4 amino acid sequence

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK

서열번호 19: IGHA1 mRNA 염기서열SEQ ID NO: 19: IGHA1 mRNA base sequence

GCATCCCCGACCAGCCCCAAGGTCTTCCCGCTGAGCCTCTGCAGCACCCAGCCAGATGGGAACGTGGTCATCGCCTGCCTGGTCCAGGGCTTCTTCCCCCAGGAGCCACTCAGTGTGACCTGGAGCGAAAGCGGACAGGGCGTGACCGCCAGAAACTTCCCACCCAGCCAGGATGCCTCCGGGGACCTGTACACCACGAGCAGCCAGCTGACCCTGCCGGCCACACAGTGCCTAGCCGGCAAGTCCGTGACATGCCACGTGAAGCACTACACGAATCCCAGCCAGGATGTGACTGTGCCCTGCCCAGTTCCCTCAACTCCACCTACCCCATCTCCCTCAACTCCACCTACCCCATCTCCCTCATGCTGCCACCCCCGACTGTCACTGCACCGACCGGCCCTCGAGGACCTGCTCTTAGGTTCAGAAGCGAACCTCACGTGCACACTGACCGGCCTGAGAGATGCCTCAGGTGTCACCTTCACCTGGACGCCCTCAAGTGGGAAGAGCGCTGTTCAAGGACCACCTGAGCGTGACCTCTGTGGCTGCTACAGCGTGTCCAGTGTCCTGCCGGGCTGTGCCGAGCCATGGAACCATGGGAAGACCTTCACTTGCACTGCTGCCTACCCCGAGTCCAAGACCCCGCTAACCGCCACCCTCTCAAAATCCGGAAACACATTCCGGCCCGAGGTCCACCTGCTGCCGCCGCCGTCGGAGGAGCTGGCCCTGAACGAGCTGGTGACGCTGACGTGCCTGGCACGCGGCTTCAGCCCCAAGGATGTGCTGGTTCGCTGGCTGCAGGGGTCACAGGAGCTGCCCCGCGAGAAGTACCTGACTTGGGCATCCCGGCAGGAGCCCAGCCAGGGCACCACCACCTTCGCTGTGACCAGCATACTGCGCGTGGCAGCCGAGGACTGGAAGAAGGGGGACACCTTCTCCTGCATGGTGGGCCACGAGGCCCTGCCGCTGGCCTTCACACAGAAGACCATCGACCGCTTGGCGGATTGGCAGATGCCGCCTCCCTATGTGGTGCTGGACTTGCCGCAGGAGACCCTGGAGGAGGAGACCCCCGGCGCCAACCTGTGGCCCACCACCATCACCTTCCTCACCCTCTTCCTGCTGAGCCTGTTCTATAGCACAGCACTGACCGTGACCAGCGTCCGGGGCCCATCTGGCAACAGGGAGGGCCCCCAGTACTGAGCAGGAGCCGGCAAGGCACAGGGAGGAAGTGTGGAGGAACCTCTTGGAGAAGCCAGCTATGCTTGCCAGAACTCAGCCCTTTCAGACATCACCGACCCGCCCTTACTCACATGGCATCCCCGACCAGCCCCAAGGTCTTCCCGCTGAGCCTCTGCAGCACCCAGCCAGATGGGAACGTGGTCATCGCCTGCCTGGTCCAGGGCTTCTTCCCCCAGGAGCCACTCAGTGTGACCTGGAGCGAAAGCGGACAGGGCGTGACCGCCAGAAACTTCCCACCCAGCCAGGATGCCTCCGGGGACCTGTACACCACGAGCAGCCAGCTGACCCTGCCGGCCACACAGTGCCTAGCCGGCAAGTCCGTGACATGCCACGTGAAGCACTACACGAATCCCAGCCAGGATGTGACTGTGCCCTGCCCAGTTCCCTCAACTCCACCTACCCCATCTCCCTCAACTCCACCTACCCCATCTCCCTCATGCTGCCACCCCCGACTGTCACTGCACCGACCGGCCCTCGAGGACCTGCTCTTAGGTTCAGAAGCGAACCTCACGTGCACACTGACCGGCCTGAGAGATGCCTCAGGTGTCACCTTCACCTGGACGCCCTCAAGTGGGAAGAGCGCTGTTCAAGGACCACCTGAGCGTGACCTCTGTGGCTGCTACAGCGTGTCCAGTGTCCTGCCGGGCTGTGCCGAGCCATGGAACCATGGGAAGACCTTCACTTGCACTGCTGCCTACCCCGAGTCCAAGACCCCGCTAACCGCCACCCTCTCAAAATCCGGAAACACATTCCGGCCCGAGGTCCACCTGCTGCCGCCGCCGTCGGAGGAGCTGGCCCTGAACGAGCTGGTGACGCTGACGTGCCTGGCACGCGGCTTCAGCCCCAAGGATGTGCTGGTTCGCTGGCTGCAGGGGTCACAGGAGCTGCCCCGCGAGAAGTACCTGACTTGGGCATCCCGGCAGGAGCCCAGCCAGGGCACCACCACCTTCGCTGTGACCAGCATACTGCGCGTGGCAGCCGAGGACTGGAAGAAGGGGGACACCTTCTCCTGCATGGTGGGCCACGAGGCCCTGCCGCTGGCCTTCACACAGAAGACCATCGACCGCTTGGCGG ATTGGCAGATGCCGCCTCCCTATGTGGTGCTGGACTTGCCGCAGGAGACCCTGGAGGAGGAGACCCCCGGCGCCAACCTGTGGCCCACCACCATCACCTTCCTCACCCTCTTCCTGCTGAGCCTGTTCTATAGCACAGCACTGACCGTGACCAGCGTCCGGGGCCCATCTGGCAACAGGGAGGGCCCCCAGTACTGAGCAGGAGCCGGCAAGGCACAGGGAGGAAGTGTGGAGGAACCTCTTGGAGAAGCCAGCTATGCTTGCCAGAACTCAGCCCTTTCAGACATCACCGACCCGCCCTTACTCACATG

서열번호 20: IGHA1 아미노산 서열SEQ ID NO: 20: IGHA1 amino acid sequence

ASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQDASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLADWQMPPPYVVLDLPQETLEEETPGANLWPTTITFLTLFLLSLFYSTALTVTSVRGPSGNREGPQYASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQDASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLADWQMPPPYVVLDLPQETLEEETPGANLWPTTITFLTLFLLSLFYSTALTVTSVRGPSGNREGPQY

서열번호 21: CD69 mRNA 염기서열SEQ ID NO: 21: CD69 mRNA nucleotide sequence

AGACTCAACAAGAGCTCCAGCAAAGACTTTCACTGTAGCTTGACTTGACCTGAGATTAACTAGGGAATCTTGAGAATAAAGATGAGCTCTGAAAATTGTTTCGTAGCAGAGAACAGCTCTTTGCATCCGGAGAGTGGACAAGAAAATGATGCCACCAGTCCCCATTTCTCAACACGTCATGAAGGGTCCTTCCAAGTTCCTGTCCTGTGTGCTGTAATGAATGTGGTCTTCATCACCATTTTAATCATAGCTCTCATTGCCTTATCAGTGGGCCAATACAATTGTCCAGGCCAATACACATTCTCAATGCCATCAGACAGCCATGTTTCTTCATGCTCTGAGGACTGGGTTGGCTACCAGAGGAAATGCTACTTTATTTCTACTGTGAAGAGGAGCTGGACTTCAGCCCAAAATGCTTGTTCTGAACATGGTGCTACTCTTGCTGTCATTGATTCTGAAAAGGACATGAACTTTCTAAAACGATACGCAGGTAGAGAGGAACACTGGGTTGGACTGAAAAAGGAACCTGGTCACCCATGGAAGTGGTCAAATGGCAAAGAATTTAACAACTGGTTCAACGTTACAGGGTCTGACAAGTGTGTTTTTCTGAAAAACACAGAGGTCAGCAGCATGGAATGTGAGAAGAATTTATACTGGATATGTAACAAACCTTACAAATAATAAGGAAACATGTTCACTTATTGACTATTATAGAATGGAACTCAAGGAAATCTGTGTCAGTGGATGCTGCTCTGTGGTCCGAAGTCTTCCATAGAGACTTTGTGAAAAAAAATTTTATAGTGTCTTGGGAATTTTCTTCCAAACAGAACTATGGAAAAAAAGGAAGAAATTCCAGGAAAATCTGCACTGTGGGCTTTTATTGCCATGAGCTAGAAGCATCACAGGTTGACCAATAACCATGCCCAAGAATGAGAAGAATGACTATGCAACCTTTGGATGCACTTTATATTATTTTGAATCCAGAAATAATGAAATAACTAGGCGTGGACTTACTATTTATTGCTGAATGACTACCAACAGTGAGAGCCCTTCATGCATTTGCACTATTGGAAGGAGTTAGATGTTGGTACTAGATACTGAATGTAAACAAAGGAATTATGGCTGGTAACATAGGTTTTTAGTCTAATTGAATCCCTTAAACTCAGGGAGCATTTATAAATGGACAAATGCTTATGAAACTAAGATTTGTAATATTTCTCTCTTTTTAGAGAAATTTGCCAATTTACTTTGTTATTTTTCCCCAAAAAGAATGGGATGATCATGTATTTATTTTTTTACTTCCTCAGCTGTAGACAGGTCCTTTTCGATGGTACATATTTCTTTGCCTTTATAATCTTTTATACAGTGTCTTACAGAGAAAAGACATAAGCAAAGACTATGAGGAATATTTGCAAGACATAGAATAGTGTTGGAAAATGTGCAATATGTGATGTGGCAAATCTCTATTAGGAAATATTCTGTAATCTTCAGACCTAGAATAATACTAGTCTTATAATAGGTTTGTGACTTTCCTAAATCAATTCTATTACGTGCAATACTTCAATACTTCATTTAAAATATTTTTATGTGCAATAAAATGTATTTGTTTGTATTTTGTGTTCAGTACAATTATAAGCTGTTTTTATATATGTGAAATAAAAGTAGAATAAACACAAAGACTCAACAAGAGCTCCAGCAAAGACTTTCACTGTAGCTTGACTTGACCTGAGATTAACTAGGGAATCTTGAGAATAAAGATGAGCTCTGAAAATTGTTTCGTAGCAGAGAACAGCTCTTTGCATCCGGAGAGTGGACAAGAAAATGATGCCACCAGTCCCCATTTCTCAACACGTCATGAAGGGTCCTTCCAAGTTCCTGTCCTGTGTGCTGTAATGAATGTGGTCTTCATCACCATTTTAATCATAGCTCTCATTGCCTTATCAGTGGGCCAATACAATTGTCCAGGCCAATACACATTCTCAATGCCATCAGACAGCCATGTTTCTTCATGCTCTGAGGACTGGGTTGGCTACCAGAGGAAATGCTACTTTATTTCTACTGTGAAGAGGAGCTGGACTTCAGCCCAAAATGCTTGTTCTGAACATGGTGCTACTCTTGCTGTCATTGATTCTGAAAAGGACATGAACTTTCTAAAACGATACGCAGGTAGAGAGGAACACTGGGTTGGACTGAAAAAGGAACCTGGTCACCCATGGAAGTGGTCAAATGGCAAAGAATTTAACAACTGGTTCAACGTTACAGGGTCTGACAAGTGTGTTTTTCTGAAAAACACAGAGGTCAGCAGCATGGAATGTGAGAAGAATTTATACTGGATATGTAACAAACCTTACAAATAATAAGGAAACATGTTCACTTATTGACTATTATAGAATGGAACTCAAGGAAATCTGTGTCAGTGGATGCTGCTCTGTGGTCCGAAGTCTTCCATAGAGACTTTGTGAAAAAAAATTTTATAGTGTCTTGGGAATTTTCTTCCAAACAGAACTATGGAAAAAAAGGAAGAAATTCCAGGAAAATCTGCACTGTGGGCTTTTATTGCCATGAGCTAGAAGCATCACAGGTTGACCAATAACCATGCCCAAGAATGAGAAGAATGACTATGCAACCTTTGGATGCACTTTATATTATTTTGAATCCAGAAATAATGAAATAACT AGGCGTGGACTTACTATTTATTGCTGAATGACTACCAACAGTGAGAGCCCTTCATGCATTTGCACTATTGGAAGGAGTTAGATGTTGGTACTAGATACTGAATGTAAACAAAGGAATTATGGCTGGTAACATAGGTTTTTAGTCTAATTGAATCCCTTAAACTCAGGGAGCATTTATAAATGGACAAATGCTTATGAAACTAAGATTTGTAATATTTCTCTCTTTTTAGAGAAATTTGCCAATTTACTTTGTTATTTTTCCCCAAAAAGAATGGGATGATCATGTATTTATTTTTTTACTTCCTCAGCTGTAGACAGGTCCTTTTCGATGGTACATATTTCTTTGCCTTTATAATCTTTTATACAGTGTCTTACAGAGAAAAGACATAAGCAAAGACTATGAGGAATATTTGCAAGACATAGAATAGTGTTGGAAAATGTGCAATATGTGATGTGGCAAATCTCTATTAGGAAATATTCTGTAATCTTCAGACCTAGAATAATACTAGTCTTATAATAGGTTTGTGACTTTCCTAAATCAATTCTATTACGTGCAATACTTCAATACTTCATTTAAAATATTTTTATGTGCAATAAAATGTATTTGTTTGTATTTTGTGTTCAGTACAATTATAAGCTGTTTTTATATATGTGAAATAAAAGTAGAATAAACACAA

서열번호 22: CD69 아미노산 서열SEQ ID NO: 22: CD69 amino acid sequence

MSSENCFVAENSSLHPESGQENDATSPHFSTRHEGSFQVPVLCAVMNVVFITILIIALIALSVGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDSEKDMNFLKRYAGREEHWVGLKKEPGHPWKWSNGKEFNNWFNVTGSDKCVFLKNTEVSSMECEKNLYWICNKPYKMSSENCFVAENSSLHPESGQENDATSPHFSTRHEGSFQVPVLCAVMNVVFITILIIALIALSVGQYNCPGQYTFSMPSDSHVSSCSEDWVGYQRKCYFISTVKRSWTSAQNACSEHGATLAVIDSEKDMNFLKRYNTEVEVSSMEVKWSNGKEFNNVKPWKWSNGKEFNNKN

서열번호 23: FOS mRNA 염기서열SEQ ID NO: 23: FOS mRNA base sequence

AACCGCATCTGCAGCGAGCATCTGAGAAGCCAAGACTGAGCCGGCGGCCGCGGCGCAGCGAACGAGCAGTGACCGTGCTCCTACCCAGCTCTGCTCCACAGCGCCCACCTGTCTCCGCCCCTCGGCCCCTCGCCCGGCTTTGCCTAACCGCCACGATGATGTTCTCGGGCTTCAACGCAGACTACGAGGCGTCATCCTCCCGCTGCAGCAGCGCGTCCCCGGCCGGGGATAGCCTCTCTTACTACCACTCACCCGCAGACTCCTTCTCCAGCATGGGCTCGCCTGTCAACGCGCAGGACTTCTGCACGGACCTGGCCGTCTCCAGTGCCAACTTCATTCCCACGGTCACTGCCATCTCGACCAGTCCGGACCTGCAGTGGCTGGTGCAGCCCGCCCTCGTCTCCTCCGTGGCCCCATCGCAGACCAGAGCCCCTCACCCTTTCGGAGTCCCCGCCCCCTCCGCTGGGGCTTACTCCAGGGCTGGCGTTGTGAAGACCATGACAGGAGGCCGAGCGCAGAGCATTGGCAGGAGGGGCAAGGTGGAACAGTTATCTCCAGAAGAAGAAGAGAAAAGGAGAATCCGAAGGGAAAGGAATAAGATGGCTGCAGCCAAATGCCGCAACCGGAGGAGGGAGCTGACTGATACACTCCAAGCGGAGACAGACCAACTAGAAGATGAGAAGTCTGCTTTGCAGACCGAGATTGCCAACCTGCTGAAGGAGAAGGAAAAACTAGAGTTCATCCTGGCAGCTCACCGACCTGCCTGCAAGATCCCTGATGACCTGGGCTTCCCAGAAGAGATGTCTGTGGCTTCCCTTGATCTGACTGGGGGCCTGCCAGAGGTTGCCACCCCGGAGTCTGAGGAGGCCTTCACCCTGCCTCTCCTCAATGACCCTGAGCCCAAGCCCTCAGTGGAACCTGTCAAGAGCATCAGCAGCATGGAGCTGAAGACCGAGCCCTTTGATGACTTCCTGTTCCCAGCATCATCCAGGCCCAGTGGCTCTGAGACAGCCCGCTCCGTGCCAGACATGGACCTATCTGGGTCCTTCTATGCAGCAGACTGGGAGCCTCTGCACAGTGGCTCCCTGGGGATGGGGCCCATGGCCACAGAGCTGGAGCCCCTGTGCACTCCGGTGGTCACCTGTACTCCCAGCTGCACTGCTTACACGTCTTCCTTCGTCTTCACCTACCCCGAGGCTGACTCCTTCCCCAGCTGTGCAGCTGCCCACCGCAAGGGCAGCAGCAGCAATGAGCCTTCCTCTGACTCGCTCAGCTCACCCACGCTGCTGGCCCTGTGAGGGGGCAGGGAAGGGGAGGCAGCCGGCACCCACAAGTGCCACTGCCCGAGCTGGTGCATTACAGAGAGGAGAAACACATCTTCCCTAGAGGGTTCCTGTAGACCTAGGGAGGACCTTATCTGTGCGTGAAACACACCAGGCTGTGGGCCTCAAGGACTTGAAAGCATCCATGTGTGGACTCAAGTCCTTACCTCTTCCGGAGATGTAGCAAAACGCATGGAGTGTGTATTGTTCCCAGTGACACTTCAGAGAGCTGGTAGTTAGTAGCATGTTGAGCCAGGCCTGGGTCTGTGTCTCTTTTCTCTTTCTCCTTAGTCTTCTCATAGCATTAACTAATCTATTGGGTTCATTATTGGAATTAACCTGGTGCTGGATATTTTCAAATTGTATCTAGTGCAGCTGATTTTAACAATAACTACTGTGTTCCTGGCAATAGTGTGTTCTGATTAGAAATGACCAATATTATACTAAGAAAAGATACGACTTTATTTTCTGGTAGATAGAAATAAATAGCTATATCCATGTACTGTAGTTTTTCTTCAACATCAATGTTCATTGTAATGTTACTGATCATGCATTGTTGAGGTGGTCTGAATGTTCTGACATTAACAGTTTTCCATGAAAACGTTTTATTGTGTTTTTAATTTATTTATTAAGATGGATTCTCAGATATTTATATTTTTATTTTATTTTTTTCTACCTTGAGGTCTTTTGACATGTGGAAAGTGAATTTGAATGAAAAATTTAAGCATTGTTTGCTTATTGTTCCAAGACATTGTCAATAAAAGCATTTAAGTTGAATGCGAAACCGCATCTGCAGCGAGCATCTGAGAAGCCAAGACTGAGCCGGCGGCCGCGGCGCAGCGAACGAGCAGTGACCGTGCTCCTACCCAGCTCTGCTCCACAGCGCCCACCTGTCTCCGCCCCTCGGCCCCTCGCCCGGCTTTGCCTAACCGCCACGATGATGTTCTCGGGCTTCAACGCAGACTACGAGGCGTCATCCTCCCGCTGCAGCAGCGCGTCCCCGGCCGGGGATAGCCTCTCTTACTACCACTCACCCGCAGACTCCTTCTCCAGCATGGGCTCGCCTGTCAACGCGCAGGACTTCTGCACGGACCTGGCCGTCTCCAGTGCCAACTTCATTCCCACGGTCACTGCCATCTCGACCAGTCCGGACCTGCAGTGGCTGGTGCAGCCCGCCCTCGTCTCCTCCGTGGCCCCATCGCAGACCAGAGCCCCTCACCCTTTCGGAGTCCCCGCCCCCTCCGCTGGGGCTTACTCCAGGGCTGGCGTTGTGAAGACCATGACAGGAGGCCGAGCGCAGAGCATTGGCAGGAGGGGCAAGGTGGAACAGTTATCTCCAGAAGAAGAAGAGAAAAGGAGAATCCGAAGGGAAAGGAATAAGATGGCTGCAGCCAAATGCCGCAACCGGAGGAGGGAGCTGACTGATACACTCCAAGCGGAGACAGACCAACTAGAAGATGAGAAGTCTGCTTTGCAGACCGAGATTGCCAACCTGCTGAAGGAGAAGGAAAAACTAGAGTTCATCCTGGCAGCTCACCGACCTGCCTGCAAGATCCCTGATGACCTGGGCTTCCCAGAAGAGATGTCTGTGGCTTCCCTTGATCTGACTGGGGGCCTGCCAGAGGTTGCCACCCCGGAGTCTGAGGAGGCCTTCACCCTGCCTCTCCTCAATGACCCTGAGCCCAAGCCCTCAGTGGAACCTGTCAAGAGCATCAGCAGCATGGAGCTGAAGACCGAGCCCTTTGATGACTTCCTGTTCCCAGCATCATCCAGGCCCAGTGG CTCTGAGACAGCCCGCTCCGTGCCAGACATGGACCTATCTGGGTCCTTCTATGCAGCAGACTGGGAGCCTCTGCACAGTGGCTCCCTGGGGATGGGGCCCATGGCCACAGAGCTGGAGCCCCTGTGCACTCCGGTGGTCACCTGTACTCCCAGCTGCACTGCTTACACGTCTTCCTTCGTCTTCACCTACCCCGAGGCTGACTCCTTCCCCAGCTGTGCAGCTGCCCACCGCAAGGGCAGCAGCAGCAATGAGCCTTCCTCTGACTCGCTCAGCTCACCCACGCTGCTGGCCCTGTGAGGGGGCAGGGAAGGGGAGGCAGCCGGCACCCACAAGTGCCACTGCCCGAGCTGGTGCATTACAGAGAGGAGAAACACATCTTCCCTAGAGGGTTCCTGTAGACCTAGGGAGGACCTTATCTGTGCGTGAAACACACCAGGCTGTGGGCCTCAAGGACTTGAAAGCATCCATGTGTGGACTCAAGTCCTTACCTCTTCCGGAGATGTAGCAAAACGCATGGAGTGTGTATTGTTCCCAGTGACACTTCAGAGAGCTGGTAGTTAGTAGCATGTTGAGCCAGGCCTGGGTCTGTGTCTCTTTTCTCTTTCTCCTTAGTCTTCTCATAGCATTAACTAATCTATTGGGTTCATTATTGGAATTAACCTGGTGCTGGATATTTTCAAATTGTATCTAGTGCAGCTGATTTTAACAATAACTACTGTGTTCCTGGCAATAGTGTGTTCTGATTAGAAATGACCAATATTATACTAAGAAAAGATACGACTTTATTTTCTGGTAGATAGAAATAAATAGCTATATCCATGTACTGTAGTTTTTCTTCAACATCAATGTTCATTGTAATGTTACTGATCATGCATTGTTGAGGTGGTCTGAATGTTCTGACATTAACAGTTTTCCATGAAAACGTTTTATTGTGTTTTTAATTTATTTATTAAGATGGATTCTCAGATATTTATATTTTTATTTTATTTTTTTCTACCT TGAGGTCTTTTGACATGTGGAAAGTGAATTTGAATGAAAAATTTAAGCATTGTTTGCTTATTGTTCCAAGACATTGTCAATAAAAGCATTTAAGTTGAATGCGA

서열번호 24: FOS 아미노산 서열SEQ ID NO: 24: FOS amino acid sequence

MMFSGFNADYEASSSRCSSASPAGDSLSYYHSPADSFSSMGSPVNAQDFCTDLAVSSANFIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGVPAPSAGAYSRAGVVKTMTGGRAQSIGRRGKVEQLSPEEEEKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAFTLPLLNDPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDLSGSFYAADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVFTYPEADSFPSCAAAHRKGSSSNEPSSDSLSSPTLLALMMFSGFNADYEASSSRCSSASPAGDSLSYYHSPADSFSSMGSPVNAQDFCTDLAVSSANFIPTVTAISTSPDLQWLVQPALVSSVAPSQTRAPHPFGVPAPSAGAYSRAGVVKTMTGGRAQSIGRRGKVEQLSPEEEEKRRIRRERNKMAAAKCRNRRRELTDTLQAETDQLEDEKSALQTEIANLLKEKEKLEFILAAHRPACKIPDDLGFPEEMSVASLDLTGGLPEVATPESEEAFTLPLLNDPEPKPSVEPVKSISSMELKTEPFDDFLFPASSRPSGSETARSVPDMDLSGSFYAADWEPLHSGSLGMGPMATELEPLCTPVVTCTPSCTAYTSSFVFTYPEADSFPSCAAAHRKGSSSNEPSSDSLSSPTLLAL

서열번호 25: CCR7 mRNA 염기서열SEQ ID NO: 25: CCR7 mRNA base sequence

AGACAGGGGTAGTGCGAGGCCGGGCACAGCCTTCCTGTGTGGTTTTACCGCCCAGAGAGCGTCATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACAGCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGGCGACTCTTCTGCCTGGACTAGAGGGACCTCTCCCAGGGTCCCTGGGGTGGGGATAGGGAGCAGATGCAATGACTCAGGACATCCCCCCGCCAAAAGCTGCTCAGGGAAAAGCAGCTCTCCCCTCAGAGTGCAAGCCCCTGCTCCAGAAGATAGCTTCACCCCAATCCCAGCTACCTCAACCAATGCCAAAAAAAGACAGGGCTGATAAGCTAACACCAGACAGACAACACTGGGAAACAGAGGCTATTGTCCCCTAAACCAAAAACTGAAAGTGAAAGTCCAGAAACTGTTCCCACCTGCTGGAGTGAAGGGGCCAAGGAGGGTGAGTGCAAGGGGCGTGGGAGTGGCCTGAAGAGTCCTCTGAATGAACCTTCTGGCCTCCCACAGACTCAAATGCTCAGACCAGCTCTTCCGAAAACCAGGCCTTATCTCCAAGACCAGAGATAGTGGGGAGACTTCTTGGCTTGGTGAGGAAAAGCGGACATCAGCTGGTCAAACAAACTCTCTGAACCCCTCCCTCCATCGTTTTCTTCACTGTCCTCCAAGCCAGCGGGAATGGCAGCTGCCACGCCGCCCTAAAAGCACACTCATCCCCTCACTTGCCGCGTCGCCCTCCCAGGCTCTCAACAGGGGAGAGTGTGGTGTTTCCTGCAGGCCAGGCCAGCTGCCTCCGCGTGATCAAAGCCACACTCTGGGCTCCAGAGTGGGGATGACATGCACTCAGCTCTTGGCTCCACTGGGATGGGAGGAGAGGACAAGGGAAATGTCAGGGGCGGGGAGGGTGACAGTGGCCGCCCAAGGCCCACGAGCTTGTTCTTTGTTCTTTGTCACAGGGACTGAAAACCTCTCCTCATGTTCTGCTTTCGATTCGTTAAGAGAGCAACATTTTACCCACACACAGATAAAGTTTTCCCTTGAGGAAACAACAGCTTTAAAAGAAAAAGAAAAAAAAAGTCTTTGGTAAATGGCAAAAGACAGGGGTAGTGCGAGGCCGGGCACAGCCTTCCTGTGTGGTTTTACCGCCCAGAGAGCGTCATGGACCTGGGGAAACCAATGAAAAGCGTGCTGGTGGTGGCTCTCCTTGTCATTTTCCAGGTATGCCTGTGTCAAGATGAGGTCACGGACGATTACATCGGAGACAACACCACAGTGGACTACACTTTGTTCGAGTCTTTGTGCTCCAAGAAGGACGTGCGGAACTTTAAAGCCTGGTTCCTCCCTATCATGTACTCCATCATTTGTTTCGTGGGCCTACTGGGCAATGGGCTGGTCGTGTTGACCTATATCTATTTCAAGAGGCTCAAGACCATGACCGATACCTACCTGCTCAACCTGGCGGTGGCAGACATCCTCTTCCTCCTGACCCTTCCCTTCTGGGCCTACAGCGCGGCCAAGTCCTGGGTCTTCGGTGTCCACTTTTGCAAGCTCATCTTTGCCATCTACAAGATGAGCTTCTTCAGTGGCATGCTCCTACTTCTTTGCATCAGCATTGACCGCTACGTGGCCATCGTCCAGGCTGTCTCAGCTCACCGCCACCGTGCCCGCGTCCTTCTCATCAGCAAGCTGTCCTGTGTGGGCATCTGGATACTAGCCACAGTGCTCTCCATCCCAGAGCTCCTGTACAGTGACCTCCAGAGGAGCAGCAGTGAGCAAGCGATGCGATGCTCTCTCATCACAGAGCATGTGGAGGCCTTTATCACCATCCAGGTGGCCCAGATGGTGATCGGCTTTCTGGTCCCCCTGCTGGCCATGAGCTTCTGTTACCTTGTCATCATCCGCACCCTGCTCCAGGCACGCAACTTTGAGCGCAACAAGGCCATCAAGGTGATCATCGCTGTGGTCGTGGTCTTCATAGTCTTCCAGCTGCCCTACAATGGGGTGGTCCTGGCCCAGACGGTGGCCAACTTCAACATCACCAGTAGCACCTGTGAGCTCAGTAAGCAACTCAACATCGCCTACGACGTCACCTACA GCCTGGCCTGCGTCCGCTGCTGCGTCAACCCTTTCTTGTACGCCTTCATCGGCGTCAAGTTCCGCAACGATCTCTTCAAGCTCTTCAAGGACCTGGGCTGCCTCAGCCAGGAGCAGCTCCGGCAGTGGTCTTCCTGTCGGCACATCCGGCGCTCCTCCATGAGTGTGGAGGCCGAGACCACCACCACCTTCTCCCCATAGGCGACTCTTCTGCCTGGACTAGAGGGACCTCTCCCAGGGTCCCTGGGGTGGGGATAGGGAGCAGATGCAATGACTCAGGACATCCCCCCGCCAAAAGCTGCTCAGGGAAAAGCAGCTCTCCCCTCAGAGTGCAAGCCCCTGCTCCAGAAGATAGCTTCACCCCAATCCCAGCTACCTCAACCAATGCCAAAAAAAGACAGGGCTGATAAGCTAACACCAGACAGACAACACTGGGAAACAGAGGCTATTGTCCCCTAAACCAAAAACTGAAAGTGAAAGTCCAGAAACTGTTCCCACCTGCTGGAGTGAAGGGGCCAAGGAGGGTGAGTGCAAGGGGCGTGGGAGTGGCCTGAAGAGTCCTCTGAATGAACCTTCTGGCCTCCCACAGACTCAAATGCTCAGACCAGCTCTTCCGAAAACCAGGCCTTATCTCCAAGACCAGAGATAGTGGGGAGACTTCTTGGCTTGGTGAGGAAAAGCGGACATCAGCTGGTCAAACAAACTCTCTGAACCCCTCCCTCCATCGTTTTCTTCACTGTCCTCCAAGCCAGCGGGAATGGCAGCTGCCACGCCGCCCTAAAAGCACACTCATCCCCTCACTTGCCGCGTCGCCCTCCCAGGCTCTCAACAGGGGAGAGTGTGGTGTTTCCTGCAGGCCAGGCCAGCTGCCTCCGCGTGATCAAAGCCACACTCTGGGCTCCAGAGTGGGGATGACATGCACTCAGCTCTTGGCTCCACTGGGATGGGAGGAGAGGACAAGGGAAATGTCAGGGGCGGGGAGGGTGACAGTGGCCGCCCAA GGCCCACGAGCTTGTTCTTTGTTCTTTGTCACAGGGACTGAAAACCTCTCCTCATGTTCTGCTTTCGATTCGTTAAGAGAGCAACATTTTACCCACACACAGATAAAGTTTTCCCTTGAGGAAACAACAGCTTTAAAAGAAAAAAAGAAAAAAAGTCTTTGGTAAATGGCAAA

서열번호 26: CCR7 아미노산 서열SEQ ID NO: 26: CCR7 amino acid sequence

MDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSPMDLGKPMKSVLVVALLVIFQVCLCQDEVTDDYIGDNTTVDYTLFESLCSKKDVRNFKAWFLPIMYSIICFVGLLGNGLVVLTYIYFKRLKTMTDTYLLNLAVADILFLLTLPFWAYSAAKSWVFGVHFCKLIFAIYKMSFFSGMLLLLCISIDRYVAIVQAVSAHRHRARVLLISKLSCVGIWILATVLSIPELLYSDLQRSSSEQAMRCSLITEHVEAFITIQVAQMVIGFLVPLLAMSFCYLVIIRTLLQARNFERNKAIKVIIAVVVVFIVFQLPYNGVVLAQTVANFNITSSTCELSKQLNIAYDVTYSLACVRCCVNPFLYAFIGVKFRNDLFKLFKDLGCLSQEQLRQWSSCRHIRRSSMSVEAETTTTFSP

서열번호 27: CXCR3 mRNA 염기서열SEQ ID NO: 27: CXCR3 mRNA base sequence

CAAGCACCAAAGCAGAGGGGCAGGCAGCACACCACCCAGCAGCCAGAGCACCAGCCCAGCCATGGTCCTTGAGGGGTCCCTGGGCCGATGGGATCACGCAGAAGAATGCGAGAGAAGCAGCCTTTGAGAAGGGAAGTCACTATCCCAGAGCCCAGGCTGAGCGGATGGAGTTGAGGAAGTACGGCCCTGGAAGACTGGCGGGGACAGTTATAGGAGGAGCTGCTCAGAGTAAATCACAGACTAAATCAGACTCAATCACAAAAGAGTTCCTGCCAGGCCTTTACACAGCCCCTTCCTCCCCGTTCCCGCCCTCACAGGTGAGTGACCACCAAGTGCTAAATGACGCCGAGGTTGCCGCCCTCCTGGAGAACTTCAGCTCTTCCTATGACTATGGAGAAAACGAGAGTGACTCGTGCTGTACCTCCCCGCCCTGCCCACAGGACTTCAGCCTGAACTTCGACCGGGCCTTCCTGCCAGCCCTCTACAGCCTCCTCTTTCTGCTGGGGCTGCTGGGCAACGGCGCGGTGGCAGCCGTGCTGCTGAGCCGGCGGACAGCCCTGAGCAGCACCGACACCTTCCTGCTCCACCTAGCTGTAGCAGACACGCTGCTGGTGCTGACACTGCCGCTCTGGGCAGTGGACGCTGCCGTCCAGTGGGTCTTTGGCTCTGGCCTCTGCAAAGTGGCAGGTGCCCTCTTCAACATCAACTTCTACGCAGGAGCCCTCCTGCTGGCCTGCATCAGCTTTGACCGCTACCTGAACATAGTTCATGCCACCCAGCTCTACCGCCGGGGGCCCCCGGCCCGCGTGACCCTCACCTGCCTGGCTGTCTGGGGGCTCTGCCTGCTTTTCGCCCTCCCAGACTTCATCTTCCTGTCGGCCCACCACGACGAGCGCCTCAACGCCACCCACTGCCAATACAACTTCCCACAGGTGGGCCGCACGGCTCTGCGGGTGCTGCAGCTGGTGGCTGGCTTTCTGCTGCCCCTGCTGGTCATGGCCTACTGCTATGCCCACATCCTGGCCGTGCTGCTGGTTTCCAGGGGCCAGCGGCGCCTGCGGGCCATGCGGCTGGTGGTGGTGGTCGTGGTGGCCTTTGCCCTCTGCTGGACCCCCTATCACCTGGTGGTGCTGGTGGACATCCTCATGGACCTGGGCGCTTTGGCCCGCAACTGTGGCCGAGAAAGCAGGGTAGACGTGGCCAAGTCGGTCACCTCAGGCCTGGGCTACATGCACTGCTGCCTCAACCCGCTGCTCTATGCCTTTGTAGGGGTCAAGTTCCGGGAGCGGATGTGGATGCTGCTCTTGCGCCTGGGCTGCCCCAACCAGAGAGGGCTCCAGAGGCAGCCATCGTCTTCCCGCCGGGATTCATCCTGGTCTGAGACCTCAGAGGCCTCCTACTCGGGCTTGTGAGGCCGGAATCCGGGCTCCCCTTTCGCCCACAGTCTGACTTCCCCGCATTCCAGGCTCCTCCCTCCCTCTGCCGGCTCTGGCTCTCCCCAATATCCTCGCTCCCGGGACTCACTGGCAGCCCCAGCACCACCAGGTCTCCCGGGAAGCCACCCTCCCAGCTCTGAGGACTGCACCATTGCTGCTCCTTAGCTGCCAAGCCCCATCCTGCCGCCCGAGGTGGCTGCCTGGAGCCCCACTGCCCTTCTCATTTGGAAACTAAAACTTCATCTTCCCCAAGTGCGGGGAGTACAAGGCATGGCGTAGAGGGTGCTGCCCCATGAAGCCACAGCCCAGGCCTCCAGCTCAGCAGTGACTGTGGCCATGGTCCCCAAGACCTCTATATTTGCTCTTTTATTTTTATGTCTAAAATCCTGCTTAAAACTTTTCAATAAACAAGATCGTCAGGACCACAAGCACCAAAGCAGAGGGGCAGGCAGCACACCACCCAGCAGCCAGAGCACCAGCCCAGCCATGGTCCTTGAGGGGTCCCTGGGCCGATGGGATCACGCAGAAGAATGCGAGAGAAGCAGCCTTTGAGAAGGGAAGTCACTATCCCAGAGCCCAGGCTGAGCGGATGGAGTTGAGGAAGTACGGCCCTGGAAGACTGGCGGGGACAGTTATAGGAGGAGCTGCTCAGAGTAAATCACAGACTAAATCAGACTCAATCACAAAAGAGTTCCTGCCAGGCCTTTACACAGCCCCTTCCTCCCCGTTCCCGCCCTCACAGGTGAGTGACCACCAAGTGCTAAATGACGCCGAGGTTGCCGCCCTCCTGGAGAACTTCAGCTCTTCCTATGACTATGGAGAAAACGAGAGTGACTCGTGCTGTACCTCCCCGCCCTGCCCACAGGACTTCAGCCTGAACTTCGACCGGGCCTTCCTGCCAGCCCTCTACAGCCTCCTCTTTCTGCTGGGGCTGCTGGGCAACGGCGCGGTGGCAGCCGTGCTGCTGAGCCGGCGGACAGCCCTGAGCAGCACCGACACCTTCCTGCTCCACCTAGCTGTAGCAGACACGCTGCTGGTGCTGACACTGCCGCTCTGGGCAGTGGACGCTGCCGTCCAGTGGGTCTTTGGCTCTGGCCTCTGCAAAGTGGCAGGTGCCCTCTTCAACATCAACTTCTACGCAGGAGCCCTCCTGCTGGCCTGCATCAGCTTTGACCGCTACCTGAACATAGTTCATGCCACCCAGCTCTACCGCCGGGGGCCCCCGGCCCGCGTGACCCTCACCTGCCTGGCTGTCTGGGGGCTCTGCCTGCTTTTCGCCCTCCCAGACTTCATCTTCCTGTCGGCCCACCACGACGAGCGCCTCAACGCCACCCACTGCCAATACAACTTCCCACAGGTGGGCCGCACGGCTCTGCGGGTGCTGCAGCTGGTGGCTGGCTTTCTGCTGCCCCTGCTGGTCATGGC CTACTGCTATGCCCACATCCTGGCCGTGCTGCTGGTTTCCAGGGGCCAGCGGCGCCTGCGGGCCATGCGGCTGGTGGTGGTGGTCGTGGTGGCCTTTGCCCTCTGCTGGACCCCCTATCACCTGGTGGTGCTGGTGGACATCCTCATGGACCTGGGCGCTTTGGCCCGCAACTGTGGCCGAGAAAGCAGGGTAGACGTGGCCAAGTCGGTCACCTCAGGCCTGGGCTACATGCACTGCTGCCTCAACCCGCTGCTCTATGCCTTTGTAGGGGTCAAGTTCCGGGAGCGGATGTGGATGCTGCTCTTGCGCCTGGGCTGCCCCAACCAGAGAGGGCTCCAGAGGCAGCCATCGTCTTCCCGCCGGGATTCATCCTGGTCTGAGACCTCAGAGGCCTCCTACTCGGGCTTGTGAGGCCGGAATCCGGGCTCCCCTTTCGCCCACAGTCTGACTTCCCCGCATTCCAGGCTCCTCCCTCCCTCTGCCGGCTCTGGCTCTCCCCAATATCCTCGCTCCCGGGACTCACTGGCAGCCCCAGCACCACCAGGTCTCCCGGGAAGCCACCCTCCCAGCTCTGAGGACTGCACCATTGCTGCTCCTTAGCTGCCAAGCCCCATCCTGCCGCCCGAGGTGGCTGCCTGGAGCCCCACTGCCCTTCTCATTTGGAAACTAAAACTTCATCTTCCCCAAGTGCGGGGAGTACAAGGCATGGCGTAGAGGGTGCTGCCCCATGAAGCCACAGCCCAGGCCTCCAGCTCAGCAGTGACTGTGGCCATGGTCCCCAAGACCTCTATATTTGCTCTTTTATTTTTATGTCTAAAATCCTGCTTAAAACTTTTCAATAAACAAGATCGTCAGGACCA

서열번호 28: CXCR3 아미노산 서열SEQ ID NO: 28: CXCR3 amino acid sequence

*MVLEVSDHQVLNDAEVAALLENFSSSYDYGENESDSCCTSPPCPQDFSLNFDRAFLPALYSLLFLLGLLGNGAVAAVLLSRRTALSSTDTFLLHLAVADTLLVLTLPLWAVDAAVQWVFGSGLCKVAGALFNINFYAGALLLACISFDRYLNIVHATQLYRRGPPARVTLTCLAVWGLCLLFALPDFIFLSAHHDERLNATHCQYNFPQVGRTALRVLQLVAGFLLPLLVMAYCYAHILAVLLVSRGQRRLRAMRLVVVVVVAFALCWTPYHLVVLVDILMDLGALARNCGRESRVDVAKSVTSGLGYMHCCLNPLLYAFVGVKFRERMWMLLLRLGCPNQRGLQRQPSSSRRDSSWSETSEASYSGL*MVLEVSDHQVLNDAEVAALLENFSSSYDYGENESDSCCTSPPCPQDFSLNFDRAFLPALYSLLFLLGLLGNGAVAAVLLSRRTALSSTDTFLLHLAVADTLLVLTLPLWAVDAAVQWVFGSGLCKVAGALFNINFYAGALLLACISFDRYLNIVHATQLYRRGPPARVTLTCLAVWGLCLLFALPDFIFLSAHHDERLNATHCQYNFPQVGRTALRVLQLVAGFLLPLLVMAYCYAHILAVLLVSRGQRRLRAMRLVVVVVVAFALCWTPYHLVVLVDILMDLGALARNCGRESRVDVAKSVTSGLGYMHCCLNPLLYAFVGVKFRERMWMLLLRLGCPNQRGLQRQPSSSRRDSSWSETSEASYSGL

서열번호 29: CCR2 mRNA 염기서열SEQ ID NO: 29: CCR2 mRNA base sequence

TTTATTCTCTGGAACATGAAACATTCTGTTGTGCTCATATCATGCAAATTATCACTAGTAGGAGAGCAGAGAGTGGAAATGTTCCAGGTATAAAGACCCACAAGATAAAGAAGCTCAGAGTCGTTAGAAACAGGAGCAGATGTACAGGGTTTGCCTGACTCACACTCAAGGTTGCATAAGCAAGATTTCAAAATTAATCCTATTCTGGAGACCTCAACCCAATGTACAATGTTCCTGACTGGAAAAGAAGAACTATATTTTTCTGATTTTTTTTTTCAAATCTTTACCATTAGTTGCCCTGTATCTCCGCCTTCACTTTCTGCAGGAAACTTTATTTCCTACTTCTGCATGCCAAGTTTCTACCTCTAGATCTGTTTGGTTCAGTTGCTGAGAAGCCTGACATACCAGGACTGCCTGAGACAAGCCACAAGCTGAACAGAGAAAGTGGATTGAACAAGGACGCATTTCCCCAGTACATCCACAACATGCTGTCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGAGCGGTGAAGAAGTCACCACCTTTTTTGATTATGATTACGGTGCTCCCTGTCATAAATTTGACGTGAAGCAAATTGGGGCCCAACTCCTGCCTCCGCTCTACTCGCTGGTGTTCATCTTTGGTTTTGTGGGCAACATGCTGGTCGTCCTCATCTTAATAAACTGCAAAAAGCTGAAGTGCTTGACTGACATTTACCTGCTCAACCTGGCCATCTCTGATCTGCTTTTTCTTATTACTCTCCCATTGTGGGCTCACTCTGCTGCAAATGAGTGGGTCTTTGGGAATGCAATGTGCAAATTATTCACAGGGCTGTATCACATCGGTTATTTTGGCGGAATCTTCTTCATCATCCTCCTGACAATCGATAGATACCTGGCTATTGTCCATGCTGTGTTTGCTTTAAAAGCCAGGACGGTCACCTTTGGGGTGGTGACAAGTGTGATCACCTGGTTGGTGGCTGTGTTTGCTTCTGTCCCAGGAATCATCTTTACTAAATGCCAGAAAGAAGATTCTGTTTATGTCTGTGGCCCTTATTTTCCACGAGGATGGAATAATTTCCACACAATAATGAGGAACATTTTGGGGCTGGTCCTGCCGCTGCTCATCATGGTCATCTGCTACTCGGGAATCCTGAAAACCCTGCTTCGGTGTCGAAACGAGAAGAAGAGGCATAGGGCAGTGAGAGTCATCTTCACCATCATGATTGTTTACTTTCTCTTCTGGACTCCCTATAATATTGTCATTCTCCTGAACACCTTCCAGGAATTCTTCGGCCTGAGTAACTGTGAAAGCACCAGTCAACTGGACCAAGCCACGCAGGTGACAGAGACTCTTGGGATGACTCACTGCTGCATCAATCCCATCATCTATGCCTTCGTTGGGGAGAAGTTCAGAAGCCTTTTTCACATAGCTCTTGGCTGTAGGATTGCCCCACTCCAAAAACCAGTGTGTGGAGGTCCAGGAGTGAGACCAGGAAAGAATGTGAAAGTGACTACACAAGGACTCCTCGATGGTCGTGGAAAAGGAAAGTCAATTGGCAGAGCCCCTGAAGCCAGTCTTCAGGACAAAGAAGGAGCCTAGAGACAGAAATGACAGATCTCTGCTTTGGAAATCACACGTCTGGCTTCACAGATGTGTGATTCACAGTGTGAATCTTGGTGTCTACGTTACCAGGCAGGAAGGCTGAGAGGAGAGAGACTCCAGCTGGGTTGGAAAACAGTATTTTCCAAACTACCTTCCAGTTCCTCATTTTTGAATACAGGCATAGAGTTCAGACTTTTTTTAAATAGTAAAAATAAAATTAAAGCTGAAAACTGCAACTTGTAAATGTGGTAAAGAGTTAGTTTGAGTTACTATCATGTCAAACGTGAAAATGCTGTATTAGTCACAGAGATAATTCTAGCTTTGAGCTTAAGAATTTTGAGCAGGTGGTATGTTTGGGAGACTGCTGAGTCAACCCAATAGTTGTTGATTGGCAGGAGTTGGAAGTGTGTGATCTGTGGGCACATTAGCCTATGTGCATGCAGCATCTAAGTAATGATGTCGTTTGAATCACAGTATACGCTCCATCGCTGTCATCTCAGCTGGATCTCCATTCTCTCAGGCTTGCTGCCAAAAGCCTTTTGTGTTTTGTTTTGTATCATTATGAAGTCATGCGTTTAATCACATTCGAGTGTTTCAGTGCTTCGCAGATGTCCTTGATGCTCATATTGTTCCCTATTTTGCCAGTGGGAACTCCTAAATCAAGTTGGCTTCTAATCAAAGCTTTTAAACCCTATTGGTAAAGAATGGAAGGTGGAGAAGCTCCCTGAAGTAAGCAAAGACTTTCCTCTTAGTCGAGCCAAGTTAAGAATGTTCTTATGTTGCCCAGTGTGTTTCTGATCTGATGCAAGCAAGAAACACTGGGCTTCTAGAACCAGGCAACTTGGGAACTAGACTCCCAAGCTGGACTATGGCTCTACTTTCAGGCCACATGGCTAAAGAAGGTTTCAGAAAGAAGTGGGGACAGAGCAGAACTTTCACCTTCATATATTTGTATGATCCTAATGAATGCATAAAATGTTAAGTTGATGGTGATGAAATGTAAATACTGTTTTTAACAACTATGATTTGGAAAATAAATCAATGCTATAACTATGTTGTTTATTCTCTGGAACATGAAACATTCTGTTGTGCTCATATCATGCAAATTATCACTAGTAGGAGAGCAGAGAGTGGAAATGTTCCAGGTATAAAGACCCACAAGATAAAGAAGCTCAGAGTCGTTAGAAACAGGAGCAGATGTACAGGGTTTGCCTGACTCACACTCAAGGTTGCATAAGCAAGATTTCAAAATTAATCCTATTCTGGAGACCTCAACCCAATGTACAATGTTCCTGACTGGAAAAGAAGAACTATATTTTTCTGATTTTTTTTTTCAAATCTTTACCATTAGTTGCCCTGTATCTCCGCCTTCACTTTCTGCAGGAAACTTTATTTCCTACTTCTGCATGCCAAGTTTCTACCTCTAGATCTGTTTGGTTCAGTTGCTGAGAAGCCTGACATACCAGGACTGCCTGAGACAAGCCACAAGCTGAACAGAGAAAGTGGATTGAACAAGGACGCATTTCCCCAGTACATCCACAACATGCTGTCCACATCTCGTTCTCGGTTTATCAGAAATACCAACGAGAGCGGTGAAGAAGTCACCACCTTTTTTGATTATGATTACGGTGCTCCCTGTCATAAATTTGACGTGAAGCAAATTGGGGCCCAACTCCTGCCTCCGCTCTACTCGCTGGTGTTCATCTTTGGTTTTGTGGGCAACATGCTGGTCGTCCTCATCTTAATAAACTGCAAAAAGCTGAAGTGCTTGACTGACATTTACCTGCTCAACCTGGCCATCTCTGATCTGCTTTTTCTTATTACTCTCCCATTGTGGGCTCACTCTGCTGCAAATGAGTGGGTCTTTGGGAATGCAATGTGCAAATTATTCACAGGGCTGTATCACATCGGTTATTTTGGCGGAATCTTCTTCATCATCCTCCTGACAATCGATAGATACCTGGCTATTGTCCATGCTGTGTTTGCTTTAAAAGCCAGGACGGTCACCTTTGGGGTGGTGACAAGTGTGATCACCTGGTTGGTGGCTGTGTTTGCTTC TGTCCCAGGAATCATCTTTACTAAATGCCAGAAAGAAGATTCTGTTTATGTCTGTGGCCCTTATTTTCCACGAGGATGGAATAATTTCCACACAATAATGAGGAACATTTTGGGGCTGGTCCTGCCGCTGCTCATCATGGTCATCTGCTACTCGGGAATCCTGAAAACCCTGCTTCGGTGTCGAAACGAGAAGAAGAGGCATAGGGCAGTGAGAGTCATCTTCACCATCATGATTGTTTACTTTCTCTTCTGGACTCCCTATAATATTGTCATTCTCCTGAACACCTTCCAGGAATTCTTCGGCCTGAGTAACTGTGAAAGCACCAGTCAACTGGACCAAGCCACGCAGGTGACAGAGACTCTTGGGATGACTCACTGCTGCATCAATCCCATCATCTATGCCTTCGTTGGGGAGAAGTTCAGAAGCCTTTTTCACATAGCTCTTGGCTGTAGGATTGCCCCACTCCAAAAACCAGTGTGTGGAGGTCCAGGAGTGAGACCAGGAAAGAATGTGAAAGTGACTACACAAGGACTCCTCGATGGTCGTGGAAAAGGAAAGTCAATTGGCAGAGCCCCTGAAGCCAGTCTTCAGGACAAAGAAGGAGCCTAGAGACAGAAATGACAGATCTCTGCTTTGGAAATCACACGTCTGGCTTCACAGATGTGTGATTCACAGTGTGAATCTTGGTGTCTACGTTACCAGGCAGGAAGGCTGAGAGGAGAGAGACTCCAGCTGGGTTGGAAAACAGTATTTTCCAAACTACCTTCCAGTTCCTCATTTTTGAATACAGGCATAGAGTTCAGACTTTTTTTAAATAGTAAAAATAAAATTAAAGCTGAAAACTGCAACTTGTAAATGTGGTAAAGAGTTAGTTTGAGTTACTATCATGTCAAACGTGAAAATGCTGTATTAGTCACAGAGATAATTCTAGCTTTGAGCTTAAGAATTTTGAGCAGGTGGTATGTTTGGGAGACTGCTGAGTCAACCCAATAGTTGTTG ATTGGCAGGAGTTGGAAGTGTGTGATCTGTGGGCACATTAGCCTATGTGCATGCAGCATCTAAGTAATGATGTCGTTTGAATCACAGTATACGCTCCATCGCTGTCATCTCAGCTGGATCTCCATTCTCTCAGGCTTGCTGCCAAAAGCCTTTTGTGTTTTGTTTTGTATCATTATGAAGTCATGCGTTTAATCACATTCGAGTGTTTCAGTGCTTCGCAGATGTCCTTGATGCTCATATTGTTCCCTATTTTGCCAGTGGGAACTCCTAAATCAAGTTGGCTTCTAATCAAAGCTTTTAAACCCTATTGGTAAAGAATGGAAGGTGGAGAAGCTCCCTGAAGTAAGCAAAGACTTTCCTCTTAGTCGAGCCAAGTTAAGAATGTTCTTATGTTGCCCAGTGTGTTTCTGATCTGATGCAAGCAAGAAACACTGGGCTTCTAGAACCAGGCAACTTGGGAACTAGACTCCCAAGCTGGACTATGGCTCTACTTTCAGGCCACATGGCTAAAGAAGGTTTCAGAAAGAAGTGGGGACAGAGCAGAACTTTCACCTTCATATATTTGTATGATCCTAATGAATGCATAAAATGTTAAGTTGATGGTGATGAAATGTAAATACTGTTTTTAACAACTATGATTTGGAAAATAAATCAATGCTATAACTATGTTG

서열번호 30: CCR2 아미노산 서열SEQ ID NO: 30: CCR2 amino acid sequence

MLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYSLVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAHSAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALKARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNNFHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVIFTIMIVYFLFWTPYNIVILLNTFQEFFGLSNCESTSQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSLFHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGLLDGRGKGKSIGRAPEASLQDKEGAMLSTSRSRFIRNTNESGEEVTTFFDYDYGAPCHKFDVKQIGAQLLPPLYSLVFIFGFVGNMLVVLILINCKKLKCLTDIYLLNLAISDLLFLITLPLWAHSAANEWVFGNAMCKLFTGLYHIGYFGGIFFIILLTIDRYLAIVHAVFALKARTVTFGVVTSVITWLVAVFASVPGIIFTKCQKEDSVYVCGPYFPRGWNNFHTIMRNILGLVLPLLIMVICYSGILKTLLRCRNEKKRHRAVRVIFTIMIVYFLFWTPYNIVILLNTFQEFFGLSNCESTSQLDQATQVTETLGMTHCCINPIIYAFVGEKFRSLFHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGLLDGRGKGKSIGRAPEASLQDKEGA

*서열번호 31: CCR10 mRNA 염기서열* SEQ ID NO: 31: CCR10 mRNA base sequence

AGAAACCTGTGTAGCCAGAGATGGGGACGGAGGCCACAGAGCAGGTTTCCTGGGGCCATTACTCTGGGGATGAAGAGGACGCATACTCGGCTGAGCCACTGCCGGAGCTTTGCTACAAGGCCGATGTCCAGGCCTTCAGCCGGGCCTTCCAACCCAGTGTCTCCCTGACCGTGGCTGCGCTGGGTCTGGCCGGCAATGGCCTGGTCCTGGCCACCCACCTGGCAGCCCGACGCGCAGCGCGCTCGCCCACCTCTGCCCACCTGCTCCAGCTGGCCCTGGCCGACCTCTTGCTGGCCCTGACTCTGCCCTTCGCGGCAGCAGGGGCTCTTCAGGGCTGGAGTCTGGGAAGTGCCACCTGCCGCACCATCTCTGGCCTCTACTCGGCCTCCTTCCACGCCGGCTTCCTCTTCCTGGCCTGTATCAGCGCCGACCGCTACGTGGCCATCGCGCGAGCGCTCCCAGCCGGGCCGCGGCCCTCCACTCCCGGCCGCGCACACTTGGTCTCCGTCATCGTGTGGCTGCTGTCACTGCTCCTGGCGCTGCCTGCGCTGCTCTTCAGCCAGGATGGGCAGCGGGAAGGCCAACGACGCTGTCGCCTCATCTTCCCCGAGGGCCTCACGCAGACGGTGAAGGGGGCGAGCGCCGTGGCGCAGGTGGCCCTGGGCTTCGCGCTGCCGCTGGGCGTCATGGTAGCCTGCTACGCGCTTCTGGGCCGCACGCTGCTGGCCGCCAGGGGGCCCGAGCGCCGGCGTGCGCTGCGCGTCGTGGTGGCTCTGGTGGCGGCCTTCGTGGTGCTGCAGCTGCCCTACAGCCTCGCCCTGCTGCTGGATACTGCCGATCTACTGGCTGCGCGCGAGCGGAGCTGCCCTGCCAGCAAACGCAAGGATGTCGCACTGCTGGTGACCAGCGGCTTGGCCCTCGCCCGCTGTGGCCTCAATCCCGTTCTCTACGCCTTCCTGGGCCTGCGCTTCCGCCAGGACCTGCGGAGGCTGCTACGGGGTGGGAGCTGCCCCTCAGGGCCTCAACCCCGCCGCGGCTGCCCCCGCCGGCCCCGCCTTTCTTCCTGCTCAGCTCCCACGGAGACCCACAGTCTCTCCTGGGACAACTAGGGCTGCGAATCTAGAGGAGGGGGCAGGCTGAGGGTCGTGGGAAAGGGGAGTAGGTGGGGGAACACTGAGAAAGAGGCAGGGACCTAAAGGGACTACCTCTGTGCCTTGCCACATTAAATTGATAACATGGAAATGAGATGCAACCCAACAACTGTTACTATTTTTGAGTCACCGACTTGGAAGTGATTTGTGGCGGGGCAGAACCGGTGGGTTAACACCCCGCCCCCGCCCCACCCCCCGCCCTGCCCCGCGCTTGGCTCTCTGAGTGGAAGACGCTGAGGGCCTGGGTGGGGGTGGGGGGCTGCTGAGTCTGCTAAAGCTCTAGCCACTGACACCCCCTCCACCGTCACCTGGCCTCAGCCAACAGAGGTGAGGTGGGAAAGCTGCCAGGCAAGGAGGGGCGGTGGTTCCTCTTGCAATACTGTAAGGAAGAGCTTTCTAACAACCAGAGCGCTCTCCAGTAATGGCTGCCTTAGCAAATACTGAGTTCCCGCTATTGGAATGTTCAGACTGTCGGGGACGCTGTGGGCCTTTGCGTGGTGTGGGGGGAGGGGGAGGGGCAGGGGATTCCCGTTTTTGGTGGGCGTTTGGATTTCATAACCACTTTACAATCCCTTCCTAGTGTCTGTGATGGAAAGAAAAAATGAAAAAATGAATTGTAAAAAGAAACCTGTGTAGCCAGAGATGGGGACGGAGGCCACAGAGCAGGTTTCCTGGGGCCATTACTCTGGGGATGAAGAGGACGCATACTCGGCTGAGCCACTGCCGGAGCTTTGCTACAAGGCCGATGTCCAGGCCTTCAGCCGGGCCTTCCAACCCAGTGTCTCCCTGACCGTGGCTGCGCTGGGTCTGGCCGGCAATGGCCTGGTCCTGGCCACCCACCTGGCAGCCCGACGCGCAGCGCGCTCGCCCACCTCTGCCCACCTGCTCCAGCTGGCCCTGGCCGACCTCTTGCTGGCCCTGACTCTGCCCTTCGCGGCAGCAGGGGCTCTTCAGGGCTGGAGTCTGGGAAGTGCCACCTGCCGCACCATCTCTGGCCTCTACTCGGCCTCCTTCCACGCCGGCTTCCTCTTCCTGGCCTGTATCAGCGCCGACCGCTACGTGGCCATCGCGCGAGCGCTCCCAGCCGGGCCGCGGCCCTCCACTCCCGGCCGCGCACACTTGGTCTCCGTCATCGTGTGGCTGCTGTCACTGCTCCTGGCGCTGCCTGCGCTGCTCTTCAGCCAGGATGGGCAGCGGGAAGGCCAACGACGCTGTCGCCTCATCTTCCCCGAGGGCCTCACGCAGACGGTGAAGGGGGCGAGCGCCGTGGCGCAGGTGGCCCTGGGCTTCGCGCTGCCGCTGGGCGTCATGGTAGCCTGCTACGCGCTTCTGGGCCGCACGCTGCTGGCCGCCAGGGGGCCCGAGCGCCGGCGTGCGCTGCGCGTCGTGGTGGCTCTGGTGGCGGCCTTCGTGGTGCTGCAGCTGCCCTACAGCCTCGCCCTGCTGCTGGATACTGCCGATCTACTGGCTGCGCGCGAGCGGAGCTGCCCTGCCAGCAAACGCAAGGATGTCGCACTGCTGGTGACCAGCGGCTTGGCCCTCGCCCGCTGTGGCCTCAATCCCGTTCTCTACGCCTTCCTGGGCCTGCGCTTCCGCCAGGACCTGCGGAGGCTGCTACGGGG TGGGAGCTGCCCCTCAGGGCCTCAACCCCGCCGCGGCTGCCCCCGCCGGCCCCGCCTTTCTTCCTGCTCAGCTCCCACGGAGACCCACAGTCTCTCCTGGGACAACTAGGGCTGCGAATCTAGAGGAGGGGGCAGGCTGAGGGTCGTGGGAAAGGGGAGTAGGTGGGGGAACACTGAGAAAGAGGCAGGGACCTAAAGGGACTACCTCTGTGCCTTGCCACATTAAATTGATAACATGGAAATGAGATGCAACCCAACAACTGTTACTATTTTTGAGTCACCGACTTGGAAGTGATTTGTGGCGGGGCAGAACCGGTGGGTTAACACCCCGCCCCCGCCCCACCCCCCGCCCTGCCCCGCGCTTGGCTCTCTGAGTGGAAGACGCTGAGGGCCTGGGTGGGGGTGGGGGGCTGCTGAGTCTGCTAAAGCTCTAGCCACTGACACCCCCTCCACCGTCACCTGGCCTCAGCCAACAGAGGTGAGGTGGGAAAGCTGCCAGGCAAGGAGGGGCGGTGGTTCCTCTTGCAATACTGTAAGGAAGAGCTTTCTAACAACCAGAGCGCTCTCCAGTAATGGCTGCCTTAGCAAATACTGAGTTCCCGCTATTGGAATGTTCAGACTGTCGGGGACGCTGTGGGCCTTTGCGTGGTGTGGGGGGAGGGGGAGGGGCAGGGGATTCCCGTTTTTGGTGGGCGTTTGGATTTCATAACCACTTTACAATCCCTTCCTAGTGTCTGTGATGGAAAGAAAAAATGAAAAAATGAATTGTAAAA

서열번호 32: CCR10 아미노산 서열SEQ ID NO: 32: CCR10 amino acid sequence

MGTEATEQVSWGHYSGDEEDAYSAEPLPELCYKADVQAFSRAFQPSVSLTVAALGLAGNGLVLATHLAARRAARSPTSAHLLQLALADLLLALTLPFAAAGALQGWSLGSATCRTISGLYSASFHAGFLFLACISADRYVAIARALPAGPRPSTPGRAHLVSVIVWLLSLLLALPALLFSQDGQREGQRRCRLIFPEGLTQTVKGASAVAQVALGFALPLGVMVACYALLGRTLLAARGPERRRALRVVVALVAAFVVLQLPYSLALLLDTADLLAARERSCPASKRKDVALLVTSGLALARCGLNPVLYAFLGLRFRQDLRRLLRGGSCPSGPQPRRGCPRRPRLSSCSAPTETHSLSWDNMGTEATEQVSWGHYSGDEEDAYSAEPLPELCYKADVQAFSRAFQPSVSLTVAALGLAGNGLVLATHLAARRAARSPTSAHLLQLALADLLLALTLPFAAAGALQGWSLGSATCRTISGLYSASFHAGFLFLACISADRYVAIARALPAGPRPSTPGRAHLVSVIVWLLSLLLALPALLFSQDGQREGQRRCRLIFPEGLTQTVKGASAVAQVALGFALPLGVMVACYALLGRTLLAARGPERRRALRVVVALVAAFVVLQLPYSLALLLDTADLLAARERSCPASKRKDVALLVTSGLALARCGLNPVLYAFLGLRFRQDLRRLLRGGSCPSGPQPRRGCPRRPRLSSCSAPTETHSLSWDN

서열번호 33: CCR4 mRNA 염기서열SEQ ID NO: 33: CCR4 mRNA base sequence

GGCATTGCCTCACAGACCTTCCTCAGAGCCGCTTTCAGAAAAGCAAGCTGCTTCTGGTTGGGCCCAGACCTGCCTTGAGGAGCCTGTAGAGTTAAAAAATGAACCCCACGGATATAGCAGACACCACCCTCGATGAAAGCATATACAGCAATTACTATCTGTATGAAAGTATCCCCAAGCCTTGCACCAAAGAAGGCATCAAGGCATTTGGGGAGCTCTTCCTGCCCCCACTGTATTCCTTGGTTTTTGTATTTGGTCTGCTTGGAAATTCTGTGGTGGTTCTGGTCCTGTTCAAATACAAGCGGCTCAGGTCCATGACTGATGTGTACCTGCTCAACCTTGCCATCTCGGATCTGCTCTTCGTGTTTTCCCTCCCTTTTTGGGGCTACTATGCAGCAGACCAGTGGGTTTTTGGGCTAGGTCTGTGCAAGATGATTTCCTGGATGTACTTGGTGGGCTTTTACAGTGGCATATTCTTTGTCATGCTCATGAGCATTGATAGATACCTGGCAATTGTGCACGCGGTGTTTTCCTTGAGGGCAAGGACCTTGACTTATGGGGTCATCACCAGTTTGGCTACATGGTCAGTGGCTGTGTTCGCCTCCCTTCCTGGCTTTCTGTTCAGCACTTGTTATACTGAGCGCAACCATACCTACTGCAAAACCAAGTACTCTCTCAACTCCACGACGTGGAAGGTTCTCAGCTCCCTGGAAATCAACATTCTCGGATTGGTGATCCCCTTAGGGATCATGCTGTTTTGCTACTCCATGATCATCAGGACCTTGCAGCATTGTAAAAATGAGAAGAAGAACAAGGCGGTGAAGATGATCTTTGCCGTGGTGGTCCTCTTCCTTGGGTTCTGGACACCTTACAACATAGTGCTCTTCCTAGAGACCCTGGTGGAGCTAGAAGTCCTTCAGGACTGCACCTTTGAAAGATACTTGGACTATGCCATCCAGGCCACAGAAACTCTGGCTTTTGTTCACTGCTGCCTTAATCCCATCATCTACTTTTTTCTGGGGGAGAAATTTCGCAAGTACATCCTACAGCTCTTCAAAACCTGCAGGGGCCTTTTTGTGCTCTGCCAATACTGTGGGCTCCTCCAAATTTACTCTGCTGACACCCCCAGCTCATCTTACACGCAGTCCACCATGGATCATGATCTCCATGATGCTCTGTAGAAAAATGAAATGGTGAAATGCAGAGTCAATGAACTTTCCACATTCAGAGCTTACTTAAAATTGTATTTTAGTAAGAGATTCCTGAGCCAGTGTCAGGAGGAAGGCTTACACCCACAGTGGAAAGACAGCTTCTCATCCTGCAGGCAGCTTTTTCTCTCCCACTAGACAAGTCCAGCCTGGCAAGGGTTCACCTGGGCTGAGGCATCCTTCCTCACACCAGGCTTGCCTGCAGGCATGAGTCAGTCTGATGAGAACTCTGAGCAGTGCTTGAATGAAGTTGTAGGTAATATTGCAAGGCAAAGACTATTCCCTTCTAACCTGAACTGATGGGTTTCTCCAGAGGGAATTGCAGAGTACTGGCTGATGGAGTAAATCGCTACCTTTTGCTGTGGCAAATGGGCCCTCTAATTAATTTCTTGCTTTTGCGGAACAATATAGATAACTGTTTTTCTAATAACATATCTCAGGCAAAGTATATTCCATTGAGCCAGATGTATGAAGAAACAATTAGCGAAGTGATGAAACCAGATCTCAATTATTTATTGTAAAGGATTATCTGTTAATTGAAACCAAACTTTTTATACTGATATAAGGGTAAGGATATGAAGACATTAGCCAAGGTCTGCTTTCCAAACGTGAACTACAAGGCATTCAAAATCCAAACATATTTATGAAAATTCAAACACAGTTTCTCACTTGTTTGTGGACATGTTTTGTTCTAATTTTAACAGAGGAATATTAAAAAATTTTAAATAGGCTGGGCACGGTGGCCTGTAATCCCAGCACTGTGGGAGGCCAAGGTGGGCGGATCACCTGAGGTCAGGAGTTCGAGACCAGCCTGGCCAACATGGAGAAACCCTGTCTCTACTAAAAAATACAAAATTAGCCAGGTGTGGTGGCGCATGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCTGGAGAATAACTTGAATCCGGGAGGTGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGTACTCCAACCTGGGCAAAAAGAGCGAAACTCTGTCTCAAAAAAAAAAAAAAAAAATTAAATAATACATAGGCCAAGAATACATTTATTTGAGGTCATTTACTTGTTTTTTTTTTTTTTTTTTTTTTTGAGATGGAATCTTGCTCTGTCACCCAGTCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTCTGCCTCACGGGTTCGCACCATTCTCCTGCCTCAGCCTCCCAAGTAGGTGGGACTACAGGCACCTGCCCCCATGCCTGGCTAATTTTTTGTATTTTCAGTAGAGATGGGGTTTCACCATGTTAGCAAGGATGGTTTTAATCTCCTGACCTCGTGATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCATCACGCCCGGCCACTTGTTTATTTTTTATTTTATTTTATTTTATTTTTGAGATGGAGTCTCACTCTGTCACCCAAGCTGGAGTGCAGTGGCACTCGGTTCACTGCAAAGTCTGCCTCCCAGGTTCAAGCGATTCTCCTGCCTCAGCTTCTCAAGCAGCTGGGATTAGAGGTGTGCACCACTACGCCAGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATATTGGCCAGGCTAGTCTTGAACTCCTGACCTCAGGTGATCTGCCTGCTTCAGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCTCGCCCAGCCAAGGTCTTTTACTTGTTTATAAACAGTCTCTTCATAATTAAAATTAAGGATTAATAAAGTATGACAATACCTCCTTAATCATTTTGAAGTGCCTGCTATCAATTGAAATAAAAACAATCAACTAAAAGGCATTGCCTCACAGACCTTCCTCAGAGCCGCTTTCAGAAAAGCAAGCTGCTTCTGGTTGGGCCCAGACCTGCCTTGAGGAGCCTGTAGAGTTAAAAAATGAACCCCACGGATATAGCAGACACCACCCTCGATGAAAGCATATACAGCAATTACTATCTGTATGAAAGTATCCCCAAGCCTTGCACCAAAGAAGGCATCAAGGCATTTGGGGAGCTCTTCCTGCCCCCACTGTATTCCTTGGTTTTTGTATTTGGTCTGCTTGGAAATTCTGTGGTGGTTCTGGTCCTGTTCAAATACAAGCGGCTCAGGTCCATGACTGATGTGTACCTGCTCAACCTTGCCATCTCGGATCTGCTCTTCGTGTTTTCCCTCCCTTTTTGGGGCTACTATGCAGCAGACCAGTGGGTTTTTGGGCTAGGTCTGTGCAAGATGATTTCCTGGATGTACTTGGTGGGCTTTTACAGTGGCATATTCTTTGTCATGCTCATGAGCATTGATAGATACCTGGCAATTGTGCACGCGGTGTTTTCCTTGAGGGCAAGGACCTTGACTTATGGGGTCATCACCAGTTTGGCTACATGGTCAGTGGCTGTGTTCGCCTCCCTTCCTGGCTTTCTGTTCAGCACTTGTTATACTGAGCGCAACCATACCTACTGCAAAACCAAGTACTCTCTCAACTCCACGACGTGGAAGGTTCTCAGCTCCCTGGAAATCAACATTCTCGGATTGGTGATCCCCTTAGGGATCATGCTGTTTTGCTACTCCATGATCATCAGGACCTTGCAGCATTGTAAAAATGAGAAGAAGAACAAGGCGGTGAAGATGATCTTTGCCGTGGTGGTCCTCTTCCTTGGGTTCTGGACACCTTACAACATAGTGCTCTTCCTAGAGACCCTGGTGGAGCTAGAAGTCCTTCAGGACTGCACCTTTGAAAGATACTTGGACTATGCCATCCAGGCCACAGAAACTCTGGCTTTTGTTCACTGCTGCCTTAATCC CATCATCTACTTTTTTCTGGGGGAGAAATTTCGCAAGTACATCCTACAGCTCTTCAAAACCTGCAGGGGCCTTTTTGTGCTCTGCCAATACTGTGGGCTCCTCCAAATTTACTCTGCTGACACCCCCAGCTCATCTTACACGCAGTCCACCATGGATCATGATCTCCATGATGCTCTGTAGAAAAATGAAATGGTGAAATGCAGAGTCAATGAACTTTCCACATTCAGAGCTTACTTAAAATTGTATTTTAGTAAGAGATTCCTGAGCCAGTGTCAGGAGGAAGGCTTACACCCACAGTGGAAAGACAGCTTCTCATCCTGCAGGCAGCTTTTTCTCTCCCACTAGACAAGTCCAGCCTGGCAAGGGTTCACCTGGGCTGAGGCATCCTTCCTCACACCAGGCTTGCCTGCAGGCATGAGTCAGTCTGATGAGAACTCTGAGCAGTGCTTGAATGAAGTTGTAGGTAATATTGCAAGGCAAAGACTATTCCCTTCTAACCTGAACTGATGGGTTTCTCCAGAGGGAATTGCAGAGTACTGGCTGATGGAGTAAATCGCTACCTTTTGCTGTGGCAAATGGGCCCTCTAATTAATTTCTTGCTTTTGCGGAACAATATAGATAACTGTTTTTCTAATAACATATCTCAGGCAAAGTATATTCCATTGAGCCAGATGTATGAAGAAACAATTAGCGAAGTGATGAAACCAGATCTCAATTATTTATTGTAAAGGATTATCTGTTAATTGAAACCAAACTTTTTATACTGATATAAGGGTAAGGATATGAAGACATTAGCCAAGGTCTGCTTTCCAAACGTGAACTACAAGGCATTCAAAATCCAAACATATTTATGAAAATTCAAACACAGTTTCTCACTTGTTTGTGGACATGTTTTGTTCTAATTTTAACAGAGGAATATTAAAAAATTTTAAATAGGCTGGGCACGGTGGCCTGTAATCCCAGCACTGTGGGAGGCCAAGGTGGGCGGATCACCTGAGG TCAGGAGTTCGAGACCAGCCTGGCCAACATGGAGAAACCCTGTCTCTACTAAAAAATACAAAATTAGCCAGGTGTGGTGGCGCATGCCTGTAATCCCAGCTACTCAGGAGGCTGAGGCTGGAGAATAACTTGAATCCGGGAGGTGGAGGTTGCGGTGAGCCGAGATCGCGCCATTGTACTCCAACCTGGGCAAAAAGAGCGAAACTCTGTCTCAAAAAAAAAAAAAAAAAATTAAATAATACATAGGCCAAGAATACATTTATTTGAGGTCATTTACTTGTTTTTTTTTTTTTTTTTTTTTTTGAGATGGAATCTTGCTCTGTCACCCAGTCTGGAGTGCAGTGGCGCGATCTCGGCTCACTGCAAGCTCTGCCTCACGGGTTCGCACCATTCTCCTGCCTCAGCCTCCCAAGTAGGTGGGACTACAGGCACCTGCCCCCATGCCTGGCTAATTTTTTGTATTTTCAGTAGAGATGGGGTTTCACCATGTTAGCAAGGATGGTTTTAATCTCCTGACCTCGTGATCCACCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGTGTGAGCCATCACGCCCGGCCACTTGTTTATTTTTTATTTTATTTTATTTTATTTTTGAGATGGAGTCTCACTCTGTCACCCAAGCTGGAGTGCAGTGGCACTCGGTTCACTGCAAAGTCTGCCTCCCAGGTTCAAGCGATTCTCCTGCCTCAGCTTCTCAAGCAGCTGGGATTAGAGGTGTGCACCACTACGCCAGGCTAATTTTTGTATTTTTAGTAGAGATGGGGTTTCACCATATTGGCCAGGCTAGTCTTGAACTCCTGACCTCAGGTGATCTGCCTGCTTCAGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCTCGCCCAGCCAAGGTCTTTTACTTGTTTATAAACAGTCTCTTCATAATTAAAATTAAGGATTAATAAAGTATGACAATACCTCCTTAATCATTTTGAAGTGCCTGCTATCAA TTGAAATAAAAACAATCAACTAAAA

서열번호 34: CCR4 아미노산 서열SEQ ID NO: 34: CCR4 amino acid sequence

MNPTDIADTTLDESIYSNYYLYESIPKPCTKEGIKAFGELFLPPLYSLVFVFGLLGNSVVVLVLFKYKRLRSMTDVYLLNLAISDLLFVFSLPFWGYYAADQWVFGLGLCKMISWMYLVGFYSGIFFVMLMSIDRYLAIVHAVFSLRARTLTYGVITSLATWSVAVFASLPGFLFSTCYTERNHTYCKTKYSLNSTTWKVLSSLEINILGLVIPLGIMLFCYSMIIRTLQHCKNEKKNKAVKMIFAVVVLFLGFWTPYNIVLFLETLVELEVLQDCTFERYLDYAIQATETLAFVHCCLNPIIYFFLGEKFRKYILQLFKTCRGLFVLCQYCGLLQIYSADTPSSSYTQSTMDHDLHDALMNPTDIADTTLDESIYSNYYLYESIPKPCTKEGIKAFGELFLPPLYSLVFVFGLLGNSVVVLVLFKYKRLRSMTDVYLLNLAISDLLFVFSLPFWGYYAADQWVFGLGLCKMISWMYLVGFYSGIFFVMLMSIDRYLAIVHAVFSLRARTLTYGVITSLATWSVAVFASLPGFLFSTCYTERNHTYCKTKYSLNSTTWKVLSSLEINILGLVIPLGIMLFCYSMIIRTLQHCKNEKKNKAVKMIFAVVVLFLGFWTPYNIVLFLETLVELEVLQDCTFERYLDYAIQATETLAFVHCCLNPIIYFFLGEKFRKYILQLFKTCRGLFVLCQYCGLLQIYSADTPSSSYTQSTMDHDLHDAL

본 발명은 코로나바이러스감염증-19 중증 환자 진단용 조성물에 관한 것으로서, 목적하는 개체의 대식세포, B 세포 및 플라즈마 세포로부터 유래된 다양한 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준을 비교함으로써 항체 의존적 감염 촉진 현상이 유도되며, B 세포가 활성화될 뿐만 아니라 과도한 염증반응이 일어나는 코로나바이러스감염증-19 중증 환자를 특이적으로 진단해낼 수 있다.The present invention relates to a composition for diagnosing a patient with severe coronavirus infection-19, comprising: a variety of genes derived from macrophages, B cells and plasma cells of a target individual; Alternatively, by comparing the expression level of the protein encoded by it, an antibody-dependent infection promotion phenomenon is induced, and it is possible to specifically diagnose a severe patient with coronavirus infection-19, in which B cells are activated as well as an excessive inflammatory response.

도 1은 본 발명의 일 실시예에 따른 염증반응과 관련된 유전자의 발현 수준을 비교한 결과를 나타낸 것이다.
도 2는 본 발명의 일 실시예에 따른 염증 반응 유전자 세트의 유의성을 유전자 세트 농축 분석 결과를 나타낸 것이다.
도 3은 본 발명의 일 실시예에 따른 항체 불변부위 수용체(Fc receptor)의 발현 수준을 비교한 결과를 나타낸 것이다.
도 4는 본 발명의 일 실시예에 따른 항체 불변부위 수용체로 활성화되는 대식 작용 및 이와 관련된 세포신호전달과 관련된 유전자 세트의 유의성을 분석한 결과를 나타낸 것이다.
도 5 내지 도 6은 본 발명의 일 실시예에 따른 항체 불변부위 수용체로 활성화되는 대식 작용 및 이와 관련된 세포신호전달과 관련된 유전자 세트의 유의성을 유전자 세트 농축 분석 통해 분석한 결과를 나타낸 것이다.
도 7은 본 발명의 일 실시예에 따른 B 세포 활성인자의 유전자 발현 특징 비교한 결과를 나타낸 것이다.
도 8은 본 발명의 일 실시예에 따른 B 세포의 항체 유전자 발현 수준 변화를 비교한 결과를 나타낸 것이다.
도 9는 본 발명의 일 실시예에 따른 B 세포의 활성화 마커 유전자 발현 수준 변화를 비교한 결과를 나타낸 것이다.
도 10은 본 발명의 일 실시예에 따른 유전자 세트 농축 분석을 통해 면역글로불린 복합체 유전자 세트와의 유의성을 분석한 결과를 나타낸 것이다.
도 11은 본 발명의 일 실시예에 따른 플라즈마 세포의 유전자 발현 수준을 비교한 결과를 나타낸 것이다.
여기서, 상기 도면에서 Healthy는 건강한 대조군, Mild는 COVID-19 경증 환자군, SEVERE는 COVID-19 중증 환자군을 의미한다.1 shows a result of comparing the expression level of a gene related to an inflammatory response according to an embodiment of the present invention.
Figure 2 shows the results of gene set enrichment analysis of the significance of the inflammatory response gene set according to an embodiment of the present invention.
3 shows a result of comparing the expression level of an antibody constant region receptor (Fc receptor) according to an embodiment of the present invention.
4 shows the results of analyzing the significance of a gene set related to phagocytosis and related cell signaling activated by an antibody constant region receptor according to an embodiment of the present invention.
5 to 6 show the results of analyzing the significance of gene sets related to phagocytosis and related cell signaling activated by antibody constant region receptors according to an embodiment of the present invention through gene set enrichment analysis.
7 shows the results of comparing the gene expression characteristics of the B cell activator according to an embodiment of the present invention.
8 shows a comparison result of changes in antibody gene expression level in B cells according to an embodiment of the present invention.
9 shows a result of comparing the change in the expression level of the activation marker gene of B cells according to an embodiment of the present invention.
10 shows the results of analysis of significance with the immunoglobulin complex gene set through gene set enrichment analysis according to an embodiment of the present invention.
11 shows a result of comparing the gene expression level of plasma cells according to an embodiment of the present invention.
Here, in the figure, Healthy means a healthy control group, Mild means a mild COVID-19 patient group, and SEVERE means a severe COVID-19 patient group.

이하, 본 발명을 하기의 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are only illustrative of the present invention, and the content of the present invention is not limited by the following examples.

실시예Example

[실험 방법][Experiment method]

[실험 방법 1] [Test Method 1] 분석 대상 및 단세포 RNA 시퀀싱Analytical and single-cell RNA sequencing

아래의 실험에 사용된 scRNA-seq 로우 데이터(Raw data)는 GEO(GSE145926)에 공개된 것을 사용하였다. 여기서, 상기 scRNA-seq 로우 데이터는 중국 선전 제3인민병원 연구팀에 의해 네이처 메디슨 2020(Nature medicine 2020)에 공개된 코로나바이러스감염증-19(Coronavirus disease 2019, 이하, 'COVID-19'라고 함) 환자들의 폐 세척액으로부터 분리된 단일 세포의 전사체 분석을 통해 확인된 유전자의 리스트이다. 상기 로우 데이터에 포함된 환자의 중위연령은 57세였으며, 남성 6명과 여성 3명에 해당하였다.The scRNA-seq raw data used in the experiment below was published in GEO (GSE145926). Here, the scRNA-seq raw data is a Coronavirus disease 2019 (hereinafter referred to as 'COVID-19') patient published in Nature medicine 2020 by a research team at the 3rd People's Hospital in Shenzhen, China. List of genes identified through transcriptomic analysis of single cells isolated from their lung lavage fluid. The median age of the patients included in the raw data was 57 years old, 6 males and 3 females.

상기 scRNA-seq에 대한 로우 데이터에서, 환자를 증상에 따라 건강한 경우(Healthy), 경증인 경우(Mild), 또는 중증(Severe)인 경우에 해당하도록 분류하였다. 구체적으로, 환자의 분류를 위해 발열, 호흡기 증상 및 CT(Computer tomography) 촬영 이미지를 통한 폐렴 여부를 확인하였으며, 아래의 (1) 내지 (4)의 기준에 따라 중증 환자를 선별하였다.In the raw data for the scRNA-seq, patients were classified according to symptoms as being healthy (Healthy), mild (Mild), or severe (Severe). Specifically, fever, respiratory symptoms, and pneumonia through CT (Computer Tomography) images were checked for patient classification, and severe patients were selected according to the criteria of (1) to (4) below.

(1) 호흡률에 따른 호흡 곤란 ≥ 30분(1) dyspnea with respiratory rate ≥ 30 minutes

(2) 휴식 상태에서, 손끝 산소 포화도 ≤ 93%(2) At rest, fingertip oxygen saturation ≤ 93%

(3) 흡기에서 산소 분포율(PaO2/FiO2)에 대한 동맥산소의 부분압 비율 ≤ 300mmHg (1mmHg=0.133 kPa)(3) Partial pressure ratio of arterial oxygen to oxygen distribution ratio (PaO 2 /FiO 2 ) in inspiration ≤ 300 mmHg (1 mmHg=0.133 kPa)

(4) 폐 CT 영상에서 24시간 내지 48시간에 보여진 명확한 병변 진행 > 50%(4) Clear lesion progression >50% seen at 24-48 hours on lung CT images

여기서, 건강한 사람 군(Healthy)은 3명이고, COVID-19 경증 환자(Mild)는 3명이며, COVID-19 중증 환자(Severe)는 6명이었다. Seurat R 패키지의 버전 3.1.5을 분석에 사용하였다.Here, there were 3 healthy people, 3 mild COVID-19 patients, and 6 severe COVID-19 patients. Version 3.1.5 of the Seurat R package was used for analysis.

샘플들 중에서 200-7500 사이에서 발현되는 수준의 유전자를 포함하고, 미토콘드리아 유전자 비율이 10~20% 미만인 세포들에 대해서만 분석을 수행하였다. 이와 같은 세포들은 'LogNormailize' 방법을 이용하여 정규화하였으며, 'FindVariableFeatures' 함수의 'vst' 방법을 사용하여 2000개의 가변 유전자를 선별하였다. 그런 다음, 모든 샘플을 'FindIntegrationAnchors'와 'IntegrateData' 함수를 사용하여 하나의 매트릭스로 합쳤으며, 이렇게 합쳐진 매트릭스를 'ScaleData' 함수를 사용하여 축척하였다. 또한, 주성분 분석(Principal component analysis)를 수행하였으며, 'FindClusters'함수를 사용하여 각각의 세포들을 군집화하였다.Among the samples, the analysis was performed only on cells that contained genes expressed at a level between 200-7500 and whose mitochondrial gene ratio was less than 10-20%. These cells were normalized using the 'LogNormailize' method, and 2000 variable genes were selected using the 'vst' method of the 'FindVariableFeatures' function. Then, all samples were combined into one matrix using the 'FindIntegrationAnchors' and 'IntegrateData' functions, and the combined matrix was scaled using the 'ScaleData' function. In addition, principal component analysis was performed, and each cell was grouped using the 'FindClusters' function.

[실험 방법 2] [Experimental method 2] 유전자 발현 시각화Gene Expression Visualization

상기 실험 방법 1에서 얻어진 세포들의 군집은 특정 종류의 세포 이름으로 다시 명명하였으며, 같은 종류의 세포들끼리 하나의 군집으로 합쳐주었다. 이후, 바이올린 플롯(Violin polt)과 피쳐 플롯(Feature plot)을 사용하여 각 세포들에서 특정 유전자의 발현을 시각화하였고, 점 플롯(Dot polt)을 사용하여 동시에 여러가지 유전자의 발현 수준을 비교하였다.The cluster of cells obtained in Experimental Method 1 was renamed to a specific type of cell name, and cells of the same type were merged into one cluster. Thereafter, the expression of specific genes in each cell was visualized using a Violin plot and a feature plot, and the expression levels of various genes were compared simultaneously using a dot plot.

[실험 방법 3] [Experimental method 3] 차등 유전자 발현 분석(Differential gene expression analysis)Differential gene expression analysis

'FindMarkers' 함수를 사용하여, COVID-19 중증 및 경증 환자의 대식세포, B 세포 및 플라즈마 세포들에서 차등적으로 발현되는 유전자를 비교하고, 발현 수준의 차이가 존재하는 유전자를 확인하였다. COVID-19 중증 환자와 비교하여, COVID-19 경증 환자에서 더 높은 수준으로 발현되는 유전자의 경우에는 양수로 표시하였으며, 반대로 COVID-19 경증 환자와 비교하여, COVID-19 중증 환자에서 더 높은 수준으로 발현되는 유전자의 경우에는 음수로 표시하였다. 이와 같이 발현 수준의 차이가 존재하는 유전자들은 p-값(p-value)을 기준으로 정렬하였다.By using the 'FindMarkers' function, genes differentially expressed in macrophages, B cells and plasma cells of severe and mild COVID-19 patients were compared, and genes with differences in expression levels were identified. Compared to patients with severe COVID-19, genes expressed at higher levels in patients with mild COVID-19 were expressed as positive numbers, and conversely, compared to patients with mild COVID-19, higher levels in patients with severe COVID-19. In the case of expressed genes, negative numbers were indicated. As described above, genes having different expression levels were sorted based on the p-value.

[실험 방법 4] [Test Method 4] 유전자 세트 농축 분석(Gene set enrichment analysis)Gene set enrichment analysis

상기 실험 방법 3에서 p-값을 기준으로 정렬된 발현 수준 차이가 존재하는 유전자들을 유전자 세트 농축 분석(Gene set enrichment analysis; GSEA) 소프트웨어(ver 4.0.3)를 사용하여 분석을 수행하였다. 이와 같은 분석을 통해, COVID-19 중증 환자와 COVID-19 경증 환자에게서 유의미하게 발현 수준의 차이가 있는 유전자 세트를 확인하였다. 여기서, 유전자 세트의 경우 HALLMARK, the cyoto encyclopedia of Genes and Genomes(KEGG) 및 Gene ontology(GO)를 활용하였다.Gene set enrichment analysis (GSEA) software (ver 4.0.3) was used to analyze genes having different expression levels sorted based on the p-value in Experimental Method 3 above. Through this analysis, a set of genes with significantly different expression levels in patients with severe COVID-19 and patients with mild COVID-19 were identified. Here, for the gene set, HALLMARK, the cyoto encyclopedia of Genes and Genomes (KEGG), and Gene ontology (GO) were utilized.

[결과][result]

[실험 결과 1] [Experimental Result 1] 대식세포의 유전자 발현 특징 비교 확인Comparative confirmation of gene expression characteristics of macrophages

[1-1] 염증 반응 촉진 유전자 세트의 발현 분석[1-1] Expression analysis of inflammatory response promoting gene set

도 1에서 보는 바와 같이, 염증 반응을 촉진한다고 알려져 있는 사이토카인에 해당하는 종양괴사인자(Tumor necrosis factor-α; TNF), 인터루킨-6(Interleukin-6, IL-6) 및 인터루킨-1β(Interleukin-1β, IL1B)와, 케모카인에 해당하는 케모카인 리간드 2(Chemokine ligand 2, CCL2)의 발현 수준이 COVID-19 경증 환자와 비교하여 COVID-19 중증 환자에서 증가된 것을 확인하였다.As shown in Figure 1, tumor necrosis factor (Tumor necrosis factor-α; TNF), interleukin-6 (Interleukin-6, IL-6) and interleukin-1β (Interleukin) corresponding to cytokines known to promote the inflammatory response. It was confirmed that the expression levels of -1β, IL1B) and chemokine ligand 2 (CCL2) corresponding to the chemokine were increased in patients with severe COVID-19 compared to patients with mild COVID-19.

또한, 도 2에서 보는 바와 같이, 앞서 확인된 염증 반응 유전자 세트의 유의성을 유전자 세트 농축 분석을 이용하여 확인한 결과, COVID-19 경증 환자(MILD)와 비교하여, COVID-19 중증 환자(SEVERE)의 대식세포에서 염증 반응 유전자 세트에 해당하는 유전자의 발현 수준이 더욱 많은 것을 확인하였다.In addition, as shown in Figure 2, as a result of confirming the significance of the previously identified inflammatory response gene set using gene set enrichment analysis, compared to mild COVID-19 patients (MILD), It was confirmed that the expression level of the gene corresponding to the inflammatory response gene set was higher in macrophages.

상기 결과를 통해, COVID-19 중증 환자에서는 폐 조직에 존재하는 면역세포 중 대식세포가 가장 많은 영향을 미치며, 이와 같은 세포에서 염증 관련 유전자가 COVID-19 경증 환자에 비하여 높은 수준으로 증가되어 이를 통해 과도한 염증 반응이 일어나는 것임을 알 수 있다.Through the above results, in severe COVID-19 patients, macrophages have the most influence among immune cells in the lung tissue, and inflammation-related genes in these cells are increased to a higher level than in patients with mild COVID-19, and through this It can be seen that an excessive inflammatory reaction occurs.

[1-2] 항체 불변부위 수용체(Fc receptor) 및 신호 전달 체계 유전자 세트의 발현 분석[1-2] Expression analysis of antibody constant region receptor (Fc receptor) and signal transduction system gene set

도 3 및 하기 표 1에서 보는 바와 같이, COVDI-19 경증 환자와 비교하여, COVID-19 중증 환자의 대식세포에서 FCGR1A(FcγR1A), FCGR2A(FcγR2A) 및 FCAR(FcαR) 유전자의 발현 수준이 증가된 것을 확인하였다.As shown in Figure 3 and Table 1 below, compared to patients with mild COVDI-19, the expression levels of FCGR1A (FcγR1A), FCGR2A (FcγR2A) and FCAR (FcαR) genes in macrophages of severe COVID-19 patients were increased confirmed that.

유전자gene 건강한 사람 군
(Healthy)healthy people
(Healthy) COVID-19 경증 환자
(Mild)Patients with mild symptoms of COVID-19
(Mild) COVID-19 중증 환자
(Severe)Severe patients with COVID-19
(Severe) FCGR1AFCGR1A 1.0773681.077368 1.014421.01442 1.3430141.343014 FCGR2AFCGR2A 1.0885381.088538 0.966850.96685 1.2590071.259007 FCARFCAR 0.0036320.003632 0.0152790.015279 0.0582970.058297

상기 결과를 통해, 바이러스에 특이적으로 결합하는 항체가 항체 불변부위 수용체를 통해서 면역세포 내 유입되어 감염이 촉진되는 항체 의존적 감염 촉진 현상이 COVID-19 중증 환자에서 일어나는 것을 예상할 수 있다.Through the above results, it can be expected that an antibody-dependent infection-promoting phenomenon in which an antibody that specifically binds to a virus is introduced into immune cells through an antibody constant region receptor to promote infection occurs in patients with severe COVID-19.

[1-3] 유전자 세트 농축 분석 결과[1-3] Results of gene set enrichment analysis

도 4 내지 도 6에서 보는 바와 같이, 유전자 세트 농축 분석을 통해, 항체 불변부위 수용체로 활성화되는 대식 작용 및 이와 관련된 세포신호전달과 관련된 유전자 세트의 유의성을 분석한 결과, COVID-19 경증 환자(MILD)와 비교하여 COVID-19 중증 환자(SEVERE)의 대식세포가 대식세포 작용과 관련된 신호전달체계에 해당하는 유전자 세트의 유전자를 더 많이 발현하는 것으로 확인되었다.As shown in FIGS. 4 to 6, through gene set enrichment analysis, as a result of analyzing the significance of gene sets related to phagocytosis activated by antibody constant region receptors and related cell signaling, COVID-19 mild patients (MILD ), it was confirmed that macrophages from severe COVID-19 patients (SEVERE) expressed more genes in the gene set corresponding to signaling pathways related to macrophage action.

상기 결과를 통해, COVID-19 경증 환자와 비교하여, COVID-19 중증 환자의 대식세포에서 항체 의존적 감염을 촉진하는 항체 불변부위 수용체 뿐만 아니라, 이의 기능과 관련된 유전자의 발현 수준이 더 높은 것을 알 수 있다.Through the above results, it can be seen that the expression level of genes related to its function as well as the antibody constant region receptor that promotes antibody-dependent infection in macrophages of severe COVID-19 patients is higher than that of patients with mild COVID-19. have.

[실험 결과 2] [Experimental Result 2] B 세포 활성인자의 유전자 발현 특징 비교 확인Comparative confirmation of gene expression characteristics of B cell activators

도 7 및 하기 표 2에서 보는 바와 같이, TNFSF13B(BAFF) 및 TNFSF13(APRIL) 유전자의 발현 수준을 확인한 결과, COVID-19 경증 환자(Mild)와 비교하여 COVID-19 중증 환자(Severe)의 대식세포에서 TNFSF13B 유전자의 발현 수준이 증가되었고, TNFSF13 유전자의 발현 수준은 감소되었다. 특히, TNFSF13 유전자의 발현 수준이 COVID-19 중증 및 경증 환자에서 발현의 차이가 크게 나타나는 것으로 확인되었다.As shown in Figure 7 and Table 2 below, as a result of confirming the expression levels of TNFSF13B (BAFF) and TNFSF13 (APRIL) genes, as compared with mild COVID-19 patients (Mild), macrophages of severe COVID-19 patients (Severe) The expression level of the TNFSF13B gene was increased, and the expression level of the TNFSF13 gene was decreased. In particular, it was confirmed that the expression level of the TNFSF13 gene showed a large difference in expression in patients with severe and mild COVID-19.

유전자gene 건강한 사람 군
(Healthy)healthy people
(Healthy) COVID-19 경증 환자
(Mild)Patients with mild symptoms of COVID-19
(Mild) COVID-19 중증 환자
(Severe)Severe patients with COVID-19
(Severe) TNFSF13BTNFSF13B 0.6286780.628678 1.4693461.469346 2.109952.10995 TNFSF13TNFSF13 0.0519410.051941 0.8866870.886687 0.2179860.217986

상기 결과를 통해 COVID-19 경증 환자와 비교하여, COVID-19 중증 환자에서 B 세포의 활성화에 작용하는 B세포활성인자(B cell-activating factor; BAFF) 단백질의 발현 수준은 증가되고, 증식 유도 리간드(A proliferation-inducing ligand; APRIL)의 발현 수준이 감소되는 것을 알 수 있다.Through the above results, compared to patients with mild COVID-19, the expression level of B cell-activating factor (BAFF) protein, which acts on the activation of B cells, is increased in patients with severe COVID-19, and the proliferation-inducing ligand It can be seen that the expression level of (A proliferation-inducing ligand; APRIL) is reduced.

[실험 결과 3] [Experimental Result 3] B 세포의 유전자 발현 특징 비교 확인Comparison of gene expression characteristics of B cells

[3-1] B 세포의 항체 유전자 발현 수준 변화 확인[3-1] Confirmation of changes in antibody gene expression level in B cells

도 8 및 하기 표 3에서 보는 바와 같이, COVID-19 경증 환자(B cell_Mild)와 비교하여, COVID-19 중증 환자의 B 세포(B cell_Severe)에서 IGHG1, IGHG2, IGHG3, IGHG4 및 IGHGA1 유전자의 발현 수준이 증가되었다.As shown in FIG. 8 and Table 3 below, the expression levels of IGHG1, IGHG2, IGHG3, IGHG4 and IGHGA1 genes in B cells (B cell_Severe) of patients with severe COVID-19 compared to patients with mild COVID-19 (B cell_Mild) This was increased.

유전자gene 건강한 사람 군
(Healthy)healthy people
(Healthy) COVID-19 경증 환자
(Mild)Patients with mild symptoms of COVID-19
(Mild) COVID-19 중증 환자
(Severe)Severe patients with COVID-19
(Severe) IGHG1IGHG1 0.0276330.027633 0.0361190.036119 2.5630032.563003 IGHG2IGHG2 0.0002370.000237 0.0457610.045761 0.2269990.226999 IGHG3IGHG3 0.0017940.001794 0.009120.00912 0.3454680.345468 IGHG4IGHG4 0.0703940.070394 0.0273580.027358 2.3033862.303386 IGHA1IGHA1 0.0139220.013922 0.0444560.044456 1.8258921.825892

상기 결과를 통해, 일반적으로 B 세포는 항원이 존재할 때 활성화되어 항체 유전자를 생성하기 때문에, COVID-19 경증 환자와 비교하여 COVID-19 중증 환자에서 B 세포가 더욱 활성화되어 있는 것을 알 수 있다.From the above results, it can be seen that B cells are more activated in patients with severe COVID-19 compared to patients with mild COVID-19, because B cells are generally activated in the presence of antigen to produce antibody genes.

[3-2] B 세포의 활성화 마커 유전자 발현 수준 확인[3-2] Confirmation of expression level of activation marker gene in B cells

도 9 및 하기 표 4에서 보는 바와 같이, COVID-19 경증 환자(Mild)와 비교하여, COVID-19 중증 환자(Severe)에서 CD69 및 FOS 유전자의 발현 수준이 증가되었다.As shown in Figure 9 and Table 4 below, compared to the mild COVID-19 patient (Mild), the expression level of the CD69 and FOS genes in severe COVID-19 patients (Severe) was increased.

유전자gene 건강한 사람 군
(Healthy)healthy people
(Healthy) COVID-19 경증 환자
(Mild)Patients with mild symptoms of COVID-19
(Mild) COVID-19 중증 환자
(Severe)Severe patients with COVID-19
(Severe) CD69CD69 0.2477010.247701 1.3405841.340584 1.2021881.202188 FOSFOS 1.4756581.475658 1.1320741.132074 2.4685522.468552

상기 결과를 통해, COVID-19 경증 환자와 비교하여 COVID-19 중증 환자에서 B 세포가 더욱 활성화되어 있는 것을 알 수 있다.From the above results, it can be seen that B cells are more activated in patients with severe COVID-19 compared to patients with mild COVID-19.

[실험 결과 4] [Experimental Result 4] 플라즈마 세포의 유전자 발현 특징 비교 확인Comparison of gene expression characteristics of plasma cells

도 10에서 보는 바와 같이, 유전자 세트 농축 분석을 통해 면역글로불린 복합체 유전자 세트와의 유의성을 분석한 결과, COVID-19 경증 환자(MILD)와 비교하여, COVID-19 중증 환자(SEVERE)의 플라즈마 세포에서 유전자 세트의 유전자가 더 많이 발현되는 것을 확인하였다.As shown in Figure 10, as a result of analyzing the significance with the immunoglobulin complex gene set through gene set enrichment analysis, compared to mild COVID-19 patients (MILD), in plasma cells of severe COVID-19 patients (SEVERE) It was confirmed that more genes of the gene set were expressed.

또한, COVID-19 중증 및 경증 환자에서 확인된 플라즈마 세포 수를 기준으로 해당 세포에서 발현되는 유전자의 발현 수준을 일반화하여 그 결과를 도 11에 나타내었다. 그 결과, 도 11에서 보는 바와 같이, COVID-19 경증 환자와 비교하여 COVID-19 중증 환자에서 CCR2 및 CCR10 유전자의 발현 수준이 증가되었고, CCR7, CCR4 및 CXCR3 유전자의 발현 수준이 감소되었다.In addition, based on the number of plasma cells identified in patients with severe and mild COVID-19, the expression level of the gene expressed in the cells was generalized, and the results are shown in FIG. 11 . As a result, as shown in FIG. 11, the expression levels of CCR2 and CCR10 genes were increased in patients with severe COVID-19 compared to patients with mild COVID-19, and the expression levels of CCR7, CCR4 and CXCR3 genes were decreased.

상기 결과를 통해, 본 발명에 따른 COVID-19 중증 환자와 COVID-19 경증 환자의 플라즈마 세포에서 발현되는 케모카인 수용체 유전자의 발현 수준이 다르고, 즉, COVID-19 중증 환자와 COVID-19 경증 환자의 플라즈마 세포가 서로 다른 종류에 해당하는 것을 알 수 있다.Through the above results, the expression level of the chemokine receptor gene expressed in the plasma cells of the severe COVID-19 patient and the mild COVID-19 patient according to the present invention is different, that is, the plasma of the severe COVID-19 patient and the COVID-19 mild patient It can be seen that the cells correspond to different types.

이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As described above in detail a specific part of the present invention, for those of ordinary skill in the art, this specific description is only a preferred embodiment, and it is clear that the scope of the present invention is not limited thereto. Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

<110> Korea Advanced Institute of Science and Technology <120> A composition for diagnosing severe patient of COVID-19 <130> PDPB204145d01 <160> 34 <170> KoPatentIn 3.0 <210> 1 <211> 1333 <212> RNA <213> homo sapiens <400> 1 aatatcttgc atgttacaga tttcactgct cccaccagct tggagacaac atgtggttct 60 tgacaactct gctcctttgg gttccagttg atgggcaagt ggacaccaca aaggcagtga 120 tcactttgca gcctccatgg gtcagcgtgt tccaagagga aaccgtaacc ttgcactgtg 180 aggtgctcca tctgcctggg agcagctcta cacagtggtt tctcaatggc acagccactc 240 agacctcgac ccccagctac agaatcacct ctgccagtgt caatgacagt ggtgaataca 300 ggtgccagag aggtctctca gggcgaagtg accccataca gctggaaatc cacagaggct 360 ggctactact gcaggtctcc agcagagtct tcacggaagg agaacctctg gccttgaggt 420 gtcatgcgtg gaaggataag ctggtgtaca atgtgcttta ctatcgaaat ggcaaagcct 480 ttaagttttt ccactggaat tctaacctca ccattctgaa aaccaacata agtcacaatg 540 gcacctacca ttgctcaggc atgggaaagc atcgctacac atcagcagga atatctgtca 600 ctgtgaaaga gctatttcca gctccagtgc tgaatgcatc tgtgacatcc ccactcctgg 660 aggggaatct ggtcaccctg agctgtgaaa caaagttgct cttgcagagg cctggtttgc 720 agctttactt ctccttctac atgggcagca agaccctgcg aggcaggaac acatcctctg 780 aataccaaat actaactgct agaagagaag actctgggtt atactggtgc gaggctgcca 840 cagaggatgg aaatgtcctt aagcgcagcc ctgagttgga gcttcaagtg cttggcctcc 900 agttaccaac tcctgtctgg tttcatgtcc ttttctatct ggcagtggga ataatgtttt 960 tagtgaacac tgttctctgg gtgacaatac gtaaagaact gaaaagaaag aaaaagtggg 1020 atttagaaat ctctttggat tctggtcatg agaagaaggt aatttccagc cttcaagaag 1080 acagacattt agaagaagag ctgaaatgtc aggaacaaaa agaagaacag ctgcaggaag 1140 gggtgcaccg gaaggagccc cagggggcca cgtagcagcg gctcagtggg tggccatcga 1200 tctggaccgt cccctgccca cttgctcccc gtgagcactg cgtacaaaca tccaaaagtt 1260 caacaacacc agaactgtgt gtctcatggt atgtaactct taaagcaaat aaatgaactg 1320 acttcaactg gga 1333 <210> 2 <211> 374 <212> PRT <213> homo sapiens <400> 2 Met Trp Phe Leu Thr Thr Leu Leu Leu Trp Val Pro Val Asp Gly Gln 1 5 10 15 Val Asp Thr Thr Lys Ala Val Ile Thr Leu Gln Pro Pro Trp Val Ser 20 25 30 Val Phe Gln Glu Glu Thr Val Thr Leu His Cys Glu Val Leu His Leu 35 40 45 Pro Gly Ser Ser Ser Thr Gln Trp Phe Leu Asn Gly Thr Ala Thr Gln 50 55 60 Thr Ser Thr Pro Ser Tyr Arg Ile Thr Ser Ala Ser Val Asn Asp Ser 65 70 75 80 Gly Glu Tyr Arg Cys Gln Arg Gly Leu Ser Gly Arg Ser Asp Pro Ile 85 90 95 Gln Leu Glu Ile His Arg Gly Trp Leu Leu Leu Gln Val Ser Ser Arg 100 105 110 Val Phe Thr Glu Gly Glu Pro Leu Ala Leu Arg Cys His Ala Trp Lys 115 120 125 Asp Lys Leu Val Tyr Asn Val Leu Tyr Tyr Arg Asn Gly Lys Ala Phe 130 135 140 Lys Phe Phe His Trp Asn Ser Asn Leu Thr Ile Leu Lys Thr Asn Ile 145 150 155 160 Ser His Asn Gly Thr Tyr His Cys Ser Gly Met Gly Lys His Arg Tyr 165 170 175 Thr Ser Ala Gly Ile Ser Val Thr Val Lys Glu Leu Phe Pro Ala Pro 180 185 190 Val Leu Asn Ala Ser Val Thr Ser Pro Leu Leu Glu Gly Asn Leu Val 195 200 205 Thr Leu Ser Cys Glu Thr Lys Leu Leu Leu Gln Arg Pro Gly Leu Gln 210 215 220 Leu Tyr Phe Ser Phe Tyr Met Gly Ser Lys Thr Leu Arg Gly Arg Asn 225 230 235 240 Thr Ser Ser Glu Tyr Gln Ile Leu Thr Ala Arg Arg Glu Asp Ser Gly 245 250 255 Leu Tyr Trp Cys Glu Ala Ala Thr Glu Asp Gly Asn Val Leu Lys Arg 260 265 270 Ser Pro Glu Leu Glu Leu Gln Val Leu Gly Leu Gln Leu Pro Thr Pro 275 280 285 Val Trp Phe His Val Leu Phe Tyr Leu Ala Val Gly Ile Met Phe Leu 290 295 300 Val Asn Thr Val Leu Trp Val Thr Ile Arg Lys Glu Leu Lys Arg Lys 305 310 315 320 Lys Lys Trp Asp Leu Glu Ile Ser Leu Asp Ser Gly His Glu Lys Lys 325 330 335 Val Ile Ser Ser Leu Gln Glu Asp Arg His Leu Glu Glu Glu Leu Lys 340 345 350 Cys Gln Glu Gln Lys Glu Glu Gln Leu Gln Glu Gly Val His Arg Lys 355 360 365 Glu Pro Gln Gly Ala Thr 370 <210> 3 <211> 2646 <212> RNA <213> homo sapiens <400> 3 acagtgctgg gatgactatg gagacccaaa tgtctcagaa tgtatgtccc agaaacctgt 60 ggctgcttca accattgaca gttttgctgc tgctggcttc tgcagacagt caagctgcag 120 ctcccccaaa ggctgtgctg aaacttgagc ccccgtggat caacgtgctc caggaggact 180 ctgtgactct gacatgccag ggggctcgca gccctgagag cgactccatt cagtggttcc 240 acaatgggaa tctcattccc acccacacgc agcccagcta caggttcaag gccaacaaca 300 atgacagcgg ggagtacacg tgccagactg gccagaccag cctcagcgac cctgtgcatc 360 tgactgtgct ttccgaatgg ctggtgctcc agacccctca cctggagttc caggagggag 420 aaaccatcat gctgaggtgc cacagctgga aggacaagcc tctggtcaag gtcacattct 480 tccagaatgg aaaatcccag aaattctccc atttggatcc caccttctcc atcccacaag 540 caaaccacag tcacagtggt gattaccact gcacaggaaa cataggctac acgctgttct 600 catccaagcc tgtgaccatc actgtccaag tgcccagcat gggcagctct tcaccaatgg 660 ggatcattgt ggctgtggtc attgcgactg ctgtagcagc cattgttgct gctgtagtgg 720 ccttgatcta ctgcaggaaa aagcggattt cagccaattc cactgatcct gtgaaggctg 780 cccaatttga gccacctgga cgtcaaatga ttgccatcag aaagagacaa cttgaagaaa 840 ccaacaatga ctatgaaaca gctgacggcg gctacatgac tctgaacccc agggcaccta 900 ctgacgatga taaaaacatc tacctgactc ttcctcccaa cgaccatgtc aacagtaata 960 actaaagagt aacgttatgc catgtggtca tactctcagc ttgctgagtg gatgacaaaa 1020 agaggggaat tgttaaagga aaatttaaat ggagactgga aaaatcctga gcaaacaaaa 1080 ccacctggcc cttagaaata gctttaactt tgcttaaact acaaacacaa gcaaaacttc 1140 acggggtcat actacataca agcataagca aaacttaact tggatcattt ctggtaaatg 1200 cttatgttag aaataagaca accccagcca atcacaagca gcctactaac atataattag 1260 gtgactaggg actttctaag aagataccta cccccaaaaa acaattatgt aattgaaaac 1320 caaccgattg cctttatttt gcttccacat tttcccaata aatacttgcc tgtgacattt 1380 tgccactgga acactaaact tcatgaattg cgcctcagat ttttccttta acatcttttt 1440 tttttttgac agagtctcaa tctgttaccc aggctggagt gcagtggtgc tatcttggct 1500 cactgcaaac ccgcctccca ggtttaagcg attctcatgc ctcagcctcc cagtagctgg 1560 gattagaggc atgtgccatc atacccagct aatttttgta ttttttattt ttttttttta 1620 gtagagacag ggtttcgcaa tgttggccag gccgatctcg aacttctggc ctctagcgat 1680 ctgcccgcct cggcctccca aagtgctggg atgaccagca tcagccccaa tgtccagcct 1740 ctttaacatc ttctttccta tgccctctct gtggatccct actgctggtt tctgccttct 1800 ccatgctgag aacaaaatca cctattcact gcttatgcag tcggaagctc cagaagaaca 1860 aagagcccaa ttaccagaac cacattaagt ctccattgtt ttgccttggg atttgagaag 1920 agaattagag aggtgaggat ctggtatttc ctggactaaa ttccccttgg ggaagacgaa 1980 gggatgctgc agttccaaaa gagaaggact cttccagagt catctacctg agtcccaaag 2040 ctccctgtcc tgaaagccac agacaatatg gtcccaaatg actgactgca ccttctgtgc 2100 ctcagccgtt cttgacatca agaatcttct gttccacatc cacacagcca atacaattag 2160 tcaaaccact gttattaaca gatgtagcaa catgagaaac gcttatgtta caggttacat 2220 gagagcaatc atgtaagtct atatgacttc agaaatgtta aaatagacta acctctaaca 2280 acaaattaaa agtgattgtt tcaaggtgat gcaattattg atgacctatt ttatttttct 2340 ataatgatca tatattacct ttgtaataaa acattataac caaaacattc tgtttacctt 2400 ttcagggctg tattgattgg ggtgtagact gaactatccg gggtctgttt cttttcggtg 2460 atgaaagtct tgagaaggta gtaatggata agatgtgagg gagaggagag agggagattt 2520 ggagtgtagg gtgagtgccc ctcttcttag aactgaatac tcttcttcta atgaacttgt 2580 attcttgttt ccatgtcttc ttccctttcc ttctatagca aataaagcat tcactttgtt 2640 ttggaa 2646 <210> 4 <211> 317 <212> PRT <213> homo sapiens <400> 4 Met Thr Met Glu Thr Gln Met Ser Gln Asn Val Cys Pro Arg Asn Leu 1 5 10 15 Trp Leu Leu Gln Pro Leu Thr Val Leu Leu Leu Leu Ala Ser Ala Asp 20 25 30 Ser Gln Ala Ala Ala Pro Pro Lys Ala Val Leu Lys Leu Glu Pro Pro 35 40 45 Trp Ile Asn Val Leu Gln Glu Asp Ser Val Thr Leu Thr Cys Gln Gly 50 55 60 Ala Arg Ser Pro Glu Ser Asp Ser Ile Gln Trp Phe His Asn Gly Asn 65 70 75 80 Leu Ile Pro Thr His Thr Gln Pro Ser Tyr Arg Phe Lys Ala Asn Asn 85 90 95 Asn Asp Ser Gly Glu Tyr Thr Cys Gln Thr Gly Gln Thr Ser Leu Ser 100 105 110 Asp Pro Val His Leu Thr Val Leu Ser Glu Trp Leu Val Leu Gln Thr 115 120 125 Pro His Leu Glu Phe Gln Glu Gly Glu Thr Ile Met Leu Arg Cys His 130 135 140 Ser Trp Lys Asp Lys Pro Leu Val Lys Val Thr Phe Phe Gln Asn Gly 145 150 155 160 Lys Ser Gln Lys Phe Ser His Leu Asp Pro Thr Phe Ser Ile Pro Gln 165 170 175 Ala Asn His Ser His Ser Gly Asp Tyr His Cys Thr Gly Asn Ile Gly 180 185 190 Tyr Thr Leu Phe Ser Ser Lys Pro Val Thr Ile Thr Val Gln Val Pro 195 200 205 Ser Met Gly Ser Ser Ser Pro Met Gly Ile Ile Val Ala Val Val Ile 210 215 220 Ala Thr Ala Val Ala Ala Ile Val Ala Ala Val Val Ala Leu Ile Tyr 225 230 235 240 Cys Arg Lys Lys Arg Ile Ser Ala Asn Ser Thr Asp Pro Val Lys Ala 245 250 255 Ala Gln Phe Glu Pro Pro Gly Arg Gln Met Ile Ala Ile Arg Lys Arg 260 265 270 Gln Leu Glu Glu Thr Asn Asn Asp Tyr Glu Thr Ala Asp Gly Gly Tyr 275 280 285 Met Thr Leu Asn Pro Arg Ala Pro Thr Asp Asp Asp Lys Asn Ile Tyr 290 295 300 Leu Thr Leu Pro Pro Asn Asp His Val Asn Ser Asn Asn 305 310 315 <210> 5 <211> 2476 <212> RNA <213> homo sapiens <400> 5 atcctgctaa tgtgcattga aaggagagca acggggctga ggccgtgtca gcacgatgga 60 ccccaaacag accaccctcc tgtgtcttgt gctctgtctg ggccagagga ttcaggcaca 120 ggaaggggac tttcccatgc ctttcatatc tgccaaatcg agtcctgtga ttcccttgga 180 tggatctgtg aaaatccagt gccaggccat tcgtgaagct tacctgaccc agctgatgat 240 cataaaaaac tccacgtacc gagagatagg cagaagactg aagttttgga atgagactga 300 tcctgagttc gtcattgacc acatggacgc aaacaaggca gggcgctatc agtgccaata 360 taggataggg cactacaggt tccggtacag tgacaccctg gagctggtag tgacaggctt 420 gtatggcaaa cccttcctct ctgcagatcg gggtctggtg ttgatgccag gagagaatat 480 ttccctcacg tgcagctcag cacacatccc atttgataga ttttcactgg ccaaggaggg 540 agaactttct ctgccacagc accaaagtgg ggaacacccg gccaacttct ctttgggtcc 600 tgtggacctc aatgtctcag ggatctacag gtgctacggt tggtacaaca ggagccccta 660 cctgtggtcc ttccccagta atgccttgga gcttgtggtc acagactcca tccaccaaga 720 ttacacgacg cagaacttga tccgcatggc cgtggcagga ctggtcctcg tggctctctt 780 ggccatactg gttgaaaatt ggcacagcca tacggcactg aacaaggaag cctcggcaga 840 tgtggctgaa ccgagctgga gccaacagat gtgtcagcca ggattgacct ttgcacgaac 900 accaagtgtc tgcaagtaaa cacctggagg tgaaggcaga gaggagccag gactgtggag 960 tccgacaaag ctacttgaag gacacaagag agaaaagctc actaagaagc ttgaatctac 1020 tttttttttt ttttgagaca gagtctggct ctgtcaccca ggctggagtg cagtggagca 1080 atctcggctc attgaacctc ttgggttcaa gtgattcttg tgcctcagcc tcccaagtag 1140 ctggaattac aggcacatac cactgcaccc agctaatttt tgtattttta gtagagatgg 1200 ggtttcactg tgttggccag gctggtctcg aactcctgac ctcaggtgat ccacccacct 1260 tggcctccca aagtgctgag attataggca tgagccacca cgcctggcca gatgcatgtt 1320 caaaccaatc aaatggtgtt ttcttatgca ggactgatcg atttgcaccc acctttctgc 1380 acataagtta tggttttcca tcttatctgt cttctgattt tttatatcct gtttaatttc 1440 ttccttcatt gttcttctct ttttttattt attttattta tttttatttt tatttttatt 1500 tgagacagag tctcactctg ttgcccaggc tggagtgcag tggcacgatc tcggctcact 1560 gcaacctctg cctcctgggt tcaagtgatt ctcctgcctc ggcctcccaa gtagctggga 1620 ttgcaggctc ccaccatcac gcccagctac ttttacagta tttttagtag agacggggtt 1680 tcatcacatt ggccaagctg gtctcaaact tctgacctcg tgatctgccc gcctcggcct 1740 cccaaagtgc tgggattaca gatgtgagcc actgcgccca gccttctttt tatattttta 1800 aatgtgtctt ccccaaatat aaatggttgg taagcatgcc aaatatattc aataaccccc 1860 ctcctttatt tttttttgtt gaagtgaggc tctccctatg ttgcctaagc tggtcttgaa 1920 ctcctggtct caagcaatcc tcctacctca gcctcctgct gtgttcatct acaaattgat 1980 aagagtgaaa gtcataatcc tacaggagga ttaccctatt tatttcacaa accctatttc 2040 taccggattt tcatacaagg aatacaggca tgtgtttcac ctcattaatt tattttttca 2100 cttagttttg atgatattca catatattat caagtgtgca aacattaaat tcttgtgtac 2160 aaaactcaaa tggtcttcca aataattccc cattcttttt tcttataaac tttcacagct 2220 ttacccttga cagactttac tcaaggaaat ctaagttggt catatgtggc tctttcactg 2280 attgctattt acttcattgt ccagtagctt atgtatgaaa atataattat aaaatgtaag 2340 ggtcctactt ccagtgaaac tgaagggact taggcccact tttatccttt actgagagct 2400 tatctctact tgataaaatt tctactgtat tcttggctta actcaggtcc tgtgattaaa 2460 aaaaaaatgc aaagta 2476 <210> 6 <211> 287 <212> PRT <213> homo sapiens <400> 6 Met Asp Pro Lys Gln Thr Thr Leu Leu Cys Leu Val Leu Cys Leu Gly 1 5 10 15 Gln Arg Ile Gln Ala Gln Glu Gly Asp Phe Pro Met Pro Phe Ile Ser 20 25 30 Ala Lys Ser Ser Pro Val Ile Pro Leu Asp Gly Ser Val Lys Ile Gln 35 40 45 Cys Gln Ala Ile Arg Glu Ala Tyr Leu Thr Gln Leu Met Ile Ile Lys 50 55 60 Asn Ser Thr Tyr Arg Glu Ile Gly Arg Arg Leu Lys Phe Trp Asn Glu 65 70 75 80 Thr Asp Pro Glu Phe Val Ile Asp His Met Asp Ala Asn Lys Ala Gly 85 90 95 Arg Tyr Gln Cys Gln Tyr Arg Ile Gly His Tyr Arg Phe Arg Tyr Ser 100 105 110 Asp Thr Leu Glu Leu Val Val Thr Gly Leu Tyr Gly Lys Pro Phe Leu 115 120 125 Ser Ala Asp Arg Gly Leu Val Leu Met Pro Gly Glu Asn Ile Ser Leu 130 135 140 Thr Cys Ser Ser Ala His Ile Pro Phe Asp Arg Phe Ser Leu Ala Lys 145 150 155 160 Glu Gly Glu Leu Ser Leu Pro Gln His Gln Ser Gly Glu His Pro Ala 165 170 175 Asn Phe Ser Leu Gly Pro Val Asp Leu Asn Val Ser Gly Ile Tyr Arg 180 185 190 Cys Tyr Gly Trp Tyr Asn Arg Ser Pro Tyr Leu Trp Ser Phe Pro Ser 195 200 205 Asn Ala Leu Glu Leu Val Val Thr Asp Ser Ile His Gln Asp Tyr Thr 210 215 220 Thr Gln Asn Leu Ile Arg Met Ala Val Ala Gly Leu Val Leu Val Ala 225 230 235 240 Leu Leu Ala Ile Leu Val Glu Asn Trp His Ser His Thr Ala Leu Asn 245 250 255 Lys Glu Ala Ser Ala Asp Val Ala Glu Pro Ser Trp Ser Gln Gln Met 260 265 270 Cys Gln Pro Gly Leu Thr Phe Ala Arg Thr Pro Ser Val Cys Lys 275 280 285 <210> 7 <211> 2618 <212> RNA <213> homo sapiens <400> 7 gaaattctta caaaaactga aagtgaaatg aggaagacag attgagcaat ccaatcggag 60 ggtaaatgcc agcaaaccta ctgtacagta ggggtagaga tgcagaaagg cagaaaggag 120 aaaattcagg ataactctcc tgaggggtga gccaagccct gccatgtagt gcacgcagga 180 catcaacaaa cacagataac aggaaatgat ccattccctg tggtcactta ttctaaaggc 240 cccaaccttc aaagttcaag tagtgatatg gatgactcca cagaaaggga gcagtcacgc 300 cttacttctt gccttaagaa aagagaagaa atgaaactga aggagtgtgt ttccatcctc 360 ccacggaagg aaagcccctc tgtccgatcc tccaaagacg gaaagctgct ggctgcaacc 420 ttgctgctgg cactgctgtc ttgctgcctc acggtggtgt ctttctacca ggtggccgcc 480 ctgcaagggg acctggccag cctccgggca gagctgcagg gccaccacgc ggagaagctg 540 ccagcaggag caggagcccc caaggccggc ctggaggaag ctccagctgt caccgcggga 600 ctgaaaatct ttgaaccacc agctccagga gaaggcaact ccagtcagaa cagcagaaat 660 aagcgtgccg ttcagggtcc agaagaaaca ggatcttaca catttgttcc atggcttctc 720 agctttaaaa ggggaagtgc cctagaagaa aaagagaata aaatattggt caaagaaact 780 ggttactttt ttatatatgg tcaggtttta tatactgata agacctacgc catgggacat 840 ctaattcaga ggaagaaggt ccatgtcttt ggggatgaat tgagtctggt gactttgttt 900 cgatgtattc aaaatatgcc tgaaacacta cccaataatt cctgctattc agctggcatt 960 gcaaaactgg aagaaggaga tgaactccaa cttgcaatac caagagaaaa tgcacaaata 1020 tcactggatg gagatgtcac attttttggt gcattgaaac tgctgtgacc tacttacacc 1080 atgtctgtag ctattttcct ccctttctct gtacctctaa gaagaaagaa tctaactgaa 1140 aataccaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaagta gttaccattg ccttttctgt 1200 gagctatttg ttttggtttg ctgaaactag tccaaaacag gaaatttaac agacagccac 1260 agccaaagag tgtcatgtga attacaagaa atagagccca tttagggaaa gatagaacta 1320 gaaaggcttt tcattataat tccatgttga acaattgagt catagcttct tatcttggag 1380 gaaggacaca attcaaaggg gcagtaagga ttttgtaaaa cgtggcatcc ataatttact 1440 atggagcaag tgcccacatc tctaggacat taagacattt atgagaaatc tcaggattca 1500 tcttctgttt ttatgttaaa tgcactccct ccttttcagt taacattata aaaagtaaaa 1560 aatgaaaatt ttagaaatct tgcattagac acatgaaaaa ataactaaaa gtttaaattt 1620 aaatatgaaa caattttgct gaaaatagta tccatatact atttaagtct tttatggtta 1680 tttcaagtat acaatttcta tctgtaatgt aatatattac ccacacattt ttttcacagg 1740 agagagagaa tatcctcatt tgtttatgct catgtgtatt ttctatagtg aatttcagaa 1800 acttttaata tcaggtaatt tcaatttatg cctataaagc attgattgaa aaataactag 1860 aattgtgcat atataacaca taatctccaa cagaagttac tgaatacatt catactaatg 1920 taatgtaatt tccctttatt tcttgctctt ctgtttcaaa ctgctgctat tgtagtttac 1980 atatcccaac ctttaaaaat attcctctta ttagctttat attcacttta tagaagttga 2040 gttttaatta aaattcttgg catcctgaag tatgtcacat agcatgtgct ccttataaat 2100 atgttgatat ctcagaagac agcatcccgg ttttcatttt ataaagtacc atacttaaga 2160 atgctgtaat acttatcttt tataacatgt ttccttcgct ttgcttgtct tttatgtcat 2220 cagttttaac tgtttacttc atttaacagt ttacatcatt caacagttta cttcattaaa 2280 cagtaggtgg aaaaatagat gccagtctat gaaaatcttc ccatctatat caaaatactt 2340 ttcaaggata tacttttcaa aacaaacgat ttaaatttta tgtttaaaat ataaacttta 2400 gatttaaact ttatttaaat atctggttcc tatgattttg acttcagtaa gttcaaataa 2460 aatatatttt gcaattcatt tttacattat aatttaaaaa gaagaagcga taagtggagt 2520 cagtttcaat gctaggtggg gtggttaatg atttttctgg tgttgctgct aatgtggatt 2580 aacaaataaa aacattcatt gccttttgcc tcataaaa 2618 <210> 8 <211> 266 <212> PRT <213> homo sapiens <400> 8 Met Asp Asp Ser Thr Glu Arg Glu Gln Ser Arg Leu Thr Ser Cys Leu 1 5 10 15 Lys Lys Arg Glu Glu Met Lys Leu Lys Glu Cys Val Ser Ile Leu Pro 20 25 30 Arg Lys Glu Ser Pro Ser Val Arg Ser Ser Lys Asp Gly Lys Leu Leu 35 40 45 Ala Ala Thr Leu Leu Leu Ala Leu Leu Ser Cys Cys Leu Thr Val Val 50 55 60 Ser Phe Tyr Gln Val Ala Ala Leu Gln Gly Asp Leu Ala Ser Leu Arg 65 70 75 80 Ala Glu Leu Gln Gly His His Ala Glu Lys Leu Pro Ala Gly Ala Gly 85 90 95 Ala Pro Lys Ala Gly Leu Glu Glu Ala Pro Ala Val Thr Ala Gly Leu 100 105 110 Lys Ile Phe Glu Pro Pro Ala Pro Gly Glu Gly Asn Ser Ser Gln Asn 115 120 125 Ser Arg Asn Lys Arg Ala Val Gln Gly Pro Glu Glu Thr Gly Ser Tyr 130 135 140 Thr Phe Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser Ala Leu Glu 145 150 155 160 Glu Lys Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile 165 170 175 Tyr Gly Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met Gly His Leu 180 185 190 Ile Gln Arg Lys Lys Val His Val Phe Gly Asp Glu Leu Ser Leu Val 195 200 205 Thr Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu Pro Asn Asn 210 215 220 Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly Asp Glu Leu 225 230 235 240 Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu Asp Gly Asp 245 250 255 Val Thr Phe Phe Gly Ala Leu Lys Leu Leu 260 265 <210> 9 <211> 2212 <212> RNA <213> homo sapiens <400> 9 ccggaaccct gtgtgctggg gaggaatccc gcagtggccg gggggcttga ggccgctgct 60 ttgtctcttc gtccagagcc ttatgtaaga gcttttctcg ggaaacagga agtcctgctt 120 gccaatttca gcacagggag tagtgcaggc cttattccaa cacacccggc ccagccttaa 180 ccccagaact cagccagttt cttgcttccg tgcccctggt tctcctcccc atcgagccca 240 cccctccttt cccaccttca gtcaccccta gtgaactgcc ccagcgatct ctgctgtgct 300 tgaccccgag ggtcttccac cctcgccctg accctggaca ctgcccagct tggcccccca 360 tcctgctcct ggcacaatgc cctctagcca gccaaccttc cctcccccaa ccctggggcc 420 gccccagggt tcctgcgcac tgcctgttcc tcctgggtgt cactggcagc cctgtccttc 480 ctagagggac tggaacctaa ttctcctgag gctgagggag ggtggagggt ctcaaggcaa 540 cgctggcccc acgacggagt gccaggagca ctaacagtac ccttagcttg ctttcctcct 600 ccctcctttt tattttcaag ttccttttta tttctccttg cgtaacaacc ttcttccctt 660 ctgcaccact gcccgtaccc ttacccgccc cgccacctcc ttgctacccc actcttgaaa 720 ccacagctgt tggcagggtc cccagctcat gccagcctca tctcctttct tgctagcccc 780 caaagggcct ccaggcaaca tggggggccc agtcagagag ccggcactct cagttgccct 840 ctggttgagt tggggggcag ctctgggggc cgtggcttgt gccatggctc tgctgaccca 900 acaaacagag ctgcagagcc tcaggagaga ggtgagccgg ctgcagggga caggaggccc 960 ctcccagaat ggggaagggt atccctggca gagtctcccg gagcagcagc actctgtcct 1020 gcacctggtt cccattaacg ccacctccaa ggatgactcc gatgtgacag aggtgatgtg 1080 gcaaccagct cttaggcgtg ggagaggcct acaggcccaa ggatatggtg tccgaatcca 1140 ggatgctgga gtttatctgc tgtatagcca ggtcctgttt caagacgtga ctttcaccat 1200 gggtcaggtg gtgtctcgag aaggccaagg aaggcaggag actctattcc gatgtataag 1260 aagtatgccc tcccacccgg accgggccta caacagctgc tatagcgcag gtgtcttcca 1320 tttacaccaa ggggatattc tgagtgtcat aattccccgg gcaagggcga aacttaacct 1380 ctctccacat ggaaccttcc tggggtttgt gaaactgtga ttgtgttata aaaagtggct 1440 cccagcttgg aagaccaggg tgggtacata ctggagacag ccaagagctg agtatataaa 1500 ggagagggaa tgtgcaggaa cagaggcgtc ttcctgggtt tggctccccg ttcctcactt 1560 ttcccttttc attcccaccc cctagacttt gattttacgg atatcttgct tctgttcccc 1620 atggagctcc gaattcttgc gtgtgtgtag atgaggggcg ggggacgggc gccaggcatt 1680 gtccagacct ggtcggggcc cactggaagc atccagaaca gcaccaccat ctagcggccg 1740 ctcgagggaa gcacccgccg gttggccgaa gtccacgaag ccgccctctg ctagggaaaa 1800 cccctggttc tccatgccac acctctctcc aggtgccctc tgcctcttca ccccacaaga 1860 agccttatcc tacgtccttc tctccatcta tcggacccca gtttccatca ctatctccag 1920 agatgtagct attatgcgcc cgtctacagg gggtgcccga cgatgacggt gccttcgcag 1980 tcaaattact cttcgggtcc caaggtttgg ctttcacgcg ctccattgcc ccggcgtggc 2040 aggccattcc aagcccttcc gggctggaac tggtgtcgga ggagcctcgg gtgtatcgta 2100 cgccctggtg ttggtgttgc ctcactcctc tgagctcttc tttctgatca agccctgctt 2160 aaagttaaat aaaatagaat gaatgatacc ccggcaaaaa aaaaaaaaaa aa 2212 <210> 10 <211> 223 <212> PRT <213> homo sapiens <400> 10 Met Pro Ala Ser Ser Pro Phe Leu Leu Ala Pro Lys Gly Pro Pro Gly 1 5 10 15 Asn Met Gly Gly Pro Val Arg Glu Pro Ala Leu Ser Val Ala Leu Trp 20 25 30 Leu Ser Trp Gly Ala Ala Leu Gly Ala Val Ala Cys Ala Met Ala Leu 35 40 45 Leu Thr Gln Gln Thr Glu Leu Gln Ser Leu Arg Arg Glu Val Ser Arg 50 55 60 Leu Gln Gly Thr Gly Gly Pro Ser Gln Asn Gly Glu Gly Tyr Pro Trp 65 70 75 80 Gln Ser Leu Pro Glu Gln Gln His Ser Val Leu His Leu Val Pro Ile 85 90 95 Asn Ala Thr Ser Lys Asp Asp Ser Asp Val Thr Glu Val Met Trp Gln 100 105 110 Pro Ala Leu Arg Arg Gly Arg Gly Leu Gln Ala Gln Gly Tyr Gly Val 115 120 125 Arg Ile Gln Asp Ala Gly Val Tyr Leu Leu Tyr Ser Gln Val Leu Phe 130 135 140 Gln Asp Val Thr Phe Thr Met Gly Gln Val Val Ser Arg Glu Gly Gln 145 150 155 160 Gly Arg Gln Glu Thr Leu Phe Arg Cys Ile Arg Ser Met Pro Ser His 165 170 175 Pro Asp Arg Ala Tyr Asn Ser Cys Tyr Ser Ala Gly Val Phe His Leu 180 185 190 His Gln Gly Asp Ile Leu Ser Val Ile Ile Pro Arg Ala Arg Ala Lys 195 200 205 Leu Asn Leu Ser Pro His Gly Thr Phe Leu Gly Phe Val Lys Leu 210 215 220 <210> 11 <211> 2619 <212> RNA <213> homo sapiens <400> 11 gcctccacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg 60 ggcacagcag ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120 tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180 ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240 tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc 300 aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga 360 ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420 gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480 tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540 agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600 gagtacaagt gcaaggtctc caacaaagcc ctcccagccg gcagccccga gaaccacagg 660 tgtacaccct gcccccatcc cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc 720 tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat gggcagccgg 780 agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc ttcctctaca 840 gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca tgctccgtga 900 tgcatgaggc tctgcacaac cactacacac agaagagcct ctccctgtct ccggcccatc 960 gagaaaacca tctccaaagc caaagagctg caactggagg agagctgtgc ggaggcgcag 1020 gacggggagc tggacgggct gtggacgacc atcaccatct tcatcacact cttcctgtta 1080 agcgtgtgct acagtgccac cgtcaccttc ttcaaggtga agtggatctt ctcctcggtg 1140 gtggacctga agcagaccat catccccgac tacaggaaca tgatcggaca gggggcctag 1200 ggccaccctc tgcggggtgt ccagggccgc ccagacccca cacaccagcc atgggccatg 1260 ctcagccacc acccaggcca cacctgcccc cgacctcacc gccctcaacc ccatgactct 1320 ctggcctcgc agttgccctc tgaccctgac acacctgaca cgcccccctt ccagaccctg 1380 tgcatagcag gtctacccca gacctccgct gcttggtgca tgcagggcac tgggggccag 1440 gtgtcccctc agcaggacgt ccttgccctc cggaccacaa ggtgctcaca caaaaggagg 1500 cagtgaccgg tatcccaggc ccccacccag gcaggacctc gccctggagc caaccccgtc 1560 cacgccagcc tcctgaacac aggcgtggtt tccagatggt gagtgggagc gtcagccgcc 1620 aaggtaggga agccacagca ccatcaggcc ctgttgggga ggcttccgag agctgcgaag 1680 gctcactcag acggccttcc tcccagcccg cagccagcca gcctccattc cgggcactcc 1740 cgtgaactcc tgacatgagg aatgaggttg ttctgatttc aagcaaagaa cgctgctctc 1800 tggctcctgg gaacagtctc agtgccagca ccaccccttg gctgcctgcc cacactgctg 1860 gattctcggg tggaactgga cccgcaggga cagccagccc cagagtccgc actggggaga 1920 gaaggggcca ggcccaggac actgccacct cccacccact ccagtccacc gagatcactc 1980 agagaagagc ctgggccatg tggccgctgc aggagcccca cagtgcaagg gtgaggatag 2040 cccaaggaag ggctgggcat ctgcccagac aggcctccca gagaaggctg gtgaccaggt 2100 cccaggcggg caagactcag ccttggtggg gcctgaggac agaggaggcc caggagcatc 2160 ggggagagag gtggagggac accgggagag ccaggagcgt ggacacagcc agaactcatc 2220 acagaggctg gcgtccagcc ccgggtcacg tgcagcagga acaagcagcc actctggggg 2280 caccaggtgg agaggcaaga cgacaaagag ggtgcccgtg ttcttgcgaa agcagggctg 2340 ctggccacga gtgctggaca gaggccccca cgctctgctg cccccatcac gccgttccgt 2400 gactgtcacg cagaatctgc agacaggaag ggagactcga gcgggagtgc ggccagcgcc 2460 tgcctcggcc gtcagggagg actcctgggc tcactcgaag gaggtgccac catttcagct 2520 ttggtagctt ttcttcttct tttaaatttt ctaaagctca ttaattgtct ttgatgtttc 2580 ttttgtgatg acaataaaat atccttttta agtcttgta 2619 <210> 12 <211> 399 <212> PRT <213> homo sapiens <400> 12 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Glu Leu Gln Leu Glu Glu Ser Cys 325 330 335 Ala Glu Ala Gln Asp Gly Glu Leu Asp Gly Leu Trp Thr Thr Ile Thr 340 345 350 Ile Phe Ile Thr Leu Phe Leu Leu Ser Val Cys Tyr Ser Ala Thr Val 355 360 365 Thr Phe Phe Lys Val Lys Trp Ile Phe Ser Ser Val Val Asp Leu Lys 370 375 380 Gln Thr Ile Ile Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ala 385 390 395 <210> 13 <211> 2279 <212> RNA <213> homo sapiens <400> 13 gcctccacca agggcccatc ggtcttcccc ctggcgccct gctccaggag cacctccgag 60 agcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120 tggaactcag gcgctctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180 ggactctact ccctcagcag cgtggtgacc gtgccctcca gcaacttcgg cacccagacc 240 tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagac agttgagcgc 300 aaatgttgtg tcgagtgccc accgtgccca gcaccacctg tggcaggacc gtcagtcttc 360 ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacgtgc 420 gtggtggtgg acgtgagcca cgaagacccc gaggtccagt tcaactggta cgtggacggc 480 gtggaggtgc ataatgccaa gacaaagcca cgggaggagc agttcaacag cacgttccgt 540 gtggtcagcg tcctcaccgt cgtgcaccag gactggctga acggcaagga gtacaagtgc 600 aaggtctcca acaaaggcct cccagccccc atcgagaaaa ccatctccaa aaccaaagag 660 ctgcaactgg aggagagctg tgcggaggcg caggacgggg agctggacgg gctgtggacc 720 accatcacca tcttcatcac actcttcctg ctaagcgtgt gctacagtgc caccatcacc 780 ttcttcaagg tgaagtggat cttctcctca gtggtggacc tgaagcagac catcgtcccc 840 gactacagga acatgatcag gcagggggcc tagggccacc ctctgtgggg tgtccagggc 900 cgcccagacc ccacacagga gccgtgggcc atgctcagcc atcacccagg ccacacctgc 960 ccccgacctc accgccctca accccatggc tctctggcct cgcagtcgcc ctctgaccct 1020 gacacgcccc ccttccagac cctgtgcata gcaggtctac cccagacctc cgctgcttgg 1080 tgcatgcagg gcgctggggg ccaagtgtcc cctcagcagg acgtccctgc cctccggccc 1140 gccaggtgct cacacaaaag gaggtagtga ccagcatccc aggcccccac tcaggcagga 1200 cctcgccctg gagccaaccc tgtccacgcc agcctcctga acacaggcgt ggtttccaga 1260 tggtgagtgg gagcatcagt cgccaaggta gggaagtcac agcaccatca ggccctgttg 1320 gggaggcttc cgagagctgc gaaggctcac tcagacggcc ttcctcccag cccgcagcca 1380 gccagcctcc attccaggca ctcccgtgaa ctcctgacat gaggaatgag gttgttctga 1440 tttcaagcaa agaacgctgc tctctggctc ctgggaacag tctcagtgcc agcaccaccc 1500 cttggctgcc tgcccacact gctggattct cgggtggaac tcgacccgca gggacagcca 1560 gccccagagt ccgcactggg gagagaaggg gccaggccca ggacactgcc acctaccacc 1620 cactccagtc caccgagatc actcggagaa gagcctgggc catgtggccg ctgcaggagc 1680 cccacggtgc aagggtgagg atagcccaag gaagggctgg gcatctgccc agacaggcct 1740 cccagagaag gctggtgacc aggtcccagg cgggcaagac tcagccttgg tggggcctga 1800 ggacagagga ggcccaggag catcggggag agaggtggag ggacaccggg agagccagga 1860 gcgtggacac agccagaact catcacagag gctggcgtcc agccccgggt cacgtgcagc 1920 aggaacaagc agccactctg ggggcaccag gtggagaggc aagacgacaa agagggtgcc 1980 cgtgttcttg tgaaagcggg gctgctggcc acgagtgctg gacagaggcc cccacgctct 2040 gctgccccca tcacgccgtt ccgtgactgt cacgcagaat ccgcagacag ggagactcga 2100 gcgggagtgc ggccagcgcc tgcctcagct gtcagggagg actcccgggc tcactcgaag 2160 gaggtgccac catttcagct ttggtagctt ttcttcttct tttaaatttt ctaaagctca 2220 ttaattgtct ttgatgtttc ttttgtgatg acaataaaat atccttttta agtcttgta 2279 <210> 14 <211> 326 <212> PRT <213> homo sapiens <400> 14 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro 100 105 110 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 115 120 125 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 130 135 140 Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 145 150 155 160 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn 165 170 175 Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp 180 185 190 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro 195 200 205 Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu 210 215 220 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 225 230 235 240 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 245 250 255 Ser Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 260 265 270 Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 275 280 285 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 290 295 300 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 305 310 315 320 Ser Leu Ser Pro Gly Lys 325 <210> 15 <211> 1256 <212> RNA <213> homo sapiens <400> 15 cttccaccaa gggcccatcg gtcttccccc tggcgccctg ctccaggagc acctctgggg 60 gcacagcggc cctgggctgc ctggtcaagg actacttccc agaaccggtg acggtgtcgt 120 ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta cagtcctcag 180 gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct 240 acacctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga gttgagctca 300 aaaccccact tggtgacaca actcacacat gcccacggtg cccagagccc aaatcttgtg 360 acacacctcc cccgtgccca cggtgcccag agcccaaatc ttgtgacaca cctcccccat 420 gcccacggtg cccagagccc aaatcttgtg acacacctcc cccgtgccca aggtgcccag 480 cacctgaact cctgggagga ccgtcagtct tcctcttccc cccaaaaccc aaggataccc 540 ttatgatttc ccggacccct gaggtcacgt gcgtggtggt ggacgtgagc cacgaagacc 600 ccgaggtcca gttcaagtgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc 660 cgcgggagga gcagtacaac agcacgttcc gtgtggtcag cgtcctcacc gtcctgcacc 720 aggactggct gaacggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc 780 ccatcgagaa aaccatctcc aaaaccaaag gacagccccg agaaccacag gtgtacaccc 840 tgcccccatc ccgggaggag atgaccaaga accaggtcag cctgacctgc ctggtcaaag 900 gcttctaccc cagcgacatc gccgtggagt gggagagcag cgggcagccg gagaacaact 960 acaacaccac gcctcccatg ctggactccg acggctcctt cttcctctac agcaagctca 1020 ccgtggacaa gagcaggtgg cagcagggga acatcttctc atgctccgtg atgcatgagg 1080 ctctgcacaa ccgcttcacg cagaagagcc tctccctgtc tccggagctg caactggagg 1140 agagctgtgc ggaggcgcag gacggggagc tggacgggct gtggacgacc atcaccatct 1200 tcatcacact cttcctgtta agcgtgtgct acagtgccac cgtcaccttc ttcaag 1256 <210> 16 <211> 377 <212> PRT <213> homo sapiens <400> 16 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Thr Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro 100 105 110 Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg 115 120 125 Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys 130 135 140 Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 145 150 155 160 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 165 170 175 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 180 185 190 Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Lys Trp Tyr 195 200 205 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 210 215 220 Gln Tyr Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu His 225 230 235 240 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 245 250 255 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln 260 265 270 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 275 280 285 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 290 295 300 Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gln Pro Glu Asn Asn 305 310 315 320 Tyr Asn Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 325 330 335 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Ile 340 345 350 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln 355 360 365 Lys Ser Leu Ser Leu Ser Pro Gly Lys 370 375 <210> 17 <211> 1119 <212> RNA <213> homo sapiens <400> 17 gcttccacca agggcccatc ggtcttcccc ctggcgccct gctccaggag cacctccgag 60 agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120 tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180 ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 240 tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc 300 aaatatggtc ccccatgccc atcatgccca gcacctgagt tcctgggggg accatcagtc 360 ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc tgaggtcacg 420 tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat 480 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagttcaa cagcacgtac 540 cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaacggcaa ggagtacaag 600 tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa 660 gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga gatgaccaag 720 aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 780 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 840 gacggctcct tcttcctcta cagcaggctc accgtggaca agagcaggtg gcaggagggg 900 aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc 960 ctctccctgt ctctgggtaa atgagtgcca gggccggcaa gcccccgctc cccgggctct 1020 cggggtcgcg cgaggatgct tggcacgtac cccgtgtaca tacttcccgg gcgcccagca 1080 tggaaataaa gcacccagcg ctgccctggg cccctgcga 1119 <210> 18 <211> 327 <212> PRT <213> homo sapiens <400> 18 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser Leu Ser Leu Gly Lys 325 <210> 19 <211> 1310 <212> RNA <213> homo sapiens <400> 19 gcatccccga ccagccccaa ggtcttcccg ctgagcctct gcagcaccca gccagatggg 60 aacgtggtca tcgcctgcct ggtccagggc ttcttccccc aggagccact cagtgtgacc 120 tggagcgaaa gcggacaggg cgtgaccgcc agaaacttcc cacccagcca ggatgcctcc 180 ggggacctgt acaccacgag cagccagctg accctgccgg ccacacagtg cctagccggc 240 aagtccgtga catgccacgt gaagcactac acgaatccca gccaggatgt gactgtgccc 300 tgcccagttc cctcaactcc acctacccca tctccctcaa ctccacctac cccatctccc 360 tcatgctgcc acccccgact gtcactgcac cgaccggccc tcgaggacct gctcttaggt 420 tcagaagcga acctcacgtg cacactgacc ggcctgagag atgcctcagg tgtcaccttc 480 acctggacgc cctcaagtgg gaagagcgct gttcaaggac cacctgagcg tgacctctgt 540 ggctgctaca gcgtgtccag tgtcctgccg ggctgtgccg agccatggaa ccatgggaag 600 accttcactt gcactgctgc ctaccccgag tccaagaccc cgctaaccgc caccctctca 660 aaatccggaa acacattccg gcccgaggtc cacctgctgc cgccgccgtc ggaggagctg 720 gccctgaacg agctggtgac gctgacgtgc ctggcacgcg gcttcagccc caaggatgtg 780 ctggttcgct ggctgcaggg gtcacaggag ctgccccgcg agaagtacct gacttgggca 840 tcccggcagg agcccagcca gggcaccacc accttcgctg tgaccagcat actgcgcgtg 900 gcagccgagg actggaagaa gggggacacc ttctcctgca tggtgggcca cgaggccctg 960 ccgctggcct tcacacagaa gaccatcgac cgcttggcgg attggcagat gccgcctccc 1020 tatgtggtgc tggacttgcc gcaggagacc ctggaggagg agacccccgg cgccaacctg 1080 tggcccacca ccatcacctt cctcaccctc ttcctgctga gcctgttcta tagcacagca 1140 ctgaccgtga ccagcgtccg gggcccatct ggcaacaggg agggccccca gtactgagca 1200 ggagccggca aggcacaggg aggaagtgtg gaggaacctc ttggagaagc cagctatgct 1260 tgccagaact cagccctttc agacatcacc gacccgccct tactcacatg 1310 <210> 20 <211> 398 <212> PRT <213> homo sapiens <400> 20 Ala Ser Pro Thr Ser Pro Lys Val Phe Pro Leu Ser Leu Cys Ser Thr 1 5 10 15 Gln Pro Asp Gly Asn Val Val Ile Ala Cys Leu Val Gln Gly Phe Phe 20 25 30 Pro Gln Glu Pro Leu Ser Val Thr Trp Ser Glu Ser Gly Gln Gly Val 35 40 45 Thr Ala Arg Asn Phe Pro Pro Ser Gln Asp Ala Ser Gly Asp Leu Tyr 50 55 60 Thr Thr Ser Ser Gln Leu Thr Leu Pro Ala Thr Gln Cys Leu Ala Gly 65 70 75 80 Lys Ser Val Thr Cys His Val Lys His Tyr Thr Asn Pro Ser Gln Asp 85 90 95 Val Thr Val Pro Cys Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro 100 105 110 Ser Thr Pro Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser 115 120 125 Leu His Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn 130 135 140 Leu Thr Cys Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe 145 150 155 160 Thr Trp Thr Pro Ser Ser Gly Lys Ser Ala Val Gln Gly Pro Pro Glu 165 170 175 Arg Asp Leu Cys Gly Cys Tyr Ser Val Ser Ser Val Leu Pro Gly Cys 180 185 190 Ala Glu Pro Trp Asn His Gly Lys Thr Phe Thr Cys Thr Ala Ala Tyr 195 200 205 Pro Glu Ser Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn 210 215 220 Thr Phe Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu 225 230 235 240 Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser 245 250 255 Pro Lys Asp Val Leu Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro 260 265 270 Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser Gln Gly 275 280 285 Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp 290 295 300 Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu 305 310 315 320 Pro Leu Ala Phe Thr Gln Lys Thr Ile Asp Arg Leu Ala Asp Trp Gln 325 330 335 Met Pro Pro Pro Tyr Val Val Leu Asp Leu Pro Gln Glu Thr Leu Glu 340 345 350 Glu Glu Thr Pro Gly Ala Asn Leu Trp Pro Thr Thr Ile Thr Phe Leu 355 360 365 Thr Leu Phe Leu Leu Ser Leu Phe Tyr Ser Thr Ala Leu Thr Val Thr 370 375 380 Ser Val Arg Gly Pro Ser Gly Asn Arg Glu Gly Pro Gln Tyr 385 390 395 <210> 21 <211> 1676 <212> RNA <213> homo sapiens <400> 21 agactcaaca agagctccag caaagacttt cactgtagct tgacttgacc tgagattaac 60 tagggaatct tgagaataaa gatgagctct gaaaattgtt tcgtagcaga gaacagctct 120 ttgcatccgg agagtggaca agaaaatgat gccaccagtc cccatttctc aacacgtcat 180 gaagggtcct tccaagttcc tgtcctgtgt gctgtaatga atgtggtctt catcaccatt 240 ttaatcatag ctctcattgc cttatcagtg ggccaataca attgtccagg ccaatacaca 300 ttctcaatgc catcagacag ccatgtttct tcatgctctg aggactgggt tggctaccag 360 aggaaatgct actttatttc tactgtgaag aggagctgga cttcagccca aaatgcttgt 420 tctgaacatg gtgctactct tgctgtcatt gattctgaaa aggacatgaa ctttctaaaa 480 cgatacgcag gtagagagga acactgggtt ggactgaaaa aggaacctgg tcacccatgg 540 aagtggtcaa atggcaaaga atttaacaac tggttcaacg ttacagggtc tgacaagtgt 600 gtttttctga aaaacacaga ggtcagcagc atggaatgtg agaagaattt atactggata 660 tgtaacaaac cttacaaata ataaggaaac atgttcactt attgactatt atagaatgga 720 actcaaggaa atctgtgtca gtggatgctg ctctgtggtc cgaagtcttc catagagact 780 ttgtgaaaaa aaattttata gtgtcttggg aattttcttc caaacagaac tatggaaaaa 840 aaggaagaaa ttccaggaaa atctgcactg tgggctttta ttgccatgag ctagaagcat 900 cacaggttga ccaataacca tgcccaagaa tgagaagaat gactatgcaa cctttggatg 960 cactttatat tattttgaat ccagaaataa tgaaataact aggcgtggac ttactattta 1020 ttgctgaatg actaccaaca gtgagagccc ttcatgcatt tgcactattg gaaggagtta 1080 gatgttggta ctagatactg aatgtaaaca aaggaattat ggctggtaac ataggttttt 1140 agtctaattg aatcccttaa actcagggag catttataaa tggacaaatg cttatgaaac 1200 taagatttgt aatatttctc tctttttaga gaaatttgcc aatttacttt gttatttttc 1260 cccaaaaaga atgggatgat catgtattta tttttttact tcctcagctg tagacaggtc 1320 cttttcgatg gtacatattt ctttgccttt ataatctttt atacagtgtc ttacagagaa 1380 aagacataag caaagactat gaggaatatt tgcaagacat agaatagtgt tggaaaatgt 1440 gcaatatgtg atgtggcaaa tctctattag gaaatattct gtaatcttca gacctagaat 1500 aatactagtc ttataatagg tttgtgactt tcctaaatca attctattac gtgcaatact 1560 tcaatacttc atttaaaata tttttatgtg caataaaatg tatttgtttg tattttgtgt 1620 tcagtacaat tataagctgt ttttatatat gtgaaataaa agtagaataa acacaa 1676 <210> 22 <211> 199 <212> PRT <213> homo sapiens <400> 22 Met Ser Ser Glu Asn Cys Phe Val Ala Glu Asn Ser Ser Leu His Pro 1 5 10 15 Glu Ser Gly Gln Glu Asn Asp Ala Thr Ser Pro His Phe Ser Thr Arg 20 25 30 His Glu Gly Ser Phe Gln Val Pro Val Leu Cys Ala Val Met Asn Val 35 40 45 Val Phe Ile Thr Ile Leu Ile Ile Ala Leu Ile Ala Leu Ser Val Gly 50 55 60 Gln Tyr Asn Cys Pro Gly Gln Tyr Thr Phe Ser Met Pro Ser Asp Ser 65 70 75 80 His Val Ser Ser Cys Ser Glu Asp Trp Val Gly Tyr Gln Arg Lys Cys 85 90 95 Tyr Phe Ile Ser Thr Val Lys Arg Ser Trp Thr Ser Ala Gln Asn Ala 100 105 110 Cys Ser Glu His Gly Ala Thr Leu Ala Val Ile Asp Ser Glu Lys Asp 115 120 125 Met Asn Phe Leu Lys Arg Tyr Ala Gly Arg Glu Glu His Trp Val Gly 130 135 140 Leu Lys Lys Glu Pro Gly His Pro Trp Lys Trp Ser Asn Gly Lys Glu 145 150 155 160 Phe Asn Asn Trp Phe Asn Val Thr Gly Ser Asp Lys Cys Val Phe Leu 165 170 175 Lys Asn Thr Glu Val Ser Ser Met Glu Cys Glu Lys Asn Leu Tyr Trp 180 185 190 Ile Cys Asn Lys Pro Tyr Lys 195 <210> 23 <211> 2104 <212> RNA <213> homo sapiens <400> 23 aaccgcatct gcagcgagca tctgagaagc caagactgag ccggcggccg cggcgcagcg 60 aacgagcagt gaccgtgctc ctacccagct ctgctccaca gcgcccacct gtctccgccc 120 ctcggcccct cgcccggctt tgcctaaccg ccacgatgat gttctcgggc ttcaacgcag 180 actacgaggc gtcatcctcc cgctgcagca gcgcgtcccc ggccggggat agcctctctt 240 actaccactc acccgcagac tccttctcca gcatgggctc gcctgtcaac gcgcaggact 300 tctgcacgga cctggccgtc tccagtgcca acttcattcc cacggtcact gccatctcga 360 ccagtccgga cctgcagtgg ctggtgcagc ccgccctcgt ctcctccgtg gccccatcgc 420 agaccagagc ccctcaccct ttcggagtcc ccgccccctc cgctggggct tactccaggg 480 ctggcgttgt gaagaccatg acaggaggcc gagcgcagag cattggcagg aggggcaagg 540 tggaacagtt atctccagaa gaagaagaga aaaggagaat ccgaagggaa aggaataaga 600 tggctgcagc caaatgccgc aaccggagga gggagctgac tgatacactc caagcggaga 660 cagaccaact agaagatgag aagtctgctt tgcagaccga gattgccaac ctgctgaagg 720 agaaggaaaa actagagttc atcctggcag ctcaccgacc tgcctgcaag atccctgatg 780 acctgggctt cccagaagag atgtctgtgg cttcccttga tctgactggg ggcctgccag 840 aggttgccac cccggagtct gaggaggcct tcaccctgcc tctcctcaat gaccctgagc 900 ccaagccctc agtggaacct gtcaagagca tcagcagcat ggagctgaag accgagccct 960 ttgatgactt cctgttccca gcatcatcca ggcccagtgg ctctgagaca gcccgctccg 1020 tgccagacat ggacctatct gggtccttct atgcagcaga ctgggagcct ctgcacagtg 1080 gctccctggg gatggggccc atggccacag agctggagcc cctgtgcact ccggtggtca 1140 cctgtactcc cagctgcact gcttacacgt cttccttcgt cttcacctac cccgaggctg 1200 actccttccc cagctgtgca gctgcccacc gcaagggcag cagcagcaat gagccttcct 1260 ctgactcgct cagctcaccc acgctgctgg ccctgtgagg gggcagggaa ggggaggcag 1320 ccggcaccca caagtgccac tgcccgagct ggtgcattac agagaggaga aacacatctt 1380 ccctagaggg ttcctgtaga cctagggagg accttatctg tgcgtgaaac acaccaggct 1440 gtgggcctca aggacttgaa agcatccatg tgtggactca agtccttacc tcttccggag 1500 atgtagcaaa acgcatggag tgtgtattgt tcccagtgac acttcagaga gctggtagtt 1560 agtagcatgt tgagccaggc ctgggtctgt gtctcttttc tctttctcct tagtcttctc 1620 atagcattaa ctaatctatt gggttcatta ttggaattaa cctggtgctg gatattttca 1680 aattgtatct agtgcagctg attttaacaa taactactgt gttcctggca atagtgtgtt 1740 ctgattagaa atgaccaata ttatactaag aaaagatacg actttatttt ctggtagata 1800 gaaataaata gctatatcca tgtactgtag tttttcttca acatcaatgt tcattgtaat 1860 gttactgatc atgcattgtt gaggtggtct gaatgttctg acattaacag ttttccatga 1920 aaacgtttta ttgtgttttt aatttattta ttaagatgga ttctcagata tttatatttt 1980 tattttattt ttttctacct tgaggtcttt tgacatgtgg aaagtgaatt tgaatgaaaa 2040 atttaagcat tgtttgctta ttgttccaag acattgtcaa taaaagcatt taagttgaat 2100 gcga 2104 <210> 24 <211> 380 <212> PRT <213> homo sapiens <400> 24 Met Met Phe Ser Gly Phe Asn Ala Asp Tyr Glu Ala Ser Ser Ser Arg 1 5 10 15 Cys Ser Ser Ala Ser Pro Ala Gly Asp Ser Leu Ser Tyr Tyr His Ser 20 25 30 Pro Ala Asp Ser Phe Ser Ser Met Gly Ser Pro Val Asn Ala Gln Asp 35 40 45 Phe Cys Thr Asp Leu Ala Val Ser Ser Ala Asn Phe Ile Pro Thr Val 50 55 60 Thr Ala Ile Ser Thr Ser Pro Asp Leu Gln Trp Leu Val Gln Pro Ala 65 70 75 80 Leu Val Ser Ser Val Ala Pro Ser Gln Thr Arg Ala Pro His Pro Phe 85 90 95 Gly Val Pro Ala Pro Ser Ala Gly Ala Tyr Ser Arg Ala Gly Val Val 100 105 110 Lys Thr Met Thr Gly Gly Arg Ala Gln Ser Ile Gly Arg Arg Gly Lys 115 120 125 Val Glu Gln Leu Ser Pro Glu Glu Glu Glu Lys Arg Arg Ile Arg Arg 130 135 140 Glu Arg Asn Lys Met Ala Ala Ala Lys Cys Arg Asn Arg Arg Arg Glu 145 150 155 160 Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Leu Glu Asp Glu Lys 165 170 175 Ser Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys 180 185 190 Leu Glu Phe Ile Leu Ala Ala His Arg Pro Ala Cys Lys Ile Pro Asp 195 200 205 Asp Leu Gly Phe Pro Glu Glu Met Ser Val Ala Ser Leu Asp Leu Thr 210 215 220 Gly Gly Leu Pro Glu Val Ala Thr Pro Glu Ser Glu Glu Ala Phe Thr 225 230 235 240 Leu Pro Leu Leu Asn Asp Pro Glu Pro Lys Pro Ser Val Glu Pro Val 245 250 255 Lys Ser Ile Ser Ser Met Glu Leu Lys Thr Glu Pro Phe Asp Asp Phe 260 265 270 Leu Phe Pro Ala Ser Ser Arg Pro Ser Gly Ser Glu Thr Ala Arg Ser 275 280 285 Val Pro Asp Met Asp Leu Ser Gly Ser Phe Tyr Ala Ala Asp Trp Glu 290 295 300 Pro Leu His Ser Gly Ser Leu Gly Met Gly Pro Met Ala Thr Glu Leu 305 310 315 320 Glu Pro Leu Cys Thr Pro Val Val Thr Cys Thr Pro Ser Cys Thr Ala 325 330 335 Tyr Thr Ser Ser Phe Val Phe Thr Tyr Pro Glu Ala Asp Ser Phe Pro 340 345 350 Ser Cys Ala Ala Ala His Arg Lys Gly Ser Ser Ser Asn Glu Pro Ser 355 360 365 Ser Asp Ser Leu Ser Ser Pro Thr Leu Leu Ala Leu 370 375 380 <210> 25 <211> 2173 <212> RNA <213> homo sapiens <400> 25 agacaggggt agtgcgaggc cgggcacagc cttcctgtgt ggttttaccg cccagagagc 60 gtcatggacc tggggaaacc aatgaaaagc gtgctggtgg tggctctcct tgtcattttc 120 caggtatgcc tgtgtcaaga tgaggtcacg gacgattaca tcggagacaa caccacagtg 180 gactacactt tgttcgagtc tttgtgctcc aagaaggacg tgcggaactt taaagcctgg 240 ttcctcccta tcatgtactc catcatttgt ttcgtgggcc tactgggcaa tgggctggtc 300 gtgttgacct atatctattt caagaggctc aagaccatga ccgataccta cctgctcaac 360 ctggcggtgg cagacatcct cttcctcctg acccttccct tctgggccta cagcgcggcc 420 aagtcctggg tcttcggtgt ccacttttgc aagctcatct ttgccatcta caagatgagc 480 ttcttcagtg gcatgctcct acttctttgc atcagcattg accgctacgt ggccatcgtc 540 caggctgtct cagctcaccg ccaccgtgcc cgcgtccttc tcatcagcaa gctgtcctgt 600 gtgggcatct ggatactagc cacagtgctc tccatcccag agctcctgta cagtgacctc 660 cagaggagca gcagtgagca agcgatgcga tgctctctca tcacagagca tgtggaggcc 720 tttatcacca tccaggtggc ccagatggtg atcggctttc tggtccccct gctggccatg 780 agcttctgtt accttgtcat catccgcacc ctgctccagg cacgcaactt tgagcgcaac 840 aaggccatca aggtgatcat cgctgtggtc gtggtcttca tagtcttcca gctgccctac 900 aatggggtgg tcctggccca gacggtggcc aacttcaaca tcaccagtag cacctgtgag 960 ctcagtaagc aactcaacat cgcctacgac gtcacctaca gcctggcctg cgtccgctgc 1020 tgcgtcaacc ctttcttgta cgccttcatc ggcgtcaagt tccgcaacga tctcttcaag 1080 ctcttcaagg acctgggctg cctcagccag gagcagctcc ggcagtggtc ttcctgtcgg 1140 cacatccggc gctcctccat gagtgtggag gccgagacca ccaccacctt ctccccatag 1200 gcgactcttc tgcctggact agagggacct ctcccagggt ccctggggtg gggataggga 1260 gcagatgcaa tgactcagga catccccccg ccaaaagctg ctcagggaaa agcagctctc 1320 ccctcagagt gcaagcccct gctccagaag atagcttcac cccaatccca gctacctcaa 1380 ccaatgccaa aaaaagacag ggctgataag ctaacaccag acagacaaca ctgggaaaca 1440 gaggctattg tcccctaaac caaaaactga aagtgaaagt ccagaaactg ttcccacctg 1500 ctggagtgaa ggggccaagg agggtgagtg caaggggcgt gggagtggcc tgaagagtcc 1560 tctgaatgaa ccttctggcc tcccacagac tcaaatgctc agaccagctc ttccgaaaac 1620 caggccttat ctccaagacc agagatagtg gggagacttc ttggcttggt gaggaaaagc 1680 ggacatcagc tggtcaaaca aactctctga acccctccct ccatcgtttt cttcactgtc 1740 ctccaagcca gcgggaatgg cagctgccac gccgccctaa aagcacactc atcccctcac 1800 ttgccgcgtc gccctcccag gctctcaaca ggggagagtg tggtgtttcc tgcaggccag 1860 gccagctgcc tccgcgtgat caaagccaca ctctgggctc cagagtgggg atgacatgca 1920 ctcagctctt ggctccactg ggatgggagg agaggacaag ggaaatgtca ggggcgggga 1980 gggtgacagt ggccgcccaa ggcccacgag cttgttcttt gttctttgtc acagggactg 2040 aaaacctctc ctcatgttct gctttcgatt cgttaagaga gcaacatttt acccacacac 2100 agataaagtt ttcccttgag gaaacaacag ctttaaaaga aaaagaaaaa aaaagtcttt 2160 ggtaaatggc aaa 2173 <210> 26 <211> 378 <212> PRT <213> homo sapiens <400> 26 Met Asp Leu Gly Lys Pro Met Lys Ser Val Leu Val Val Ala Leu Leu 1 5 10 15 Val Ile Phe Gln Val Cys Leu Cys Gln Asp Glu Val Thr Asp Asp Tyr 20 25 30 Ile Gly Asp Asn Thr Thr Val Asp Tyr Thr Leu Phe Glu Ser Leu Cys 35 40 45 Ser Lys Lys Asp Val Arg Asn Phe Lys Ala Trp Phe Leu Pro Ile Met 50 55 60 Tyr Ser Ile Ile Cys Phe Val Gly Leu Leu Gly Asn Gly Leu Val Val 65 70 75 80 Leu Thr Tyr Ile Tyr Phe Lys Arg Leu Lys Thr Met Thr Asp Thr Tyr 85 90 95 Leu Leu Asn Leu Ala Val Ala Asp Ile Leu Phe Leu Leu Thr Leu Pro 100 105 110 Phe Trp Ala Tyr Ser Ala Ala Lys Ser Trp Val Phe Gly Val His Phe 115 120 125 Cys Lys Leu Ile Phe Ala Ile Tyr Lys Met Ser Phe Phe Ser Gly Met 130 135 140 Leu Leu Leu Leu Cys Ile Ser Ile Asp Arg Tyr Val Ala Ile Val Gln 145 150 155 160 Ala Val Ser Ala His Arg His Arg Ala Arg Val Leu Leu Ile Ser Lys 165 170 175 Leu Ser Cys Val Gly Ile Trp Ile Leu Ala Thr Val Leu Ser Ile Pro 180 185 190 Glu Leu Leu Tyr Ser Asp Leu Gln Arg Ser Ser Ser Glu Gln Ala Met 195 200 205 Arg Cys Ser Leu Ile Thr Glu His Val Glu Ala Phe Ile Thr Ile Gln 210 215 220 Val Ala Gln Met Val Ile Gly Phe Leu Val Pro Leu Leu Ala Met Ser 225 230 235 240 Phe Cys Tyr Leu Val Ile Ile Arg Thr Leu Leu Gln Ala Arg Asn Phe 245 250 255 Glu Arg Asn Lys Ala Ile Lys Val Ile Ile Ala Val Val Val Val Phe 260 265 270 Ile Val Phe Gln Leu Pro Tyr Asn Gly Val Val Leu Ala Gln Thr Val 275 280 285 Ala Asn Phe Asn Ile Thr Ser Ser Thr Cys Glu Leu Ser Lys Gln Leu 290 295 300 Asn Ile Ala Tyr Asp Val Thr Tyr Ser Leu Ala Cys Val Arg Cys Cys 305 310 315 320 Val Asn Pro Phe Leu Tyr Ala Phe Ile Gly Val Lys Phe Arg Asn Asp 325 330 335 Leu Phe Lys Leu Phe Lys Asp Leu Gly Cys Leu Ser Gln Glu Gln Leu 340 345 350 Arg Gln Trp Ser Ser Cys Arg His Ile Arg Arg Ser Ser Met Ser Val 355 360 365 Glu Ala Glu Thr Thr Thr Thr Phe Ser Pro 370 375 <210> 27 <211> 1861 <212> RNA <213> homo sapiens <400> 27 caagcaccaa agcagagggg caggcagcac accacccagc agccagagca ccagcccagc 60 catggtcctt gaggggtccc tgggccgatg ggatcacgca gaagaatgcg agagaagcag 120 cctttgagaa gggaagtcac tatcccagag cccaggctga gcggatggag ttgaggaagt 180 acggccctgg aagactggcg gggacagtta taggaggagc tgctcagagt aaatcacaga 240 ctaaatcaga ctcaatcaca aaagagttcc tgccaggcct ttacacagcc ccttcctccc 300 cgttcccgcc ctcacaggtg agtgaccacc aagtgctaaa tgacgccgag gttgccgccc 360 tcctggagaa cttcagctct tcctatgact atggagaaaa cgagagtgac tcgtgctgta 420 cctccccgcc ctgcccacag gacttcagcc tgaacttcga ccgggccttc ctgccagccc 480 tctacagcct cctctttctg ctggggctgc tgggcaacgg cgcggtggca gccgtgctgc 540 tgagccggcg gacagccctg agcagcaccg acaccttcct gctccaccta gctgtagcag 600 acacgctgct ggtgctgaca ctgccgctct gggcagtgga cgctgccgtc cagtgggtct 660 ttggctctgg cctctgcaaa gtggcaggtg ccctcttcaa catcaacttc tacgcaggag 720 ccctcctgct ggcctgcatc agctttgacc gctacctgaa catagttcat gccacccagc 780 tctaccgccg ggggcccccg gcccgcgtga ccctcacctg cctggctgtc tgggggctct 840 gcctgctttt cgccctccca gacttcatct tcctgtcggc ccaccacgac gagcgcctca 900 acgccaccca ctgccaatac aacttcccac aggtgggccg cacggctctg cgggtgctgc 960 agctggtggc tggctttctg ctgcccctgc tggtcatggc ctactgctat gcccacatcc 1020 tggccgtgct gctggtttcc aggggccagc ggcgcctgcg ggccatgcgg ctggtggtgg 1080 tggtcgtggt ggcctttgcc ctctgctgga ccccctatca cctggtggtg ctggtggaca 1140 tcctcatgga cctgggcgct ttggcccgca actgtggccg agaaagcagg gtagacgtgg 1200 ccaagtcggt cacctcaggc ctgggctaca tgcactgctg cctcaacccg ctgctctatg 1260 cctttgtagg ggtcaagttc cgggagcgga tgtggatgct gctcttgcgc ctgggctgcc 1320 ccaaccagag agggctccag aggcagccat cgtcttcccg ccgggattca tcctggtctg 1380 agacctcaga ggcctcctac tcgggcttgt gaggccggaa tccgggctcc cctttcgccc 1440 acagtctgac ttccccgcat tccaggctcc tccctccctc tgccggctct ggctctcccc 1500 aatatcctcg ctcccgggac tcactggcag ccccagcacc accaggtctc ccgggaagcc 1560 accctcccag ctctgaggac tgcaccattg ctgctcctta gctgccaagc cccatcctgc 1620 cgcccgaggt ggctgcctgg agccccactg cccttctcat ttggaaacta aaacttcatc 1680 ttccccaagt gcggggagta caaggcatgg cgtagagggt gctgccccat gaagccacag 1740 cccaggcctc cagctcagca gtgactgtgg ccatggtccc caagacctct atatttgctc 1800 ttttattttt atgtctaaaa tcctgcttaa aacttttcaa taaacaagat cgtcaggacc 1860 a 1861 <210> 28 <211> 368 <212> PRT <213> homo sapiens <400> 28 Met Val Leu Glu Val Ser Asp His Gln Val Leu Asn Asp Ala Glu Val 1 5 10 15 Ala Ala Leu Leu Glu Asn Phe Ser Ser Ser Tyr Asp Tyr Gly Glu Asn 20 25 30 Glu Ser Asp Ser Cys Cys Thr Ser Pro Pro Cys Pro Gln Asp Phe Ser 35 40 45 Leu Asn Phe Asp Arg Ala Phe Leu Pro Ala Leu Tyr Ser Leu Leu Phe 50 55 60 Leu Leu Gly Leu Leu Gly Asn Gly Ala Val Ala Ala Val Leu Leu Ser 65 70 75 80 Arg Arg Thr Ala Leu Ser Ser Thr Asp Thr Phe Leu Leu His Leu Ala 85 90 95 Val Ala Asp Thr Leu Leu Val Leu Thr Leu Pro Leu Trp Ala Val Asp 100 105 110 Ala Ala Val Gln Trp Val Phe Gly Ser Gly Leu Cys Lys Val Ala Gly 115 120 125 Ala Leu Phe Asn Ile Asn Phe Tyr Ala Gly Ala Leu Leu Leu Ala Cys 130 135 140 Ile Ser Phe Asp Arg Tyr Leu Asn Ile Val His Ala Thr Gln Leu Tyr 145 150 155 160 Arg Arg Gly Pro Pro Ala Arg Val Thr Leu Thr Cys Leu Ala Val Trp 165 170 175 Gly Leu Cys Leu Leu Phe Ala Leu Pro Asp Phe Ile Phe Leu Ser Ala 180 185 190 His His Asp Glu Arg Leu Asn Ala Thr His Cys Gln Tyr Asn Phe Pro 195 200 205 Gln Val Gly Arg Thr Ala Leu Arg Val Leu Gln Leu Val Ala Gly Phe 210 215 220 Leu Leu Pro Leu Leu Val Met Ala Tyr Cys Tyr Ala His Ile Leu Ala 225 230 235 240 Val Leu Leu Val Ser Arg Gly Gln Arg Arg Leu Arg Ala Met Arg Leu 245 250 255 Val Val Val Val Val Val Ala Phe Ala Leu Cys Trp Thr Pro Tyr His 260 265 270 Leu Val Val Leu Val Asp Ile Leu Met Asp Leu Gly Ala Leu Ala Arg 275 280 285 Asn Cys Gly Arg Glu Ser Arg Val Asp Val Ala Lys Ser Val Thr Ser 290 295 300 Gly Leu Gly Tyr Met His Cys Cys Leu Asn Pro Leu Leu Tyr Ala Phe 305 310 315 320 Val Gly Val Lys Phe Arg Glu Arg Met Trp Met Leu Leu Leu Arg Leu 325 330 335 Gly Cys Pro Asn Gln Arg Gly Leu Gln Arg Gln Pro Ser Ser Ser Arg 340 345 350 Arg Asp Ser Ser Trp Ser Glu Thr Ser Glu Ala Ser Tyr Ser Gly Leu 355 360 365 <210> 29 <211> 2671 <212> RNA <213> homo sapiens <400> 29 tttattctct ggaacatgaa acattctgtt gtgctcatat catgcaaatt atcactagta 60 ggagagcaga gagtggaaat gttccaggta taaagaccca caagataaag aagctcagag 120 tcgttagaaa caggagcaga tgtacagggt ttgcctgact cacactcaag gttgcataag 180 caagatttca aaattaatcc tattctggag acctcaaccc aatgtacaat gttcctgact 240 ggaaaagaag aactatattt ttctgatttt ttttttcaaa tctttaccat tagttgccct 300 gtatctccgc cttcactttc tgcaggaaac tttatttcct acttctgcat gccaagtttc 360 tacctctaga tctgtttggt tcagttgctg agaagcctga cataccagga ctgcctgaga 420 caagccacaa gctgaacaga gaaagtggat tgaacaagga cgcatttccc cagtacatcc 480 acaacatgct gtccacatct cgttctcggt ttatcagaaa taccaacgag agcggtgaag 540 aagtcaccac cttttttgat tatgattacg gtgctccctg tcataaattt gacgtgaagc 600 aaattggggc ccaactcctg cctccgctct actcgctggt gttcatcttt ggttttgtgg 660 gcaacatgct ggtcgtcctc atcttaataa actgcaaaaa gctgaagtgc ttgactgaca 720 tttacctgct caacctggcc atctctgatc tgctttttct tattactctc ccattgtggg 780 ctcactctgc tgcaaatgag tgggtctttg ggaatgcaat gtgcaaatta ttcacagggc 840 tgtatcacat cggttatttt ggcggaatct tcttcatcat cctcctgaca atcgatagat 900 acctggctat tgtccatgct gtgtttgctt taaaagccag gacggtcacc tttggggtgg 960 tgacaagtgt gatcacctgg ttggtggctg tgtttgcttc tgtcccagga atcatcttta 1020 ctaaatgcca gaaagaagat tctgtttatg tctgtggccc ttattttcca cgaggatgga 1080 ataatttcca cacaataatg aggaacattt tggggctggt cctgccgctg ctcatcatgg 1140 tcatctgcta ctcgggaatc ctgaaaaccc tgcttcggtg tcgaaacgag aagaagaggc 1200 atagggcagt gagagtcatc ttcaccatca tgattgttta ctttctcttc tggactccct 1260 ataatattgt cattctcctg aacaccttcc aggaattctt cggcctgagt aactgtgaaa 1320 gcaccagtca actggaccaa gccacgcagg tgacagagac tcttgggatg actcactgct 1380 gcatcaatcc catcatctat gccttcgttg gggagaagtt cagaagcctt tttcacatag 1440 ctcttggctg taggattgcc ccactccaaa aaccagtgtg tggaggtcca ggagtgagac 1500 caggaaagaa tgtgaaagtg actacacaag gactcctcga tggtcgtgga aaaggaaagt 1560 caattggcag agcccctgaa gccagtcttc aggacaaaga aggagcctag agacagaaat 1620 gacagatctc tgctttggaa atcacacgtc tggcttcaca gatgtgtgat tcacagtgtg 1680 aatcttggtg tctacgttac caggcaggaa ggctgagagg agagagactc cagctgggtt 1740 ggaaaacagt attttccaaa ctaccttcca gttcctcatt tttgaataca ggcatagagt 1800 tcagactttt tttaaatagt aaaaataaaa ttaaagctga aaactgcaac ttgtaaatgt 1860 ggtaaagagt tagtttgagt tactatcatg tcaaacgtga aaatgctgta ttagtcacag 1920 agataattct agctttgagc ttaagaattt tgagcaggtg gtatgtttgg gagactgctg 1980 agtcaaccca atagttgttg attggcagga gttggaagtg tgtgatctgt gggcacatta 2040 gcctatgtgc atgcagcatc taagtaatga tgtcgtttga atcacagtat acgctccatc 2100 gctgtcatct cagctggatc tccattctct caggcttgct gccaaaagcc ttttgtgttt 2160 tgttttgtat cattatgaag tcatgcgttt aatcacattc gagtgtttca gtgcttcgca 2220 gatgtccttg atgctcatat tgttccctat tttgccagtg ggaactccta aatcaagttg 2280 gcttctaatc aaagctttta aaccctattg gtaaagaatg gaaggtggag aagctccctg 2340 aagtaagcaa agactttcct cttagtcgag ccaagttaag aatgttctta tgttgcccag 2400 tgtgtttctg atctgatgca agcaagaaac actgggcttc tagaaccagg caacttggga 2460 actagactcc caagctggac tatggctcta ctttcaggcc acatggctaa agaaggtttc 2520 agaaagaagt ggggacagag cagaactttc accttcatat atttgtatga tcctaatgaa 2580 tgcataaaat gttaagttga tggtgatgaa atgtaaatac tgtttttaac aactatgatt 2640 tggaaaataa atcaatgcta taactatgtt g 2671 <210> 30 <211> 374 <212> PRT <213> homo sapiens <400> 30 Met Leu Ser Thr Ser Arg Ser Arg Phe Ile Arg Asn Thr Asn Glu Ser 1 5 10 15 Gly Glu Glu Val Thr Thr Phe Phe Asp Tyr Asp Tyr Gly Ala Pro Cys 20 25 30 His Lys Phe Asp Val Lys Gln Ile Gly Ala Gln Leu Leu Pro Pro Leu 35 40 45 Tyr Ser Leu Val Phe Ile Phe Gly Phe Val Gly Asn Met Leu Val Val 50 55 60 Leu Ile Leu Ile Asn Cys Lys Lys Leu Lys Cys Leu Thr Asp Ile Tyr 65 70 75 80 Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Ile Thr Leu Pro 85 90 95 Leu Trp Ala His Ser Ala Ala Asn Glu Trp Val Phe Gly Asn Ala Met 100 105 110 Cys Lys Leu Phe Thr Gly Leu Tyr His Ile Gly Tyr Phe Gly Gly Ile 115 120 125 Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile Val His 130 135 140 Ala Val Phe Ala Leu Lys Ala Arg Thr Val Thr Phe Gly Val Val Thr 145 150 155 160 Ser Val Ile Thr Trp Leu Val Ala Val Phe Ala Ser Val Pro Gly Ile 165 170 175 Ile Phe Thr Lys Cys Gln Lys Glu Asp Ser Val Tyr Val Cys Gly Pro 180 185 190 Tyr Phe Pro Arg Gly Trp Asn Asn Phe His Thr Ile Met Arg Asn Ile 195 200 205 Leu Gly Leu Val Leu Pro Leu Leu Ile Met Val Ile Cys Tyr Ser Gly 210 215 220 Ile Leu Lys Thr Leu Leu Arg Cys Arg Asn Glu Lys Lys Arg His Arg 225 230 235 240 Ala Val Arg Val Ile Phe Thr Ile Met Ile Val Tyr Phe Leu Phe Trp 245 250 255 Thr Pro Tyr Asn Ile Val Ile Leu Leu Asn Thr Phe Gln Glu Phe Phe 260 265 270 Gly Leu Ser Asn Cys Glu Ser Thr Ser Gln Leu Asp Gln Ala Thr Gln 275 280 285 Val Thr Glu Thr Leu Gly Met Thr His Cys Cys Ile Asn Pro Ile Ile 290 295 300 Tyr Ala Phe Val Gly Glu Lys Phe Arg Ser Leu Phe His Ile Ala Leu 305 310 315 320 Gly Cys Arg Ile Ala Pro Leu Gln Lys Pro Val Cys Gly Gly Pro Gly 325 330 335 Val Arg Pro Gly Lys Asn Val Lys Val Thr Thr Gln Gly Leu Leu Asp 340 345 350 Gly Arg Gly Lys Gly Lys Ser Ile Gly Arg Ala Pro Glu Ala Ser Leu 355 360 365 Gln Asp Lys Glu Gly Ala 370 <210> 31 <211> 1773 <212> RNA <213> homo sapiens <400> 31 agaaacctgt gtagccagag atggggacgg aggccacaga gcaggtttcc tggggccatt 60 actctgggga tgaagaggac gcatactcgg ctgagccact gccggagctt tgctacaagg 120 ccgatgtcca ggccttcagc cgggccttcc aacccagtgt ctccctgacc gtggctgcgc 180 tgggtctggc cggcaatggc ctggtcctgg ccacccacct ggcagcccga cgcgcagcgc 240 gctcgcccac ctctgcccac ctgctccagc tggccctggc cgacctcttg ctggccctga 300 ctctgccctt cgcggcagca ggggctcttc agggctggag tctgggaagt gccacctgcc 360 gcaccatctc tggcctctac tcggcctcct tccacgccgg cttcctcttc ctggcctgta 420 tcagcgccga ccgctacgtg gccatcgcgc gagcgctccc agccgggccg cggccctcca 480 ctcccggccg cgcacacttg gtctccgtca tcgtgtggct gctgtcactg ctcctggcgc 540 tgcctgcgct gctcttcagc caggatgggc agcgggaagg ccaacgacgc tgtcgcctca 600 tcttccccga gggcctcacg cagacggtga agggggcgag cgccgtggcg caggtggccc 660 tgggcttcgc gctgccgctg ggcgtcatgg tagcctgcta cgcgcttctg ggccgcacgc 720 tgctggccgc cagggggccc gagcgccggc gtgcgctgcg cgtcgtggtg gctctggtgg 780 cggccttcgt ggtgctgcag ctgccctaca gcctcgccct gctgctggat actgccgatc 840 tactggctgc gcgcgagcgg agctgccctg ccagcaaacg caaggatgtc gcactgctgg 900 tgaccagcgg cttggccctc gcccgctgtg gcctcaatcc cgttctctac gccttcctgg 960 gcctgcgctt ccgccaggac ctgcggaggc tgctacgggg tgggagctgc ccctcagggc 1020 ctcaaccccg ccgcggctgc ccccgccggc cccgcctttc ttcctgctca gctcccacgg 1080 agacccacag tctctcctgg gacaactagg gctgcgaatc tagaggaggg ggcaggctga 1140 gggtcgtggg aaaggggagt aggtggggga acactgagaa agaggcaggg acctaaaggg 1200 actacctctg tgccttgcca cattaaattg ataacatgga aatgagatgc aacccaacaa 1260 ctgttactat ttttgagtca ccgacttgga agtgatttgt ggcggggcag aaccggtggg 1320 ttaacacccc gcccccgccc caccccccgc cctgccccgc gcttggctct ctgagtggaa 1380 gacgctgagg gcctgggtgg gggtgggggg ctgctgagtc tgctaaagct ctagccactg 1440 acaccccctc caccgtcacc tggcctcagc caacagaggt gaggtgggaa agctgccagg 1500 caaggagggg cggtggttcc tcttgcaata ctgtaaggaa gagctttcta acaaccagag 1560 cgctctccag taatggctgc cttagcaaat actgagttcc cgctattgga atgttcagac 1620 tgtcggggac gctgtgggcc tttgcgtggt gtggggggag ggggaggggc aggggattcc 1680 cgtttttggt gggcgtttgg atttcataac cactttacaa tcccttccta gtgtctgtga 1740 tggaaagaaa aaatgaaaaa atgaattgta aaa 1773 <210> 32 <211> 362 <212> PRT <213> homo sapiens <400> 32 Met Gly Thr Glu Ala Thr Glu Gln Val Ser Trp Gly His Tyr Ser Gly 1 5 10 15 Asp Glu Glu Asp Ala Tyr Ser Ala Glu Pro Leu Pro Glu Leu Cys Tyr 20 25 30 Lys Ala Asp Val Gln Ala Phe Ser Arg Ala Phe Gln Pro Ser Val Ser 35 40 45 Leu Thr Val Ala Ala Leu Gly Leu Ala Gly Asn Gly Leu Val Leu Ala 50 55 60 Thr His Leu Ala Ala Arg Arg Ala Ala Arg Ser Pro Thr Ser Ala His 65 70 75 80 Leu Leu Gln Leu Ala Leu Ala Asp Leu Leu Leu Ala Leu Thr Leu Pro 85 90 95 Phe Ala Ala Ala Gly Ala Leu Gln Gly Trp Ser Leu Gly Ser Ala Thr 100 105 110 Cys Arg Thr Ile Ser Gly Leu Tyr Ser Ala Ser Phe His Ala Gly Phe 115 120 125 Leu Phe Leu Ala Cys Ile Ser Ala Asp Arg Tyr Val Ala Ile Ala Arg 130 135 140 Ala Leu Pro Ala Gly Pro Arg Pro Ser Thr Pro Gly Arg Ala His Leu 145 150 155 160 Val Ser Val Ile Val Trp Leu Leu Ser Leu Leu Leu Ala Leu Pro Ala 165 170 175 Leu Leu Phe Ser Gln Asp Gly Gln Arg Glu Gly Gln Arg Arg Cys Arg 180 185 190 Leu Ile Phe Pro Glu Gly Leu Thr Gln Thr Val Lys Gly Ala Ser Ala 195 200 205 Val Ala Gln Val Ala Leu Gly Phe Ala Leu Pro Leu Gly Val Met Val 210 215 220 Ala Cys Tyr Ala Leu Leu Gly Arg Thr Leu Leu Ala Ala Arg Gly Pro 225 230 235 240 Glu Arg Arg Arg Ala Leu Arg Val Val Val Ala Leu Val Ala Ala Phe 245 250 255 Val Val Leu Gln Leu Pro Tyr Ser Leu Ala Leu Leu Leu Asp Thr Ala 260 265 270 Asp Leu Leu Ala Ala Arg Glu Arg Ser Cys Pro Ala Ser Lys Arg Lys 275 280 285 Asp Val Ala Leu Leu Val Thr Ser Gly Leu Ala Leu Ala Arg Cys Gly 290 295 300 Leu Asn Pro Val Leu Tyr Ala Phe Leu Gly Leu Arg Phe Arg Gln Asp 305 310 315 320 Leu Arg Arg Leu Leu Arg Gly Gly Ser Cys Pro Ser Gly Pro Gln Pro 325 330 335 Arg Arg Gly Cys Pro Arg Arg Pro Arg Leu Ser Ser Cys Ser Ala Pro 340 345 350 Thr Glu Thr His Ser Leu Ser Trp Asp Asn 355 360 <210> 33 <211> 3025 <212> RNA <213> homo sapiens <400> 33 ggcattgcct cacagacctt cctcagagcc gctttcagaa aagcaagctg cttctggttg 60 ggcccagacc tgccttgagg agcctgtaga gttaaaaaat gaaccccacg gatatagcag 120 acaccaccct cgatgaaagc atatacagca attactatct gtatgaaagt atccccaagc 180 cttgcaccaa agaaggcatc aaggcatttg gggagctctt cctgccccca ctgtattcct 240 tggtttttgt atttggtctg cttggaaatt ctgtggtggt tctggtcctg ttcaaataca 300 agcggctcag gtccatgact gatgtgtacc tgctcaacct tgccatctcg gatctgctct 360 tcgtgttttc cctccctttt tggggctact atgcagcaga ccagtgggtt tttgggctag 420 gtctgtgcaa gatgatttcc tggatgtact tggtgggctt ttacagtggc atattctttg 480 tcatgctcat gagcattgat agatacctgg caattgtgca cgcggtgttt tccttgaggg 540 caaggacctt gacttatggg gtcatcacca gtttggctac atggtcagtg gctgtgttcg 600 cctcccttcc tggctttctg ttcagcactt gttatactga gcgcaaccat acctactgca 660 aaaccaagta ctctctcaac tccacgacgt ggaaggttct cagctccctg gaaatcaaca 720 ttctcggatt ggtgatcccc ttagggatca tgctgttttg ctactccatg atcatcagga 780 ccttgcagca ttgtaaaaat gagaagaaga acaaggcggt gaagatgatc tttgccgtgg 840 tggtcctctt ccttgggttc tggacacctt acaacatagt gctcttccta gagaccctgg 900 tggagctaga agtccttcag gactgcacct ttgaaagata cttggactat gccatccagg 960 ccacagaaac tctggctttt gttcactgct gccttaatcc catcatctac ttttttctgg 1020 gggagaaatt tcgcaagtac atcctacagc tcttcaaaac ctgcaggggc ctttttgtgc 1080 tctgccaata ctgtgggctc ctccaaattt actctgctga cacccccagc tcatcttaca 1140 cgcagtccac catggatcat gatctccatg atgctctgta gaaaaatgaa atggtgaaat 1200 gcagagtcaa tgaactttcc acattcagag cttacttaaa attgtatttt agtaagagat 1260 tcctgagcca gtgtcaggag gaaggcttac acccacagtg gaaagacagc ttctcatcct 1320 gcaggcagct ttttctctcc cactagacaa gtccagcctg gcaagggttc acctgggctg 1380 aggcatcctt cctcacacca ggcttgcctg caggcatgag tcagtctgat gagaactctg 1440 agcagtgctt gaatgaagtt gtaggtaata ttgcaaggca aagactattc ccttctaacc 1500 tgaactgatg ggtttctcca gagggaattg cagagtactg gctgatggag taaatcgcta 1560 ccttttgctg tggcaaatgg gccctctaat taatttcttg cttttgcgga acaatataga 1620 taactgtttt tctaataaca tatctcaggc aaagtatatt ccattgagcc agatgtatga 1680 agaaacaatt agcgaagtga tgaaaccaga tctcaattat ttattgtaaa ggattatctg 1740 ttaattgaaa ccaaactttt tatactgata taagggtaag gatatgaaga cattagccaa 1800 ggtctgcttt ccaaacgtga actacaaggc attcaaaatc caaacatatt tatgaaaatt 1860 caaacacagt ttctcacttg tttgtggaca tgttttgttc taattttaac agaggaatat 1920 taaaaaattt taaataggct gggcacggtg gcctgtaatc ccagcactgt gggaggccaa 1980 ggtgggcgga tcacctgagg tcaggagttc gagaccagcc tggccaacat ggagaaaccc 2040 tgtctctact aaaaaataca aaattagcca ggtgtggtgg cgcatgcctg taatcccagc 2100 tactcaggag gctgaggctg gagaataact tgaatccggg aggtggaggt tgcggtgagc 2160 cgagatcgcg ccattgtact ccaacctggg caaaaagagc gaaactctgt ctcaaaaaaa 2220 aaaaaaaaaa attaaataat acataggcca agaatacatt tatttgaggt catttacttg 2280 tttttttttt tttttttttt tttgagatgg aatcttgctc tgtcacccag tctggagtgc 2340 agtggcgcga tctcggctca ctgcaagctc tgcctcacgg gttcgcacca ttctcctgcc 2400 tcagcctccc aagtaggtgg gactacaggc acctgccccc atgcctggct aattttttgt 2460 attttcagta gagatggggt ttcaccatgt tagcaaggat ggttttaatc tcctgacctc 2520 gtgatccacc cgcctcggcc tcccaaagtg ctgggattac aggtgtgagc catcacgccc 2580 ggccacttgt ttatttttta ttttatttta ttttattttt gagatggagt ctcactctgt 2640 cacccaagct ggagtgcagt ggcactcggt tcactgcaaa gtctgcctcc caggttcaag 2700 cgattctcct gcctcagctt ctcaagcagc tgggattaga ggtgtgcacc actacgccag 2760 gctaattttt gtatttttag tagagatggg gtttcaccat attggccagg ctagtcttga 2820 actcctgacc tcaggtgatc tgcctgcttc agcctcccaa agtgctggga ttacaggcgt 2880 gagccacctc gcccagccaa ggtcttttac ttgtttataa acagtctctt cataattaaa 2940 attaaggatt aataaagtat gacaatacct ccttaatcat tttgaagtgc ctgctatcaa 3000 ttgaaataaa aacaatcaac taaaa 3025 <210> 34 <211> 360 <212> PRT <213> homo sapiens <400> 34 Met Asn Pro Thr Asp Ile Ala Asp Thr Thr Leu Asp Glu Ser Ile Tyr 1 5 10 15 Ser Asn Tyr Tyr Leu Tyr Glu Ser Ile Pro Lys Pro Cys Thr Lys Glu 20 25 30 Gly Ile Lys Ala Phe Gly Glu Leu Phe Leu Pro Pro Leu Tyr Ser Leu 35 40 45 Val Phe Val Phe Gly Leu Leu Gly Asn Ser Val Val Val Leu Val Leu 50 55 60 Phe Lys Tyr Lys Arg Leu Arg Ser Met Thr Asp Val Tyr Leu Leu Asn 65 70 75 80 Leu Ala Ile Ser Asp Leu Leu Phe Val Phe Ser Leu Pro Phe Trp Gly 85 90 95 Tyr Tyr Ala Ala Asp Gln Trp Val Phe Gly Leu Gly Leu Cys Lys Met 100 105 110 Ile Ser Trp Met Tyr Leu Val Gly Phe Tyr Ser Gly Ile Phe Phe Val 115 120 125 Met Leu Met Ser Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe 130 135 140 Ser Leu Arg Ala Arg Thr Leu Thr Tyr Gly Val Ile Thr Ser Leu Ala 145 150 155 160 Thr Trp Ser Val Ala Val Phe Ala Ser Leu Pro Gly Phe Leu Phe Ser 165 170 175 Thr Cys Tyr Thr Glu Arg Asn His Thr Tyr Cys Lys Thr Lys Tyr Ser 180 185 190 Leu Asn Ser Thr Thr Trp Lys Val Leu Ser Ser Leu Glu Ile Asn Ile 195 200 205 Leu Gly Leu Val Ile Pro Leu Gly Ile Met Leu Phe Cys Tyr Ser Met 210 215 220 Ile Ile Arg Thr Leu Gln His Cys Lys Asn Glu Lys Lys Asn Lys Ala 225 230 235 240 Val Lys Met Ile Phe Ala Val Val Val Leu Phe Leu Gly Phe Trp Thr 245 250 255 Pro Tyr Asn Ile Val Leu Phe Leu Glu Thr Leu Val Glu Leu Glu Val 260 265 270 Leu Gln Asp Cys Thr Phe Glu Arg Tyr Leu Asp Tyr Ala Ile Gln Ala 275 280 285 Thr Glu Thr Leu Ala Phe Val His Cys Cys Leu Asn Pro Ile Ile Tyr 290 295 300 Phe Phe Leu Gly Glu Lys Phe Arg Lys Tyr Ile Leu Gln Leu Phe Lys 305 310 315 320 Thr Cys Arg Gly Leu Phe Val Leu Cys Gln Tyr Cys Gly Leu Leu Gln 325 330 335 Ile Tyr Ser Ala Asp Thr Pro Ser Ser Ser Tyr Thr Gln Ser Thr Met 340 345 350 Asp His Asp Leu His Asp Ala Leu 355 360 <110> Korea Advanced Institute of Science and Technology <120> A composition for diagnosing severe patient of COVID-19 <130> PDPB204145d01 <160> 34 <170> KoPatentIn 3.0 <210> 1 <211> 1333 <212> RNA <213 > homo sapiens <400> 1 aatatcttgc atgttacaga tttcactgct cccaccagct tggagacaac atgtggttct 60 tgacaactct gctcctttgg gttccagttg atgggcaagt ggacaccaca aaggcagtga 120 tcactttgca gcctccatgg gtcagcgtgt tccaagagga aaccgtaacc ttgcactgtg 180 aggtgctcca tctgcctggg agcagctcta cacagtggtt tctcaatggc acagccactc 240 agacctcgac ccccagctac agaatcacct ctgccagtgt caatgacagt ggtgaataca 300 ggtgccagag aggtctctca gggcgaagtg accccataca gctggaaatc cacagaggct 360 ggctactact gcaggtctcc agcagagtct tcacggaagg agaacctctg gccttgaggt 420 gtcatgcgtg gaaggataag ctggtgtaca atgtgcttta ctatcgaaat ggcaaagcct 480 ttaagttttt ccactggaat tctaacctca ccattctgaa aaccaacata agtcacaatg 540 gcacctacca ttgctcaggc atgggaaagc atcgctacac atcagcagga atatctgtca 600 ctgtgaaaga gctatttcca gctccagtgc tgaatgcatc tgtgacatcc ccactcctgg 660 agggga atct ggtcaccctg agctgtgaaa caaagttgct cttgcagagg cctggtttgc 720 agctttactt ctccttctac atgggcagca agaccctgcg aggcaggaac acatcctctg 780 aataccaaat actaactgct agaagagaag actctgggtt atactggtgc gaggctgcca 840 cagaggatgg aaatgtcctt aagcgcagcc ctgagttgga gcttcaagtg cttggcctcc 900 agttaccaac tcctgtctgg tttcatgtcc ttttctatct ggcagtggga ataatgtttt 960 tagtgaacac tgttctctgg gtgacaatac gtaaagaact gaaaagaaag aaaaagtggg 1020 atttagaaat ctctttggat tctggtcatg agaagaaggt aatttccagc cttcaagaag 1080 acagacattt agaagaagag ctgaaatgtc aggaacaaaa agaagaacag ctgcaggaag 1140 gggtgcaccg gaaggagccc cagggggcca cgtagcagcg gctcagtggg tggccatcga 1200 tctggaccgt cccctgccca cttgctcccc gtgagcactg cgtacaaaca tccaaaagtt 1260 caacaacacc agaactgtgt gtctcatggt atgtaactct taaagcaaat aaatgaactg 1320 acttcaactg gga 1333 <210> 2 <211> 374 <212> PRT <213> homo sapiens <400> 2 Met Trp Phe Leu Thr Thr Leu Leu Leu Trp Val Pro Val Asp Gly Gln 1 5 10 15 Val Asp Thr Thr Lys Ala Val Ile Thr Leu Gln Pro Pro Trp Val Ser 20 25 30 Val Phe Gin Glu Glu Thr Val Thr Leu His Cys Glu Val Leu His Leu 35 40 45 Pro Gly Ser Ser Ser Thr Gln Trp Phe Leu Asn Gly Thr Ala Thr Gln 50 55 60 Thr Ser Thr Pro Ser Tyr Arg Ile Thr Ser Ala Ser Val Asn Asp Ser 65 70 75 80 Gly Glu Tyr Arg Cys Gln Arg Gly Leu Ser Gly Arg Ser Asp Pro Ile 85 90 95 Gln Leu Glu Ile His Arg Gly Trp Leu Leu Leu Gln Val Ser Ser Arg 100 105 110 Val Phe Thr Glu Gly Glu Pro Leu Ala Leu Arg Cys His Ala Trp Lys 115 120 125 Asp Lys Leu Val Tyr Asn Val Leu Tyr Tyr Arg Asn Gly Lys Ala Phe 130 135 140 Lys Phe Phe His Trp Asn Ser Asn Leu Thr Ile Leu Lys Thr Asn Ile 145 150 155 160 Ser His Asn Gly Thr Tyr His Cys Ser Gly Met Gly Lys His Arg Tyr 165 170 175 Thr Ser Ala Gly Ile Ser Val Thr Val Lys Glu Leu Phe Pro Ala Pro 180 185 190 Val Leu Asn Ala Ser Val Thr Ser Pro Leu Leu Glu Gly Asn Leu Val 195 200 205 Thr Leu Ser Cys Glu Thr Lys Leu Leu Leu Gln Arg Pro Gly Leu Gln 210 215 220 Leu Tyr Phe Ser Phe Tyr Met Gly Ser Lys Thr Leu Arg Gly Arg Asn 225 230 235 240 Thr Ser Ser Glu Tyr Gln Ile Leu Thr Ala Arg Arg Glu Asp Ser Gly 245 250 255 Leu Tyr Trp Cys Glu Ala Ala Thr Glu Asp Gly Asn Val Leu Lys Arg 260 265 270 Ser Pro Glu Leu Glu Leu Gln Val Leu Gly Leu Gln Leu Pro Thr Pro 275 280 285 Val Trp Phe His Val Leu Phe Tyr Leu Ala Val Gly Ile Met Phe Leu 290 295 300 Val Asn Thr Val Leu Trp Val Thr Ile Arg Lys Glu Leu Lys Arg Lys 305 310 315 320 Lys Lys Trp Asp Leu Glu Ile Ser Leu Asp Ser Gly His Glu Lys Lys 325 330 335 Val Ile Ser Ser Leu Gln Glu Asp Arg His Leu Glu Glu Glu Leu Lys 340 345 350 Cys Gln Glu Gln Lys Glu Glu Gln Leu Gln Glu Gly Val His Arg Lys 355 360 365 Glu Pro Gln Gly Ala Thr 370 <210> 3 <211> 2646 <212 > RNA <213> homo sapiens <400> 3 acagtgctgg gatgactatg gagacccaaa tgtctcagaa tgtatgtccc agaaacctgt 60 ggctgcttca accattgaca gttttgctgc tgctggcttc tgcagacagt caagctgcag 120 ctcccccaaa ggctgtgctg aaacttgagc ccccgtggat caacgtgctc caggaggact 180 ctgtgactct gacatgccag ggggctcgca gccctgagag cgactccatt cagtggttcc 240 acaatgggaa tctcattccc acccacacgc agcccagcta caggttcaag gccaacaaca 300 atgacagcgg ggagtacacg tgccagactg gccagaccag cctcagcgac cctgtgcatc 360 tgactgtgct ttccgaatgg ctggtgctcc agacccctca cctggagttc caggagggag 420 aaaccatcat gctgaggtgc cacagctgga aggacaagcc tctggtcaag gtcacattct 480 tccagaatgg aaaatcccag aaattctccc atttggatcc caccttctcc atcccacaag 540 caaaccacag tcacagtggt gattaccact gcacaggaaa cataggctac acgctgttct 600 catccaagcc tgtgaccat c actgtccaag tgcccagcat gggcagctct tcaccaatgg 660 ggatcattgt ggctgtggtc attgcgactg ctgtagcagc cattgttgct gctgtagtgg 720 ccttgatcta ctgcaggaaa aagcggattt cagccaattc cactgatcct gtgaaggctg 780 cccaatttga gccacctgga cgtcaaatga ttgccatcag aaagagacaa cttgaagaaa 840 ccaacaatga ctatgaaaca gctgacggcg gctacatgac tctgaacccc agggcaccta 900 ctgacgatga taaaaacatc tacctgactc ttcctcccaa cgaccatgtc aacagtaata 960 actaaagagt aacgttatgc catgtggtca tactctcagc ttgctgagtg gatgacaaaa 1020 agaggggaat tgttaaagga aaatttaaat ggagactgga aaaatcctga gcaaacaaaa 1080 ccacctggcc cttagaaata gctttaactt tgcttaaact acaaacacaa gcaaaacttc 1140 acggggtcat actacataca agcataagca aaacttaact tggatcattt ctggtaaatg 1200 cttatgttag aaataagaca accccagcca atcacaagca gcctactaac atataattag 1260 gtgactaggg actttctaag aagataccta cccccaaaaa acaattatgt aattgaaaac 1320 caaccgattg cctttatttt gcttccacat tttcccaata aatacttgcc tgtgacattt 1380 tgccactgga acactaaact tcatgaattg cgcctcagat ttttccttta acatcttttt 1440 tttttttgac agagtctcaa tctgttaccc aggctggagt gcagtggtgc tatcttggct 1500 cactgcaaac ccgcctccca ggtttaagcg attctcatgc ctcagcctcc cagtagctgg 1560 gattagaggc atgtgccatc atacccagct aatttttgta ttttttattt ttttttttta 1620 gtagagacag ggtttcgcaa tgttggccag gccgatctcg aacttctggc ctctagcgat 1680 ctgcccgcct cggcctccca aagtgctggg atgaccagca tcagccccaa tgtccagcct 1740 ctttaacatc ttctttccta tgccctctct gtggatccct actgctggtt tctgccttct 1800 ccatgctgag aacaaaatca cctattcact gcttatgcag tcggaagctc cagaagaaca 1860 aagagcccaa ttaccagaac cacattaagt ctccattgtt ttgccttggg atttgagaag 1920 agaattagag aggtgaggat ctggtatttc ctggactaaa ttccccttgg ggaagacgaa 1980 gggatgctgc agttccaaaa gagaaggact cttccagagt catctacctg agtcccaaag 2040 ctccctgtcc tgaaagccac agacaatatg gtcccaaatg actgactgca ccttctgtgc 2100 ctcagccgtt cttgacatca agaatcttct gttccacatc cacacagcca atacaattag 2160 tcaaaccact gttattaaca gatgtagcaa catgagaaac gcttatgtta caggttacat 2220 gagagcaatc atgtaagtct atatgacttc agaaatgtta aaatagacta acctctaaca 2280 acaaattaaa agtgattgtt tcaaggtgat gcaat tattg atgacctatt ttatttttct 2340 ataatgatca tatattacct ttgtaataaa acattataac caaaacattc tgtttacctt 2400 ttcagggctg tattgattgg ggtgtagact gaactatccg gggtctgttt cttttcggtg 2460 atgaaagtct tgagaaggta gtaatggata agatgtgagg gagaggagag agggagattt 2520 ggagtgtagg gtgagtgccc ctcttcttag aactgaatac tcttcttcta atgaacttgt 2580 attcttgttt ccatgtcttc ttccctttcc ttctatagca aataaagcat tcactttgtt 2640 ttggaa 2646 <210> 4 <211> 317 < 212> PRT <213> homo sapiens <400> 4 Met Thr Met Glu Thr Gln Met Ser Gln Asn Val Cys Pro Arg Asn Leu 1 5 10 15 Trp Leu Leu Gln Pro Leu Thr Val Leu Leu Leu Leu Leu Ala Ser Ala Asp 20 25 30 Ser Gln Ala Ala Ala Pro Lys Ala Val Leu Lys Leu Glu Pro 35 40 45 Trp Ile Asn Val Leu Gln Glu Asp Ser Val Thr Leu Thr Cys Gln Gly 50 55 60 Ala Arg Ser Pro Glu Ser Asp Ser Ile Gln Trp Phe His Asn Gly Asn 65 70 75 80 Leu Ile Pro Thr His Thr Gln Pro Ser Tyr Arg Phe Lys Ala Asn Asn 85 90 95 Asn Asp Ser Gly Glu Tyr Thr Cys Gln Thr Gly Gln Thr Ser Leu Ser 100 105 110 Asp Pro Val His Leu Thr Val Leu Ser Glu Trp Leu Val Leu Gln Thr 115 120 125 Pro His Leu Glu Phe Gln Glu Gly Glu Thr Ile Met Leu Arg Cys His 130 135 140 Ser Trp Lys Asp Lys Pro Leu Val Lys Val Thr Phe Phe Gln Asn Gly 145 150 155 160 Lys Ser Gln Lys Phe Ser His Leu Asp Pro Thr Phe Ser Ile Pro Gln 165 170 175 Ala Asn His Ser His Ser Gly Asp Tyr His Cys Thr Gly Asn Ile Gly 180 185 190 Tyr Thr Leu Phe Ser Ser Lys Pro Val Thr Ile Thr Val Gln Val Pro 195 200 205 Ser Met Gly Ser Ser Ser Pro Met Gly Ile Ile Val Ala Val Val Ile 210 215 220 Ala Thr Ala Val Ala Ala Ile Val Ala Ala Val Val Ala Leu Ile Tyr 225 230 235 240 Cys Arg Lys Lys Arg Ile Ser Ala Asn Ser Thr Asp Pro Val Lys Ala 245 250 255 Ala Gln Phe Glu Pro Gly Arg Gln Met Ile Ala Ile Arg Lys Arg 260 265 270 Gln Leu Glu Glu Thr Asn Asn Asp Tyr Glu Thr Ala Asp Gly Gly Tyr 275 280 285 Met Thr Leu Asn Pro Arg Ala Pro Thr Asp Asp Asp Lys Asn Ile Tyr 290 295 300 Leu Thr Leu Pro Pro Asn Asp His Val Asn Ser Asn Asn 305 310 315 <210> 5 <211> 2476 <212> RNA <213> homo sapiens <400> 5 atcctgctaa tgtgcattga aaggagagca acggggctga ggccgtgtca gcacgatgga 60 ccccaaacag accaccctcc tgtgtcttgt gctctgtctg ggccagagga ttcaggcaca 120 ggaaggggac tttcccatgc ctttcatatc tgccaaatcg agtcctgtga ttcccttgga 180 tggatctgtg aaaatccagt gccaggccat tcgtgaagct tacctgaccc agctgatgat 240 cataaaaaac tccacgtacc gagagatagg cagaagactg aagttttgga atgagactga 300 tcctgagttc gtcattgacc acatggacgc aaacaaggca gggcgctatc agtgccaata 360 taggataggg cactacaggt tccggtacag tgacaccctg gagctggtag tgacaggctt 420 gtat ggcaaa cccttcctct ctgcagatcg gggtctggtg ttgatgccag gagagaatat 480 ttccctcacg tgcagctcag cacacatccc atttgataga ttttcactgg ccaaggaggg 540 agaactttct ctgccacagc accaaagtgg ggaacacccg gccaacttct ctttgggtcc 600 tgtggacctc aatgtctcag ggatctacag gtgctacggt tggtacaaca ggagccccta 660 cctgtggtcc ttccccagta atgccttgga gcttgtggtc acagactcca tccaccaaga 720 ttacacgacg cagaacttga tccgcatggc cgtggcagga ctggtcctcg tggctctctt 780 ggccatactg gttgaaaatt ggcacagcca tacggcactg aacaaggaag cctcggcaga 840 tgtggctgaa ccgagctgga gccaacagat gtgtcagcca ggattgacct ttgcacgaac 900 accaagtgtc tgcaagtaaa cacctggagg tgaaggcaga gaggagccag gactgtggag 960 tccgacaaag ctacttgaag gacacaagag agaaaagctc actaagaagc ttgaatctac 1020 tttttttttt ttttgagaca gagtctggct ctgtcaccca ggctggagtg cagtggagca 1080 atctcggctc attgaacctc ttgggttcaa gtgattcttg tgcctcagcc tcccaagtag 1140 ctggaattac aggcacatac cactgcaccc agctaatttt tgtattttta gtagagatgg 1200 ggtttcactg tgttggccag gctggtctcg aactcctgac ctcaggtgat ccacccacct 1260 tggcctccca aagtgctg ag attataggca tgagccacca cgcctggcca gatgcatgtt 1320 caaaccaatc aaatggtgtt ttcttatgca ggactgatcg atttgcaccc acctttctgc 1380 acataagtta tggttttcca tcttatctgt cttctgattt tttatatcct gtttaatttc 1440 ttccttcatt gttcttctct ttttttattt attttattta tttttatttt tatttttatt 1500 tgagacagag tctcactctg ttgcccaggc tggagtgcag tggcacgatc tcggctcact 1560 gcaacctctg cctcctgggt tcaagtgatt ctcctgcctc ggcctcccaa gtagctggga 1620 ttgcaggctc ccaccatcac gcccagctac ttttacagta tttttagtag agacggggtt 1680 tcatcacatt ggccaagctg gtctcaaact tctgacctcg tgatctgccc gcctcggcct 1740 cccaaagtgc tgggattaca gatgtgagcc actgcgccca gccttctttt tatattttta 1800 aatgtgtctt ccccaaatat aaatggttgg taagcatgcc aaatatattc aataaccccc 1860 ctcctttatt tttttttgtt gaagtgaggc tctccctatg ttgcctaagc tggtcttgaa 1920 ctcctggtct caagcaatcc tcctacctca gcctcctgct gtgttcatct acaaattgat 1980 aagagtgaaa gtcataatcc tacaggagga ttaccctatt tatttcacaa accctatttc 2040 taccggattt tcatacaagg aatacaggca tgtgtttcac ctcattaatt tattttttca 2100 cttagttttg atgatattca cat atattat caagtgtgca aacattaaat tcttgtgtac 2160 aaaactcaaa tggtcttcca aataattccc cattcttttt tcttataaac tttcacagct 2220 ttacccttga cagactttac tcaaggaaat ctaagttggt catatgtggc tctttcactg 2280 attgctattt acttcattgt ccagtagctt atgtatgaaa atataattat aaaatgtaag 2340 ggtcctactt ccagtgaaac tgaagggact taggcccact tttatccttt actgagagct 2400 tatctctact tgataaaatt tctactgtat tcttggctta actcaggtcc tgtgattaaa 2460 aaaaaaatgc aaagta 2476 <210> 6 <211> 287 <212> PRT <213> homo sapiens <400> 6 Met Asp Pro Lys Gln Thr Thr Leu Leu Cys Leu Val Leu Cys Leu Gly 1 5 10 15 Gln Arg Ile Gln Ala Gln Glu Gly Asp Phe Pro Met Pro Phe Ile Ser 20 25 30 Ala Lys Ser Ser Pro Val Ile Pro Leu Asp Gly Ser Val Lys Ile Gln 35 40 45 Cys Gln Ala Ile Arg Glu Ala Tyr Leu Thr Gln Leu Met Ile Ile Lys 50 55 60 Asn Ser Thr Tyr Arg Glu Ile Gly Arg Arg Leu Lys Phe Trp Asn Glu 65 70 75 80 Thr Asp Pro Glu Phe Val Ile Asp His Met Asp Ala Asn Lys Ala Gly 85 90 95 Arg Tyr Gln Cys Gln Tyr Arg Ile Gly His Tyr Arg Phe Arg Tyr Ser 1 00 105 110 Asp Thr Leu Glu Leu Val Val Thr Gly Leu Tyr Gly Lys Pro Phe Leu 115 120 125 Ser Ala Asp Arg Gly Leu Val Leu Met Pro Gly Glu Asn Ile Ser Leu 130 135 140 Thr Cys Ser Ser Ala His Ile Pro Phe Asp Arg Phe Ser Leu Ala Lys 145 150 155 160 Glu Gly Glu Leu Ser Leu Pro Gln His Gln Ser Gly Glu His Pro Ala 165 170 175 Asn Phe Ser Leu Gly Pro Val Asp Leu Asn Val Ser Gly Ile Tyr Arg 180 185 190 Cys Tyr Gly Trp Tyr Asn Arg Ser Pro Tyr Leu Trp Ser Phe Pro Ser 195 200 205 Asn Ala Leu Glu Leu Val Val Thr Asp Ser Ile His Gln Asp Tyr Thr 210 215 220 Thr Gln Asn Leu Ile Arg Met Ala Val Ala Gly Leu Val Leu Val Ala 225 230 235 240 Leu Leu Ala Ile Leu Val Glu Asn Trp His Ser His Thr A la Leu Asn 245 250 255 Lys Glu Ala Ser Ala Asp Val Ala Glu Pro Ser Trp Ser Gln Gln Met 260 265 270 Cys Gln Pro Gly Leu Thr Phe Ala Arg Thr Pro Ser Val Cys Lys 275 280 285 <210> 7 <211> 2618 <212> RNA <213> homo sapiens <400> 7 gaaattctta caaaaactga aagtgaaatg aggaagacag attgagcaat ccaatcggag 60 ggtaaatgcc agcaaaccta ctgtacagta ggggtagaga tgcagaaagg cagaaaggag 120 aaaattcagg ataactctcc tgaggggtga gccaagccct gccatgtagt gcacgcagga 180 catcaacaaa cacagataac aggaaatgat ccattccctg tggtcactta ttctaaaggc 240 cccaaccttc aaagttcaag tagtgatatg gatgactcca cagaaaggga gcagtcacgc 300 cttacttctt gccttaagaa aagagaagaa atgaaactga aggagtgtgt ttccatcctc 360 ccacggaagg aaagcccctc tgtccgatcc tccaaagacg gaaagctgct ggctgcaacc 420 ttgctgctgg cactgctgtc ttgctgcctc acggtggtgt ctttctacca ggtggccgcc 480 ctgcaagggg acctggccag cctccgggca gagctgcagg gccaccacgc ggagaagctg 540 ccagcaggag caggagcccc caaggccggc ctggaggaag ctcc agctgt caccgcggga 600 ctgaaaatct ttgaaccacc agctccagga gaaggcaact ccagtcagaa cagcagaaat 660 aagcgtgccg ttcagggtcc agaagaaaca ggatcttaca catttgttcc atggcttctc 720 agctttaaaa ggggaagtgc cctagaagaa aaagagaata aaatattggt caaagaaact 780 ggttactttt ttatatatgg tcaggtttta tatactgata agacctacgc catgggacat 840 ctaattcaga ggaagaaggt ccatgtcttt ggggatgaat tgagtctggt gactttgttt 900 cgatgtattc aaaatatgcc tgaaacacta cccaataatt cctgctattc agctggcatt 960 gcaaaactgg aagaaggaga tgaactccaa cttgcaatac caagagaaaa tgcacaaata 1020 tcactggatg gagatgtcac attttttggt gcattgaaac tgctgtgacc tacttacacc 1080 atgtctgtag ctattttcct ccctttctct gtacctctaa gaagaaagaa tctaactgaa 1140 aataccaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaagta gttaccattg ccttttctgt 1200 gagctatttg ttttggtttg ctgaaactag tccaaaacag gaaatttaac agacagccac 1260 agccaaagag tgtcatgtga attacaagaa atagagccca tttagggaaa gatagaacta 1320 gaaaggcttt tcattataat tccatgttga acaattgagt catagcttct tatcttggag 1380 gaaggacaca attcaaaggg gcagtaagga ttttgtaaaa cgtggcatcc ataatt tact 1440 atggagcaag tgcccacatc tctaggacat taagacattt atgagaaatc tcaggattca 1500 tcttctgttt ttatgttaaa tgcactccct ccttttcagt taacattata aaaagtaaaa 1560 aatgaaaatt ttagaaatct tgcattagac acatgaaaaa ataactaaaa gtttaaattt 1620 aaatatgaaa caattttgct gaaaatagta tccatatact atttaagtct tttatggtta 1680 tttcaagtat acaatttcta tctgtaatgt aatatattac ccacacattt ttttcacagg 1740 agagagagaa tatcctcatt tgtttatgct catgtgtatt ttctatagtg aatttcagaa 1800 acttttaata tcaggtaatt tcaatttatg cctataaagc attgattgaa aaataactag 1860 aattgtgcat atataacaca taatctccaa cagaagttac tgaatacatt catactaatg 1920 taatgtaatt tccctttatt tcttgctctt ctgtttcaaa ctgctgctat tgtagtttac 1980 atatcccaac ctttaaaaat attcctctta ttagctttat attcacttta tagaagttga 2040 gttttaatta aaattcttgg catcctgaag tatgtcacat agcatgtgct ccttataaat 2100 atgttgatat ctcagaagac agcatcccgg ttttcatttt ataaagtacc atacttaaga 2160 atgctgtaat acttatcttt tataacatgt ttccttcgct ttgcttgtct tttatgtcat 2220 cagttttaac tgtttacttc atttaacagt ttacatcatt caacagttta cttcattaaa 2280 cagtaggtgg aaaaatagat gccagtctat gaaaatcttc ccatctatat caaaatactt 2340 ttcaaggata tacttttcaa aacaaacgat ttaaatttta tgtttaaaat ataaacttta 2400 gatttaaact ttatttaaat atctggttcc tatgattttg acttcagtaa gttcaaataa 2460 aatatatttt gcaattcatt tttacattat aatttaaaaa gaagaagcga taagtggagt 2520 cagttt caat gctaggtggg gtggttaatg atttttctgg tgttgctgct aatgtggatt 2580 aacaaataaa aacattcatt gccttttttgcc tcataaaa 2618 <210> 8 <211> 266 <212> PRT <213> homo Ar sapiens <400> 8 Met Thr Leu Asp Glu Gln Ser Cyg Thr Glu Arp Asp Ser Cys 5 10 15 Lys Lys Arg Glu Glu Met Lys Leu Lys Glu Cys Val Ser Ile Leu Pro 20 25 30 Arg Lys Glu Ser Pro Ser Val Arg Ser Ser Lys Asp Gly Lys Leu Leu 35 40 45 Ala Ala Thr Leu Leu Leu Ala Leu Leu Ser Cys Cys Leu Thr Val Val 50 55 60 Ser Phe Tyr Gln Val Ala Ala Leu Gln Gly Asp Leu Ala Ser Leu Arg 65 70 75 80 Ala Glu Leu Gln Gly His His Ala Glu Lys Leu Pro Ala Gly Ala Gly 85 90 95 Ala Pro Lys Ala Gly Leu Glu Glu Ala Pro Ala Val Thr Ala Gly Leu 100 105 110 Lys Ile Phe Glu Pro Pro Ala Pro Gly Glu Gly Asn Ser Ser Gln Asn 115 120 125 Ser Arg Asn Lys Arg Ala Val Gln Gly Pro Glu Glu Thr Gly Ser Tyr 130 135 140 Thr Phe Val Pro Trp Leu Leu Ser Phe Lys Arg Gly Ser A la Leu Glu 145 150 155 160 Glu Lys Glu Asn Lys Ile Leu Val Lys Glu Thr Gly Tyr Phe Phe Ile 165 170 175 Tyr Gly Gln Val Leu Tyr Thr Asp Lys Thr Tyr Ala Met Gly His Leu 180 185 190 Ile Gln Arg Lys Lys Val His Val Phe Gly Asp Glu Leu Ser Leu Val 195 200 205 Thr Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr Leu Pro Asn Asn 210 215 220 Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu Gly Asp Glu Leu 225 230 235 240 Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser Leu Asp Gly Asp 245 250 255 Val Thr Phe Phe Gly Ala Leu Lys Leu Leu 260 265 <210> 9 <211> 2212 <212> RNA <213> homo sapiens <400> 9 ccggaaccct gtgtgctggg gaggaatccc gcagtggccg gggggcttga ggccgctgct 60 ttgtctcttc gtccagagcc ttatgtaaga gcttttctcg ggaaacagga agtcctgctt 12 0 gccaatttca gcacagggag tagtgcaggc cttattccaa cacacccggc ccagccttaa 180 ccccagaact cagccagttt cttgcttccg tgcccctggt tctcctcccc atcgagccca 240 cccctccttt cccaccttca gtcaccccta gtgaactgcc ccagcgatct ctgctgtgct 300 tgaccccgag ggtcttccac cctcgccctg accctggaca ctgcccagct tggcccccca 360 tcctgctcct ggcacaatgc cctctagcca gccaaccttc cctcccccaa ccctggggcc 420 gccccagggt tcctgcgcac tgcctgttcc tcctgggtgt cactggcagc cctgtccttc 480 ctagagggac tggaacctaa ttctcctgag gctgagggag ggtggagggt ctcaaggcaa 540 cgctggcccc acgacggagt gccaggagca ctaacagtac ccttagcttg ctttcctcct 600 ccctcctttt tattttcaag ttccttttta tttctccttg cgtaacaacc ttcttccctt 660 ctgcaccact gcccgtaccc ttacccgccc cgccacctcc ttgctacccc actcttgaaa 720 ccacagctgt tggcagggtc cccagctcat gccagcctca tctcctttct tgctagcccc 780 caaagggcct ccaggcaaca tggggggccc agtcagagag ccggcactct cagttgccct 840 ctggttgagt tggggggcag ctctgggggc cgtggcttgt gccatggctc tgctgaccca 900 acaaacagag ctgcagagcc tcaggagaga ggtgagccgg ctgcagggga caggaggccc 960 ctcccagaat ggggaag ggt atccctggca gagtctcccg gagcagcagc actctgtcct 1020 gcacctggtt cccattaacg ccacctccaa ggatgactcc gatgtgacag aggtgatgtg 1080 gcaaccagct cttaggcgtg ggagaggcct acaggcccaa ggatatggtg tccgaatcca 1140 ggatgctgga gtttatctgc tgtatagcca ggtcctgttt caagacgtga ctttcaccat 1200 gggtcaggtg gtgtctcgag aaggccaagg aaggcaggag actctattcc gatgtataag 1260 aagtatgccc tcccacccgg accgggccta caacagctgc tatagcgcag gtgtcttcca 1320 tttacaccaa ggggatattc tgagtgtcat aattccccgg gcaagggcga aacttaacct 1380 ctctccacat ggaaccttcc tggggtttgt gaaactgtga ttgtgttata aaaagtggct 1440 cccagcttgg aagaccaggg tgggtacata ctggagacag ccaagagctg agtatataaa 1500 ggagagggaa tgtgcaggaa cagaggcgtc ttcctgggtt tggctccccg ttcctcactt 1560 ttcccttttc attcccaccc cctagacttt gattttacgg atatcttgct tctgttcccc 1620 atggagctcc gaattcttgc gtgtgtgtag atgaggggcg ggggacgggc gccaggcatt 1680 gtccagacct ggtcggggcc cactggaagc atccagaaca gcaccaccat ctagcggccg 1740 ctcgagggaa gcacccgccg gttggccgaa gtccacgaag ccgccctctg ctagggaaaa 1800 cccctggttc tccatgccac ac ctctctcc aggtgccctc tgcctcttca ccccacaaga 1860 agccttatcc tacgtccttc tctccatcta tcggacccca gtttccatca ctatctccag 1920 agatgtagct attatgcgcc cgtctacagg gggtgcccga cgatgacggt gccttcgcag 1980 tcaaattact cttcgggtcc caaggtttgg ctttcacgcg ctccattgcc ccggcgtggc 2040 aggccattcc aagcccttcc gggctggaac tggtgtcgga ggagcctcgg gtgtatcgta 2100 cgccctggtg ttggtgttgc ctcactcctc tgagctcttc tttctgatca agccctgctt 2160 aaagttaaat aaaatagaat gaatgatacc ccggcaaaaa aaaaaaaaaa aa 2212 <210> 10 <211> 223 <212> PRT <213> homo sapiens <400> 10 Met Pro Ala Ser Pro Phe Leu Leu Ala Pro Lys Gly Pro Pro Gly 1 5 10 15 Asn Met Gly Gly Pro Val Arg Glu Pro Ala Leu Ser Val Ala Leu Trp 20 25 30 Leu Ser Trp Gly Ala Ala Leu Gly Ala Val Ala Cys Ala Met Ala Leu 35 40 45 Leu Thr Gln Gln Thr Glu Leu Gln Ser Leu Arg Arg Glu Val Ser Arg 50 55 60 Leu Gln Gly Thr Gly Gly Pro Ser Gln Asn Gly Glu Gly Tyr Pro Trp 65 70 75 80 Gln Ser Leu Pro Glu Gln Gln His Ser Val Leu His Leu Val Pro Ile 85 90 95 Asn Ala Thr Ser Lys As p Asp Ser Asp Val Thr Glu Val Met Trp Gln 100 105 110 Pro Ala Leu Arg Arg Gly Arg Gly Leu Gln Ala Gln Gly Tyr Gly Val 115 120 125 Arg Ile Gln Asp Ala Gly Val Tyr Leu Leu Tyr Ser Gln Val Leu Phe 130 135 140 Gln Asp Val Thr Phe Thr Met Gly Gln Val Val Ser Arg Glu Gly Gln 145 150 155 160 Gly Arg Gln Glu Thr Leu Phe Arg Cys Ile Arg Ser Met Pro Ser His 165 170 175 Pro Asp Arg Ala Tyr Asn Ser Cys Tyr Ser Ala Gly Val Phe His Leu 180 185 190 His Gln Gly Asp Ile Leu Ser Val Ile Ile Pro Arg Ala Arg Ala Lys 195 200 205 Leu Asn Leu Ser Pro His Gly Thr Phe Leu Gly Phe Val Lys Leu 210 215 220 <210> 11 <211> 2619 <212> RNA <213> homo sapiens <400> 11 gcctccacca agggcccatc ggtcttcccc ctggcaccct cctccaagag cacctctggg 60 ggcacagcag ccct gggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120 tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180 ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240 tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc 300 aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga 360 ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420 gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480 tacgtggacg gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac 540 agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag 600 gagtacaagt gcaaggtctc caacaaagcc ctcccagccg gcagccccga gaaccacagg 660 tgtacaccct gcccccatcc cgggatgagc tgaccaagaa ccaggtcagc ctgacctgcc 720 tggtcaaagg cttctatccc agcgacatcg ccgtggagtg ggagagcaat gggcagccgg 780 agaacaacta caagaccacg cctcccgtgc tggactccga cggctccttc ttcctctaca 840 gcaagctcac cgtggacaag agcaggtggc agcaggggaa cgtcttctca tgctccgtga 900 tgcatgaggc tctgcacaac cactacacac ag aagagcct ctccctgtct ccggcccatc 960 gagaaaacca tctccaaagc caaagagctg caactggagg agagctgtgc ggaggcgcag 1020 gacggggagc tggacgggct gtggacgacc atcaccatct tcatcacact cttcctgtta 1080 agcgtgtgct acagtgccac cgtcaccttc ttcaaggtga agtggatctt ctcctcggtg 1140 gtggacctga agcagaccat catccccgac tacaggaaca tgatcggaca gggggcctag 1200 ggccaccctc tgcggggtgt ccagggccgc ccagacccca cacaccagcc atgggccatg 1260 ctcagccacc acccaggcca cacctgcccc cgacctcacc gccctcaacc ccatgactct 1320 ctggcctcgc agttgccctc tgaccctgac acacctgaca cgcccccctt ccagaccctg 1380 tgcatagcag gtctacccca gacctccgct gcttggtgca tgcagggcac tgggggccag 1440 gtgtcccctc agcaggacgt ccttgccctc cggaccacaa ggtgctcaca caaaaggagg 1500 cagtgaccgg tatcccaggc ccccacccag gcaggacctc gccctggagc caaccccgtc 1560 cacgccagcc tcctgaacac aggcgtggtt tccagatggt gagtgggagc gtcagccgcc 1620 aaggtaggga agccacagca ccatcaggcc ctgttgggga ggcttccgag agctgcgaag 1680 gctcactcag acggccttcc tcccagcccg cagccagcca gcctccattc cgggcactcc 1740 cgtgaactcc tgacatgagg aatgaggttg ttctgattt c aagcaaagaa cgctgctctc 1800 tggctcctgg gaacagtctc agtgccagca ccaccccttg gctgcctgcc cacactgctg 1860 gattctcggg tggaactgga cccgcaggga cagccagccc cagagtccgc actggggaga 1920 gaaggggcca ggcccaggac actgccacct cccacccact ccagtccacc gagatcactc 1980 agagaagagc ctgggccatg tggccgctgc aggagcccca cagtgcaagg gtgaggatag 2040 cccaaggaag ggctgggcat ctgcccagac aggcctccca gagaaggctg gtgaccaggt 2100 cccaggcggg caagactcag ccttggtggg gcctgaggac agaggaggcc caggagcatc 2160 ggggagagag gtggagggac accgggagag ccaggagcgt ggacacagcc agaactcatc 2220 acagaggctg gcgtccagcc ccgggtcacg tgcagcagga acaagcagcc actctggggg 2280 caccaggtgg agaggcaaga cgacaaagag ggtgcccgtg ttcttgcgaa agcagggctg 2340 ctggccacga gtgctggaca gaggccccca cgctctgctg cccccatcac gccgttccgt 2400 gactgtcacg cagaatctgc agacaggaag ggagactcga gcgggagtgc ggccagcgcc 2460 tgcctcggcc gtcagggagg actcctgggc tcactcgaag gaggtgccac catttcagct 2520 ttggtagctt ttcttcttct tttaaatttt ctaaagctca ttaattgtct ttgatgtttc 2580 ttttgtgatg acaataaaat atccttttta agtcttgta 2619 <210> 12 <211> 399 <212> PRT <213> homo sapiens <400> 12 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Glu Leu Gln Leu Glu Glu Ser Cys 325 330 335 Ala Glu Ala Gln Asp Gly Glu Leu Asp Gly Leu Trp Thr Thr Ile Thr 340 345 350 Ile Phe Ile Thr Leu Phe Leu Leu Ser Val Cys Tyr Ser Ala Thr Val 355 360 365 Thr Phe Phe Lys Val Lys Trp Ile Phe Ser Ser Val Val Asp Leu Lys 370 375 380 Gln Thr Ile Ile Pro Asp Tyr Arg Asn Met Ile Gly Gln Gly Ala 385 390 395 <210> 13 <211> 2279 <212> RNA <213> homo sapiens <400> 13 gcctccacca agggcccatc ggtcttcccc ctggcgccct gctccaggag cacctccgag 60 agcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120 tggaactcag gcgctctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180 ggactctact ccctcagcag cgtggtgacc gtgccctcca gcaacttcgg cacccagacc 240 tacacctgca acgtagatca caagcccagc aacaccaag g tggacaagac agttgagcgc 300 aaatgttgtg tcgagtgccc accgtgccca gcaccacctg tggcaggacc gtcagtcttc 360 ctcttccccc caaaacccaa ggacaccctc atgatctccc ggacccctga ggtcacgtgc 420 gtggtggtgg acgtgagcca cgaagacccc gaggtccagt tcaactggta cgtggacggc 480 gtggaggtgc ataatgccaa gacaaagcca cgggaggagc agttcaacag cacgttccgt 540 gtggtcagcg tcctcaccgt cgtgcaccag gactggctga acggcaagga gtacaagtgc 600 aaggtctcca acaaaggcct cccagccccc atcgagaaaa ccatctccaa aaccaaagag 660 ctgcaactgg aggagagctg tgcggaggcg caggacgggg agctggacgg gctgtggacc 720 accatcacca tcttcatcac actcttcctg ctaagcgtgt gctacagtgc caccatcacc 780 ttcttcaagg tgaagtggat cttctcctca gtggtggacc tgaagcagac catcgtcccc 840 gactacagga acatgatcag gcagggggcc tagggccacc ctctgtgggg tgtccagggc 900 cgcccagacc ccacacagga gccgtgggcc atgctcagcc atcacccagg ccacacctgc 960 ccccgacctc accgccctca accccatggc tctctggcct cgcagtcgcc ctctgaccct 1020 gacacgcccc ccttccagac cctgtgcata gcaggtctac cccagacctc cgctgcttgg 1080 tgcatgcagg gcgctggggg ccaagtgtcc cctcagcagg acgtccctgc cctcc ggccc 1140 gccaggtgct cacacaaaag gaggtagtga ccagcatccc aggcccccac tcaggcagga 1200 cctcgccctg gagccaaccc tgtccacgcc agcctcctga acacaggcgt ggtttccaga 1260 tggtgagtgg gagcatcagt cgccaaggta gggaagtcac agcaccatca ggccctgttg 1320 gggaggcttc cgagagctgc gaaggctcac tcagacggcc ttcctcccag cccgcagcca 1380 gccagcctcc attccaggca ctcccgtgaa ctcctgacat gaggaatgag gttgttctga 1440 tttcaagcaa agaacgctgc tctctggctc ctgggaacag tctcagtgcc agcaccaccc 1500 cttggctgcc tgcccacact gctggattct cgggtggaac tcgacccgca gggacagcca 1560 gccccagagt ccgcactggg gagagaaggg gccaggccca ggacactgcc acctaccacc 1620 cactccagtc caccgagatc actcggagaa gagcctgggc catgtggccg ctgcaggagc 1680 cccacggtgc aagggtgagg atagcccaag gaagggctgg gcatctgccc agacaggcct 1740 cccagagaag gctggtgacc aggtcccagg cgggcaagac tcagccttgg tggggcctga 1800 ggacagagga ggcccaggag catcggggag agaggtggag ggacaccggg agagccagga 1860 gcgtggacac agccagaact catcacagag gctggcgtcc agccccgggt cacgtgcagc 1920 aggaacaagc agccactctg ggggcaccag gtggagaggc aagacgacaa agagggtgcc 1980 cgtgttcttg tgaaagcggg gctgctggcc acgagtgctg gacagaggcc cccacgctct 2040 gctgccccca tcacgccgtt ccgtgactgt cacgcagaat ccgcagacag ggagactcga 2100 gcgggagtgc ggccagcgcc tgcctcagct gtcagggagg actcccgggc tcactcgaag 2160 gaggtgccac catttcagct ttggtagctt ttcttcttct tttaaatttt ctaaagctca 2220 ttaattgtct ttgatgtttc ttttgtgatg acaataaaat atccttttta agtcttgta 2279 <210> 14 <211> 326 <212> PRT <213 > homo sapiens <400> 14 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Thr Val Glu Arg Lys Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro 100 105 110 Pro Val Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 115 120 125 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 130 135 140 Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 145 150 155 160 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn 165 170 175 Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gln Asp Trp 180 185 190 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro 195 200 205 Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg Glu 210 215 220 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn 225 230 235 240 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 245 250 255 Ser Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 260 265 270 Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 275 280 285 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 290 295 300 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 305 310 315 320 Ser Leu Ser Pro Gly Lys 325 <210> 15 <211> 1256 <212> RNA <213> homo sapiens <400> 15 cttccaccaa gggcccatcg gtcttccccc tggcgccctg ctccaggagc acctctgggg 60 gcacagcggc cctgggctgc ctggtcaagg actacttccc agaaccggtg acggtgtcgt 120 ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta cagtcctcag 180 gactctactc cctcagcagc gtggtgaccg tgccctccag cagcttgggc acccagacct 240 acacctgcaa cgtgaatcac aagcccagca acaccaaggt ggacaagaga gttgagctca 300 aaaccccact tggtgacaca actcacacat gcccacggtg cccagagccc aaatcttgtg 360 acacacctcc cccgtgccca cggtgcccag agcccaaatc ttgtgacaca cctcccccat 420 gcccacggtg cccagagccc aaatcttgtg acacacctcc cccgtgccca aggtgcccag 480 cacctgaact cctgggagga ccgtcagtct tcctcttccc cccaaaaccc aaggataccc 540 ttatgatttc ccggacccct gaggtcacgt gcgt ggtggt ggacgtgagc cacgaagacc 600 ccgaggtcca gttcaagtgg tacgtggacg gcgtggaggt gcataatgcc aagacaaagc 660 cgcgggagga gcagtacaac agcacgttcc gtgtggtcag cgtcctcacc gtcctgcacc 720 aggactggct gaacggcaag gagtacaagt gcaaggtctc caacaaagcc ctcccagccc 780 ccatcgagaa aaccatctcc aaaaccaaag gacagccccg agaaccacag gtgtacaccc 840 tgcccccatc ccgggaggag atgaccaaga accaggtcag cctgacctgc ctggtcaaag 900 gcttctaccc cagcgacatc gccgtggagt gggagagcag cgggcagccg gagaacaact 960 acaacaccac gcctcccatg ctggactccg acggctcctt cttcctctac agcaagctca 1020 ccgtggacaa gagcaggtgg cagcagggga acatcttctc atgctccgtg atgcatgagg 1080 ctctgcacaa ccgcttcacg cagaagagcc tctccctgtc tccggagctg caactggagg 1140 agagctgtgc ggaggcgcag gacggggagc tggacgggct gtggacgacc atcaccatct 1200 tcatcacact cttcctgtta agcgtgtgct acagtgccac cgtcaccttc ttcaag 1256 <210> 16 <211> 377 <212> PRT <213> homo sapiens <400 > 16 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Thr Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro 100 105 110 Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg 115 120 125 Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys 130 135 140 Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro 145 150 155 160 Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys 165 170 175 Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val 180 185 190 Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Lys Trp Tyr 195 200 205 Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 210 215 220 Gln Tyr Asn Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Leu His 225 230 235 240 Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 245 250 255 Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln 260 265 270 Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met 275 280 285 Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro 290 295 300 Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gin Pro Glu Asn Asn 305 310 315 320 Tyr Asn Thr Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu 325 330 335 Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Ile 340 345 350 Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Phe Thr Gln 355 360 365 Lys Ser Leu Ser Leu Ser Pro Gly Lys 370 375 <210 > 17 <211> 1119 <212> RNA <213> homo sapiens <400> 17 gcttccacca agggcccatc ggtcttcccc ctggcgccct gctccaggag cacctccgag 60 agcacagccg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120 tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180 ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacgaagacc 240 tacacctgca acgtagatca caagcccagc aacaccaagg tggacaagag agttgagtcc 300 aaatatggtc ccccatgccc atcatgccca gcacctgagt tcctgggggg accatcagtc 360 ttcctgttcc ccccaaaacc caaggacact ctcatgatct cccggacccc tgaggtcacg 420 tgcgtggtgg tggacgtgag ccaggaagac cccgaggtcc agttcaactg gtacgtggat 480 ggcgtggagg tgcataatgc caagacaaag ccgcgggagg agcagttcaa cagcacgtac 540 cgtgtggtca gcgtcctcac cgtcctgcac caggact ggc tgaacggcaa ggagtacaag 600 tgcaaggtct ccaacaaagg cctcccgtcc tccatcgaga aaaccatctc caaagccaaa 660 gggcagcccc gagagccaca ggtgtacacc ctgcccccat cccaggagga gatgaccaag 720 aaccaggtca gcctgacctg cctggtcaaa ggcttctacc ccagcgacat cgccgtggag 780 tgggagagca atgggcagcc ggagaacaac tacaagacca cgcctcccgt gctggactcc 840 gacggctcct tcttcctcta cagcaggctc accgtggaca agagcaggtg gcaggagggg 900 aatgtcttct catgctccgt gatgcatgag gctctgcaca accactacac acagaagagc 960 ctctccctgt ctctgggtaa atgagtgcca gggccggcaa gcccccgctc cccgggctct 1020 cggggtcgcg cgaggatgct tggcacgtac cccgtgtaca tacttcccgg gcgcccagca 1080 tggaaataaa gcacccagcg ctgccctggg cccctgcga 1119 ctgccctggg cccctgcga 1119 Ala Sers < 212> Thr PRT G U Pro Serial <210> 18 <211> 3 Ala Sers < 18 <211> 3 Ala Sers < 18 <211> Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser Leu Ser Leu Gly Lys 325 <210> 19 <211> 1310 <212> RNA <213> homo sapiens <400> 19 gcatccccga ccagccccaa ggtcttcccg ctgagcctct gcagcaccca gccagatggg 60 aacgtggtca tcgcctgcct ggtccagggc ttcttccccc aggagccact cagtgtgacc 120 tggagcgaaa gcggacaggg cgtgaccgcc agaaacttcc cacccagcca ggatgcctcc 180 ggggacctgt acaccacgag cagccagctg accctgccgg ccacacagtg cctagccggc 240 aagtccgtga catgccacgt gaagcactac acgaatccca gccaggatgt gactgtgccc 300 tgcccagttc cctcaactcc acctacccca tctccctcaa ctccacctac cccatctccc 360 tcatgctgcc acccccgact gtcactgcac cgaccggccc tcgaggacct gctcttaggt 420 tcagaagcga acctcacgtg cacactgacc ggcctgagag atgcctcagg tgtcaccttc 480 acctggacgc cctcaagtgg gaagagcgct gttcaaggac cacctgagcg tgacctctgt 540 ggctgctaca gcgtgtccag tgtcctgccg ggctgtgccg agccatggaa ccatgggaag 600 accttcactt gcactgctgc ctaccccgag tccaagaccc cgctaaccgc caccctctca 660 aaatccggaa acacattccg gcccgaggtc cacctgctgc cgccgccgtc ggaggagctg 720 gccctgaacg agctggtgac gctgacgtgc ctggcacgcg gcttcagccc caaggatgtg 780 ctggttcgct ggctgcaggg gtcacaggag ctgccccgcg agaagtacct gacttgggca 840 tcccggcagg agcccagcca gggcaccacc accttcgctg tgaccagcat actgcgcgtg 900 gcagccgagg actggaagaa gggggacacc ttctcctgca tggtgggcca cgaggccctg 960 ccgctggcct tcacacagaa gaccatcgac cgcttggcgg attggcagat gccgcctccc 1020 tatgtggtgc tggacttgcc gcaggagacc ctggaggagg agacccccgg cgccaacctg 1080 tggcccacca ccatcacctt cctcaccctc ttcctgctga gcctgttcta tagcacagca 1140 ctgaccgtga ccagcgtccg gggcccatct ggcaacaggg agggccccca gtactgagca 1200 ggagccggca aggcacaggg aggaagtgtg gaggaacctc ttggagaagc cagctatgct 1260 tgccagaact cagccctttc agacatcacc gacccgccct tactcacatg 1310 <210> 20 <211> 398 <212> PRT <213> homo sapiens <400> 20 Ala Ser Pro Thr Ser Pro Lys Val Phe Pro Leu Ser Leu Cys Ser Thr 1 5 10 15 Gln Pro Asp Gly Asn Val Val Ile Ala Cys Leu Val Gln Gly Phe Phe 20 25 30 Pro Gln Glu Pro Leu Ser Val Thr Trp Ser Glu Ser Gly Gln Gly Val 35 40 45 Thr Ala Arg Asn Phe Pro Ser Gln Asp Ala Ser Gly Asp Leu Tyr 50 55 60 Thr Thr Ser Ser Gln Leu Thr Leu Pro Ala Thr Gln Cys Leu Ala Gly 65 70 75 80 Lys Ser Val Thr Cys His Va l Lys His Tyr Thr Asn Pro Ser Gln Asp 85 90 95 Val Thr Val Pro Cys Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro 100 105 110 Ser Thr Pro Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser 115 120 125 Leu His Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn 130 135 140 Leu Thr Cys Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe 145 150 155 160 Thr Trp Thr Pro Ser Ser Gly Lys Ser Ala Val Gln Gly Pro Pro Glu 165 170 175 Arg Asp Leu Cys Gly Cys Tyr Ser Val Ser Ser Val Leu Pro Gly Cys 180 185 190 Ala Glu Pro Trp Asn His Gly Lys Thr Phe Thr Cys Thr Ala Ala Tyr 195 200 205 Pro Glu Ser Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn 210 215 220 Thr Phe Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu 225 230 235 240 Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser 245 250 255 Pro Lys Asp Val Leu Val Arg Trp Leu Gln Gly Ser Gln Glu Leu Pro 260 265 270 Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro Ser Gln Gly 275 280 285 Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp 290 295 300 Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu 305 310 315 320 Pro Leu Ala Phe Thr Gln Lys Thr Ile Asp Arg Leu Ala Asp Trp Gln 325 330 335 Met Pro Pro Pro Tyr Val Val Leu Asp Leu Pro Gln Glu Thr Leu Glu 340 345 350 Glu Glu Thr Pro Gly Ala Asn Leu Trp Pro Thr Thr Ile Thr Phe Leu 355 360 365 Thr Leu Phe Leu Leu Ser Leu Phe Tyr Ser Thr Ala Leu Thr V al Thr 370 375 380 Ser Val Arg Gly Pro Ser Gly Asn Arg Glu Gly Pro Gln Tyr 385 390 395 <210> 21 <211> 1676 <212> RNA <213> homo sapiens <400> 21 agactcaaca agagctccag caaagacttt cactgtagct tgacttgacc 60 t tagggaatct tgagaataaa gatgagctct gaaaattgtt tcgtagcaga gaacagctct 120 ttgcatccgg agagtggaca agaaaatgat gccaccagtc cccatttctc aacacgtcat 180 gaagggtcct tccaagttcc tgtcctgtgt gctgtaatga atgtggtctt catcaccatt 240 ttaatcatag ctctcattgc cttatcagtg ggccaataca attgtccagg ccaatacaca 300 ttctcaatgc catcagacag ccatgtttct tcatgctctg aggactgggt tggctaccag 360 aggaaatgct actttatttc tactgtgaag aggagctgga cttcagccca aaatgcttgt 420 tctgaacatg gtgctactct tgctgtcatt gattctgaaa aggacatgaa ctttctaaaa 480 cgatacgcag gtagagagga acactgggtt ggactgaaaa aggaacctgg tcacccatgg 540 aagtggtcaa atggcaaaga atttaacaac tggttcaacg ttacagggtc tgacaagtgt 600 gtttttctga aaaacacaga ggtacaa gtg cttaagaaattatat ataaggaaac atgttcactt attgactatt atagaatgga 720 actcaaggaa atctgtgtca gtggatgctg ctctgtggtc cgaagtcttc catagagact 780 ttgtgaaaaa aaattttata gtgtcttggg aattttcttc caaacagaac tatggaaaaa 840 aaggaagaaa ttccaggaaa atctgcactg tgggctttta ttgccatgag ctagaagcat 900 cacaggttga ccaataacca tgcccaagaa tgagaagaat gactatgcaa cctttggatg 960 cactttatat tattttgaat ccagaaataa tgaaataact aggcgtggac ttactattta 1020 ttgctgaatg actaccaaca gtgagagccc ttcatgcatt tgcactattg gaaggagtta 1080 gatgttggta ctagatactg aatgtaaaca aaggaattat ggctggtaac ataggttttt 1140 agtctaattg aatcccttaa actcagggag catttataaa tggacaaatg cttatgaaac 1200 taagatttgt aatatttctc tctttttaga gaaatttgcc aatttacttt gttatttttc 1260 cccaaaaaga atgggatgat catgtattta tttttttact tcctcagctg tagacaggtc 1320 cttttcgatg gtacatattt ctttgccttt ataatctttt atacagtgtc ttacagagaa 1380 aagacataag caaagactat gaggaatatt tgcaagacat agaatagtgt tggaaaatgt 1440 gcaatatgtg atgtggcaaa tctctattag gaaatattct gtaatcttca gacctagaat 1500 aatactagtc ttataatagg tttgtgactt tcctaaatca attctattac gtgcaatact 1560 tcaatacttc atttaaaata tttttatgtg caataaaatg tatttgttttg tattttgtgt 1620 tcagtacaat tataagctgt tataagctgt SerGluaca 211 < agtla s Gluaca 211 < agtagaatas 22 Ser Ser Leu His Pro 1 5 10 15 Glu Ser Gly Gin Glu Asn Asp Ala Thr Ser Pro His Phe Ser Thr Arg 20 25 30 His Glu Gly Ser Phe Gln Val Pro Val Leu Cys Ala Val Met Asn Val 35 40 45 Val Phe Ile Thr Ile Leu Ile Ile Ala Leu Ile Ala Leu Ser Val Gly 50 55 60 Gln Tyr Asn Cys Pro Gly Gln Tyr Thr Phe Ser Met Pro Ser Asp Ser 65 70 75 80 His Val Ser Ser Cys Ser Glu Asp Trp Val Gly Tyr Gln Arg Lys Cys 85 90 95 Tyr Phe Ile Ser Thr Val Lys Arg Ser Trp Thr Ser Ala Gln Asn Ala 100 105 110 Cys Ser Glu His Gly Ala Thr Leu Ala Val Ile Asp Ser Glu Lys Asp 115 120 125 Met Asn Phe Leu Lys Arg Tyr Ala Gly Arg Glu Glu His Trp Val Gly 130 135 140 Leu Lys Lys Glu Pro Gly His Pro Trp Lys Trp Ser Asn Gly Lys Glu 145 150 155 160 Phe Asn Asn Trp Phe Asn Val Thr Gly Ser Asp Lys Cys Val Phe Leu 165 170 175 Lys Asn Thr Glu Val Ser Ser Met Glu Cys Glu Lys Asn Leu Tyr Trp 180 185 190 Ile Cys Asn Lys Pro Tyr Lys 195 <210> 23 <211> 2104 <212> RNA <213> homo sapiens <400> 23 aaccgcatct gcagcgagca tctgagaagc caagactgag ccggcggccg cggcgcagcg 60 aacgagcagt gaccgtgctc ctacccagct ctgctccaca gcgcccacct gtctccgccc 120 ctcggcccct cgcccggctt tgcctaaccg ccacgatgat gttctcgggc ttcaacgcag 180 actacgaggc gtcatcctcc cgctgcagca gcgcgtcccc ggccggggat agcctctctt 240 actaccactc acccgcagac tccttctcca gcatgggctc gcctgtcaac gcgcaggact 300 tctgcacgga cctggccgtc tccagtgcca acttcattcc cacggtcact gccatctcga 360 ccagtccgga cctgcagtgg ctggtgcagc ccgccctcgt ctcctccgtg gccccatcgc 420 agaccagagc ccctcaccct ttcggagtcc ccgccccctc cgctggggct tactccaggg 480 ctggcgttgt gaagaccatg acaggaggcc gagcgcagag cattggcagg aggggcaagg 540 tggaacagtt atctccagaa gaagaagaga aaaggagaat ccgaagggaa aggaataaga 600 tggctgcagc caaatgccgc aaccggagga gggagctgac tgatacactc caagcggaga 660 cagaccaact agaagatgag aagtctgctt tgcagaccga gattgccaac ctgctgaagg 720 agaaggaaaa actagagttc atcctggcag ctcaccgacc tgcctgcaag atccctgatg 780 acctgggctt cccagaagag atgtctgtgg cttcccttga tctgactggg ggcctgccag 840 aggttgccac c ccggagtct gaggaggcct tcaccctgcc tctcctcaat gaccctgagc 900 ccaagccctc agtggaacct gtcaagagca tcagcagcat ggagctgaag accgagccct 960 ttgatgactt cctgttccca gcatcatcca ggcccagtgg ctctgagaca gcccgctccg 1020 tgccagacat ggacctatct gggtccttct atgcagcaga ctgggagcct ctgcacagtg 1080 gctccctggg gatggggccc atggccacag agctggagcc cctgtgcact ccggtggtca 1140 cctgtactcc cagctgcact gcttacacgt cttccttcgt cttcacctac cccgaggctg 1200 actccttccc cagctgtgca gctgcccacc gcaagggcag cagcagcaat gagccttcct 1260 ctgactcgct cagctcaccc acgctgctgg ccctgtgagg gggcagggaa ggggaggcag 1320 ccggcaccca caagtgccac tgcccgagct ggtgcattac agagaggaga aacacatctt 1380 ccctagaggg ttcctgtaga cctagggagg accttatctg tgcgtgaaac acaccaggct 1440 gtgggcctca aggacttgaa agcatccatg tgtggactca agtccttacc tcttccggag 1500 atgtagcaaa acgcatggag tgtgtattgt tcccagtgac acttcagaga gctggtagtt 1560 agtagcatgt tgagccaggc ctgggtctgt gtctcttttc tctttctcct tagtcttctc 1620 atagcattaa ctaatctatt gggttcatta ttggaattaa cctggtgctg gatattttca 1680 aattgtatct agtgcagct g attttaacaa taactactgt gttcctggca atagtgtgtt 1740 ctgattagaa atgaccaata ttatactaag aaaagatacg actttatttt ctggtagata 1800 gaaataaata gctatatcca tgtactgtag tttttcttca acatcaatgt tcattgtaat 1860 gttactgatc atgcattgtt gaggtggtct gaatgttctg acattaacag ttttccatga 1920 aaacgtttta ttgtgttttt aatttattta ttaagatgga ttctcagata tttatatttt 1980 tattttattt ttttctacct tgaggtcttt tgacatgtgg aaagtgaatt tgaatgaaaa 2040 atttaagcat tgtttgctta ttgttccaag acattgtcaa taaaagcatt taagttgaat 2100 gcga 2104 <210> 24 <211> 380 <212> PRT <213> homo sapiens <400> 24 Met Met Phe Ser Gly Phe Asn Ala Asp Tyr Glu Ala Ser Ser Ser Arg 1 5 10 15 Cys Ser Ser Ala Ser Pro Ala Gly Asp Ser Leu Ser Tyr Tyr His Ser 20 25 30 Pro Ala Asp Ser Phe Ser Ser Met Gly Ser Pro Val Asn Ala Gln Asp 35 40 45 Phe Cys Thr Asp Leu Ala Val Ser Ser Ala Asn Phe Ile Pro Thr Val 50 55 60 Thr Ala Ile Ser Thr Ser Pro Asp Leu Gln Trp Leu Val Gln Pro Ala 65 70 75 80 Leu Val Ser Ser Val Ala Pro Ser Gln Thr Arg Ala Pro His Pro Phe 85 90 95 Gly Val Pro Ala Pro Ser Ala Gly Ala Tyr Ser Arg Ala Gly Val Val 100 105 110 Lys Thr Met Thr Gly Gly Arg Ala Gln Ser Ile Gly Arg Arg Gly Lys 115 120 125 Val Glu Gln Leu Ser Pro Glu Glu Glu Glu Lys Arg Arg Ile Arg Arg 130 135 140 Glu Arg Asn Lys Met Ala Ala Ala Lys Cys Arg Asn Arg Arg Arg Glu 145 150 155 160 Leu Thr Asp Thr Leu Gln Ala Glu Thr Asp Gln Leu Glu Asp Glu Lys 165 170 175 Ser Ala Leu Gln Thr Glu Ile Ala Asn Leu Leu Lys Glu Lys Glu Lys 180 185 190 Leu Glu Phe Ile Leu Ala Ala His Arg Pro Ala Cys Lys Ile Pro Asp 195 200 205 Asp Leu Gly Phe Pro Glu Glu Met Ser Val Ala Ser Leu Asp Leu Thr 210 215 220 Gly Gly Leu Pro Glu Val Ala Thr Pro Glu Ser Glu Glu Ala Phe Thr 225 230 235 240 Leu Pro Leu Leu Asn Asp Pro Glu Pro Lys Pro Ser Val Glu Pro Val 245 250 255 Lys Ser Ile Ser Ser Met Glu Leu Lys Thr Glu Pro Phe Asp Asp Phe 260 265 270 Leu Phe Pro Ala Ser Ser Arg Pro Ser Gly Ser Glu Thr Ala Arg Ser 275 280 285 Val Pro Asp Met Asp Leu Ser Gly Ser Phe Tyr Ala Ala Asp Trp Glu 290 295 300 Pro Leu His Ser Gly Ser Leu Gly Met Gly Pro Met Ala Thr Glu Leu 305 310 315 320 Glu Pro Leu Cys Thr Pro Val Val Thr Cys Thr Pro Ser Cys Thr Ala 325 330 335 Tyr Thr Ser Ser Phe Val Phe Thr Tyr Pro Glu Ala Asp Ser Phe Pro 340 345 350 Ser Cys Ala Ala Ala His Arg Lys Gly Ser Ser Ser Asn Glu Pro Ser 355 360 365 Ser Asp Ser Leu Ser Ser Pro Thr Leu Leu Ala Leu 370 375 380 <210> 25 <21 1> 2173 <212> RNA <213> homo sapiens <400> 25 agacaggggt agtgcgaggc cgggcacagc cttcctgtgt ggttttaccg cccagagagc 60 gtcatggacc tggggaaacc aatgaaaagc gtgctggtgg tggctctcct tgtcattttc 120 caggtatgcc tgtgtcaaga tgaggtcacg gacgattaca tcggagacaa caccacagtg 180 gactacactt tgttcgagtc tttgtgctcc aagaaggacg tgcggaactt taaagcctgg 240 ttcctcccta tcatgtactc catcatttgt ttcgtgggcc tactgggcaa tgggctggtc 300 gtgttgacct atatctattt caagaggctc aagaccatga ccgataccta cctgctcaac 360 ctggcggtgg cagacatcct cttcctcctg acccttccct tctgggccta cagcgcggcc 420 aagtcctggg tcttcggtgt ccacttttgc aagctcatct ttgccatcta caagatgagc 480 ttcttcagtg gcatgctcct acttctttgc atcagcattg accgctacgt ggccatcgtc 540 caggctgtct cagctcaccg ccaccgtgcc cgcgtccttc tcatcagcaa gctgtcctgt 600 gtgggcatct ggatactagc cacagtgctc tccatcccag agctcctgta cagtgacctc 660 cagaggagca gcagtgagca agcgatgcga tgctctctca tcacagagca tgtggaggcc 720 tttatcacca tccaggtggc ccagatggtg atcggctttc tggtccccct gctggccatg 780 agcttctgtt accttgtcat catccgcacc ctgctccagg c acgcaactt tgagcgcaac 840 aaggccatca aggtgatcat cgctgtggtc gtggtcttca tagtcttcca gctgccctac 900 aatggggtgg tcctggccca gacggtggcc aacttcaaca tcaccagtag cacctgtgag 960 ctcagtaagc aactcaacat cgcctacgac gtcacctaca gcctggcctg cgtccgctgc 1020 tgcgtcaacc ctttcttgta cgccttcatc ggcgtcaagt tccgcaacga tctcttcaag 1080 ctcttcaagg acctgggctg cctcagccag gagcagctcc ggcagtggtc ttcctgtcgg 1140 cacatccggc gctcctccat gagtgtggag gccgagacca ccaccacctt ctccccatag 1200 gcgactcttc tgcctggact agagggacct ctcccagggt ccctggggtg gggataggga 1260 gcagatgcaa tgactcagga catccccccg ccaaaagctg ctcagggaaa agcagctctc 1320 ccctcagagt gcaagcccct gctccagaag atagcttcac cccaatccca gctacctcaa 1380 ccaatgccaa aaaaagacag ggctgataag ctaacaccag acagacaaca ctgggaaaca 1440 gaggctattg tcccctaaac caaaaactga aagtgaaagt ccagaaactg ttcccacctg 1500 ctggagtgaa ggggccaagg agggtgagtg caaggggcgt gggagtggcc tgaagagtcc 1560 tctgaatgaa ccttctggcc tcccacagac tcaaatgctc agaccagctc ttccgaaaac 1620 caggccttat ctccaagacc agagatagtg gggagacttc ttggcttggt gaggaaaagc 1680 ggacatcagc tggtcaaaca aactctctga acccctccct ccatcgtttt cttcactgtc 1740 ctccaagcca gcgggaatgg cagctgccac gccgccctaa aagcacactc atcccctcac 1800 ttgccgcgtc gccctcccag gctctcaaca ggggagagtg tggtgtttcc tgcaggccag 1860 gccagctgcc tccgcgtgat caaagccaca ctctgggctc cagagtgggg atgacatgca 1920 ctcagctctt ggctccactg ggatgggagg agaggacaag ggaaatgtca ggggcgggga 1980 gggtgacagt ggccgcccaa ggcccacgag cttgttcttt gttctttgtc acagggactg 2040 aaaacctctc ctcatgttct gctttcgatt cgttaagaga gcaacatttt acccacacac 2100 agataaagtt ttcccttgag gaaacaacag ctttaaaaga aaaagaaaaaa aaaagtcttt 2160 ggtaaatggc aaa 2173 <210> 26 <211> 378 <212> PRT <213> homo sapiens <400> 26 Met Asp Leu Gly Leu Val Le Valla Valla Met 10 15 Val Ile Phe Gln Val Cys Leu Cys Gln Asp Glu Val Thr Asp Asp Tyr 20 25 30 Ile Gly Asp Asn Thr Thr Val Asp Tyr Thr Leu Phe Glu Ser Leu Cys 35 40 45 Ser Lys Lys Asp Val Arg Asn Phe Lys Ala Trp Phe Leu Pro Ile Met 50 55 60 Tyr Ser Ile Ile Cys Phe Val Gly Leu Leu Gly Asn Gly Leu Val Val 65 70 75 80 Leu Thr Tyr Ile Tyr Phe Lys Arg Leu Lys Thr Met Thr Asp Thr Tyr 85 90 95 Leu Leu Asn Leu Ala Val Ala Asp Ile Leu Phe Leu Leu Thr Leu Pro 100 105 110 Phe Trp Ala Tyr Ser Ala Ala Lys Ser Trp Val Phe Gly Val His Phe 115 120 125 Cys Lys Leu Ile Phe Ala Ile Tyr Lys Met Ser Phe Phe Ser Gly Met 130 135 140 Leu Leu Leu Leu Cys Ile Ser Ile Asp Arg Tyr Val Ala Ile Val Gln 145 150 155 160 Ala Val Ser Ala His Arg His Arg Ala Arg Val Leu Leu Ile Ser Lys 165 170 175 Leu Ser Cys Val Gly Ile Trp Ile Leu Ala Thr Val Leu Ser Ile Pro 180 185 190 Glu Leu Leu Tyr Ser Asp Leu Gln Arg Ser Ser Ser Glu Gln Ala Met 195 200 205 Arg Cys Ser Leu Ile Thr Glu His Val Glu Ala Phe Ile Thr Ile Gln 210 215 22 0 Val Ala Gln Met Val Ile Gly Phe Leu Val Pro Leu Leu Ala Met Ser 225 230 235 240 Phe Cys Tyr Leu Val Ile Ile Arg Thr Leu Leu Gln Ala Arg Asn Phe 245 250 255 Glu Arg Asn Lys Ala Ile Lys Val Ile Ile Ala Val Val Val Val Phe 260 265 270 Ile Val Phe Gln Leu Pro Tyr Asn Gly Val Val Leu Ala Gln Thr Val 275 280 285 Ala Asn Phe Asn Ile Thr Ser Ser Ser Thr Cys Glu Leu Ser Lys Gln Leu 290 295 300 Asn Ile Ala Tyr Asp Val Thr Tyr Ser Leu Ala Cys Val Arg Cys Cys 305 310 315 320 Val Asn Pro Phe Leu Tyr Ala Phe Ile Gly Val Lys Phe Arg Asn Asp 325 330 335 Leu Phe Lys Leu Phe Lys Asp Leu Gly Cys Leu Ser Gln Glu Gln Leu 340 345 350 Arg Gln Trp Ser Ser Cys Arg His Ile Arg Arg Ser Ser Met Ser Val 355 360 365 Glu Ala Glu Thr Thr Thr Thr Phe Ser Pro 370 375 <210> 27 <211> 1861 <212> RNA <213> homo sapiens <400> 27 caagcaccaa agcagagggg caggcagcac accacccagc agccagagca ccagt agaccat g ccag cc gagg tagaccat g ccag 60 catggt agaccatg gagg tatcccagag cccaggctga gcggatggag ttgaggaagt 180 acggccctgg aagactggcg gggacagtta taggaggagc tgctcagagt aaatcacaga 240 ctaaatcaga ctcaatcaca aaagagttcc tgccaggcct ttacacagcc ccttcctccc 300 cgttcccgcc ctcacaggtg agtgaccacc aagtgctaaa tgacgccgag gttgccgccc 360 tcctggagaa cttcagctct tcctatgact atggagaaaa cgagagtgac tcgtgctgta 420 cctccccgcc ctgcccacag gacttcagcc tgaacttcga ccgggccttc ctgccagccc 480 tctacagcct cctctttctg ctggggctgc tgggcaacgg cgcggtggca gccgtgctgc 540 tgagccggcg gacagccctg agcagcaccg acaccttcct gctccaccta gctgtagcag 600 acacgctgct ggtgctgaca ctgccgctct gggcagtgga cgctgccgtc cagtgggtct 660 ttggctctgg cctctgcaaa gtggcaggtg ccctctttcaa catcagcct gt tttgacc gctacctgaa catagttcat gccacccagc 780 tctaccgccg ggggcccccg gcccgcgtga ccctcacctg cctggctgtc tgggggctct 840 gcctgctttt cgccctccca gacttcatct tcctgtcggc ccaccacgac gagcgcctca 900 acgccaccca ctgccaatac aacttcccac aggtgggccg cacggctctg cgggtgctgc 960 agctggtggc tggctttctg ctgcccctgc tggtcatggc ctactgctat gcccacatcc 1020 tggccgtgct gctggtttcc aggggccagc ggcgcctgcg ggccatgcgg ctggtggtgg 1080 tggtcgtggt ggcctttgcc ctctgctgga ccccctatca cctggtggtg ctggtggaca 1140 tcctcatgga cctgggcgct ttggcccgca actgtggccg agaaagcagg gtagacgtgg 1200 ccaagtcggt cacctcaggc ctgggctaca tgcactgctg cctcaacccg ctgctctatg 1260 cctttgtagg ggtcaagttc cgggagcgga tgtggatgct gctcttgcgc ctgggctgcc 1320 ccaaccagag agggctccag aggcagccat cgtcttcccg ccgggattca tcctggtctg 1380 agacctcaga ggcctcctac tcgggcttgt gaggccggaa tccgggctcc cctttcgccc 1440 acagtctgac ttccccgcat tccaggctcc tccctccctc tgccggctct ggctctcccc 1500 aatatcctcg ctcccgggac tcactggcag ccccagcacc accaggtctc ccgggaagcc 1560 accctcccag ctctgaggac tgcaccattg ct gctcctta gctgccaagc cccatcctgc 1620 cgcccgaggt ggctgcctgg agccccactg cccttctcat ttggaaacta aaacttcatc 1680 ttccccaagt gcggggagta caaggcatgg cgtagagggt gctgccccat gaagccacag 1740 cccaggcctc cagctcagca gtgactgtgg ccatggtccc caagacctct atatttgctc 1800 ttttattttt atgtctaaaa tcctgcttaa aacttttcaa taaacaagat cgtcaggacc 1860 a 1861 <210> 28 <211> 368 <212> PRT <213> homo sapiens <400> 28 Met Val Leu Glu Val Ser Asp His Gln Val Leu Asn Asp Ala Glu Val 1 5 10 15 Ala Ala Ala Leu Leu Glu Asn Phe Ser Ser Ser Tyr Asp Tyr Gly Glu Asn 20 25 30 Glu Ser Asp Ser Cys Cys Thr Ser Pro Pro Cys Pro Gln Asp Phe Ser 35 40 45 Leu Asn Phe Asp Arg Ala Phe Leu Pro Ala Leu Tyr Ser Leu Leu Phe 50 55 60 Leu Leu Gly Leu Leu Gly Asn Gly Ala Val Ala Ala Val Leu Leu Ser 65 70 75 80 Arg Arg Thr Ala Leu Ser Ser Thr Asp Thr Phe Leu Leu His Leu Ala 85 90 95 Val Ala Asp Thr Leu Leu Val Leu Thr Leu Pro Leu Trp Ala Val Asp 100 105 110 Ala Ala Val Gln Trp Val Phe Gly Ser Gly Leu Cys Lys Val Ala Gly 115 120 125 Ala Leu Phe Asn Ile Asn Phe Tyr Ala Gly Ala Leu Leu Leu Ala Cys 130 135 140 Ile Ser Phe Asp Arg Tyr Leu Asn Ile Val His Ala Thr Gln Leu Tyr 145 150 155 160 Arg Arg Gly Pro Pro Ala Arg Val Thr Leu Thr Cys Leu Ala Val Trp 165 170 175 Gly Leu Cys Leu Leu Phe Ala Leu Pro Asp Phe Ile Phe Leu Ser Ala 180 185 190 His His Asp Glu Arg Leu Asn Ala Thr His Cys Gln Tyr Asn Phe Pro 195 200 205 Gln Val Gly Arg Thr Ala Leu Arg Val Leu Gln Leu Val Ala Gly Phe 210 215 220 Leu Leu Pro Leu Leu Val Met Ala Tyr Cys Tyr Ala His Ile Leu Ala 225 230 235 240 Val Leu Leu Val Ser Arg Gly Gln Arg Arg Leu Arg Ala Met Arg Leu 245 250 255 Val Val Val Val Val Val Val Ala Phe Ala Leu Cys Trp Thr Pro Tyr His 260 265 270 Leu Val Val Leu Val Asp Ile Leu Met Asp Leu Gly Ala Leu Ala Arg 275 280 285 Asn Cys Gly Arg Glu Ser Arg Val Asp Val Ala Lys Ser Val Thr Ser 290 295 300 Gly Leu Gly Tyr Met His Cys Cys Leu Asn Pro Leu Leu Tyr Ala Phe 305 310 315 320 Val Gly Val Lys Phe Arg Glu Arg Met Trp Met Leu Leu Leu Arg Leu 325 330 335 Gly Cys Pro Asn Gln Arg Gly Leu Gln Arg Gln Pro Ser Ser Ser Arg 340 345 350 Arg Asp Ser Ser Trp Ser Glu Thr Ser Glu Ala Ser Tyr Ser Gly Leu 355 360 365 <210> 29 <211> 2671 <212> RNA <213> homo sapiens <400> 29 tttattctct ggaacatgaa acattctgtt gtgctcatat catgcaaatt atcactagta 60 ggagagcaga gagtggaaat gttccaggta taaagaccca caagataaag aagctcagag 120 tcgttagaaa caggagcaga tgtacagggt ttgcctgact cacactcaag gttgcataag 1 80 caagatttca aaattaatcc tattctggag acctcaaccc aatgtacaat gttcctgact 240 ggaaaagaag aactatattt ttctgatttt ttttttcaaa tctttaccat tagttgccct 300 gtatctccgc cttcactttc tgcaggaaac tttatttcct acttctgcat gccaagtttc 360 tacctctaga tctgtttggt tcagttgctg agaagcctga cataccagga ctgcctgaga 420 caagccacaa gctgaacaga gaaagtggat tgaacaagga cgcatttccc cagtacatcc 480 acaacatgct gtccacatct cgttctcggt ttatcagaaa taccaacgag agcggtgaag 540 aagtcaccac cttttttgat tatgattacg gtgctccctg tcataaattt gacgtgaagc 600 aaattggggc ccaactcctg cctccgctct actcgctggt gttcatcttt ggttttgtgg 660 gcaacatgct ggtcgtcctc atcttaataa actgcaaaaa gctgaagtgc ttgactgaca 720 tttacctgct caacctggcc atctctgatc tgctttttct tattactctc ccattgtggg 780 ctcactctgc tgcaaatgag tgggtctttg ggaatgcaat gtgcaaatta ttcacagggc 840 tgtatcacat cggttatttt ggcggaatct tcttcatcat cctcctgaca atcgatagat 900 acctggctat tgtccatgct gtgtttgctt taaaagccag gacggtcacc tttggggtgg 960 tgacaagtgt gatcacctgg ttggtggctg tgtttgcttc tgtcccagga atcatcttta 1020 ctaaatgcca gaaag aagat tctgtttatg tctgtggccc ttattttcca cgaggatgga 1080 ataatttcca cacaataatg aggaacattt tggggctggt cctgccgctg ctcatcatgg 1140 tcatctgcta ctcgggaatc ctgaaaaccc tgcttcggtg tcgaaacgag aagaagaggc 1200 atagggcagt gagagtcatc ttcaccatca tgattgttta ctttctcttc tggactccct 1260 ataatattgt cattctcctg aacaccttcc aggaattctt cggcctgagt aactgtgaaa 1320 gcaccagtca actggaccaa gccacgcagg tgacagagac tcttgggatg actcactgct 1380 gcatcaatcc catcatctat gccttcgttg gggagaagtt cagaagcctt tttcacatag 1440 ctcttggctg taggattgcc ccactccaaa aaccagtgtg tggaggtcca ggagtgagac 1500 caggaaagaa tgtgaaagtg actacacaag gactcctcga tggtcgtgga aaaggaaagt 1560 caattggcag agcccctgaa gccagtcttc aggacaaaga aggagcctag agacagaaat 1620 gacagatctc tgctttggaa atcacacgtc tggcttcaca gatgtgtgat tcacagtgtg 1680 aatcttggtg tctacgttac caggcaggaa ggctgagagg agagagactc cagctgggtt 1740 ggaaaacagt attttccaaa ctaccttcca gttcctcatt tttgaataca ggcatagagt 1800 tcagactttt tttaaatagt aaaaataaaa ttaaagctga aaactgcaac ttgtaaatgt 1860 ggtaaagagt tagtttgagt tactatcatg tcaaacgtga aaatgctgta ttagtcacag 1920 agataattct agctttgagc ttaagaattt tgagcaggtg gtatgtttgg gagactgctg 1980 agtcaaccca atagttgttg attggcagga gttggaagtg tgtgatctgt gggcacatta 2040 gcctatgtgc atgcagcatc taagtaatga tgtcgtttga atcacagtat acgctccatc 2100 gctgtc atct cagctggatc tccattctct caggcttgct gccaaaagcc ttttgtgttt 2160 tgttttgtat cattatgaag tcatgcgttt aatcacattc gagtgtttca gtgcttcgca 2220 gatgtccttg atgctcatat tgttccctat tttgccagtg ggaactccta aatcaagttg 2280 gcttctaatc aaagctttta aaccctattg gtaaagaatg gaaggtggag aagctccctg 2340 aagtaagcaa agactttcct cttagtcgag ccaagttaag aatgttctta tgttgcccag 2400 tgtgtttctg atctgatgca agcaagaaac actgggcttc tagaaccagg caacttggga 2460 actagactcc caagctggac tatggctcta ctttcaggcc acatggctaa agaaggtttc 2520 agaaagaagt Iggggacagag cagaactttc accttcatat atttgtatga tcctaatgaa 2580 tgcataaaat gttaagttga tggtgatgaa atgtaaatac tgtttttaac aactatgatt 2640 tg Serg Meaaaataa atcaatgcta 212 Serg <211 Serg <211 Serg 212 Artaact <211> Asn Thr Asn Glu Ser 1 5 10 15 Gly Glu Glu Val Thr Thr Phe Phe Asp Tyr Asp Tyr Gly Ala Pro Cys 20 25 30 His Lys Phe Asp Val Lys Gln Ile Gly Ala Gln Leu Leu Pro Pro Leu 35 40 45 Tyr Ser Leu Val Phe Ile Phe Gly Phe Val Gly Asn Met Leu Val Val 50 55 60 Leu Ile Leu Ile Asn Cys Lys Lys Leu Lys Cys Leu Thr Asp Ile Tyr 65 70 75 80 Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Ile Thr Leu Pro 85 90 95 Leu Trp Ala His Ser Ala Ala Asn Glu Trp Val Phe Gly Asn Ala Met 100 105 110 Cys Lys Leu Phe Thr Gly Leu Tyr His Ile Gly Tyr Phe Gly Gly Ile 115 120 125 Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile Val His 130 135 140 Ala Val Phe Ala Leu Lys Ala Arg Thr Val Thr Phe Gly Val Val Thr 145 150 155 160 Ser Val Ile Thr Trp Leu Val Ala Val Phe Ala Ser Val Pro Gly Ile 165 170 175 Ile Phe Thr Lys Cys Gln Lys Glu Asp Ser Val Tyr Val Cys Gly Pro 180 185 190 Tyr Phe Pro Arg Gly Trp Asn Asn Phe His Thr Ile Met Arg Asn Ile 195 200 205 Leu Gly Leu Val Leu Pro Leu Leu Ile Me t Val Ile Cys Tyr Ser Gly 210 215 220 Ile Leu Lys Thr Leu Leu Arg Cys Arg Asn Glu Lys Lys Arg His Arg 225 230 235 240 Ala Val Arg Val Ile Phe Thr Ile Met Ile Val Tyr Phe Leu Phe Trp 245 250 255 Thr Pro Tyr Asn Ile Val Ile Leu Leu Asn Thr Phe Gln Glu Phe Phe 260 265 270 Gly Leu Ser Asn Cys Glu Ser Thr Ser Gln Leu Asp Gln Ala Thr Gln 275 280 285 Val Thr Glu Thr Leu Gly Met Thr His Cys Cys Ile Asn Pro Ile Ile 290 295 300 Tyr Ala Phe Val Gly Glu Lys Phe Arg Ser Leu Phe His Ile Ala Leu 305 310 315 320 Gly Cys Arg Ile Ala Pro Leu Gln Lys Pro Val Cys Gly Gly Pro Gly 325 330 335 Val Arg Pro Gly Lys Asn Val Lys Val Thr Thr Gln Gly Leu Leu Asp 340 345 350 Gly Arg Gly Lys Gly Lys Se r Ile Gly Arg Ala Pro Glu Ala Ser Leu 355 360 365 Gln Asp Lys Glu Gly Ala 370 <210> 31 <211> 1773 <212> RNA <213> homo sapiens <400> 31 agaaacctgt gtagcc actagag atggggacgg aggccacaga gcaggagatttcc tggggccatt 60 gcatactcgg ctgagccact gccggagctt tgctacaagg 120 ccgatgtcca ggccttcagc cgggccttcc aacccagtgt ctccctgacc gtggctgcgc 180 tgggtctggc cggcaatggc ctggtcctgg ccacccacct ggcagcccga cgcgcagcgc 240 gctcgcccac ctctgcccac ctgctccagc tggccctggc cgacctcttg ctggccctga 300 ctctgccctt cgcggcagca ggggctcttc agggctggag tctgggaagt gccacctgcc 360 gcaccatctc tggcctctac tcggcctcct tccacgccgg cttcctcttc ctggcctgta 420 tcagcgccga ccgctacgtg gccatcgcgc gagcgctccc agccgggccg cggccctcca 480 ctcccggccg cgcacacttg gtctccgtca tcgtgtggct gctgtcactg ctcctggcgc 540 tgcctgcgct gctcttcagc caggatgggc agcgggaagg ccaacgacgc tgtcgcctca 600 tcttccccga gggcctcacg cagacggtga agggggcgag cgccgtggcg caggtggccc 660 tgggcttcgc gctgccgctg ggcgtcatgg tagcctgcta cgcgcttctg ggccgcac gc 720 tgctggccgc cagggggccc gagcgccggc gtgcgctgcg cgtcgtggtg gctctggtgg 780 cggccttcgt ggtgctgcag ctgccctaca gcctcgccct gctgctggat actgccgatc 840 tactggctgc gcgcgagcgg agctgccctg ccagcaaacg caaggatgtc gcactgctgg 900 tgaccagcgg cttggccctc gcccgctgtg gcctcaatcc cgttctctac gccttcctgg 960 gcctgcgctt ccgccaggac ctgcggaggc tgctacgggg tgggagctgc ccctcagggc 1020 ctcaaccccg ccgcggctgc ccccgccggc cccgcctttc ttcctgctca gctcccacgg 1080 agacccacag tctctcctgg gacaactagg gctgcgaatc tagaggaggg ggcaggctga 1140 gggtcgtggg aaaggggagt aggtggggga acactgagaa agaggcaggg acctaaaggg 1200 actacctctg tgccttgcca cattaaattg ataacatgga aatgagatgc aacccaacaa 1260 ctgttactat ttttgagtca ccgacttgga agtgatttgt ggcggggcag aaccggtggg 1320 ttaacacccc gcccccgccc caccccccgc cctgccccgc gcttggctct ctgagtggaa 1380 gacgctgagg gcctgggtgg gggtgggggg ctgctgagtc tgctaaagct ctagccactg 1440 acaccccctc caccgtcacc tggcctcagc caacagaggt gaggtgggaa agctgccagg 1500 caaggagggg cggtggttcc tcttgcaata ctgtaaggaa gagctttcta acaaccagag 1560 cgc tctccag taatggctgc cttagcaaat actgagttcc cgctattgga atgttcagac 1620 tgtcggggac gctgtgggcc tttgcgtggt gtggggggag ggggaggggc aggggattcc 1680 cgtttttggt gggcgtttgg atttcataac cactttacaa tcccttccta gtgtctgtga 1740 tggaaagaaa aaatgaaaaa atgaattgta aaa 1773 <210> 32 <211> 362 <212> PRT <213> homo sapiens <400> 32 Met Gly Thr Glu Ala Thr Glu Gln Val Ser Trp Gly His Tyr Ser Gly 1 5 10 15 Asp Glu Glu Asp Ala Tyr Ser Ala Glu Pro Leu Pro Glu Leu Cys Tyr 20 25 30 Lys Ala Asp Val Gln Ala Phe Ser Arg Ala Phe Gln Pro Ser Val Ser 35 40 45 Leu Thr Val Ala Ala Leu Gly Leu Ala Gly Asn Gly Leu Val Leu Ala 50 55 60 Thr His Leu Ala Ala Arg Arg Ala Ala Arg Ser Pro Thr Ser Ala His 65 70 75 80 Leu Leu Gln Leu Ala Leu Ala Asp Leu Leu Leu Ala Leu Thr Leu Pro 85 90 95 Phe Ala Ala Ala Gly Ala Leu Gln Gly Trp Ser Leu Gly Ser Ala Thr 100 105 110 Cys Arg Thr Ile Ser Gly Leu Tyr Ser Ala Ser Phe His Ala Gly Phe 115 120 125 Leu Phe Leu Ala Cys Ile Ser Ala Asp Arg Tyr Val Ala Ile Ala Arg 130 135 140 Ala Leu Pro Ala Gly Pro Arg Pro Ser Thr Pro Gly Arg Ala His Leu 145 150 155 160 Val Ser Val Ile Val Trp Leu Leu Ser Leu Leu Leu Ala Leu Pro Ala 165 170 175 Leu Leu Phe Ser Gln Asp Gly Gln Arg Glu Gly Gln Arg Arg Cys Arg 180 185 190 Leu Ile Phe Pro Glu Gly Leu Thr Gln Thr Val Lys Gly Ala Ser Ala 195 200 205 Val Ala Gln Val Ala Leu Gly Phe Ala Leu Pro Leu Gly Val Met Val 210 215 220 Ala Cys Tyr Ala Leu Leu Gly Arg Thr Leu Leu Ala Ala Arg Gly Pro 225 230 235 240 Glu Arg Arg Arg Ala Leu Arg Val Val Val Val Ala Leu Val Ala Ala Phe 245 250 255 Val Val Leu Gln Leu Pro Tyr Ser Leu Ala Leu Leu Leu Asp Thr Ala 260 265 270 Asp Leu Leu Ala Ala Arg Glu Arg Ser Cys Pro Ala Ser Lys Arg Lys 275 280 285 Asp Val Ala Leu Leu Val Thr Ser Gly Leu Ala Leu Ala Arg Cys Gly 290 295 300 Leu Asn Pro Val Leu Tyr Ala Phe Leu Gly Leu Arg Phe Arg Gln Asp 305 310 315 320 Leu Arg Arg Leu Leu Arg Gly Gly Ser Cys Pro Ser Gly Pro Gln Pro 325 330 335 Arg Arg Gly Cys Pro Arg Arg Pro Arg Leu Ser Ser Cys Ser Ala Pro 340 345 350 Thr Glu Thr His Ser Leu Ser Trp Asp Asn 355 360 <210> 33 <211> 3025 <212> RNA <213> homo sapiens <400> 33 ggcattgcct cacagacctt cctcagagcc gctttcagaa aagcaagctg cttctggttg 60 ggcccagacc tgccttgagg agcctgtaga gttaaaaaat gaaccccacg gatatagcag 120 acaccaccct cgatgaaagc atatacagca attactatct gtatgaaagt atccccaagc 180 cttgcaccaa agaaggcatc aaggcatttg gggagctctt cctgccccca ctgtattcct 240 tggtttttgt atttggtctg cttggaaatt ctgtggtggt tc tggtcctg ttcaaataca 300 agcggctcag gtccatgact gatgtgtacc tgctcaacct tgccatctcg gatctgctct 360 tcgtgttttc cctccctttt tggggctact atgcagcaga ccagtgggtt tttgggctag 420 gtctgtgcaa gatgatttcc tggatgtact tggtgggctt ttacagtggc atattctttg 480 tcatgctcat gagcattgat agatacctgg caattgtgca cgcggtgttt tccttgaggg 540 caaggacctt gacttatggg gtcatcacca gtttggctac atggtcagtg gctgtgttcg 600 cctcccttcc tggctttctg ttcagcactt gttatactga gcgcaaccat acctactgca 660 aaaccaagta ctctctcaac tccacgacgt ggaaggttct cagctccctg gaaatcaaca 720 ttctcggatt ggtgatcccc ttagggatca tgctgttttg ctactccatg atcatcagga 780 ccttgcagca ttgtaaaaat gagaagaaga acaaggcggt gaagatgatc tttgccgtgg 840 tggtcctctt ccttgggttc tggacacctt acaacatagt gctcttccta gagaccctgg 900 tggagctaga agtccttcag gactgcacct ttgaaagata cttggactat gccatccagg 960 ccacagaaac tctggctttt gttcactgct gccttaatcc catcatctac ttttttctgg 1020 gggagaaatt tcgcaagtac atcctacagc tcttcaaaac ctgcaggggc ctttttgtgc 1080 tctgccaata ctgtgggctc ctccaaattt actctgctga cacccccagc tcatcttac a 1140 cgcagtccac catggatcat gatctccatg atgctctgta gaaaaatgaa atggtgaaat 1200 gcagagtcaa tgaactttcc acattcagag cttacttaaa attgtatttt agtaagagat 1260 tcctgagcca gtgtcaggag gaaggcttac acccacagtg gaaagacagc ttctcatcct 1320 gcaggcagct ttttctctcc cactagacaa gtccagcctg gcaagggttc acctgggctg 1380 aggcatcctt cctcacacca ggcttgcctg caggcatgag tcagtctgat gagaactctg 1440 agcagtgctt gaatgaagtt gtaggtaata ttgcaaggca aagactattc ccttctaacc 1500 tgaactgatg ggtttctcca gagggaattg cagagtactg gctgatggag taaatcgcta 1560 ccttttgctg tggcaaatgg gccctctaat taatttcttg cttttgcgga acaatataga 1620 taactgtttt tctaataaca tatctcaggc aaagtatatt ccattgagcc agatgtatga 1680 agaaacaatt agcgaagtga tgaaaccaga tctcaattat ttattgtaaa ggattatctg 1740 ttaattgaaa ccaaactttt tatactgata taagggtaag gatatgaaga cattagccaa 1800 ggtctgcttt ccaaacgtga actacaaggc attcaaaatc caaacatatt tatgaaaatt 1860 caaacacagt ttctcacttg tttgtggaca tgttttgttc taattttaac agaggaatat 1920 taaaaaattt taaataggct gggcacggtg gcctgtaatc ccagcactgt gggaggccaa 1980 ggtgggcgga tcacctgagg tcaggagttc gagaccagcc tggccaacat ggagaaaccc 2040 tgtctctact aaaaaataca aaattagcca ggtgtggtgg cgcatgcctg taatcccagc 2100 tactcaggag gctgaggctg gagaataact tgaatccggg aggtggaggt tgcggtgagc 2160 cgagatcgcg ccattgtact ccaacctggg caaaaagagc gaaactctgt ctcaaaaaaa 2220 aaaaaaaaaa attaaataat acataggcca agaatacatt tatttgaggt catttacttg 2280 tttttttttt tttttttttt tttgagatgg aatcttgctc tgtcacccag tctggagtgc 2340 agtggcgcga tctcggctca ctgcaagctc tgcctcacgg gttcgcacca ttctcctgcc 2400 tcagcctccc aagtaggtgg gactacaggc acctgccccc atgcctggct aattttttgt 2460 attttcagta gagatggggt ttcaccatgt tagcaaggat ggttttaatc tcctgacctc 2520 gtgatccacc cgcctcggcc tcccaaagtg ctgggattac aggtgtgagc catcacgccc 2580 ggccacttgt ttatttttta ttttatttta ttttattttt gagatggagt ctcactctgt 2640 cacccaagct ggagtgcagt ggcactcggt tcactgcaaa gtctgcctcc caggttcaag 2700 cgattctcct gcctcagctt ctcaagcagc tgggattaga ggtgtgcacc actacgccag 2760 gctaattttt gtatttttag tagagatggg gtttcaccat attggccagg ctagtcttga 2820 actcc tgacc tcaggtgatc tgcctgcttc agcctcccaa agtgctggga ttacaggcgt 2880 gagccacctc gcccagccaa ggtcttttac ttgtttataa acagtctctt cataattaaa 2940 attaaggatt aataaagtat gacaatacct ccttaatcat tttgaagtgc ctgctatcaa 3000 ttgaaataaa aacaatcaac taaaa 3025 <210> 34 <211> 360 <212> PRT <213> homo sapiens <400> 34 Met Asn Pro Thr Asp Ile Ala Asp Thr Thr Leu Asp Glu Ser Ile Tyr 1 5 10 15 Ser Asn Tyr Tyr Leu Tyr Glu Ser Ile Pro Lys Pro Cys Thr Lys Glu 20 25 30 Gly Ile Lys Ala Phe Gly Glu Leu Phe Leu Pro Pro Leu Tyr Ser Leu 35 40 45 Val Phe Val Phe Gly Leu Leu Gly Asn Ser Val Val Val Leu Val Leu 50 55 60 Phe Lys Tyr Lys Arg Leu Arg Ser Met Thr Asp Val Tyr Leu Leu Asn 65 70 75 80 Leu Ala Ile Ser Asp Leu Leu Phe Val Phe Ser Leu Pro Phe Trp Gly 85 90 95 Tyr Tyr Ala Ala Asp Gln Trp Val Phe Gly Leu Gly Leu Cys Lys Met 100 105 110 Ile Ser Trp Met Tyr Leu Val Gly Phe Tyr Ser Gly Ile Phe Phe Val 115 120 125 Met Leu Met Ser Ile Asp Arg Ty r Leu Ala Ile Val His Ala Val Phe 130 135 140 Ser Leu Arg Ala Arg Thr Leu Thr Tyr Gly Val Ile Thr Ser Leu Ala 145 150 155 160 Thr Trp Ser Val Ala Val Phe Ala Ser Leu Pro Gly Phe Leu Phe Ser 165 170 175 Thr Cys Tyr Thr Glu Arg Asn His Thr Tyr Cys Lys Thr Lys Tyr Ser 180 185 190 Leu Asn Ser Thr Thr Trp Lys Val Leu Ser Ser Leu Glu Ile Asn Ile 195 200 205 Leu Gly Leu Val Ile Pro Leu Gly Ile Met Leu Phe Cys Tyr Ser Met 210 215 220 Ile Ile Arg Thr Leu Gln His Cys Lys Asn Glu Lys Lys Asn Lys Ala 225 230 235 240 Val Lys Met Ile Phe Ala Val Val Val Leu Phe Leu Gly Phe Trp Thr 245 250 255 Pro Tyr Asn Ile Val Leu Phe Leu Glu Thr Leu Val Glu Leu Glu Val 260 265 270 Leu Gln Asp Cys Th r Phe Glu Arg Tyr Leu Asp Tyr Ala Ile Gln Ala 275 280 285 Thr Glu Thr Leu Ala Phe Val His Cys Cys Leu Asn Pro Ile Ile Tyr 290 295 300 Phe Phe Leu Gly Glu Lys Phe Arg Lys Tyr Ile Leu Gln Leu Phe Lys 305 310 315 320 Thr Cys Arg Gly Leu Phe Val Leu Cys Gln Tyr Cys Gly Leu Leu Gln 325 330 335 Ile Tyr Ser Ala Asp Thr Pro Ser Ser Ser Tyr Thr Gln Ser Thr Met 340 345 350Asp His Asp Leu His Asp Ala Leu 355 360

Claims (10)

FCGR1A, FCGR2A, FCAR, TNFSF13B, TNFSF13, IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, FOS, CCR7, CXCR3, CCR2, CCR10, 및 CXCR4으로 구성된 그룹에서 선택되는 어느 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질을 측정하는 제제를 포함하는 코로나바이러스감염증-19(Coronavirus disease 2019; COVID-19) 중증 환자의 진단용 조성물.Any one or more genes selected from the group consisting of FCGR1A, FCGR2A, FCAR, TNFSF13B, TNFSF13, IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, FOS, CCR7, CXCR3, CCR2, CCR10, and CXCR4; Or a composition for diagnosis of severe patients with Coronavirus disease 2019; 제1항에 있어서,
상기 유전자의 발현 수준을 측정할 수 있는 제제는 상기 유전자에 상보적으로 결합하는 프라이머, 프로브 및 안티센스 뉴클레오티드로 이루어진 군으로부터 선택되는 적어도 하나인 것인, 진단용 조성물.According to claim 1,
The agent capable of measuring the expression level of the gene is at least one selected from the group consisting of primers, probes and antisense nucleotides that complementarily bind to the gene, diagnostic composition. 제1항에 있어서,
상기 단백질의 발현 수준을 측정할 수 있는 제제는 상기 단백질에 특이적으로 결합하는 항체, 올리고펩타이드, 리간드, PNA(Peptide nucleic acid) 및 앱타머(aptamer)로 이루어진 군으로부터 선택되는 적어도 하나인 것인, 진단용 조성물.According to claim 1,
The agent capable of measuring the expression level of the protein is at least one selected from the group consisting of an antibody, oligopeptide, ligand, PNA (peptide nucleic acid) and aptamer that specifically binds to the protein. , a diagnostic composition. 제1항에 있어서,
상기 FCGR1A, FCGR2A, FCAR, TNFSF13B, 또는 TNFSF13은 대식세포로부터 유래된 유전자이고,
상기 IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, 또는 FOS는 B세포로부터 유래된 것이며,
상기 CCR7, CXCR3, CCR2, CCR10, 또는 CXCR4는 플라즈마 세포로부터 유래된 것인, 진단용 조성물.According to claim 1,
The FCGR1A, FCGR2A, FCAR, TNFSF13B, or TNFSF13 is a gene derived from macrophages,
The IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, or FOS are derived from B cells,
The CCR7, CXCR3, CCR2, CCR10, or CXCR4 is a plasma cell-derived composition for diagnosis. 제1항 내지 제4항 중 어느 한 항의 진단용 조성물을 포함하는 코로나바이러스감염증-19 중증 환자의 진단용 키트.[Claim 5] A diagnostic kit for patients with severe coronavirus infection-19, comprising the composition for diagnosis of any one of claims 1 to 4. 목적하는 개체로부터 분리된 생물학적 시료에서, FCGR1A, FCGR2A, FCAR, TNFSF13B, TNFSF13, IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, FOS, CCR7, CXCR3, CCR2, CCR10, 및 CXCR4으로 구성된 그룹에서 선택되는 어느 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준을 측정하는 단계를 포함하는, 코로나바이러스감염증-19 중증 환자를 진단하기 위한 정보 제공 방법.In a biological sample isolated from a subject of interest, FCGR1A, FCGR2A, FCAR, TNFSF13B, TNFSF13, IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, FOS, CCR7, CXCR3, CCR2, CCR10, and CXCR4 selected from the group consisting of any one or more genes; Or comprising the step of measuring the expression level of the protein encoded thereby, a method of providing information for diagnosing a patient with severe coronavirus infection-19. 제 6항에 있어서,
대조군과 비교하여, 상기 TNFSF13, CD69, CCR7, CXCR4 및 CXCR3에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준이 감소되고,
상기 FCGR1A, FCGR2A, FCAR, TNFSF13B, IGHG1, IGHG2, IGHG3, IGHG4 및 IGHA1, FOS, CCR2 및 CCR10에서 선택되는 적어도 하나 이상의 유전자; 또는 이에 의해 암호화되는 단백질의 발현 수준이 증가된 경우, 코로나바이러스감염증-19 중증 환자로 진단하는 것인, 정보 제공 방법.7. The method of claim 6,
Compared to the control, at least one gene selected from TNFSF13, CD69, CCR7, CXCR4 and CXCR3; or the expression level of the protein encoded thereby is reduced,
at least one gene selected from the group consisting of FCGR1A, FCGR2A, FCAR, TNFSF13B, IGHG1, IGHG2, IGHG3, IGHG4 and IGHA1, FOS, CCR2 and CCR10; Or, when the expression level of the protein encoded thereby is increased, the diagnosis of severe coronavirus infection-19 is a method of providing information. 제7항에 있어서,
상기 유전자의 발현 수준을 측정하는 방법은 역전사 중합효소반응(RT-PCR), 경쟁적 역전사 중합효소반응(Competitive RT-PCR), 실시간 역전사 중합효소반응(Real-time RT-PCR), RNase 보호 분석법(RPA; RNase protection assay), 노던 블랏팅(Northern blotting) 및 DNA 칩으로 이루어진 군으로부터 선택되는 적어도 하나인, 정보 제공 방법.8. The method of claim 7,
Methods for measuring the expression level of the gene include reverse transcription polymerase reaction (RT-PCR), competitive reverse transcription polymerase reaction (Competitive RT-PCR), real-time reverse transcription polymerase reaction (Real-time RT-PCR), RNase protection assay ( RPA; RNase protection assay), Northern blotting (Northern blotting) and at least one selected from the group consisting of a DNA chip, information providing method. 제7항에 있어서,
상기 단백질의 발현 수준을 측정하는 방법은 단백질 칩 분석, 면역측정법, 리간드 바인딩 어세이, MALDI-TOF(Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, SELDI-TOF(Sulface Enhanced Laser Desorption/Ionization Time of Flight Mass Spectrometry) 분석, 방사선 면역 분석, 방사 면역 확산법, 오우크테로니 면역 확산법, 로케트 면역전기영동, 조직면역 염색, 보체 고정 분석법, 2차원 전기영동 분석, 액상 크로마토그래피-질량분석(liquid chromatography-Mass Spectrometry, LC-MS), LC-MS/MS(liquid chromatography-Mass Spectrometry/ Mass Spectrometry), 웨스턴 블랏팅 및 ELISA(enzyme linked immunosorbentassay)로 이루어진 군으로부터 선택되는 적어도 하나인, 정보 제공 방법.8. The method of claim 7,
Methods for measuring the expression level of the protein include protein chip analysis, immunoassay, ligand binding assay, MALDI-TOF (Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) analysis, SELDI-TOF (Sulface Enhanced Laser Desorption/Ionization) assay. Time of Flight Mass Spectrometry analysis, radioimmunoassay, radioimmunodiffusion method, octeroni immunodiffusion method, rocket immunoelectrophoresis, tissue immunostaining, complement fixation assay, two-dimensional electrophoresis analysis, liquid chromatography-mass spectrometry (liquid) At least one selected from the group consisting of chromatography-Mass Spectrometry, LC-MS, LC-MS/MS (liquid chromatography-Mass Spectrometry/ Mass Spectrometry), Western blotting, and ELISA (enzyme linked immunosorbent assay), an information providing method. 제7항에 있어서,
상기 FCGR1A, FCGR2A, FCAR, TNFSF13B, 또는 TNFSF13은 대식세포로부터 유래된 유전자이고,
상기 IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, 또는 FOS는 B세포로부터 유래된 것이며,
상기 CCR7, CXCR3, CCR2, CCR10, 또는 CXCR4는 플라즈마 세포로부터 유래된 것인, 정보 제공 방법.8. The method of claim 7,
The FCGR1A, FCGR2A, FCAR, TNFSF13B, or TNFSF13 is a gene derived from macrophages,
The IGHG1, IGHG2, IGHG3, IGHG4, IGHA1, CD69, or FOS are derived from B cells,
The CCR7, CXCR3, CCR2, CCR10, or CXCR4 is derived from plasma cells, the information providing method.
KR1020220066643A 2020-08-20 2022-05-31 A composition for diagnosing severe patient of COVID-19 KR102578616B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020220066643A KR102578616B1 (en) 2020-08-20 2022-05-31 A composition for diagnosing severe patient of COVID-19

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020200104327A KR102405649B1 (en) 2020-08-20 2020-08-20 A composition for diagnosing severe patient of COVID-19
KR1020220066643A KR102578616B1 (en) 2020-08-20 2022-05-31 A composition for diagnosing severe patient of COVID-19

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020200104327A Division KR102405649B1 (en) 2020-08-20 2020-08-20 A composition for diagnosing severe patient of COVID-19

Publications (2)

Publication Number Publication Date
KR20220078552A true KR20220078552A (en) 2022-06-10
KR102578616B1 KR102578616B1 (en) 2023-09-15

Family

ID=80815233

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020200104327A KR102405649B1 (en) 2020-08-20 2020-08-20 A composition for diagnosing severe patient of COVID-19
KR1020220066643A KR102578616B1 (en) 2020-08-20 2022-05-31 A composition for diagnosing severe patient of COVID-19

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020200104327A KR102405649B1 (en) 2020-08-20 2020-08-20 A composition for diagnosing severe patient of COVID-19

Country Status (1)

Country Link
KR (2) KR102405649B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405649B1 (en) * 2020-08-20 2022-06-07 한국과학기술원 A composition for diagnosing severe patient of COVID-19

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405649B1 (en) * 2020-08-20 2022-06-07 한국과학기술원 A composition for diagnosing severe patient of COVID-19

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102405649B1 (en) * 2020-08-20 2022-06-07 한국과학기술원 A composition for diagnosing severe patient of COVID-19

Also Published As

Publication number Publication date
KR20220022980A (en) 2022-03-02
KR102405649B1 (en) 2022-06-07
KR102578616B1 (en) 2023-09-15

Similar Documents

Publication Publication Date Title
CN111592594B (en) Monoclonal antibody for resisting novel coronavirus and application thereof
CN116249785A (en) Space transcriptomics for antigen-receptor
AU2012311286B2 (en) Antibodies, variable domains and chains tailored for human use
KR102272932B1 (en) Oncolytic adenoviruses armed with heterologous genes
KR20140097336A (en) Methods of treatment using an antibody against interferon gamma
KR20070092737A (en) Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
CN113929774A (en) Novel monoclonal antibody of coronavirus and mutant thereof and application of monoclonal antibody
CN107530431B (en) Biomarkers
KR102578616B1 (en) A composition for diagnosing severe patient of COVID-19
KR20170044194A (en) A process for the ppoduction of adenovirus
KR20220150320A (en) On-demand expression of exogenous factors in lymphocytes for the treatment of HIV
KR20140056142A (en) Stem cell factor inhibitor
CN112390891A (en) Chimeric antigen receptor and construction method and application thereof
CN114989291B (en) RBD-targeted anti-SARS-CoV-2 fully humanized monoclonal antibody and application thereof
KR101789910B1 (en) Use of SIGLEC5 as a marker for the diagnosis of Sjogren&#39;s syndrome
CN110903386B (en) Fully human monoclonal antibody with high neutralizing activity and resisting chikungunya fever and application
CN1435433A (en) Long-acting broad-spectrum chemotactic factor receptor inhibiting matter
CN114174536A (en) anti-TREM-1 antibodies and uses thereof
CN113429483A (en) Development and application of immune cell activator
CN107557367B (en) IGHG1 gene mutant and application thereof
CN110954697A (en) Method for detecting anti-PD-1 antibody expression positive immune effector cells and application thereof
CN114989292B (en) anti-SARS-CoV-2 full-humanized monoclonal antibody and application thereof
US20230203150A1 (en) Methods and Treatment Involving Antibodies to IL-18
US20240059762A1 (en) Anti-sars coronavirus-2 nucleocapsid protein antibodies
US20240084386A1 (en) Markers and cellular antecedents of rheumatoid arthritis flares

Legal Events

Date Code Title Description
A107 Divisional application of patent
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant